CAPLIN POINT Laboratories

Caplin Point Laboratories Limited
Regd. office: Ashvich Tower, 3rd Floor,
No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.
Phone : +91 44 24968000 / +91 80127 72888 / +91 44 71148000
E-mail : info@caplinpoint.net / Website : www.caplinpoint.net
CIN : L24231TN1990PLC019053

September 03, 2026

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G,Bandra Kurla Complex,
Bandra (E),Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Annual Report for the Financial Year 2025-26 – Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

The 35th Annual General Meeting ("AGM") of the Company is scheduled to be held on **Friday, September 25, 2026,** at **10.00 A.M (IST)** through Video Conferencing / Other Audio-Visual Means ("VC/OAVM"), in accordance with the relevant circulars issued by Ministry of Corporate Affairs ("MCA") and Securities and Exchange Board of India ("SEBI").

Pursuant to Regulation 34(1) of SEBI Listing Regulations, we are submitting herewith the Annual Report along with the Notice of the 35th AGM which has been sent to members through electronic mode. For those members whose email addresses are not registered with the Registrar and Share Transfer Agent ("RTA")/ Depositories, a letter containing the web link for accessing the Annual Report and Notice is being sent.

The Annual Report along with Notice convening the 35th AGM has also been uploaded on the Company's website at https://www.caplinpoint.net/index.php/annual-report/

This is for your kind information and records.

Thanking You,

Sincerely yours,
For Caplin Point Laboratories Limited
VENKATRAM GANAPATHISUBRAMANIAN
Digitally signed by VENKATRAM GANAPATHISUBRAMANIAN
Date: 2026.09.03 12:16:40 +05'30'
Venkatram G
General Counsel & Company Secretary
Membership No A23989

Encl: A/a

CAPLIN POINT®
Laboratories

Compounding Without Compromise

Caplin Point Laboratories Limited
Annual Report 2025-26


COMPOUNDING
WITHOUT
COMPROMISE

Fifteen years. One direction. Caplin's FY26 numbers, revenue of ₹2,187 Crores with 12.89% growth, net profit ₹650 Crores, up by 20.08% Y-o-Y, are not an aberration. But the latest entry in a decade-long pattern: profit has compounded at roughly 27%* over the past decade, without a single year of debt funding the climb.

This foundational rigour now propels us into more sophisticated territories. Caplin Steriles USA turned profitable within its first year. Backward integration, Blow-Fill-Seal technology and pre-filled syringes are reshaping the product mix toward complexity. Our core business of LatAm received a fresh impetus in the form of land acquisition in Mexico for setting up our first facility in that region along with a proposed state-of-the-art liquid oral facility in Guatemala. None of it requires leverage, dilution, or a pause in cash generation, with free cash reserves standing at ₹1,471 Crores, 21X** growth over the past decade.

For us, expansion does not translate to a compromise on stability. Instead, we continue to demonstrate that ambitious scale and fiscal discipline are twin forces that compound together, year after year.

* Net Profit CAGR between FY16 (₹58 Crores) and FY26 (₹650 Crores)

** Cash Reserves (Free Cash Reserves) ₹68 Crores in FY16 to ₹1,471 Crores in FY26

COMPOUNDING NUMBERS, WITHOUT COMPROMISE









THE PASSION FOR COMPOUNDING NUMBERS

TOTAL REVENUE
22.1%
10 Years CAGR
313 Cr to 2,303 Cr
2015-16 to 2025-26 (₹ Cr.)

16.2%
5 Years CAGR
1,085 Cr to 2,303 Cr
2020-21 to 2025-26 (₹ Cr.)

OPERATING REVENUE
21.6%
10 Years CAGR
310 Cr to 2,187 Cr
2015-16 to 2025-26 (₹ Cr.)

15.6%
5 Years CAGR
1,061 Cr to 2,187 Cr
2020-21 to 2025-26 (₹ Cr.)

EBITDA
26.0%
10 Years CAGR
87 Cr to 876 Cr
2015-16 to 2025-26 (₹ Cr.)

20.0%
5 Years CAGR
352 Cr to 876 Cr
2020-21 to 2025-26 (₹ Cr.)

PAT
27.3%
10 Years CAGR
58 Cr to 650 Cr
2015-16 to 2025-26 (₹ Cr.)

21.0%
5 Years CAGR
251 Cr to 650 Cr
2020-21 to 2025-26 (₹ Cr.)

FREE CASH RESERVES
68 Cr to 1,471 Cr
2015-16 to 2025-26 (₹ Cr.)

470 Cr to 1,471 Cr
2020-21 to 2025-26 (₹ Cr.)

PBT
26.5%
10 Years CAGR
77 Cr to 803 Cr
2015-16 to 2025-26 (₹ Cr.)

20.7%
5 Years CAGR
314 Cr to 803 Cr
2020-21 to 2025-26 (₹ Cr.)

ANOTHER YEAR OF YEAR-ON-YEAR COMPOUNDING

Operating Revenue FY26
₹2187.19 Crores
12.89% Y-o-Y Growth

EBITDA FY26
₹876.39 Crores
17.90% Y-o-Y Growth

Net Profit FY26
₹649.73 Crores
20.08% Y-o-Y Growth

PBT FY26
₹802.79 Crores
18.62% Y-o-Y Growth

EPS FY26
₹84.36
19.54% Y-o-Y Growth

Gross R&D Investment FY26
₹101 Crores
13.50% Y-o-Y Growth

COMPOUNDING OPERATIONS, WITHOUT COMPROMISE

OPERATIONAL HIGHLIGHTS:

New Therapeutic Areas Entered

- GLP-1 (weight management and diabetes) with filings
- Oncology Injectables nearing commercialization
- Biosimilars and Peptides under development
- API Manufacturing with complete R&D scale and refurbished plant

New Product Launches

- 29 US Injectable Products - CSL USA
- 3 Ophthalmic Products – CSL USA

Multiple USFDA Approvals (2025-2026):

- Acetaminophen Injection, Infusion Bags
- Linezolid
- Nicardipine Hydrochloride
- Milrinone Lactate
- Haloperidol Decanoate Injection
- Phytonadione Injectable Emulsion
- Desmopressin Acetate Injection

Country-specific Approvals and Certificates

- 25 Product Approvals in Mexico
- 10 ANDA Approvals in US and Regulated Markets
- 15 ANDA acquired from Third Party for US and Regulated Markets
- EU GMP Renewal Certificate
- Invima approval for Puducherry Injectables site

Ongoing Capacity Additions

- In-house API Unit to cater to 60% of our products
- Oral Solid Dosage facility for regulated markets in Puducherry
- Kakkalur Oncology Injectable Section
- Oncology unit in Thervoy Kandigai
- 3X expansion of IV Bag lines


CAPLIN POINT
Laboratories Ltd.,
India.

COMPOUNDING FOR CIRCULAR ECONOMY

NON-FINANCIAL HIGHLIGHTS

Environment

- 1,15,10,433 KWh Renewable power used amounting to 36.65% of power consumed by the group.
- 52.39% water recycled and reused in FY26
- 374.07 MT Waste generated
- Out of 315.71 MT Waste disposition, 17.69% was disposed through incineration, 18.93% to Alternate Fuel Recovery Facility and 14.39% recycled
- 1 key manufacturing unit with Zero Liquid Discharge
- Scope 1 and Scope 2 GHG emission intensity per rupee of revenue improved by approximately 12% YoY.

Social

- 2,249 employees in India, 512 overseas employees in Subsidiaries and 628 contract employees. (As of 31st March, 2026)
- 33.13% women representation in Indian workforce, 46% women representation in global workforce and 62% women representation in contract workforce.
- 100% of permanent employees – both male and female – are covered by Health Insurance and Accident Insurance.
- 14,300 hospitals, pharmacies, clinics, etc. in the US. 30,000+ touchpoints across Latin America
- 100% of women employees returned to work after maternity leave in FY26, with a 90.91% retention rate among women workers a year after their return.
- ₹4.70 Crores CSR spending
- 1,156 Number of beneficiaries of direct CSR initiatives
- 3,080 Number of patients served through the CSR hospital-cum-diagnostic center
- ~3,996 man hours of training for employees
- ₹10 Crores spending on various employee welfare measures
- 81.84% local sourcing of input materials in FY26 of which 6.20% materials were sourced from MSMEs
- 64% of Caplin's total wage cost in FY26 was paid to employees and workers based in rural (22.59%) and semi-urban (41.52%) locations.

Governance

- 2 out of 5 Independent Directors exercise active oversight in Subsidiary Boards
- Significant and stable Promoter participation in risk capital
- Zero Unfavorable observations in any of the last three audits conducted by USFDA
- Operations compliant with multi-jurisdiction regulatory requirements like USFDA, INVIMA, COFEPRIS etc
- 100% of employees covered under web-based Code of Conduct sensitization
- Dedicated CSR and Sustainability Committee established for oversight on sustainability initiatives
- Zero cybersecurity incidents and data breach backed up by strong IT Governance
- Succession planning pathway to induct next generation into Board Governance
- 23 Contract Manufacturers covered under ESG covenants under the Supply contracts
- There were no instances of product recalls in FY26.


CAPLIN POINT MEENAKSHI HOSPITAL
CAPLIN POINT MEENAKSHI HOSPITAL

For more information visit
https://www.caplinpoint.net/index.php/annual-report/



Caution on Forward-looking Statements

In this annual report, we have disclosed forward-looking information to enable investors to comprehend our prospects and take informed investment decisions. This report and other statements – written and oral – that we periodically make, contain forward-looking statements that set out anticipated results based on the management's plans and assumptions. We have tried wherever possible to identify such statements by using words such as 'anticipates', 'estimates', 'expects', 'projects', 'intends', 'plans', 'believes' and words of similar substance in connection with any discussion on future performance. We cannot guarantee that these forward-looking statements will be realized, although we believe we have been prudent in our assumptions. The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Inside this report

ABOUT THE REPORT

OUR APPROACH TO REPORTING

Annual Report for Financial Year 2025-26 (FY26) of Caplin Point Laboratories Limited (Caplin / CPL) is an endeavor to report on how we are embracing integrated thinking and creating value for stakeholders. It enunciates our strategic priorities, business performance, and sustainability initiatives in a unified manner. Its narrative reflects how Caplin strategically created and retained value for stakeholders, using various resources.

This report has been developed in collaboration with cross-functional teams across Caplin's various departments. The top management provides oversight to ensure comprehensive coverage of manufacturing, R&D, distribution, financial, human, environmental, social and governance aspects. The report passes through rigorous review at multiple stages and finally, the management grants approval, ensuring transparent disclosure and high standards of corporate reporting.

REPORTING PERIOD

Financial Year – April 1, 2025 To March 31, 2026

REPORTING CYCLE

Annual

SCOPE AND BOUNDARY

This annual report encompasses the global operations of Caplin across its business operations viz. the generic and branded generic manufacturing, R&D, distribution and its social impact. The broad categories of our products and services include high-quality oral solid dosages, liquids, ointments, injectables and ophthalmic products, oncology-specific oral solid dosages and injectables.

Sustainability is evaluated for Caplin's manufacturing facilities,



R&D sites, and offices, based on key environmental indicators such as carbon emissions, energy consumption, water usage, waste management, and biodiversity preservation. At the same time, social performance is communicated through employee wellbeing, diversity and inclusion, community engagement, and adoption of ethical practices. Caplin has come up with a dedicated ESG Data Portal for detailed review of various ESG practices in place together with relevant data. This portal is available here: Caplin Point ESG Data Portal.

FRAMEWORKS, GUIDELINES AND STANDARDS

- SEBI's Business Responsibility and Sustainability Reporting (BRSR) Framework
- Companies Act, 2013
- Indian Accounting Standards
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

FEEDBACK

For Shareholders & Investor Relations	Company Secretary and Compliance Officer	investor@caplinpoint.net
For Brokerage Firms and Financial Analysts	Chief Financial Officer	investor@caplinpoint.net
For Media and Others	Vice-Chairman	info@caplinpoint.net

IMPORTANT WEB LINKS

Company's main website: https://www.caplinpoint.net/
Investors' Section on Company's Website: https://www.caplinpoint.net/index.php/investors-2/
This and other annual reports of Caplin: https://www.caplinpoint.net/index.php/annual-report/
Company's ESG Data Portal: https://esg.churchgatepartners.com/login/companyprofile?id=
Caplin Steriles Limited website: https://www.caplinsteriles.net/
Caplin Steriles USA Inc website: https://www.caplin-us.com/
Amaris Clinical CRO website: https://www.amarisclinical.com/

BENCHMARKING BUSINESS PRACTICES WITH SUSTAINABLE DEVELOPMENT GOALS (UN-SDGS)

Following is the overview of key impact areas mapped to each of the SDGs:

SDG 1 - NO POVERTY

- 1,156 Number of beneficiaries of direct CSR initiatives
- 3,080 Number of patients served through the CSR hospital-cum-diagnostic center

SDG 4 - QUALITY EDUCATION

- Support for School events benefitting 123 Students
- Support for school staff benefitting 355 Students
- Support for a trust running a school having 627 students
- Sponsoring one poor student for education
- Sponsoring school uniforms benefitting 50 students

SDG 3 - GOOD HEALTH AND WELLBEING

- 57 Countries where our products are registered.
- 3,080 Number of patients served through the CSR hospital-cum-diagnostic center.
- Tie up with leading hospital to provide regular health check-ups to the employees at the subsidized rates.
- 152 new products registered in emerging markets
- 25 products registered in Mexico
- 30 products launched so far in the US market by Caplin Steriles USA Inc

SDG 5 - GENDER EQUALITY

- 33% women representation in Indian workforce.
- 46% women representation in global workforce.
- 62% women representation in contract workforce.
- 100% of women employees returned to work after maternity leave in FY26, with a 90.91% retention rate among women workers a year after their return.

SDG 6 - CLEAN WATER AND SANITATION

- 52.39% water recycled and reused in FY26
- One key manufacturing unit with Zero Liquid Discharge

SDG 8 - DECENT WORK AND ECONOMIC GROWTH

- 12.89% growth in consolidated revenue
- ₹73.82 Crores Economic Value Retained for US Business
- ₹728.97 Crores Economic Value Retained for rest of the market (EVR= Total Revenue-Costs)
- ₹649.73 Crores reported as consolidated net profit FY26
- ~ 3,996 man hours of training hours for employees
- ₹10 Crores invested in employee wellbeing initiatives
- 100% of permanent employees — both male and female — are covered by Health Insurance and Accident Insurance.
- 64% of Caplin's total wage cost in FY26 was paid to employees and workers based in rural (22.59%) and semi-urban (41.52%) locations.

SDG 7 - AFFORDABLE AND CLEAN ENERGY

- Utilization of Renewable Power in India

  Caplin Point Laboratories Limited: 1,19,71,316 KWh (Solar: 5,28,675 KWh, Others: 1,14,42,641 KWh)

  Caplin Steriles Limited: 1,56,09,334 KWh (Solar: 1,09,81,758 KWh, Others: 46,27,576 KWh)

SDG 9 - INDUSTRY INNOVATION AND INFRASTRUCTURE

- 4.6% of the global operating revenue invested in R&D
- One manufacturing unit established
- ₹248.13 Crores spent on capital expenditure

SDG 10 - REDUCED INEQUALITY

- ₹4.70 Crores spent on CSR programs
- 1,156 Number of beneficiaries of direct CSR initiatives
- 46% women representation in global workforce.
- Serving customers through Bottom of Pyramid (BOP) approach, thereby serving patients with medicines that are reasonably priced and possess highest quality

SDG 11 - SUSTAINABLE CITIES AND COMMUNITIES

Across Tamil Nadu, Puducherry, and Odisha, our CSR initiatives drove impactful community development with a strong focus on education, rural infrastructure, and public wellness. We strengthened educational infrastructure by consistently funding government school teacher salaries, providing higher education scholarships, and supplying essential student apparel and event infrastructure. To enhance public safety and healthcare access, we executed comprehensive street electrification projects in Puducherry and funded crucial hospital approach road repairs in Thiruvallur. Furthermore, we promoted community health and broader welfare by sponsoring the "Chennai Runs 2025" marathon for 481 participants and providing substantial financial grants to regional charitable NGOs.

SDG 13 - CLIMATE ACTION

- Waste Water Treatment:

  Caplin Point Laboratories Limited: 20,601 KL (39.93% of total water withdrawn)

  Caplin Steriles Limited: 9,016 KL (72.13% of total water withdrawn)

  Caplin One Labs Limited: 14,040 KL (99.26% of total water withdrawn)

- GHG Emission Intensity:

  Scope 1 and Scope 2 GHG emission intensity per rupee of revenue improved by approximately 12% YoY.

SDG 12 - RESPONSIBLE CONSUMPTION AND PRODUCTION

- 81.84% of input materials sourced from within India
- The above includes, 6.20 % sourced from MSMEs
- 0.19% of Hazardous Waste to landfilling across all units
- 94.52% of Hazardous Waste disposed through recycling or through Alternate Fuel Recovery mechanism

SDG 15 - LIFE ON LAND

Location of manufacturing units like Caplin One Labs Limited, Kakkalur and Thervoy Kandigai in Industrial Estates which have all prior clearances and avoids location of the projects adjacent to ecologically sensitive areas, protected zones, or specific biodiversity hotspots.

SDG 17 - PARTNERSHIPS FOR THE GOALS

Partnering with numerous channel partners across the markets served by Caplin to achieve shared goals.

- Introducing contractual terms that obligate contract manufacturers and other vendors to follow sustainable and socially responsible business practices.
- Establishing strategic technology partnerships with leading, regulatory-approved manufacturing units in China to access new product licenses and deepen supplier relationships.
- Engaging with government and policymakers through consultative meetings, PHARMEXCIL engagement, and DSIR recognition to support regulatory frameworks, public health, and industrial growth

BUSINESS OVERVIEW

ABOUT THE COMPANY AND THE GROUP

Caplin Point Laboratories Limited is a progressive pharmaceutical company engaged in the manufacturing and marketing of finished formulations, manufacturing of Active Pharmaceutical Ingredients, Research & Development and Clinical Research. Its unique business model mostly caters to emerging markets of Latin America and Africa. Over the years, with focused and consistent approach, Caplin has established a growing presence in the regulated markets such as the USA.

Caplin has state-of-the-art manufacturing facilities that produce a varied range of pharmaceutical products. These facilities are located at Suthukeny (Puducherry), Kakkalur (Chennai), Gummidipoondi (Chennai), and Visakhapatnam (Andhra Pradesh). Moreover, it has outsourced manufacturing to the approved sites in India and China. Caplin manages vast manufacturing and R&D facilities and international distribution network with its various subsidiaries.

Generics and Branded Generics – Caplin Point Laboratories Limited, the parent company manufactures generics and branded generic products comprising tablets, capsules, injections (liquid & lyophilized, pre-filled syringes), softgel capsules, liquid orals, ointments, creams and gels, powder for injections, suppositories and ovules, pre-mix bags and inhalers and sprays.

Injectables and Ophthalmics – Caplin Steriles Limited has portfolio of 59 injectable and ophthalmic products including simple and complex formulations. It continues to develop and manufacture quality injectables and ophthalmic products for regulated markets and invest in newer technologies and capacities related to these products.

Emerging Market Distribution – Caplin Point Far East Limited (Hong Kong), a wholly owned subsidiary of Caplin Point Laboratories Limited and holding company of all the Latin American step-down subsidiaries, deals in pharmaceutical products and consolidates emerging market distribution network.

Oncology Products – Caplin One Labs Limited manufactures and markets oncology formulations in emerging markets and holds 5 approved ANDAs for oncology injectable products. It operates the oncology unit in Kakkalur with various ongoing projects for generic and speciality products for emerging and regulated markets.

THE JOURNEY OF COMPOUNDING MILESTONES

Caplin's journey began with the founder Mr. C.C. Paarthipan, starting a partnership pharmaceutical venture known as Triwin Pharmaceuticals in 1987 to manufacture external ointments and creams. This venture evolved into a private limited company in 1990. It then transitioned to become a public limited company thereby changing its name to Caplin Point Laboratories Limited in 1993 and it got listed on Indian stock exchange with its IPO in 1994.

Caplin pivoted to unexplored markets in Latin America and Francophone Africa from the year 2000. It established its presence and distribution networks beyond retail exports. From 2010 onwards, Caplin expanded its manufacturing footprint and product offerings to include quality injectables, ophthalmic formulations and pre-filled syringes. At the same time its subsidiary Caplin Steriles Limited, developed robust R&D capabilities and obtained global regulatory approvals including USFDA, EUGMP, and ANVISA (Brazil).

Caplin's journey has been one of meteoric rise with strong fundamentals and stakeholder value creation at the core.

HERE WE ARE CONNECTING THE DOTS:

2018 8
Initiated Commercial Shipments to the U.S.

2019 9
America's largest and most trusted financial services company Fidelity invested in Caplin Steriles

2021 10
Commences various expansion projects worth ₹600 crores. USFDA Approval Received for Contract Research Organization (CRO) wing Amaris Clinical.

2022 11
Acquisition of API Plant in Vizag for Backward Integration. ISP Chile Approval Obtained by Amaris Clinical

2023 12
Incorporation of Caplin Steriles USA Inc., to Launch Own Label in the U.S.

2024 13
Production started in Oncology OSD Facility at SIDCO Kakkalur, Chennai

2025 14
Caplin Steriles USA Inc (CSU) commenced operations.
Acquired 5 ANDAs.

2026 15
Acquired 10 ANDAs and obtained multiple USFDA Approvals. Chile Subsidiary began Commercial Operations. Acquired land in Mexico for setting up first manufacturing facility in LatAm





7 **2017**
EU and USFDA Approvals for Liquid Injectable facilities

6 **2014**
Started Operations in Regulated Market and established Injectable Unit

5 **2006**
Entered the Caribbean and Latin America Markets

4 **2005**
Started Outsourcing from China

3 **2001**
Entered Angola with Unique Stock & Sale Model

2 **1994**
Listed on Indian Stock Exchange

1 **1990**
Incorporation

THE TRANSFORMATION OF TRUE SCALE AND SHAPE

Caplin has transformed from a contract manufacturing company to technology and research-led marketing company. It has a diversified product portfolio comprising 5000+ registered products and 650+ pharmaceutical formulations. Its product mix covers 65% of WHO essential drug list. Caplin operates in 36 therapeutic segments and has lately focused towards complex space. Its wide portfolio captures a larger shelf share across pharmacies in emerging markets.

CONTRACT MANUFACTURER

- Market-led Company
- Plain vanilla generic products
- Introducing products that plugged marketplace gaps
- Negative-working capital business
- 2 main geographies 10 countries(Latin America & Francophone Africa)

BECOMING A RESPONSIBLE PHARMA COMPANY

- Technology and research-led marketing Company
- Mix of generics, branded generics and specialty molecules and Injectables
- Launch specialty niche products that Create new markets in varied therapy segments
- Selective use of Credit strategy to increase market share and remain cash surplus
- Extended to Regulated markets like USA with recent entry into Canada, Australia, Mexico and Brazil shortly

DIVERSIFIED PRODUCT PORTFOLIO

- 5,000+ Products registered and 650+ Pharmaceutical formulations
- 36 Therapeutic Segments
- Product mix covers over 65% of WHO essential drug list
- Latest focus towards complex spaces
- Accounts for larger shelf share across pharmacies on account of a widening product basket

CAPLIN GROUP STRUCTURE

DIRECT SUBSIDIARIES

- Caplin Point Far East Ltd
- Caplin Steriles Limited (CSL)
- Caplin One Labs Limited (COL)
- Argus Salud Pharma LLP
- Caplin Point (S) Pte Ltd

STEP-DOWN SUBSIDIARIES (SUBSIDIARIES OF CAPLIN POINT FAR EAST LTD)

- Caplin Point EL Salvador, S.A. DE C.V., El Salvador
- Nuevos Eticos Neo Ethicals S.A, Guatemala
- Neoethicals CIA.LTDA, Ecuador
- Drogueria Saimed de Honduras S.A., Honduras
- Neo Ethicals S.A, Nicaragua
- Caplin Point Laboratories Colombia SAS, Colombia
- Neoethicals Chile SpA
- Triwin Pharma S.A DE C.V

SUBSIDIARY OF CAPLIN STERILES LIMITED

- Caplin Steriles USA Inc., USA

ASSOCIATE OF CAPLIN STERILES LIMITED

- Sunsole Solar Private Limited

PRODUCTS THAT COMPOUND CUSTOMER OUTCOMES

Caplin Point Laboratories Limited has spent 36 years in the pharmaceutical industry and has evolved into a distinct, fast-growing company in India. It commands dominant market positions across Latin America and Francophone Africa and is expanding its business through its subsidiary Caplin Steriles Limited in the US.

The registrations for 650+ formulations and 36 therapeutic segments have roughly increased three fold from 1,600 in FY17 to 5,000+ by FY26. Caplin became a technology and research-led marketing company with a mix of generics, branded generics, and specialty molecules and injectables, launching specialty niche products that create new markets in varied therapy segments.

Caplin operates in generics and branded generics category, manufacturing them at its multiple facilities across Chennai, Puducherry, Kakkalur, Visakhapatnam and outsourcing facilities in India and China. It offers 650+ formulations across 36 therapeutic areas in 15+ dosage forms. The formulations include basic oral tablets and syrups, sterile injectables, ready-to-use (RTU) syringes, ointments, sachets, pre-mixed bags, ophthalmic solutions and the recently added Blow-fill Seal form.

Caplin's product portfolio for emerging markets of Latin America, Francophone Africa and others, comprises of following:

- Tablets and capsules
- Liquid orals and syrups
- Softgel capsules
- Injectables (liquid and lyophilized, pre-filled syringes)
- Ointments, creams, and gels
- Powder for injections
- Suppositories and ovules
- Pre-mix infusion bags
- Inhalers and sprays
- Oral rehydration salts (ORS)
- Sachets

Worldwide Presence across Geographies	Products Registered	Products Under Registration
North America USA*, Mexico*, Canada (3 countries)	65	40
Latin America & Caribbean Guatemala*, Dominican Republic, Nicaragua*, El Salvador*, Peru, Honduras*, Panama, Costa Rica, Venezuela, Paraguay, Ecuador*, Chile*, Bolivia, Colombia, Jamaica, Brazil (16 countries)	4042	424
Africa Mali, Ivory Coast, Senegal, Mauritania, Burkina Faso, Togo, Guinea, Central African Republic, Congo, Benin, Burundi, Nigeria, Cameroon, Chad, Madagascar, South Africa (16 countries)	884	10
Asia Cambodia, Turkmenistan, Laos, Thailand, UAE, Saudi Arabia, Malaysia, Afghanistan, Vietnam, Azerbaijan, Hong Kong, Philippines, China, Uzbekistan (14 countries)	99	84
Others UK, Denmark, Finland, Norway, Sweden, Poland, Australia, New Zealand (8 countries)	4	15
Total	5094	573
Totals : 5,000+ product registrations across 55+ countries; 30000+ distribution touch points in emerging markets; 14,300+ end-user touch points (hospitals, pharmacies, clinics) in the U.S. * Denotes registrations by Subsidiaries		

Caplin Steriles Limited operates in premium injectables and ophthalmic products for the US, EU, and other regulated markets. It has launched 30 products through its Subsidiary and got 59 approvals including the acquired ones. The regulated market products include:

- Lyophilized (freeze-dried) vials
- Pre-mixed infusion bags
- Pre-filled syringes
- Long-acting suspension and emulsion injectables
- Ophthalmic solutions and suspensions

With oncology manufacturing facility at Kakkalur near Chennai, Caplin One Labs Limited entered second year of operations. Its products include:

- Oncology injectables
- 5 oncology ANDAs acquired

Caplin has begun a new segment for developing biosimilars, peptides, and complex biologics for future regulated-market pipeline from this year onwards. Previously, these were outsourced from China-outsourced facilities. It has acquired an API plant in Vizag for the API segment. The products include:

- 90+ APIs developed at R&D scale
- General category APIs (via Vizag plant)
- Oncology APIs

A GLANCE AT PRODUCTS


Sodium Phosphates Injection, USP
Sodium Phosphates Injection, USP
Sodium Phosphates Injection, USP


Cisatracurium Besylate Injection, USP
CAPLIN STERILES


Flufin Tabs


Difluprednate Ophthalmic Emulsion


Labetalol Hydrochloride Injection, USP
100 mg/20 mL
CAPLIN STERILES
NDC 65145-125-01
Labetalol Hydrochloride Injection, USP
200 mg/40 mL
(5 mg/mL)
FOR INTRAVENOUS INJECTION ONLY
CAPLIN STERILES


NDC 65145-151-01
Phytonadione
Injectable Emulsion, USP
10 mg/mL
Discard unused portion.
1 mL Single-Dose Vial
CAPLIN STERILES


Sunitinib
Cápsulas 25 mg


Azitromicina
Polvo para Suspensión Oral
200 mg / 5 mL
30 mL

COMPOUNDING FACILITIES TO COMPOUNDING STRENGTHS

CAPLIN POINT LABORATORIES LIMITED

PUDUCHERRY

CHENGALPATTU

TICEL BIO PARK

VISAKHAPATNAM

CORPORATE OFFICE AND OTHER R& D UNITS: CHENNAI

CAPLIN STERILES LIMITED

CAPLIN ONE LABS LIMITED

FACILITY EXPANSION PROJECTS DURING FY26

Our journey of creating a pharmaceutical manufacturing infrastructure which is scalable, provides backward-forward integration across product stages; meets our growth ambitions as led a consistent capex investments and project delivery. Over the past three years, Caplin has added the following to its annual manufacturing capacity:

- 18 Crores of Softgels in the new Softgel line in Puducherry
- 29 Crores of OSDs and 24 Lakh units of injectables in the Oncology facility in Caplin One Labs Limited, Kakkalur

Not only did we increase the scale, we increased the depth and width with introduction of complex and high-end dosage forms like Pre-filled syringes (Single and Dual chamber) and Ready-to-Use Bags.

Caplin has invested around ₹870 Crores in various expansion projects in the last five years with approximately another ₹1,000 Crores earmarked for the next phase of expansions.

Digital Transformation

Caplin Steriles Limited's patent-pending "Project Visual Integration" has been operational by the first quarter of FY27, which digitally integrates all critical manufacturing processes and tracks them with real-time monitoring. This project is expected to improve manufacturing efficiency, productivity and scalability.

ONGOING PROJECTS

Project Summary

Facility	Location	Product	Target Market	Status	Timeline
Caplin Plant I	CP1, Suthukeny, Puducherry	Lyophilized Injectables and Dual Chamber Syringes	Existing Markets	Completed	Completed
API Facility upgradation	Visakhapatnam, Andhra Pradesh	General API	Existing and Regulated Markets	Completed	Completed
Oncology Facility	SIDCO, Kakkalur (Near Chennai)	OSD & Injectable phase	Existing and Regulated Markets	Completed	Completed
Oncology API Facility	Thervoy SIPCOT, Chennai	Oncology API	Existing and Regulated Markets	Civil activity completed	Q4 FY27
OSD Facility	Puducherry	Oral Solid Dosages	New Market such as Mexico, Brazil, US and EU	Civil activity ongoing at full swing	Q1 FY28
COL Injectable Facility	Gummidipoondi, Chennai	Injectables and Ophthalmic	Regulated Markets	Civil & Structural activity ongoing at full swing	Q1 FY28

Caplin has allocated an enhanced Capex budget of approximately ₹1000 + Crores for the investment projects, with around 50% nearing completion and the balance to be incurred over the next 2–3 years. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and Caplin will remain net cash positive throughout the process.

COMPOUNDING MARKET REACH FAR AND WIDE

Emerging Markets: 30,000+
Distribution Touch Points – Emerging Markets:

U.S. Market: 14,300+ End-user (Hospitals, Pharmacies, and Clinics)

- Products Registered
- Products Under Registration
- * Through Subsidiary



NORTH AMERICA

Country	Products Registered	Products Under Registration
USA*	38	13
Mexico*	17	18
Canada	10	9

LATIN AMERICA & CARIBBEAN

Country	Products Registered	Products Under Registration
Guatemala*	951	64
Dominican Republic	504	119
Nicaragua*	689	17
El Salvador*	468	16
Peru	51	
Honduras*	632	93
Panama	22	14
Costa Rica	81	25
Venezuela	30	7
Paraguay	40	14
Ecuador*	354	
Chile*	109	21
Bolivia	83	16
Colombia*	15	5
Jamaica	12	3
Brazil	1	10

AFRICA

Country	Products Registered	Products Under Registration
Mali	149	
Senegal	50	
Burkina Faso	85	
Guinea	113	
Ivory Coast	45	
Mauritania	38	
Togo	29	
Central African Republic	63	
Congo	63	
Burundi	27	
Cameroon	6	
Madagascar	59	
Benin	53	
Niger	59	
Chad	44	
South Africa	1	10

ASIA

Country	Products Registered	Products Under Registration
Cambodia	25	37
Turkmenistan	51	11
Laos	8	3
Thailand	2	6
UAE	4	3
Saudi Arabia	1	10
Malaysia	2	7
Afghanistan	3	
Vietnam		1
Azerbaijan	1	
Hong Kong	1	1
Philippines		1
China	1	2
Uzbekistan		2

OTHERS

Country	Products Registered	Products Under Registration
UK		3
Denmark		2
Finland		2
Norway		2
Sweden		2
Poland		3
Australia	4	
Newzealand		1

MESSAGE FROM CHAIRMAN

Caplin's Philosophy: Compounding builds the future; Strategic Redundancy protects it.

Dear Shareholders,

I have always believed that just 'Thinking Big' can never deliver the desired results unless you also 'Think Differently'. For decades, at Caplin, we have aimed for the sky while charting an unconventional course. Whether it is building an end-to-end ecosystem that extends from our manufacturing floors straight to the last mile of distribution or catering first to the underserved international markets of Latin America and Africa or focusing on molecules that are niche and involve complex delivery mechanisms. We have never shied away from taking on the hardest challenges first.

However, this is not bravado; we have always coupled ambition with a measured approach. Understanding the complexities to be dealt with in the challenging markets, prepared us better for exploiting the larger, more lucrative markets. This stratagem and roadmap have been the key drivers of our success. As we look back at our journey through Financial Year 2025-26, we find ourselves at the cusp of an exciting expansion. This year, our strategic roadmap is defined by a singular philosophy: Compounding builds the future; Strategic Redundancy protects the future, and we do this without compromise.

"Redundancy" is often mistakenly equated with waste. However, in our vocabulary, it represents deep resilience. "Compounding" is our engine for exponential growth, to expand our pipeline, and scale our geographical presence year after year. But strategic redundancy is the firewall that ensures this compounding can never be interrupted by sudden geopolitical shifts, supply chain shocks, or market disruptions. We are not here to just compete; we are here to create a global platform of delivering healthcare to the world and an ecosystem for sustained growth.

A RECAP

We have successfully delivered another stellar performance in FY2025-26 despite the headwinds of the global macro environment. Since 2020, the global economy has navigated a continuum of crises. While trade tensions dominated boardroom agendas throughout 2025, strategic focus rapidly shifted to geopolitical conflicts in the Middle East by February 2026. The primary impact of these geopolitical frictions on corporate bottom lines will likely manifest in higher raw material and logistics costs due to restricted supplies. It is also expected to play an outsized role in deceleration of the global economy from 3.4% growth in output in 2025 to a projected increase in 3.1%, as per IMF. Indian economy is also expected to be severely affected in FY2026-27 because of the war, after an accelerated GDP growth of 7.7% in the reported financial year. As per the RBI, India's GDP will see a growth of 6.6% in FY2026-27, affected by the war and possible rain deficit on account of El Niño. Hence, Caplin may have to operate in a macro environment that is unsupportive in the year ahead. However, our resilience and redundancies will help us not waver from the growth path.

The global pharmaceutical market is evolving rapidly, projected to reach US$ 2.15 trillion in 2026 as it pivots toward high-value biopharmaceuticals and precision therapies. To absorb structural pressures like patent cliffs and shifting price controls, the global supply chain is undergoing a fundamental geographic realignment. Within this changing landscape, India is executing a strategic transition from a volume-driven manufacturing hub into a value-led scientific ecosystem. Benefiting from global supply chain diversification and record exports of US$ 31.1 billion in FY2025-26, the Indian pharmaceutical industry is expanding its footprint in complex therapeutics, keeping it firmly on track to reach its US$ 130 billion vision by 2030.

With this backdrop, Caplin continued its trajectory of disciplined growth, scaling new operational and financial heights in FY2025-26. Total Revenue surged 13.2% to ₹2,303 Crore (with Revenue from Operations reaching a record ₹2,187 Crore), propelled by continued growth of its Latin American markets and a greater surge in contribution from the American market. Superior operational leverage expanded our profitability across the board, with EBITDA rising 17.9% and PAT growing 20.1% to ₹650 Crore, lifting net margins to 28.2%. Supported by a zero-debt capital structure and robust cash reserves of ₹1,471 Crore, we sustained our heavy commitment to future-ready innovation by committing 4.6% of revenue (₹101 Crore) towards R&D.

EXPANDING THE HORIZON: OUR STRATEGIC DIRECTION

To compound our value, we are stepping firmly into complex, high-entry-barrier delivery platforms. Our robust pipeline is shifting Caplin toward a high-value generic portfolio. Over the next 3 to 5 years, we intend to secure regulatory approvals from high-compliance, regulated markets like the US and Mexico for several key technological vectors such as Ophthalmic and Niche Topicals. Active execution is underway for complex delivery platforms and specialized Ophthalmic Ointments including Blow-Fill-Seal (BFS) technology, Hormone Injections and Hormone Ointments. Our philosophy of strategic redundancy is coming alive in how we deploy assets closer to our consumers, neutralizing supply chain dependencies.

In the midst of current crisis where supply chains are under increasing stress, our stock in the warehouses closer to our customers are the shock absorbers, which few companies of our size could achieve. This effectively models our B2C business on the lines of B2B business and ensures we can mitigate supply chain risks. With warehouses in Chile and Mexico and later in other geographies, this model will hold the key to our success going forward. In the US, we have achieved the same through Caplin Steriles USA Inc, which is expected to be the main stay of our business in that geography.

We are also working to take production closer to our customers. Our Mexican subsidiary has successfully secured land in Toluca and is actively laying the groundwork for a facility to manufacture localized Ointments, Suppositories, and other key therapeutic forms, reinforcing our physical asset base in Latin America. We are also planning to establish a state-of-the-art liquid oral facility in Guatemala. By moving manufacturing inside these geographies, we eliminate long-distance export dependencies from India. This ensures the products are produced right where they are consumed, securing our supply chain while driving localized cost efficiencies.

In our larger geographies, the share of highly predictable institutional tender business is steadily expanding. Concurrently, in promising markets like Chile, we are observing a beautiful dual growth engine where our private market brand equity is growing in perfect tandem with our tender business. In Mexico, product registrations are going on in full swing and this will bear fruit in the coming one to two years. Capitalizing on specialized regulatory frameworks, we are aggressively registering products in Costa Rica by leveraging our prior approvals in stringent markets like the US and EU, collapsing time-to-market.

An ecosystem is only as strong as its constituent pillars. Our clinical research arm, Amaris Clinical, is playing a foundational role in this expansion. Amaris is actively undertaking complex Bio-Equivalence (BE) and Bio-Availability (BA) studies for oncology products, specifically targeting regulated markets for complex

Oral Solid Dosages (OSDs) like Softgels and Tablets. This captive analytical strength gives us total control over our developmental timelines. Furthermore, we are ready to accelerate this momentum through inorganic pathways. We are actively seeking targeted product acquisitions to expand our immediate regulated market portfolio. By acquiring retail distribution networks, we tighten our grip on last-mile access across select markets.

True resilience demands the highest tier of quality compliance. Caplin is currently on the cusp of a major digital transformation. At Caplin Steriles unit in Gummidipoondi, all physical data is being converted to digital data and in few months the entire operations, from shop floor to quality control, will be paperless. This will further progress to visual learning and visual intelligence where we deploy remote-managed, Artificial Intelligence-powered cameras across our shop floors to revolutionize learning, automate compliance monitoring, and visually enforce SOP (Standard Operating Procedure) adherence. This real-time, automated oversight guarantees that no human error is missed out from being identified and remedied, ensuring that the reputation of Caplin's quality remains pristine across every global agency. We take the same energy, aim for the sky with thorough preparation, for executing our plans across all areas and hence, success becomes inevitable. For achieving this level of execution, we have invested heavily in building a team of committed and purposeful employees. This has been possible through our relentless focus on fostering a work culture that promotes ownership, transparency, empowerment and learning-orientation.

IN CONCLUSION

We believe strongly that there was never a night or a problem that could defeat sunshine or hope. Nevertheless, we rest not only on hope – we have built a process of wealth creation that rests on the four pillars of Integrity, Quality, Safety, and Productivity. Without these pillars, success can never be sustained in this industry. Integrating the unstoppable force of compounding growth with the defensive shield of strategic redundancy ensures that Caplin remains unshakeable. I extend my deepest gratitude to our customers, our staff, our vendor partners, our bankers, and you, our valued shareholders, for walking this unconventional path with us. We are not just building for tomorrow; we are securing it.

Warm regards,
C.C. Paarthipan
Chairman
Caplin Point Laboratories Limited

MESSAGE FROM MR. ASHOK PARTHEEBAN

VICE-CHAIRMAN

On LATAM & Rest of World Markets

"A society grows great when old men plant trees in whose shade they shall never sit."

– Greek proverb

Last year, in this same letter, I admitted to an argument I have with myself. My logical mind asked how much longer I intended to bore you with the "bottom of the pyramid" slogan. My irrational mind insisted that we are one of the few blessed companies that carries its higher calling from the top of the organization to the bottom. A year on, the irrational mind has won the argument again — and this time it has arrived with evidence.

I also wrote last year that once a company's roots run deep enough in a geography, the platform it has laid stops being a platform and becomes a vehicle: you simply keep adding products to it. Roots was the right word, and it is the reason for the proverb above. This was a year of roots. Almost everything of consequence we did in Latin America — land purchased in Mexico, an INVIMA clearance won in Puducherry, a technology filed in the region for the first time by any Indian company — has been paid for in this year's accounts and will earn its return in the years that follow. I would far rather report it in that order than the reverse.

The greatest risk to a business that has delivered year after year is not competition but fatigue, and our defence against it remains comparison.

We are told these days that comparison steals happiness; we have kept it anyway, because measuring ourselves against the largest companies operating in Latin America is what keeps our risks calculated and our action relentless.

The thread I left hanging last year was Mexico. The land has been purchased, in the city of Toluca. The landfilling and drainage works are under way, our drawings have been approved, and construction is expected to begin by the middle of 2027. Mexico rewards companies willing to be present in the country rather than merely sell into it. A tender that is closed to an importer is open to a manufacturer, and we would rather own that distinction than argue with it.

We were also waiting on INVIMA last year to inspect our sterile plant in Puducherry and our oncology facilities. The sterile plant is now approved by INVIMA. Caplin One Labs, our oncology plant, closed its inspection with a single minor observation and awaits its certification, which we expect in August and which will cover both steriles and oral solids. Thirty-five dossiers have already been filed across Colombia, Chile and Mexico, and we are completing the gap documents for the remainder of the roughly eighty we hold ready — in lyophilised, emulsion, suspension, biotech and prefilled syringe forms.

Among these, the dual chamber prefilled syringe is the one I would ask you to watch. Dossiers have been filed in Central America and in Ecuador, and will be filed across our remaining markets before the end of this calendar year. These filings are directly empowered by our manufacturing backbone in India, specifically the scale-up of dedicated capabilities at our Puducherry plant. No Indian company has brought this technology to Latin America before us. A capability of that kind is not a product; it is a door, and it stays open for years.

In our established markets the work is quieter and it compounds. In Chile, where we set up our own distribution only last year, we now hold twenty-four running contracts that will contribute $10 million in FY27 — against the fourteen products and $6.2 million I reported twelve months ago. We are also entering the Chilean private market in earnest with

thirty-five oral solid dosages, which takes us beyond the tender channel we have long relied upon, and we have submitted eight oncology dossiers for registration. Our confidence in this specialized pipeline is significantly bolstered by Amaris Clinical, our captive research arm, which actively manages the complex clinical studies necessary to accelerate these registrations. Six products were exported to Colombia during the year, and Central America — our oldest ground in the region — grew 7%. Our customers never asked us for a wider basket; they asked for a reliable one. The wider basket followed.

Our Chairman's second innings in China — what we have come to call China 2.0 — has moved from intent to contract. We have partnered with leading manufacturing units in China which have USFDA and multiple other regulatory approvals, for access to thirty oral solid dosage licences and sixteen injectables. The sixteen are worth pausing on. Every one of them is already approved in the United Kingdom and the European Union, which means each enters Chile, Mexico and Colombia through the simplified registration route rather than the full one. We are acquiring not merely the products, but the years it would ordinarily take us to register them. The logic itself has not changed: an asset-light route to products and technologies we cannot yet make in India, landing on a distribution platform whose cost we have long since absorbed. In true alignment with our Chairman's philosophy of 'Strategic Redundancy', this approach ensures profound supply chain resilience and rapid portfolio expansion without overburdening our internal R&D. Forty-six products on a platform already built is not a trial; it is a portfolio.

All of this arrives at a set of numbers. Total LATAM sales closed at $155 million against $150 million last year. Gross margin rose from 67% to 71%, and PBT from 42% to 45%. I would draw your attention to the second sentence rather than the first. We could have brought a larger top line this year. We chose instead to sell better products at better prices, and to spend the difference on land, plants, filings and inspections that contribute nothing whatsoever to this year's revenue. That is what the proverb at the top of this letter is doing there.

Part of the coming year is already written. Tender wins in Guatemala, El Salvador and Nicaragua alone come to some $24 million, with Chile's $9.5 million on top of that, against the $18 million I was able to report to you last year. Mexico will take shape on the ground, the dual chamber filings will complete across the region, and the oncology certification will open a category we have so far only prepared for.

What still brings a spring to our step in the morning is not the list above but the distance between it and the things we want and do not yet have. We have made a friend of that reflection, because it is the only reliable source of progress I know. My logical mind will raise the same objection next year. It will lose again. Until then we will go on planting trees in whose shade we may never sit, and we are in no hurry to stop.

Sincerely,
Ashok Partheeban
Vice-Chairman
Caplin Point Laboratories Limited

MESSAGE FROM MR. VIVEK PARTHEEBAN

VICE-CHAIRMAN
On US & Other Regulated Markets

MESSAGE FROM THE VICE-CHAIRMAN

The year under review has been another year of steady progress for the Caplin Group. More importantly, it has reinforced the principles that have guided us over the years — consistency, resilience, disciplined execution and a willingness to invest ahead of the curve.

Caplin has always sought to build differently. We have stayed close to our customers, developed capabilities across the pharmaceutical value chain, entered markets selectively and remained disciplined in the deployment of capital. This has allowed us to grow consistently while retaining the financial strength and flexibility to invest for the future.

Our focus today is not simply on the next year of growth. It is on building a company that will be stronger, more integrated and more resilient a decade from now.

STRENGTHENING THE FOUNDATIONS

Our Emerging Markets business remains at the heart of Caplin. Our presence in Latin America, built over 2 decades, is supported by deep local knowledge, regulatory strength, manufacturing capabilities, distribution expertise with the necessary infrastructure and a growing product portfolio.

We continue to deepen this franchise by increasing our presence in newer and much larger markets such as Mexico and Chile, expanding into higher-value segments such as Oncology and CNS, and introducing differentiated products including Pre-Filled Syringes and Niche Softgels.

Our "China 2.0" strategy is another example of how we are broadening our portfolio. By partnering with companies that have products approved in the US and Europe, we can combine their product capabilities with Caplin's established market infrastructure and local knowledge. This gives us access to a wider range of products while allowing us to remain selective in our capital allocation.

An important philosophy behind these investments is **"keeping products closer to the customer."** Our growing local presence in Latin America, the planned manufacturing facility in Mexico and our investments in distribution and quality infrastructure are all intended to make us more responsive to the markets we serve.

BUILDING A MEANINGFUL REGULATED MARKETS BUSINESS

While continuing to deepen and widen our presence at LatAm, Caplin has continued to strengthen its position in the United States and other Regulated Markets.

What began with the development of a high-quality sterile manufacturing and R&D platform has evolved into a broader business spanning complex injectables, ophthalmics, IV Bags, Pre-Filled Syringes, suspensions, emulsions and other specialised dosage forms.

We are deliberately moving towards greater complexity and differentiation. Investments in Pre-Filled Syringes and Cartridges, Blow-Fill-Seal technology, specialised ophthalmic products and other complex dosage forms are intended to create capabilities that can support sustainable growth over the long term.

Our US front-end, Caplin Steriles USA Inc., represents another important step in this evolution. What began as an initiative to establish our own



commercial presence has developed into a profitable and growing platform. We continue to grow the front end while at the same time deepening our partnerships with the B2B customers.

Staying true to our past patterns, we see opportunities to develop our own distribution infrastructure in the United States and Mexico, as well as specialised commercial platforms in areas such as Unit Dose Ophthalmics, Inhalations, Oncology products and selected Oral Solid products.

We are not simply trying to sell more of the products we make; we are progressively building greater control over where, how and to whom those products are delivered.

MANUFACTURING FOR THE FUTURE

As our businesses evolve, so must our manufacturing and distribution capabilities.

Our current investment program is much more than just adding capacity. We are investing in the architecture of the manufacturing and distribution platform itself — automation, digitalisation, real-time monitoring, advanced inspection and stronger quality systems.

Our Visual Integration initiative is an important part of this journey. By connecting critical processes and converting selected legacy systems into automated and digitally monitored processes, we aim to make quality and compliance increasingly embedded in the way we manufacture and distribute our products.

The same philosophy is being incorporated into our new facilities from inception itself. We want the plants we build today to be capable of meeting not only today's requirements, but the standards and technologies of tomorrow.

For us, automation is not merely about productivity. It is about building compliance into the process itself.

RESILIENCE THROUGH INTEGRATION

We are also investing in greater control over our supply chain.

The pharmaceutical industry has demonstrated the importance of reliable access to critical inputs, and we believe backward integration will increasingly become a source of competitive advantage. Our API facilities in Visakhapatnam and Thervoykandigai are being developed to progressively increase our ability to manufacture critical APIs for our own products.

The objective is not to eliminate external sourcing, but to create greater control, qualified sources of supply and resilience for strategically important products.

This philosophy extends to our broader manufacturing investments. Our ongoing capital program is designed simultaneously to increase capacity, broaden our product portfolio, introduce newer technologies and strengthen vertical integration.

We are making these investments from a position of financial strength, funding our expansion through internal accruals while maintaining a debt-free and net cash positive balance sheet.

PREPARING FOR A MORE DISTRIBUTED FUTURE

We believe the pharmaceutical supply chain of the future will be increasingly geographically diversified.

Our investment in Mexico is an important part of preparing for that future. With industrial land already acquired, our plans for a manufacturing facility are intended initially to focus on products where proximity to customers across North and South America can create meaningful logistical and commercial advantages.

Together with our early-stage plans for our own distribution infrastructure in the United States and Mexico, these initiatives represent a gradual evolution towards a more geographically distributed supply chain.

We do not intend to build infrastructure simply for the sake of scale. Each investment must ultimately improve customer service, strengthen resilience or create sustainable economic value.

LOOKING AHEAD

Caplin today is broader and more capable than it was a decade ago. We have a strong Emerging Markets franchise, a growing presence in the United States and other Regulated Markets, an expanding manufacturing footprint, deeper R&D capabilities and an increasingly integrated supply chain.

Our ambition now is to make these capabilities work together even more effectively.

We will continue to remain close to our customers while becoming more geographically diversified. We will increase our presence in complex and differentiated products while retaining the discipline that has served us well. We will use technology to strengthen productivity and compliance, and continue building greater control and resilience across our supply chain.

Above all, we intend to remain patient and disciplined.

The most valuable businesses are not built by pursuing every opportunity. They are built by identifying the right opportunities, investing consistently, executing well and allowing capabilities to compound over time.

That philosophy has guided Caplin through its journey so far. It will continue to guide us as we build the next phase of Caplin.

I am confident that the investments we are making today — in our people, products, technology, manufacturing, markets and supply chain — will strengthen Caplin's ability to create sustainable value for all our stakeholders for many years to come.

I would like to thank our employees for their commitment and dedication, our customers and partners for their continued trust, and our shareholders for their confidence in Caplin.

Sincerely,

Vivek Partheeban
Vice-Chairman
Caplin Point Laboratories Limited

MESSAGE FROM MANAGING DIRECTOR

Dear Shareholders,

It is with great satisfaction and immense pleasure that I present to you an overview of another stellar year of Caplin's performance, operational highlights, and key developments. FY2025-26 has seen us continue to excel and surpass past benchmarks, delivering bigger and better outcomes for all our stakeholders.

Once again, we beat the previous year's record performance and crossed the ₹2,000 Crore Operational Revenue milestone. The challenging macro environment – marked by regional conflicts, geopolitical friction, trade restrictions, and evolving regulatory barriers – failed to make a dent in our progress. Our margins expanded as profits grew at an accelerated rate due to operating leverage and our relentless focus on execution efficiency. This operational strength is reflected in our fast-growing cash and cash equivalents.

Our market-wise revenue mix reflected strategic gains in high-compliance markets. The contribution from the US & other Regulated markets expanded from 18% to 21%, driven by our focused execution in launching owned labels and direct front-end distribution. Our core Latin American markets maintained their dominant share, contributing 76% to revenues, while the African region accounted for 3%.

EMERGING MARKETS – CONSOLIDATING STRENGTHS & EXPANDING REACH

Our Emerging Markets business continues to be a rock-solid growth engine, powered by our long-established distribution moat and deep market penetration. In LATAM, we maintained our core revenue share while expanding our portfolio into differentiated formulations. We also saw increased traction across institutional tender channels in our larger LATAM markets. We strengthened our regional presence through targeted market expansion, new therapeutic entry, and physical asset localization.

We have received approvals for 25 products and built an aggressive pipeline of 120+ products to be filed over the next 18 months in Mexico.

Operations through our local subsidiary and warehouse advanced rapidly, establishing Chile as a major growth engine. Caplin now holds 135+ product licenses in Chile with several others under review. With the growing tender business and private market expansion, Chile is on track to become one of our Top 5 markets within a few years. We filed internally developed GLP-1 products across Central American markets, with revenue generation planned post-patent expirations.

We launched brand marketing in the Central Nervous System (CNS) segment across 3 LATAM markets, with plans to expand into 2 more in 2027. We also introduced a line of Branded Pre-Filled Syringes (PFS) in LATAM.

We gained access to 130+ approved dossiers from our “China 2.0” partners and completed our first Biosimilar product filing in Central America.

We secured key institutional tender wins across the region that form a committed order pipeline for us in the coming quarters. In Chile the tender wins were valued US$ 10 million, in Mexico US$ 4 million and the Central America geography accumulated nearly US$ 25 million.



We reached a total of 59 approved ANDAs in the US with a net addition of 25 ANDAs in FY2025-26, which comprised 10 from internal sources and 15 from tactical third-party ANDA acquisitions. We received notable first-cycle approvals, including our first Suspension Injectable, an Ophthalmic Emulsion, and an Injectable Emulsion.

US AND REGULATED MARKETS – SCALING CAPABILITIES & FRONT-END SUCCESS

With the US as the key regulated market for Caplin, Caplin Steriles made major operational strides in FY2025-26. Caplin has also made meaningful progress in growing its presence and penetration in other non-US regulated markets of EU, Canada, Australia, Saudi Arabia, UAE and others.

Caplin Steriles launched 30 products, built partnerships with major wholesalers and 30+ direct hospital buyers, and expanded its end-user footprint by 2.5 times over last year in the US market.

We filed 54 products (32 already approved) across non-US regulated markets including Canada, EU, Australia, Mexico, Brazil, South Africa, Saudi Arabia, and UAE. Over 50 additional filings are planned across these geographies over the next 18 months to drive meaningful revenue expansion.

Caplin received renewed EU-GMP certification after receiving NIL critical observations during the reaudit in October 2025 and also passed a Saudi FDA audit in December 2025.

RESEARCH & DEVELOPMENT AND CRO CAPABILITIES

Innovation remains the fundamental driver of our product differentiation. In FY2025-26, our total R&D spend reached a record ₹101 Crore, spread across our 5 state-of-the-art R&D centres. The total number of filings, approvals and future pipeline increased from 51, 38 and 40+ respectively at the end of FY2024-25 to 65, 59 and 55+ by the end of FY2025-26.

Development is nearing completion for our initial Unit Dose Ophthalmic and Sterile Inhalation products, supported by a robust internal pipeline of over 14 BFS formulations. Our captive clinical research organization, Amaris Clinical, is scaling its trial capacity from 2 to 3 clinical studies per month.

PROJECTS AND MANUFACTURING EXPANSIONS

FY2025-26 was a crucial year for execution across our capital expenditure projects.

- Vizag API facility received its operational manufacturing license and completed validation for 4 Active Pharmaceutical Ingredients (APIs). Validations for an additional 12 APIs are on track for completion before the end of calendar year 2026, advancing our backward integration objectives.
- Our COL Injectable facility at Gummidipoondi for injectables and ophthalmics is progressing on schedule for completion by Q1 FY2027-28.
- Our dedicated Oncology API facility at Thervoy Kandigai is moving in full swing toward its planned Q4 FY2026-27 completion timeline.
- We have made plans to establish a separate retail arm in the US, focused on our Ophthalmic products pipeline, Unit Dose Ophthalmics and Inhalations pipeline, in addition to Oral Solid products licensed from recent partnerships with Chinese companies with approved ANDAs.

ESG INITIATIVES AND HUMAN CAPITAL

Our growth trajectory remains closely aligned with sustainable operating practices and community welfare. Following the completion of our state-of-the-art Hospital-cum-Diagnostic Center at Gummidipoondi, Tamil Nadu, the facility fully commenced operations under the aegis of the Caplin Point Meenakshi CSR Trust, delivering high-quality diagnostic and medical care to underserved rural communities.

Our workforce remains our most critical execution pillar. Through our digital platform, we have scaled targeted upskilling programs to prepare our technical teams for automated, digital shop-floor operations. We continue to advance social equity and operational discipline by actively recruiting and upskilling rural women professionals for core manufacturing and laboratory roles, building a resilient workforce with low turnover rates.

LOOKING AHEAD

As we move into FY2026-27, Caplin is well-positioned to capitalize on its expanded capacity, technological investments, and deeper market access. Our Emerging Markets business will continue to consolidate its market share through distribution strength, while our Regulated Markets division expands its own-label presence and complex product offerings. With our backward integration program coming online, entry into complex platforms like BFS and Pre-Filled Syringes, and a zero-debt balance sheet, we possess the operational resilience needed to navigate any challenges that we may face.

I express my sincere gratitude to our board, partners, and shareholders for their continued trust and support for the management team and our employees in our growth journey.

Sincerely,
Dr. Sridhar Ganesan
Managing Director
Caplin Point Laboratories Limited

GOVERNANCE, ETHICS, AND COMPLIANCE

The Caplin leadership is committed to ethical, accountable and compliant business practices. Independent Boards and Executive Leadership teams at each group company anchor the governance, enabling clear separation of oversight and management responsibilities.

A strong governance framework of policies and controls leads to ethical practices, risk management and transparent decision-making. Caplin's everyday operational activities and strategic endeavors reflect integrity, fairness and responsible approach, leading to resilience and excellence in what we do. Our governance policies and practices align to the shareholders' interests, safeguarding their rights and ensuring value addition.

CORPORATE GOVERNANCE AND PROFESSIONAL BOARD SUPERVISION

At Caplin, we recognize that the long-term success is shaped by sustainable and effective governance. We have therefore designed a comprehensive governance framework aligned with regulatory compliance and our sustainability goals. The framework supports transparent and responsible decision making, upholding trust of stakeholders and maximizing value creation.

Board of Directors ensure adherence of policies and practices and actively ensure compliance. The directors periodically meet and engage with the stakeholders and review the progress and undertake corrective measures as required. The chairman of the group focuses on strategic direction of the group and provides unified strategic leadership, keeping his executive responsibilities separate. The CEOs/MDs of the Group companies look after the operational activities of their respective units. Role clarity at Caplin enhances governance, ensuring power balance.

BOARD COMPOSITION AND DIVERSITY

The Boards of Directors of Caplin Point Laboratories Limited, Caplin Steriles Limited, and Caplin One Labs Limited are diverse as per policy, exhibiting an inclusive and representative leadership.

Directors are selected based on criteria such as qualifications, expertise, experience, integrity and diversity by Nomination and Remuneration Committee (NRC). The Committee ensures selection aligned with strategic needs and governance expectations.

BOARD COMPOSITION - CAPLIN STERILES LIMITED

1. Mr. C C Paarthipan - Chairman
2. Mr. Vivek Partheeban - Non-executive Director
3. Mr. R. Viswanathan - Independent Director
4. Dr. Sridhar Ganesan - Whole Time Director
5. Dr. K C John - Independent Director
6. Dr. C K Gariyali - Independent Director
7. Mr. Prem Pavoor - Nominee Director
8. Dr. Keten Patel - Nominee Director

BOARD COMPOSITION- CAPLIN ONE LABS LIMITED

1. Mr. C C Paarthipan - Director
2. Mr. Vivek Partheeban - Director
3. Dr. Sridhar Ganesan - Director
4. Mr. Sivakumar - Whole-time Director
5. Mr. Singaram Deenadayalan - Independent Director
6. Mr. Damodaran Sathyanarayanan - Independent Director

COMMITTEES' DETAILS

Special committees have been constituted by Caplin to address key functional areas and for all-round governance in accordance with Companies Act, 2013 and SEBI Listing Regulations. Caplin Point Laboratories Limited has formed five committees - Audit Committee, Risk Management Committee, Nomination and Remuneration Committee, Stakeholders' Relationship Committee, CSR (Corporate Social Responsibility) Committees.

- Audit committee acts as a link between the management, the statutory auditors, internal auditors and the Board. It oversees financial reporting integrity, reviews financial statements, and monitors financial controls. The audit committee met four times during FY26 on May 15, 2025, August 7, 2025, November 5, 2025, and February 5, 2026.

- Nomination and Remuneration Committee identifies and recommends aspirants for Board and senior management positions and determines remuneration policy for them. It met four times on May 15, 2025, August 7, 2025, November 5, 2025, and December 29, 2025.

- Stakeholder Relationship Committee handles investor and shareholder grievances, looks after share transfers, dividend payments, and other shareholder-service matters. It is headed by chairman and Company Secretary remained present at AGM held on September 22, 2025. The Committee received 51 complaints and resolved 45 out of them during FY26. It ensures communication with stakeholders through result publication, website and ESG profile, presentations to investors, analysts and facility visits. The committee met once on February 05, 2026.

- Risk Management Committee reviews the Enterprise Risk Management (ERM) framework, tracks regulatory, competition, supply chain, cyber, and geopolitical risks, and reports risk mitigation progress to the Board (meets periodically with CFO and Independent Directors). The committee met twice on August 07, 2025 and February 05, 2026.
- Corporate Social Responsibility Committee, constituted in accordance with section 135 of the Companies Act 2013 and CSR Rules 2014, formulates and monitors the CSR policy, approves CSR projects (like the Caplin Point Meenakshi Hospital), and ensures CSR spending aligns with statutory requirements. The committee met four times during FY26 on May 15, 2025, August 7, 2025, November 5, 2025, and February 5, 2026.

In parallel, Caplin Steriles Limited has three committees – Audit Committee, Nomination and Remuneration Committee and CSR Committee to oversee the functions.

ESG GOVERNANCE FRAMEWORK

Caplin Group's ESG governance framework integrates environmental stewardship, social responsibility and ethical governance into every operational and strategic aspect. The framework, supported by Board Oversight and cross-functional leadership, enables performance monitoring, risk management, regulatory compliance and responsible decision making. We embed ESG principles across manufacturing, R&D, supply chains, quality assurance and stakeholder engagement, enhancing resilience, innovation, value creation and healthcare outcomes.

The Group follows a top-down approach for ESG framework wherein an independent Board committee from each group company provides oversight of ESG strategy and performance. The Board of Directors guides the ESG strategy through designated Board Committees with defined mandates. Unit specialists at Caplin level collaboratively develop strategies, implement initiatives and track the performance. The CSR committee meet quarterly to guide and monitor the initiatives.

ETHICS AND COMPLIANCE

Caplin Group anchors its business on the principles of integrity, trust and accountability, shaping the ethical foundation of the group companies. We underscore regulatory compliance, fairness and transparency for consistent conduct to maintain the trust of various stakeholders. We adopt zero-tolerance approach to unethical behavior and avail the whistleblower mechanisms to point out anomalies.

Caplin implements Environmental, Health, Safety, and Sustainability (EHS&S) for responsible manufacturing practices, occupational health and safety, risk management, and environmental conservation. The organization has also aligned with Prevention of sexual harassment (POSH) Policy to ensure a safe, respectful workplace for women.

ESG STRATEGY, GOALS AND PROGRESS

Caplin aims to promote accessible and affordable healthcare for people across the globe with environmentally sustainable practices. As a responsible pharmaceutical company, it works to address challenges affecting the environment, society, and patients. We define goals with timelines and targets, processes, and the responsible team members. Caplin's web-based ESG disclosure platform tracks the progress of various targets.

OUR ESG FRAMEWORK

Environment	Society	Customers
Climate Change – Scope 1, 2&3 emissions, Renewable Electricity	Diversity, Equity, and Inclusion	Product Launches – Complex Generics and injectables in regulated market, Biosimilars, APIs
Water - water recycling or reuse, positivity	Employee Engagement, Employee Well-being and Safety	Patients Assistance Programs, Local Manufacturing
Waste - Zero Waste to Landfill, circular economy,	Social Impact - CSR Programs and Beneficiaries, Hospital-cum-diagnostic center operationalized	Ensure zero observation in regulatory audits
Bio Diversity - Assessment	Supplier Sustainability – Assessment and ESG Screening of Suppliers	Rigorous Quality Compliance

BOARD OF DIRECTORS

MR. C. C. PAARTHIPAN
CHAIRMAN

Mr. Paarthipan is a first-generation Indian entrepreneur, recognized for expanding affordable pharmaceuticals in global emerging markets. He has more than 4 decades of rich experience in the pharmaceutical industry. He started his professional journey in the 80's as a medical representative. Over the decades, he has scaled multiple heights to bring Caplin to its present position. Visionary with strong decision making and absolute commitment, choosing unique opportunities and braving big challenges, he has taken Caplin's products to different corners of the globe, catering predominantly to the market's bottom of the pyramid (BoP) part with a combination of good quality and affordable products. As Chairman of the Board, he continues to actively head the organization in its multi-pronged growth journey.

MR. ASHOK PARTHEEBAN
VICE CHAIRMAN

Mr. Ashok Partheeban began his career as Business Head – LATAM at Caplin in 2002. Throughout his tenure, he has demonstrated a strong commitment to effective leadership and the adoption of agile methodologies. He is an experienced business leader with over twenty years of expertise in the pharmaceutical industry. He has spearheaded business and marketing operations across the LATAM region, driving growth and market expansion. He has been dedicated to delivering healthcare solutions with a global impact, aligning strategic initiatives with Caplin's core values of excellence and adaptability. His primary focus is on driving growth while cultivating a collaborative environment that encourages diverse perspectives and collective success.

MR. VIVEK PARTHEEBAN
VICE CHAIRMAN

Mr. Vivek Partheeban is a seasoned business leader with over twenty years of experience in the pharmaceutical industry. He has been instrumental in driving business growth, operational efficiency, and strategic expansion. He oversees the U.S. business operations, focusing on market penetration and regulatory compliance. Prior to his leadership role at the corporate headquarters, Vivek headed the outsourcing operations of Caplin in China, where he played a key role in optimizing supply chain efficiency and strengthening Caplin's global sourcing capabilities.

DR. SRIDHAR GANESAN
MANAGING DIRECTOR

Dr. Sridhar Ganesan comes with more than 40 years of experience in varied global leadership roles in the Pharmaceutical Industry. He has demonstrated his prudent skills in roles including but not limited to Profit Center Management; Global Marketing; Middle East and African engagement; international collaborative and cooperative relationship building; new pharmaceutical project planning & implementation; production; new product development; Quality Assurance; and Factory Management. Currently he is Managing Director of Caplin Point Laboratories Limited and spearheads Caplin's rapid growth with a global footprint. Previously, he has held leadership positions in several international assignments and has expertise not only in the industry but also in unique needs of developing countries in South Asia, Middle East and Africa. The Government of India's Pharmaceutical Export Promotion Council of India has designated him as an "Honorary Expert"

DR. R. NAGENDRAN
INDEPENDENT DIRECTOR

Dr R Nagendran has a Ph.D in Ecology & Ethology and an M.Sc in Zoology. He is a Former Expert Member of the National Green Tribunal and former Head of Department of Environmental Science in St. Joseph's College, Bangalore. He is a qualified ISO Environmental Auditor, approved by Environmental Auditors Registration Association (EARA) and ANSIRAB-QSD, USA. He had taught Environmental Science in various prestigious institutions like Anna University. His areas of expertise include Environmental Management, Sustainability and Policy advisory among others.

MR. S. DEENADAYALAN
INDEPENDENT DIRECTOR

Mr S Deenadayalan holds a Post Graduate degree in Social Work from the Madras School of Social Work and Graduate degree in Sociology from Annamalai University. He has extensively worked and mentored individuals, enabling them to become successful professionals. More than 30,000 municipal school students have been benefitted by his idealistic model. He is Founder of CEO (Customer, Employees, Owner or Organisation) group. His areas of expertise include entrepreneurship, leadership mentoring, Human Resource Management among others.

MR. R. VIJAYARAGHAVAN
INDEPENDENT DIRECTOR

Mr. R Vijayaraghavan is a Senior Partner at M/s. Subbaraya Aiyar, Padmanabhan & Ramamani, bringing over 35 years of expertise in taxation, consulting, and litigation across India. He represents major corporate groups, particularly in South India, on a wide range of direct tax matters, specializing in tax planning, taxation of non-residents, joint ventures, double taxation avoidance agreements (DTAA), and transfer pricing. As a trusted advisor on mergers and acquisitions, he guides clients through complex tax planning and implementation processes. His consulting practice also extends to Sales Tax, Excise Duty, and Service Tax, and he frequently acts as an Arbitrator providing insights on contracts, conveyancing, and agreements.

DR. K C JOHN
INDEPENDENT DIRECTOR

Adept at simultaneously balancing several successful careers in sustainable development, technology, innovation, and entrepreneurship for over 35 years, Dr. K.C. John navigates actively as an educator, executive coach, and entrepreneur while serving as an Independent Director on the boards of pre- and post-IPO companies in India. Over the past two decades, he has raised funding, nurtured, and scaled startup technology ventures in mobile computing, digital communications, and healthcare technology, successfully exiting three startups through high-multiple trade sales to strategic investors and leading their post-merger integrations. Notably, he also scaled up operations in India for digital communication leader QUALCOMM. Beyond his corporate achievements, Dr. John collaborated with global visionaries to conceptualize Sustainable Development Programs at the Ford Foundation and the World Bank, playing an instrumental role in nucleating human-centered design programs across South and Southeast Asia. Throughout his career, Dr. John has specialized in incubating innovative ideas into viable businesses across both commercial and impact sectors by fostering strong entrepreneurial leadership.

MS. SUSAN MATHEW
INDEPENDENT DIRECTOR

Ms. Susan Mathew, I.A.S. (Retd.), is a distinguished former civil servant with over 36 years of leadership across the energy, urban development, infrastructure, and health sectors. Her landmark roles include serving as a Collector of Madras, Director of Tourism, Special Secretary – Health & Family Welfare Department, Secretary – Energy Department, Chairman of the Tamil Nadu Electricity Board, Secretary – Commercial Taxes & Registration Department, Chairman & Managing Director of Tamil Nadu Power Finance & Infrastructure Development Corporation, Chairman of Tamil Nadu Women's Development Corporation, and Additional Chief Secretary and Vice Chairman of the Chennai Metropolitan Development Authority (CMDA).

A Lester Pearson Fellow with advanced studies from Carleton and Ottawa universities, she has represented India at numerous international forums. Post-retirement, she has served as an Advisor to the UPSC and continues to hold board positions in the corporate and development sectors, including serving as an Independent Director and a long-standing council member of CMC Vellore.

CORPORATE INFORMATION

BOARD OF DIRECTORS

- **Mr. C C Paarthipan**
  Chairman
- **Mr. Ashok Partheeban**
  Vice Chairman
- **Mr. Vivek Partheeban**
  Vice Chairman
- **Dr. Sridhar Ganesan**
  Managing Director
- **Dr. R Nagendran**
  Independent Director
- **Mr. S Deenadayalan**
  Independent Director
- **Mr. R Vijayaraghavan**
  Independent Director
- **Dr. K C John**
  Independent Director
- **Ms. Susan Mathew**
  Independent Director

CHIEF FINANCIAL OFFICER

- Mr. D Muralidharan (inducted as Additional Whole-Time Director on August 12, 2026)

GENERAL COUNSEL & COMPANY SECRETARY

- Mr. Venkatram G

STATUTORY AUDITORS

- M/s. Brahmayya & Co.
  Chartered Accountants, Chennai

SECRETARIAL AUDITORS

- M/s. Alagar & Associates LLP
  Practising Company Secretaries, Chennai

BANKERS

- CSB Bank Ltd.
- HDFC Bank Ltd.
- ICICI Bank Ltd.
- Kotak Mahindra Bank Ltd.

REGISTERED & CORPORATE OFFICE

3rd Floor, "Ashvich Towers", No.3, Developed Plots Industrial Estate, Perungudi, Chennai - 600 096.

FACILITIES

Puducherry
85/3, Suthukeny Village, Mannadipet Commune Panchayat, Puducherry - 605 502.

Gummidipoondi (Caplin Steriles Ltd.)
Survey No.895 & 897, Sirupuzhalpettai, Gummidipoondi Taluk, Thiruvallur, Tamil Nadu - 601201.

Kakkalur (Caplin One Labs Ltd.)
G44, G45, G46 in SIDCO Industrial Estate, Kakkalur, Thiruvallur, Tamil Nadu 602003.

Visakhapatnam
Plot No. 28H & 28I. AP-SEZ, Denotified Area, Atchutapuram Rambilli Mandal, Anakapalli District Andhra Pradesh -531011.

RESEARCH & DEVELOPMENT (R&D)

Amaris Clinical CRO
Plot No.44, 8th Avenue Domestic Tariff Area, Mahindra World City, Chengalpattu Taluk, Chengalpattu Tamil Nadu - 603 004.

Perungudi R&D (Caplin Steriles Limited)
Ashvich Tower, 2nd Floor, No 3, Developed Plots Industrial Estate, Perungudi, Chennai, Tamil Nadu - 600 096.

Perungudi R&D (Caplin Point Laboratories Limited)
Ashvich Towers, No. 3, 1st Floor, Developed Plots, Industrial Estates, Perungudi, Chennai, Tamil Nadu - 600 096.

Hyderabad R&D
4th Floor, Plot No. 95 & 96, Road no.9, ALEAP Industrial Estates, Gajularamarm Village, Qutbullapur Mandal, Hyderabad - 500 090.

TICEL Park R&D
Module no.307, 308 and 408, 3rd Floor, Ticel Park, Phase II, CSIR Road, Taramani, Chennai, Tamil Nadu - 600 113.

CAPLIN POINT MEENAKSHI HOSPITAL

No. 19, Chinnapuliyur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Tamil Nadu - 601 201.

STOCK EXCHANGES WHERE SHARES OF THE COMPANY ARE LISTED

National Stock Exchange of India Limited (NSE) - CAPLIPOINT
BSE Limited (BSE) - 524742

Registrar and Share Transfer Agent
M/s. Integrated Registry Management Services Private Limited
Unit: Caplin Point Laboratories Ltd.
IInd Floor, “Kences Towers”, No.1 Ramakrishna Street, North Usman Road, T Nagar, Chennai - 600 017.
Phone: 044 2814 0801 - 803
Fax: 044 2814 2479
E-mail: csdstd@integratedindia.in

Corporate Identification Number (CIN)
L24231TN1990PLC019053

RISK MANAGEMENT

Caplin Group operates in many countries of the emerging and regulated markets with its wide distribution network and multiple manufacturing facilities. Our complex, global operations and wide portfolio expose Caplin to various risks, making risk management our priority. Being a generic pharmaceutical company, we have developed effective mechanisms to proactively identify and mitigate risks. The risk management ensures continuation of operations and value creation.

RISK GOVERNANCE STRUCTURE

Caplin has a well-defined, governance structure with Board oversight, ensuring alignment and accountability. The Risk Management Committee (RMC) establishes a risk management framework based on key strategic, operational, financial, compliance and emerging risks, monitors the effectiveness of the risk mechanisms, reviews the framework, and ensures integration into business strategy.

The Risk Management Officer under RMC identifies, assesses, prioritizes, and tracks the enterprise-wide risks and reports key risk indicators to RMC. At the same time, the business and functional heads own and manage risks within their respective departments or units and ensure compliance with internal policies, SOPs and regulatory requirements. They report significant risks accidents and mitigation progress to the risk management officer. At Caplin Point Laboratories Limited, Mr. S Deenadayalan, Independent Director heads the RMC while other members are Dr Sridhar Ganesan, Managing Director, Mr Vivek Partheeban, Vice Chairman, Dr K C John, Independent Director and Mr D Muralidharan, Chief Financial Officer (subsequently inducted as Whole Time Director on the Board).

RISK MANAGEMENT PROCESS

The Group's business is exposed to the risks of global uncertainties, rising inflation, and forex rate fluctuations. These risks could disrupt supply chain, logistics, manufacturing, demand, delivery and other aspects, leading to decline in top and bottom lines and cash flows. To mitigate such risks, Caplin follows an integrated management process across critical business processes in diverse functions, aligning to the business objectives.

Stage	Actions
Risk Identification	Respective business heads identify the risks through discussion
Risk Assessment	Various risks are evaluated for their expected occurrence and impact, and tolerance limit. They are then prioritized for mitigation and the effectiveness of existing mitigation plans is evaluated.
Risk Mitigation	Business heads undertake appropriate actions within the timelines
Risk Monitoring	Risk reports are submitted to the Risk Management Committee periodically. Periodic updates are provided to the Board highlighting key risks and related points

OUR ENTERPRISE RISK UNIVERSE

Caplin categorizes its risk universe into four primary domains, ensuring specialized oversight for each category. To prevent duplication across our corporate reporting, detailed analyses of these risks and their specific mitigation architectures have been mapped to their respective statutory sections:

1. **Operational & Portfolio Risks**
   (e.g., Supply chain vulnerabilities, KSM dependency, talent attrition, and product lifecycle management).
   - Mitigation Focus: "China 2.0" sourcing diversification, vertical API backward integration, and local talent incubation.
   - A comprehensive breakdown of operational risks and corresponding mitigation strategies is available in the Structural Risks & Mitigation Architecture table within the MD&A.

2. **Regulatory & Compliance Risks**
   (e.g., Stringent USFDA/INVIMA audits, evolving validation standards, and ESG compliance).
   - Mitigation Focus: "Always-ready" audit postures, segregated manufacturing facilities for regulated markets, and digital compliance automation (Project Visual Integration).
   - Detailed compliance strategies and our environmental, social, and governance risk integrations are discussed in the MD&A and the Corporate Governance Report.

3. **Geopolitical & Market Risks**
   (e.g., Reliance on LATAM markets, global trade conflicts, and localized currency crises).
   - Mitigation Focus: Geographic diversification into the US and other regulated markets, alongside localized manufacturing expansion (Plan Mexico).
   - Strategic market positioning and geopolitical risk evaluations are covered extensively in the Economic & Industry Overview within the MD&A.

4. **Financial, Treasury & Cyber Risks**
   (e.g., Foreign exchange volatility, liquidity crunches, credit defaults, and data breaches).
   - Mitigation Focus: Maintaining a zero-debt capital structure, utilizing natural forex hedging, and deploying encrypted, air-gapped cybersecurity frameworks.
   - For an exhaustive quantitative analysis of Credit Risk, Liquidity Risk, and Market/Currency Risk, please refer to Note 43 (Standalone) and Note 44 (Consolidated) of the Financial Statements.

STRATEGY OF COMPOUNDING WITH STRATEGIC REDUNDANCY

GROUP BUSINESS STRATEGY AND ROADMAP

Caplin Group follows the philosophy of sustainable and profitable expansion, building a diversified and resilient business across geographies. It aims to deepen its presence in complex and differentiated products and continue to invest in quality, compliance, and automation while funding its own growth.

Caplin underwent three distinct phases – (1). market-led generics contract manufacturing (1990-2005), (2). technology and research-led growth (2006-2020) and (3). diversification across geographies and product lines from 2021 onwards.

At Caplin, we underline following strategic pillars of our sustainable growth and road to Caplin 2.0.

CORE BUSINESS OF EMERGING MARKETS - PENETRATING AND SUSTAINING

Caplin's core business from Latin America and Francophone Africa drives cashflows and is anticipated to grow at a steady pace with industry average margins. In Latin America, Mexico and Chile remain the strategic priority for future with various product licenses, product filings, and tender supply pipeline for various products. Caplin also plans to launch Softgels products for which Puducherry facility has passed INVIMA-Colombia inspection. It has entered a new therapeutic area CNS (Central Nervous System) in three LatAm markets in FY26 and plans to extend to two more markets by the next year.

US & OTHER REGULATED MARKET - BUSINESS ACCELERATION

Caplin considers its US business a primary growth engine. Through its subsidiary-Caplin Steriles Limited, it successfully launched 30 products and attained profitability in the first year of operations. It has filed for 65 ANDAs till date out of which 59 ANDAs were approved and targets to launch 25 more products in next year. Its diversified US pipeline comprises pre-filled syringes, ophthalmics, lyophilized injectables, infusion bags, and complex suspension injectables. CSL plans to establish a separate

US & Other Regulated Markets share in total Revenue:
FY19: 2%
FY26: 21%

US retail arm for ophthalmics and inhalation products to fetch higher margin on B2C business.

STRENGTHENING THE VALUE CHAIN

The structural strategic priority of Caplin is backward and forward integration. In line with this, Caplin acquired Vizag API facility and completed 90+ APIs at R&D scale. It operationalized the facility with 4 validated APIs and 12 more APIs on track, and targets to file first drug master file by end of FY2027. This progressive API self-sufficiency will reduce reliance on external sources, increase gross margins, and support supply chain resilience. Caplin will be able to achieve backward integration for 60% APIs as per their aspiration.

At the same time, CSL (Caplin Steriles Limited) — plans to transform manufacturing operations through complete digital integration with Project Visual Integration, a patent-pending automation and compliance monitoring system. This project will support in exceptional regulatory compliance. Our time-tested strategy of investing in and acquiring the distribution networks, especially in emerging markets is going to help us land our products closer to consumers and thus this forward integration will provide real impact to all our backward integration initiatives.

MAINTAINING FINANCIAL DISCIPLINE

Persistent financial discipline is Company's distinct and competitive feature that drives every strategic initiative. With considerable free cash reserves and total liquid assets, and a completely debt-free balance

FY26 Distribution Touchpoints in LatAm Markets: 30,000+ (~22,000 in FY25)

FY26 US End Users – Hospitals, Pharmacies, Clinics: 14,300 (5,610 in FY25)

sheet, Caplin is financing its entire capex programme solely through internal accruals — without resorting to debt. This financial strength allows Caplin to invest patiently in long-term projects for oncology, GLP-1, and biosimilars, while delivering consistent, profitable growth from its core emerging markets business. Caplin will continue to remain debt-free, supporting every strategic decision it makes. In FY26 Caplin's Cash & Cash Equivalents stood at ₹1,471 Crores.

Following are the key strategic targets over the near, medium and long term:

Time Horizon	Key Milestones Targeted
Near Term – FY27	Mexico scale-up ($4mn tenders), Chile tender execution ($10mn), completion of the civil works for injectables facility in Gummidipoondi (December, 2026), 15 US ANDA filings, non-US regulated market revenue, API validations (12 or more APIs), CNS brand marketing (5 LatAm markets).
Medium Term – FY29	BFS first product, Brazil entry, GLP-1 launches post-patent expiry, OSD facility completion (Q1 FY28), first Oncology API DMF filings, separate US retail arm for ophthalmics/inhalations, 60% APIs for backward integration
Long Term	Full biosimilar commercialization, complete API self-sufficiency, dominant oncology position in US and LatAm

STAKEHOLDER ENGAGEMENT – COMPOUNDING RELATIONS

STAKEHOLDERS AT THE HEART OF OUR JOURNEY

For Caplin, our stakeholders are integral to every decision we make and every milestone we achieve. We foster lasting relationships with our stakeholders, based on shared purposes. Their diverse perspectives and interests shape our strategies, drive innovation, and reinforce responsible business practices. With stakeholder engagement, we strive to create sustainable value, delivering meaningful outcomes for our business, communities, and the future generations.

We engage with our key stakeholders regularly and transparently to understand their expectations, identify potential issues, and collaboratively find solutions that drive positive and lasting impact. These interactions are critical to outlining our ESG roadmap as they help us manage risks, address concerns and create a sustainable value chain.

Key Stakeholders

- Shareholders/investors
- Regulatory Authorities
- Distribution Partners and Customers
- Employees
- Communities
- Government/Policymakers

Key Focus Areas for Stakeholder Engagement

- Responsible Business Conduct
- Environmental Aegis
- Community Care
- Quality Assurance

Stakeholder Engagement

At Caplin, we engage with various stakeholders in multiple ways and ensure two-way communication to enhance corporate governance and project management. It helps us to know more, promote transparency, build trust and improve business decisions. The following table describes the significance of each stakeholder, engagement tools and focus areas.

Stakeholder Group	Importance of Engagement	How we engage	Focus Areas
Shareholders/ investors	Transparent engagement with investors helps build trust and secure funds for diverse goals, promoting strong governance	◎ Quarterly earning calls ◎ Annual General Meeting ◎ Investor presentations ◎ BSE/NSE filings ◎ ESG Portal ◎ Facility visits	◎ Reporting and disclosures ◎ Dividend ◎ Strategic direction ◎ Capital allocation
Regulatory Authorities	Oversight of regulatory authorities enables Caplin to access new markets, build credibility and operate responsibly	◎ ANDA filings ◎ Inspections ◎ Quality submissions ◎ Other regulatory submissions	◎ Proactive Compliance ◎ Quality System Maintenance ◎ Multi-regulator strategy ◎ Automation and Digital compliance
Customers and Distribution Partners	Engagement with these stakeholders allows to understand the specific medicinal needs of the consumers and make them accessible and affordable.	◎ In-country subsidiaries ◎ Tender participation ◎ Robust distribution network ◎ Interaction with regulatory authorities ◎ Sponsoring/ participating in local healthcare initiatives of respective Governments	◎ Reliable uninterrupted supplies ◎ Tender Relationship management ◎ Affordable medicines ◎ B2B and B2C customer engagement ◎ Products launch ◎ High-quality medicines supplies
Employees	Our employees are critical force driving organizational success, bringing expertise, innovation and commitment. We nurture high-performing inclusive workplace.	◎ Training & Upskilling ◎ Stock based reward system ◎ Recognition ◎ Occupational Safety protocols ◎ Career development	◎ Safety and Wellbeing ◎ Upskilling and growth ◎ Leadership Development ◎ Recognition and reward
Communities	Community well-being is central to our purpose, guiding our endeavors to create positive social and environmental outcomes.	◎ CSR Trust ◎ Hospital ◎ Scholarships ◎ Access to medicines	◎ Rural healthcare ◎ Education ◎ Diversity and Inclusion ◎ Social impact
Suppliers and Contract manufacturers	Suppliers and contract manufacturers are our strategic partners enabling high-quality, consistent supplies and supporting delivery of healthcare solutions	◎ Quality audits ◎ China 2.0 partnerships ◎ backward integration	◎ Supply chain quality ◎ Strategic partnerships ◎ Business continuity
Government/Policy	The policymakers are vital stakeholders providing regulatory framework that supports innovation, public health, patient access, and sustainable industry growth.	◎ PHARMEXCIL* engagement ◎ DSIR** recognition ◎ Participation in State government industrial incentive schemes ◎ Consultative meetings with policy makers	◎ Export promotion, R&D policy, industrial development

*PHARMEXCIL - Pharmaceuticals Export Promotion Council of India

**DSIR - Department of Scientific and Industrial Research



MATERIALITY ASSESSMENT

OUR COMPASS TO VALUE CREATION

Materiality assessment at Caplin is a structured approach to understanding priorities of various stakeholders and identifying issues that matter most to them. These issues are underpinned and integrated into our strategy, governance and value creation journey.

At Caplin, we endeavour to assess the impact of material issues on business and our impact on key stakeholders. The periodic assessment of material issues, enables us to put in place the right strategies for economic, social and governance matters. The regulatory compliance, supply chain consistency and quality products are directly related to Company's financial performance while its affordable-medicine distribution across 23 countries and CSR programs for community beneficiaries create the social impact.

This dual approach is the cornerstone of Caplin's materiality approach and our sustainability narrative. The materiality assessment evaluates issues on two aspects – their importance to stakeholder decision-making and their impact on Caplin's ability to create long-term value. It has identified material topics that include regulatory compliance, product quality, sustainable supply chain, workforce wellbeing, access to medicines, environmental aegis, and financial discipline.

The material topics reflect in Caplin's strategic priorities, risk management framework, and ESG disclosures. Caplin's ESG platform maps 400+ KPIs across 35+ frameworks and provides real-time updates.

MANAGEMENT OF MATERIAL ISSUES AT CAPLIN GROUP

The table below summarizes the material topics, their business impact, key opportunities and management approach towards the priorities

Sr No	Material Topic	Business Implications	Key Opportunity	Management Approach
1	Regulatory Compliance	Business continuity	Market access; Credibility	Zero 483 Observations; 5 R&D setups; automation
2	Product Quality and Safety	Patient harm; Regulatory	Market access; Trust	Zero 483 observations; Project Visual Integration
3	Sustainable Supply Chain	Regulatory; Reputational; Supply chain disruption	Clean supply chain	Supplier audits; backward integration; Vizag API Plant; China 2.0 outsourcing
4	Workforce Wellbeing-Employee Development; Health and Safety	Attrition; Capability; Workplace injuries	Human capital moat; Retention; Morale	356-member R&D team; Safety protocols across all sites
5	Access to medicines	Social licence	ESG investor differentiation	5,000+ products; 65% in WHO list
6	Environmental Aegis – Energy, Water, and Waste Management, Environmental Compliance	Cost; Regulatory; Community; Reputational	ESG credibility; cost savings; Operational efficiency; Circular economy savings; Inspection credibility	Low carbon commitment; Water recycling; Efficient waste management; ESG Tracking
7	Financial Discipline	Capital risk	Balance sheet strength	Debt-free; ₹1,471 Crores cash reserves

VALUE CREATION MODEL

Turning shared purpose into strategic action, and strategic action into continuous value.

At Caplin, value creation is the outcome of strategic actions based on shared purpose. We endeavor to integrate science, innovation and sustainability across our diverse product lines and businesses. Our strategy emanates the belief that high-quality affordable healthcare improves lives, sustains and grows the business. We employ financial, manufactured, intellectual, human, natural, and social & relationship resources strategically, driving the qualitative growth, beyond numbers.

Our value creation model shows how we utilize resources and turn them into outputs that lead to impactful outcomes while propelling growth across geographies and markets and upholding stakeholder trust.

STRATEGIC PILLARS

Caplin operates on the foundations of integrity, quality, safety and productivity. These principles guide the high-quality standards across our manufacturing facilities and our actions for long-term sustainable cash flows.

Caplin's strategy is centered on 'Bottom of the Pyramid' market focus, unique end-to-end supply chain control and debt-free balance-sheet.

- Bottom of the Pyramid focus targets price-sensitive and underserved populations in emerging market and addresses critical gaps in medical access by delivering affordable healthcare.
- End-to-end distribution mechanism controls the logistics from manufacturing to local distribution without solely relying on third-party wholesalers, ensuring low risk with price control.
- Balanced sourcing approach combines in-house manufacturing and contract manufacturing, optimizing production costs, maximizing operational flexibility and creating free cash flows.
- Strategic regulated expansion focuses on re-investment of earnings from emerging markets into complex higher-margin, pharma fields of the US and Canada through subsidiary.

CORE CAPABILITIES

- **Pharmaceutics**

  Caplin's five dedicated R&D setups supported by sufficient skilled members and continuous capex investment focuses on formulation and analytical development, API R&D, and complex sterile products. We develop solid orals, liquids, ointments, creams, and critical care injectables and seamlessly transfer them to manufacturing plants or qualified outsourced partner sites. We cater efficiently to emerging and regulated markets focused on research and development.

- **Manufacturing**

  Caplin operates in affordable, high-quality formulations supported by advanced manufacturing facilities approved by international regulatory bodies including USFDA, EU-GMP, INVIMA, ANVISA etc. We manufacture diverse dosage forms including injectables, tablets, capsules, liquids and semi-solids. Caplin leverages vertically integrated manufacturing to supply in emerging and regulated markets. By targeting niche segments, Caplin ensures strong product pipeline and delivery with automated compliance.

- **Distribution and Commercialization**

  Caplin distributes generics across emerging markets of Latin America and the US through a distinct direct-to-retail approach, bypassing conventional distributors. This end-to-end model ensures high margins and market penetration. Caplin commercializes the required products in the underserved, semi-urban markets. We focus on robust product portfolio, localized marketing and reliable credit terms for small pharmacies to build brand loyalty.

CAPLIN POINT Laboratories

VALUE CREATION THROUGH SIX CAPITALS

RESOURCES WE UTILIZED	
Financial Capital	Shareholders' Funds (Equity Funds): **₹3,586.42 Cr.** Net Worth: **₹3,630.80 Cr.** Free Cash Reserves: **₹1,471 Cr.** Working Capital Ratio: **6.7 times**
Manufactured Capital	Manufacturing Plants: **4** Capital Expenditure (FY22-26): **₹870 Cr.** Capex Committed: **₹1,000 Crores (FY 27-29)** R&D Facilities: **5** Distribution Touchpoints (Emerging Mkt.): **30,000+** Hospitals, pharmacies, clinics (US): **14,300**
Intellectual Capital	R&D Spend FY26: **₹101 Cr.** (4.6% of Global Operating Revenue & 15.5% of FY26 PAT) R&D Completion: Backward Integration: **90+ APIs** ANDAs approved: **59** ANDAs filed: **65** ANDAs Pipeline (3-4 yrs): **55+** **Complex product capability: Pre-filled Syringes (Single & Dual Chamber) Ready-to-Use bags (RTU).**
Human Capital	Total Team Size (FY26): **3,389** India: **2,877** Rest of the World: **512** Average employee Age (years): **30.5** Employee Benefits Expenses: **₹199.15 Cr.** Average Learning hours/Employee: **~1.7**
Social & Relationship Capital	CSR Contribution – **₹4.70 Cr.** Direct CSR beneficiaries: **1,156** Patients served through the CSR hospital-cum-diagnostic center : **3,080** Supply Chain Partners: **3,604**
Natural Capital	Energy Consumed: **11,37,06,808.02 MJ** Clean Energy Consumed: **36.65%** Water Withdrawal: **78,235.22 KL** Water Recycled & Reused: **52.39%** Waste Disposed through Circularity: **80.35%** (Including E-Wastes, Plastic Wastes etc. disposed of through economic cycle to create new value)

HOW WE CREATE VALUE

VISION AND MISSION

VISION

Caplin aims to create new niches in our existing markets to ensure the current foothold remains strong and innovative. We envisage implementing our unique business model across the globe to ensure access to quality medicines at affordable prices.

MISSION

Innovate to change the rules of the game and not to compete in the game. Innovation distinguishes between a leader and a follower.

OUR VALUE CHAIN ACTIVITIES

- Research and Development
- Filing and Registration
- Manufacturing and Outsourcing
- Logistics Management
- Marketing and Distribution

THERAPEUTIC AREAS WE CATER

- Anti-infectives
- Cardiovascular
- Pain-Management and Anti-inflammatory
- Metabolic and Endocrinology
- Oncology
- Ophthalmics
- Central Nervous System
- Respiratory
- Gynaecology
- Dermatology
- Haematology
- Biosimilars and Peptides

STRATEGIES DEPLOYED

- Expansion in both - Emerging and Regulated Markets
- Backward-Forward Integration
- Automation & Digitalization
- Future Platform Building (advanced oncology, GLP-1, biosimilars, and blow-fill-seal technology)
- Balance sheet Discipline
- Diversified Manufacturing – India Vs China Outsourcing
- Diversified Product Portfolio

THE VALUE WE CREATED	OUTCOMES
Market Capitalization: **₹11,438 Cr.** Net Worth: **₹3,631 Cr.** RoNW: **17.89%** EBITDA: **₹876.39 Cr.** PAT: **₹650 Cr.** EPS: **₹84.36**	**Financial Capital: A growth-driven competitive balance sheet**
Countries served: **23** In-house manufacturing: **60%** Strategic outsourcing: **40%** Export contribution to revenue: **100%** Number of Dosage Forms filed: **15+** Capacity Expansion Puducherry (CPL) Softgel: **18 Cr. units** Kakkalur (COL)-OSD: **29 Cr. units** Injections: **24 Lakhs units** Completion of **Oncology Injectable** section in Kakkalur **Completion of First API unit** for backward integration (For 60% in-house APIs) Scaling 3 critical APIs Automation and Digital Transformation	**Manufactured Capital: Automated efficient manufacturing capabilities**
New ANDAs approved: **10** ANDAs from Third Parties: **15** Product Registrations in Chile: **135+** Product Registrations in Mexico: **25; 120+ in pipeline** Validation: **4 APIs** for General Category	**Intellectual Capital: R&D driving innovation with product pipelines**
New hires - Manufacturing: **811,** R&D: **108** Workforce: In India **85%**, In Rest of the World **15%** **33.13%** women representation in Indian workforce. **46%** women representation in global workforce. **62% women representation** in contract workforce. Onboarded **1007** Employees of which **17%** is from Rural areas and **61%** from Semi- Urban areas. **3,996** Man-hours of training	**Human Capital: A diverse and dynamic workforce**
Number of CSR Beneficiaries – **1,156** Number of beneficiaries of direct CSR initiatives **3,080** Number of patients served through the CSR hospital-cum-diagnostic center Countries Served: **23+** Strategic outsourcing from Partners: **40%** Percentage of Agreements with contract manufacturers containing Supplier Code of Conduct (SCoC): **100%** **14,300** hospitals, pharmacies, clinics, etc. in the US. **30,000+** touchpoints across Latin America	**Social and Relationship Capital: A reliable supply chain and community well-being**
CO_2 Emissions avoided: **8,368 MT** Capex Investment which has positive impact on environment: **₹67 Cr** Freshwater Conserved: **46,464.46 KL** Disposal of waste through circularity: **80.35%** CO_2 Scope 3 Emissions Avoided: **186.6 MT** **Real-time Dashboards** to Track: Emissions, Water Usage, Efficiency, Savings.	**Natural Capital: A climate-centric and resource-efficient business**

PERFORMANCE ACROSS RESOURCES

FINANCIAL CAPITAL

BUILDING VALUE FOR SHAREHOLDERS

In FY26, Caplin enhanced its financial capital through judicious fund allocation, continued profitability, and healthy cash flows. Caplin sustained manufacturing expansion, research and development, digital transformation and strategic growth initiatives with its export-driven business model, diversified revenue streams, and judicious financial management.

Revenue From Operations

₹2,187 Crores

EBITDA

₹876 Crores

Dividend Paid

₹45.61 Crores

MATERIAL TOPICS – COMPLIANCE, RISK MANAGEMENT AND BUSINESS CONTINUITY, ANTI-BRIBERY AND CORRUPTION

Caplin demonstrated financial execution across all primary operating markets in FY26. Consolidated revenue from operations grew by 12.89% to ₹2,187.19 Crores, driven by sustained demand in core emerging markets and commercial acceleration in regulated markets. Gross profit rose by 13.3% to ₹1,322 Crores, maintaining a gross margin of 60.4%.

Operating efficiency drove a 17.90% increase in EBITDA to ₹876.39 Crores, while Profit Before Tax (PBT) expanded to ₹802.79 Crores. Net profit after tax reached ₹649.73 Crores, delivering a 20.08% YoY increase and sustaining our decade-long record of compounding profitability at approximately 27% CAGR without utilizing debt financing.

OPERATING PERFORMANCES

Our diversified geographic footprint continues to provide balanced revenue momentum and foreign exchange risk mitigation:

- Regulated Markets (US & Others): Driven by our direct front-end subsidiary, Caplin Steriles USA Inc., US sales surged by 27.89% YoY. The contribution of regulated markets to total group revenue reached 21% in FY26 (up from just 2% in FY19).
- Emerging Markets (LATAM & Francophone Africa): Exports to Latin America expanded by 9.53% YoY, anchored by deep direct-to-retail distribution channels.

The above performance shows Caplin's strategic insight, operational flexibility, and success of its unique end-to-end business model, building its position as a trusted pharmaceutical company. Commensurate with the performance, Caplin had declared a dividend of ₹8 per share, subject to approval of shareholders for the final dividend at the forthcoming Annual General Meeting, which is an increase from previous years ₹ 6 per share.

Though Caplin's revenue composition based on major geographies –

LATAM, US and Africa remained the same as previous year, US exports increased by 27.89% and LATAM exports increased by 9%. Emerging markets continued to be Caplin's reliable growth engine due to enhanced presence with diversified product portfolio and institutional participation. We have accelerated our presence in regulated US market by deepening and scaling our subsidiary operations.

GENERIC AND BRANDED GENERIC REVENUE COMPOSITION



Category-based Revenue Breakup FY26



Category-based Revenue Breakup FY26



% Revenue Contribution In FY26



Distribution Channel-based
Revenue Breakup FY26



% Revenue Contribution FY26

Revenue from Operations ₹ Crores



Gross Profit ₹ Crores



EBITDA ₹ Crores



PBT ₹ Crores



PAT ₹ Crores



Profit Margins %



FINANCIAL SNAPSHOT

During FY26, Caplin expanded the range of sterile injectables and strengthened its pipeline across regulated and emerging markets. We also advanced high-value offerings, including pre-filled syringes (PFS) products, oncology formulations, and specialty pharmaceuticals, as per our long-term growth strategy.

Particulars	FY26 (₹in Crores)	FY25 (₹in Crores)	YoY Growth (%)
Revenue from Operations	2187.19	1937.47	12.89%
Gross Profit	1321.50	1,166.63	13.28%
EBITDA	876.39	743.36	17.90%
Profit Before Tax (PBT)	802.79	676.78	18.62%
Profit After Tax (PAT)	649.73	541.09	20.08%
Earnings Per Share (EPS) (₹)	84.36	70.57	19.54%
Gross R&D Investment	100.71	89.12	13.50%
Free Cash Reserves	1471.00	1180.00	24.66%
Working Capital Days	367	344	-
Dividend Per Share (₹)	8	6	33.33%

For detailed information, readers can refer to standalone and consolidated financial statements separately presented in this report.

DISCIPLINED CAPITAL ALLOCATION & STRATEGIC CAPEX

Caplin's Board maintains a structured capital allocation framework that funds future growth engines while preserving balance sheet health. Over the past five years, Caplin has deployed ₹870 Crores in Capex and committed an additional ₹1,000+ Crores for ongoing multi-site expansions (including the Thervoy Oncology API unit, Puducherry OSD facility, and Gummidipoondi Injectables expansion). All capital expenditures, facility acquisitions, and R&D pipelines (₹100.71 Crores in FY26) are funded entirely via internal cash accruals, ensuring the group remains net cash positive with zero external leverage.

ECONOMIC VALUE GENERATED AND RETAINED (EVG&D)

In alignment with GRI 201-1 and BRSR disclosures, Caplin tracks the direct economic value generated through its global pharmaceutical operations. Out of total consolidated revenues, the group generated significant net economic value after meeting operating costs, employee wages, and statutory obligations. For FY26, the Economic Value Retained (EVR) stood at ₹73.82 Crores for the US regulated business and ₹728.97 Crores across our emerging markets and rest-of-the-world operations. This retained value provides the liquidity required to self-fund long-term strategic projects without resorting to equity dilution or debt financing.

TAX STRATEGY

At Caplin we follow transparent and sustainable tax practices aligned with our code of business conduct and core values. Our tax strategy underscores compliance with applicable laws of the countries we operate in, wisely managing tax liabilities. We have a team of global tax and legal advisors, headed by Chief Financial Officer who ensures tax compliances and effective reporting. We paid ₹144.50 Crores tax for FY26, more than 13.2% over previous year, reporting significant contributions to support economies where we operate. Our commitment to transparency fulfils legal requirements while fostering trust in our tax processes.

Our backward and forward integration, diversified product portfolio and markets, digitization and automation in manufacturing and end-to-end distribution model have paved the way for sustained business growth and profitability in the forthcoming years. We recognize the challenges of certain geopolitical events influencing our business. This fact inspires us to be agile and ready to navigate these market dynamics and safeguard interest of our all stakeholders through strong risk management.

MANUFACTURED CAPITAL

MANUFACTURING TODAY, READY FOR TOMORROW

At Caplin, our manufactured capital forms the bedrock of our commitment to global healthcare. It is the physical manifestation of our promise to deliver high-quality, safe, and affordable medicines to patients across 23 countries. By synergizing advanced automation, stringent regulatory compliance, and debt-free capacity expansions, we have built an agile manufacturing network capable of serving both high-volume emerging markets and highly regulated geographies simultaneously.

MATERIAL TOPICS – COMPLIANCE, CUSTOMER HEALTH AND SAFETY, SUSTAINABLE PROCESS DESIGN, WASTE MINIMIZATION, WATER MANAGEMENT

Manufacturing Capabilities and Footprint: Caplin's manufactured capital relies on deep physical, technological, and operational strengths spanning a segment-specialized network. Caplin Group operates the following diversified facilities:

- Puducherry (Caplin Point Laboratories Limited): Our flagship multi-dosage facility catering primarily to emerging markets. It manufactures oral solids, liquid orals, softgels, topicals, and injectables (including lyophilized and dual-chamber syringes). Over the past three years, this facility successfully expanded its softgel capabilities, adding a capacity of 18 Crore units.
- **Gummidipoondi (Caplin Steriles Limited):** A dedicated sterile facility focused on the regulated markets. This plant manufactures complex sterile injectables, ophthalmics, pre-filled syringes, lyophilized vials, and ready-to-use (RTU) infusion bags.

Total Manufacturing Footprint: 4 specialized manufacturing facilities across Tamil Nadu and Andhra Pradesh.

Regulatory Accreditations: 2 highly specialized USFDA-approved units, complemented by multi-regulator approvals including EU-GMP, UK-MHRA, TGA Australia, INVIMA, ANVISA, COFEPRIS, and WHO-GMP.

Output Volume (FY26): ~137 Crore units of Oral Solid Dosages (OSDs) and ~3.7 Crore units of Liquids and Injectables.

Capital Expenditure: ₹228 Crores invested in Fixed Assets for manufacturing sites during FY26, driving an overarching ₹1,000+ Crore ongoing Capex program.

Production Mix: 60% produced in-house; 40% strategically outsourced to global partners.

Export Dominance: 100% of manufactured and outsourced revenue is generated from international export markets

Zero product recalls were reported during FY 2025-26.

- **SIDCO, Kakkalur (Caplin One Labs Limited):** A state-of-the-art facility exclusively dedicated to oncology products. This fully completed unit houses an OSD phase with a capacity of 29 Crore units and an injectable phase capable of producing 24 Lakh units, strengthening our foothold in high-value therapeutic segments.
- **Visakhapatnam (APIIC):** Our foundational Active Pharmaceutical Ingredient (API) plant. This facility anchors our backward integration strategy, operating specifically to produce General Category APIs to secure our supply chain for existing and regulated markets.

Strategic Capacity Expansion (Debt-Free Capex): To future-proof our supply chain and exponentially expand our product range, Caplin has deployed approximately ₹870 Crores over the past five years and earmarked an enhanced Capex budget of over ₹1,000 Crores for the next phase of expansion. Crucially, this entire Capex program is funded solely through internal accruals, allowing us to build immense scale while maintaining our net debt-free status. Key ongoing infrastructure projects include:

- **Oncology API Facility (Thervoy SIPCOT, Chennai):** Civil construction is complete, with commercial operations targeted for Q4 FY27, enabling full backward integration for our oncology pipeline.
- **Caplin One Labs Injectable Facility (Gummidipoondi):** Currently undergoing rapid civil and structural development, this facility is dedicated to regulated markets. Targeted for completion in Q4 FY27, it will house five specialized lines (Injectables, Ophthalmics, and Blow-Fill-Seal), with infrastructural provisions to add three more lines seamlessly.
- **OSD Facility for Regulated Markets (Puducherry):** Civil activity is in full swing for a dedicated Oral Solid Dosage plant aimed at the US, EU, Brazil, and Mexico markets, targeted for completion in Q1 FY28.
- **Infusion Bag Scaling:** We are executing a 3X capacity expansion of our IV Bag lines to meet surging hospital demand following multiple recent USFDA product approvals.

Manufacturing & Outsourcing



Exports



Balanced Manufacturing Strategy (China 2.0): Caplin leverages a highly successful, balanced manufacturing strategy, producing 60% of our products in-house while strategically outsourcing the remaining 40%. In FY26, we elevated this approach through our "China 2.0" strategy. We deepened our partnerships with elite, China-based Contract Manufacturing Organizations (CMOs) that already possess approved ANDAs and rigorous certifications for the US and European markets. This dynamic ecosystem provides us with exceptional production flexibility, cost optimization, and accelerated market access without overburdening our internal capital assets.

Quality, Compliance, and Digital Transformation: Caplin's manufacturing excellence is globally validated. We maintained impeccable compliance standards, highlighted by zero 483 observations in an Establishment Inspection Report (EIR) from the USFDA, alongside a highly successful INVIMA-Colombia inspection at our Puducherry plant in December 2025. To further elevate our operational precision, Caplin Steriles Limited is launching "Project Visual Integration". This patent-pending technological platform digitally integrates all critical manufacturing processes, providing real-time compliance monitoring and automated tracking. The above digital transformation guarantees that our rapid capacity scaling is matched by uncompromised quality assurance, efficiency, and regulatory readiness at every step.

Going further, we are committed to manufacturing and quality excellence and expand our manufacturing footprint to fulfil increasing demand with our quality products. We are accelerating digitization and automation for precision, accountability and pace and investing in workforce training for shared and sustainable progress. At the end, our purpose is to be a catalyst for healthcare with our products.

INTELLECTUAL CAPITAL

FROM DISCOVERY TO DIFFERENTIATION

Intellectual capital plays a pivotal role in every formulation and API manufactured by us. Every product reflects our innovative endeavors, scientific expertise and commitment to create long-term healthcare solutions. With our intellectual capital, we decipher complex problems, optimize delivery system, and explore new therapies, respond to unmet medical needs and develop affordable products. This enabled us to advance in the market in FY26. Caplin's teams continued hard work to develop and acquire excellent medications, ensuring international standards of quality, safety and compliance.

3 GOOD HEALTH AND WELL-BEING

9 INDUSTRY, INNOVATION AND INFRASTRUCTURE

17 PARTNERSHIPS FOR THE GOALS

MATERIAL TOPICS - DATA PRIVACY AND PROTECTION, ETHICAL MARKETING AND PRODUCT LABELLING, COMBATING COUNTERFEIT MEDICINE.

RESEARCH AND DEVELOPMENT

Caplin continues to invest heavily in research, technology, intellectual property, and strategic scientific collaborations. We have strengthened our ability to develop differentiated healthcare solutions and create long-term value for patients. Our research ecosystem spans five dedicated R&D centers, including our Amaris Clinical CRO which holds both USFDA and ISP Chile accreditations, alongside three facilities formally recognized by the Department of Scientific and Industrial Research (DSIR). Driven by a specialized team of 356 scientific experts, we sustained a robust R&D investment of ₹100.71 Crores during FY26 to address complex scientific challenges and optimize formulation development

R&D Investment: ₹100.71 Crores, constituting 4.6% of FY26 Global Operating Revenue.

R&D Infrastructure: 5 dedicated research centers, including 3 DSIR-approved setups and the USFDA-approved Amaris Clinical CRO.

Regulatory Pipeline: 59 ANDAs approved out of 65 filed to date.

Strategic Acquisitions: 10 approved ANDAs acquired for injectable and ophthalmic products, addressing a total market size of USD 473.2 million.

API Capabilities: 90+ APIs developed at R&D scale for backward integration with the first DMF filing targeted by end of FY 27.

152 new products registered in emerging markets and 25 products registered in Mexico.



REGULATORY PIPELINE AND GLOBAL APPROVALS

We systematically expanded our intellectual property and regulatory presence in the US and other regulated markets through Caplin Steriles Limited. To further accelerate our commercial strategy and bypass conventional regulatory lead times, we recently acquired 10 approved ANDAs for critical injection and ophthalmic products. This acquisition meaningfully broadens our portfolio and includes select oncology injectables poised for commercialization. In FY26 alone, our R&D and regulatory teams secured multiple critical USFDA approvals, including Acetaminophen Injection, Linezolid, Haloperidol Decanoate, Nicardipine Hydrochloride, and Brimonidine Tartrate ophthalmic solutions.

BACKWARD INTEGRATION AND API AMALGAMATION

A core component of our intellectual strategy is achieving total self-reliance through advanced process engineering for raw materials. Our R&D team has successfully completed the development of over 90 APIs at the lab scale to support backward integration across both emerging and regulated markets. In FY26, we validated 4 general category APIs and targeted our first Drug Master File (DMF) to the USFDA by the end of FY 27. The proprietary chemical processes, synthesis routes, and analytical frameworks developed by our scientists serve as the intellectual foundation that is now actively being tech-transferred to scale at our Vizag API plant and the upcoming Thervoy Oncology API facility.

NICHE TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS

Caplin is aggressively moving beyond basic generic formulations by investing in complex, specialized delivery platforms. Our intellectual capabilities now encompass the engineering of Blow-Fill-Seal (BFS) technology for ophthalmic indications to minimize contamination risks, as well as Ready-to-Use (RTU) bags and Pre-Filled Syringes (PFS) in both single and dual-chamber formats. Our R&D team successfully completed qualification standards to file 11 PFS products, driving our immediate expansion into the GLP-1 therapy segments in Mexico and Colombia. Furthermore, our pipeline continues to advance in the research of oncology formulations, biosimilars, and complex peptides. Supporting this technological leap is our patent-pending “Project Visual Integration,” which digitally integrates and monitors critical manufacturing parameters, ensuring flawless technology transfer and compliance from the lab directly to the commercial floor.

HUMAN CAPITAL

EMPOWERING MINDS, ENABLING INNOVATION

We at Caplin believe that our people are the critical force driving growth through complex R&D initiatives, backward integration and global regulatory expansion. In FY26, our large workforce comprising 3,389 highly skilled members, contract workers and overseas employees converted scientific concepts into commercial properties, leading to high growth. We foster a safe, inclusive and learning culture, ensuring high employee retention and deep expertise across our global facilities.

5 GENDER EQUALITY

8 DECENT WORK AND ECONOMIC GROWTH

10 REDUCED INEQUALITIES

MATERIAL TOPICS – HUMAN CAPITAL DEVELOPMENT, EMPLOYEE HEALTH AND SAFETY, PROTECTION OF HUMAN RIGHTS

Strategic Pillars

i. Nurturing High-Caliber R&D Professionals

A highly specialized scientific workforce is crucial to driving the development of complex pharmaceutical products. Caplin houses a 356-member R&D team focusing on generics, injectables, complex APIs, and novel delivery platforms. We prioritize the retention of tech-transfer experts who successfully convert ANDAs and product approvals into internal manufacturing pipelines.

ii. Continuous Capability Building & Future Readiness

Caplin strategically prioritizes the engagement and empowerment of local community members for shop-floor operations. By investing in their continuous upskilling, we cultivate a loyal, stable, and highly competent workforce capable of meeting the rigorous regulatory demands of global health authorities.

Total Workforce: 3,389 global employees (including 628 contract employees)

Employment Generation in Rural and Semi-Urban Areas: Onboarded 1,007 employees, of whom 173 in rural areas and 611 in semi-urban areas, constituting around 78% of total new hires.

Diversity Metric: 33.13% women representation in the Indian workforce and 20.88% women specifically in R&D units

62% women representation in contract workforce.

Training & Development: 3996 man hours of training for employees.

Skill Incubation: 75 apprentices engaged for advanced technical/ industrial training

Employee Benefits Expense: ₹199.15 Crores (of which ₹10 Crores explicitly allocated for employee welfare measures)

100% of permanent employees — both male and female — are covered by Health Insurance and Accident Insurance.

100% of women employees returned to work after maternity leave in FY26, with a 90.91% retention rate among women workers a year after their return.

To facilitate this continuous learning, we have deployed comprehensive electronic training modules across our facilities. Furthermore, capability building is actively augmented by our patent-pending "Project Visual Integration," which embeds visual learning and real-time visual intelligence directly into critical manufacturing processes.

iii. Promoting Diversity, Equity, and Inclusion

Institutionalizing diversity in highly technical fields is a strategic priority. We actively encourage and track female representation in Science, Technology, Engineering, and Mathematics (STEM) roles across our organization. Currently, women constitute 33.13% of our overall Indian workforce, 46% of our global workforce, and 20.88% of our highly specialized R&D units. By promoting equal opportunity in critical functions like quality assurance, microbiology, and formulation development, we are building a more inclusive and innovative scientific community. Reflecting this inclusive culture, women employees returned to work after maternity leave at a rate of 100% in FY26, with a 90.91% retention rate among women workers a year after their return.

HUMAN RIGHTS TRAINING

Caplin adopts a no-tolerance policy toward human rights violation and strives to protect human dignity across operational, manufacturing and R&D units. Trainings on Human Rights focus on zero tolerance for exploitation, equal opportunity and no discrimination, supply chain and security guard vigilance. Sensitization sessions comprising online modules highlight the availability of Whistle-blower mechanism and other means of complaining about grievances to local Redressal Committees/ Complaints Committee. All such reports are accorded the highest degree of confidentiality. To institutionalize this commitment and ensure accountability, Caplin has established a dedicated Ethics Committee at the corporate level which is mandated to independently inquire into and address all Code of Conduct violations, explicitly including issues related to human rights, exploitation, and workplace ethics.

For future period, Caplin Group will focus on supporting new expansions, through human capital initiatives which include upskilling in oncology technology, advanced automation and global regulations. Recognizing the essential role of extended personnel in our operational ecosystem, our vision moving forward is to systematically expand all training modules to cover 100% of our on-site contractual workforce, ensuring comprehensive awareness of workplace rights, grievance mechanisms, and ethical labor standards across all levels.

NATURAL CAPITAL

SUSTAINABILITY THAT HEALS BEYOND MEDICINES

Containing climate change is essential to sustain healthy living on the planet. We recognize our responsibility towards environment protection. We integrate environmental sustainability into every operational aspect and proactively reduce emissions, waste and conserve water. We ensure that our business remains aligned with our environmental objectives

MATERIAL TOPICS – WASTE MINIMIZATION, POLLUTION, WATER MANAGEMENT, ANTI-MICROBIAL RESISTANCE, RESPONSIBLE SUPPLY CHAIN, DECARBONIZATION, COMPLIANCE

Environmental Governance Practices

At Caplin, we optimize resources, reduce pollution and waste, and conserve energy, biodiversity, and water through our environmental governance practices. All our manufacturing facilities undergo regular environmental audits which not only checks the status of compliance with various environmental legislations but also identifies the key areas of improvement in environmental stewardship. The internal audits and periodic audits by external certifying agencies ensure minimal or no environmental harm by these facilities. The compliance audits provide us a lever for continuous improvement in environment management systems. We have set targets for water conservation, energy saving, and waste disposal and evaluate the performance against these targets to identify any gaps and implement measures to correct them.

36.65% share of renewable energy in operations, totaling 1,15,10,433 KWh.

46,464.46 KL of freshwater conserved and 52.39% of water recycled and reused in FY26.

80.35% of waste disposed of through circularity, effectively minimizing landfill impact.

0.19% of hazardous waste sent to landfill, with 94.52% diverted to recycling or Alternate Fuel Recovery.

One key manufacturing unit operating with Zero Liquid Discharge capabilities.

Avoidance of 8,368 Metric Tonnes of CO2 emissions through renewable energy use.

Scope 1 and Scope 2 GHG emission intensity per rupee of revenue improved by approximately 12% YoY.

COMPONENTS OF ENVIRONMENTAL GOVERNANCE

Renewable Energy and Carbon Footprint

Caplin Group expanded renewable energy utilization to reduce the consumption of traditional grid energy. During FY26, the group consumed 1,15,10,433 KWh of renewable power, constituting 36.65% of total energy consumption. This shift to green energy successfully avoided 8,368 Metric Tonnes of CO2 emissions. In addition, Caplin periodically conducts energy audits to identify energy-efficient practices and implement the recommendations. Caplin invested ₹67.29 Crores in Capex for energy-efficient equipment, including advanced compressors, cooling systems, and LED standardization, while replacing aging HVAC systems at Caplin Steriles Limited to further lower greenhouse emissions. As a result of these measures, Scope 1 and Scope 2 GHG emission intensity per rupee of revenue improved by approximately 12% Y-o-Y.

Water Conservation

Caplin incorporated high-efficiency multi-effect evaporators to maximize internal wastewater recycling and upgraded effluent treatment plants to treat chemical discharge before disposal. Through these comprehensive recycling efforts, 52.39% of water was successfully recycled and reused during FY26, resulting in 46,464.46 KL of freshwater conserved. Furthermore, one key manufacturing unit currently operates as a Zero Liquid Discharge facility.

Waste Management

Caplin directed harmful chemical sludge and byproducts to authorized cement companies for further co-processing. Across all units, 94.52% of hazardous waste was responsibly disposed of through recycling or an Alternate Fuel Recovery mechanism, restricting landfill disposal to a mere 0.19%.

Advancing the Circular Economy

Transitioning from traditional disposal to regenerative material loops forms a central pillar of our sustainability agenda. In FY26, 80.35% of total waste generated—including E-waste and plastic packaging—was diverted from incinerators and landfills, re-entering the economic cycle to create new value. Through these rigorous circularity processes and partnerships with authorized recycling vendors, Caplin successfully avoided approximately 186.6 Metric Tonnes of Scope 3 CO2 emissions.

Ecofriendly Land Use

Caplin consciously selected non-ecologically sensitive regions for new projects to avoid any harm to natural habitats. Upcoming projects, including Caplin One Labs Limited unit at Kakkalur and the Thervoy Kandigai API unit, are situated within approved Industrial Estates, safely distanced from ecologically sensitive zones, protected areas, and biodiversity hotspots. Wherever required, Caplin carries out Environmental Impact Assessments and obtains Environmental Clearances for projects. All operations are fully compliant with green belt requirements in addition to extended greenery developed on the periphery of the units. Manufacturing units operate real-time environmental display boards at their borders, showcasing key waste and pollution metrics.

Way forward, Caplin Group will continue to endeavors for environment protection by enhancing energy efficiency, reliance on renewable energy, water conservation and sustainable waste management practices. We are committed to reducing environmental footprint through reduced wastage and GHG emissions and green technology investments. The environmental initiatives will provide operational resilience, regulatory compliance and long-term sustainable value creation while supporting environmental goals.

SOCIAL & RELATIONSHIP CAPITAL

CREATING SHARED VALUE THROUGH COLLABORATION

Our social and relationship capital is the trust, goodwill and relationships built across our three-decade journey in pharmaceutical industry. This relationship capital spans patients, local communities, regulators, customers, employees, investors, and supply chain partners across 23 countries. Our every commercial, regulatory and operational achievement depends on this social and relationship capital, as our mission is to deliver affordable medicines to underserved populations.

CSR Investments – ₹2.06 Crores (investment in creation of Capital asset)

Number of Direct CSR Beneficiaries – 1,156

Number of Medical Service Beneficiaries – 3,080

Employee Volunteering Hours – ~2,750

Number of contract manufacturers with ESG covenant - 23 (100%)

Employee Welfare Expense – ₹14.36 Crore

14,300 Customers, including hospitals, pharmacies, clinics, etc. in the US and 30,000+ touchpoints across Latin America.

MATERIAL TOPICS – CUSTOMER HEALTH AND SAFETY, RESPONSIBLE SUPPLY CHAIN, ACCESSIBILITY AND AFFORDABILITY, ETHICAL MARKETING AND PRODUCT LABELING

Healthcare Accessibility for Caplin Group

Healthcare accessibility is a core business mission of Caplin. It supplies 650+ affordable generics covering 65% of WHO Essential Drug List to the underserved populations across 23 countries in Latin America and Francophone Africa. Eight in-country subsidiaries in Latin America hold 4,042+ registered product licenses ensuring continued availability. At the same time, Caplin Steriles Limited caters to regulated markets with 30 products in the US and will soon enter Canada, EU, US, Australia and other regulated markets with 54 product approvals. Caplin One Labs Limited has advanced oncology accessibility with 5 ANDAs.

CORPORATE SOCIAL RESPONSIBILITY

Caplin's CSR vision is to translate business growth into meaningful social impact for the most underserved communities, anchored by Chairman C.C. Paarthipan's founding philosophy of focusing on the "bottom of the pyramid".

The Caplin Point Meenakshi CSR Trust has put this mission into practice by constructing a state-of-the-art Hospital-cum-Diagnostic Center at Chinnapuliyur Village, Gummidipoondi, funded through ₹4.16 crore CSR spend in FY26. The Center offers mammogram facility specifically addressing early breast cancer detection for rural women — a targeted healthcare intervention reflecting Caplin's purposeful, community-first CSR philosophy.

PROMOTING HEALTHCARE, EDUCATION AND EMPLOYEE VOLUNTEERING

Caplin continued to invest in healthcare, education and community development initiatives. It provided financial assistance to admirable students near manufacturing locations and incentivized government school teachers. The Gummidipoondi hospital equipped with advanced diagnostics addresses healthcare gaps for local communities. Nonetheless, manufacturing site employees participated in health awareness and community development initiatives, encouraged by Caplin's community-first culture. Furthermore, we promoted community health and broader welfare by sponsoring the "Chennai Runs 2025" marathon for 481 participants and providing substantial financial grants to regional charitable NGOs.

SUPPLY CHAIN MANAGEMENT

Caplin outsources 40% manufacturing through compliant CMOs, creating a flexible, viable and compliant production ecosystem. Its China 2.0 strategy deepened supplier relationships transforming API sourcing to strategic technology partnerships, enabling product filings across Mexico, Colombia and Chile. Caplin aims self-sufficiency with own general API plant and Oncology API facility. It carried out rigorous supplier audits and CMO compliance monitoring ensuring quality and regulatory standards across the supply chain.

ETHICAL AND RESPONSIBLE MARKETING PRACTICES

Caplin's commercial objectives always comply with patient safety regulations across the geographies, delivering on its mission of affordable and accessible healthcare to underserved. The growth in branded generics reflects the trust of pharmacists and prescribers in Company's offerings. In the US, Caplin Steriles USA Inc engages group purchasing organizations, wholesalers and pharmacy chains as per compliant practices.

STAKEHOLDER COMMUNICATION

Caplin ensures rigorous, transparent disclosure to stakeholders through quarterly earnings presentations, Annual Reports, BSE/NSE filings, and dedicated IR infrastructure. The real-time ESG platform at caplinpoint.net is the most innovative external stakeholder communication tool, providing data on 400+ KPIs across 35+ frameworks with 60-day data refresh. Chairman C.C. Paarthipan personally acknowledges employee dedication in quarterly communication, creating visible recognition culture. Audit, NRC, Stakeholder Relationship, and Risk Management committees ensure governance communication to the highest standards of fiduciary responsibility and regulatory compliance.

POLICY FLUENCE AND AWARDS

Caplin's CFO received the FE CFO Award during June 2025 for excellence in financial leadership (SMEs) in Mumbai.

The three DSIR-approved R&D setups reflect sustained government science and technology engagement, aligned with national innovation policy objectives. The manufacturing facilities are benchmarked with international quality standards.

Going forward, the social and relationship capital will be critical in executional success of US business, expansion in Mexico and Brazil, GLP-1 product launches and oncology commercialization. It is durable and defensible competitive moat that no competitor can replicate. Continued CSR programs will deepen company's social license. Caplin is committed to the communities, partners and patients whose trust has built and will sustain its success.

MANAGEMENT DISCUSSION AND ANALYSIS

MANAGEMENT DISCUSSION AND ANALYSIS

GLOBAL ECONOMY

The global economy has faced sequential shocks this decade, starting with COVID-19 in 2020 –21, the Russia-Ukraine war in 2022 (and continuing), trade conflicts triggered by USA tariff imposition in 2025, and escalating Middle East war since late February 2026. The global trade conflicts restricted growth to 3.4% in 2025 and sharply accelerated deglobalization, as businesses pivoted rapidly from global networks to localized supply chains. Concurrently, the massive technology boom of 2025 experienced an AI expectations bust in early 2026, leading to a market correction that tightened credit and financial conditions.

The Middle East conflict remains the primary headwind for 2026. Despite a temporary pause following the US-Iran peace MOU, the war's economic fallout persists. Shortages in crude oil, fertilizers, and petrochemicals have triggered sticky inflation and widespread demand destruction. Major economies such as EU and Japan have raised interest rates, while the US Federal Reserve maintains a hawkish stance to curb inflation. In parallel, the developing nations face severe fiscal stress and currency depreciation driven by elevated energy and food import bills. Reflecting these headwinds, the IMF's April 2026 World Economic Outlook forecasts global growth to slow to 3.1%.

Economy	GDP Growth (%)		
	2024 (A)*	2025 (A)*	2026 (P)**
Global Economy	3.4	3.4	3.1
Advanced Economies	1.8	1.9	1.8
Emerging Market & Developing Economies	4.5	4.4	3.9
United States	2.8	2.1	2.3
Euro Area	0.9	1.4	1.1
Japan	-0.2	1.2	0.7
China	5.0	5.0	4.4
Middle East & North Africa	2.3	3.2	1.1
Sub-saharan Africa	4.2	4.5	4.3
Latin America & Caribbean	2.4	2.4	2.3

Source: *International Monetary Fund April 2026 World Economic Outlook report.* *Actuals; **Projections

INDIAN ECONOMY

India has firmly maintained its position as a major global growth engine and the fastest growing major economy despite persistent international headwinds. In spite of tariff measures enacted by the US, India's Real GDP grew by 7.7% in FY 2025-26 as per MoSPI's provisional estimates. This was a significant increase over the 7.1% rise in output during the previous fiscal. The growth in FY2025-26 was driven by robust, double-digit growth across both Manufacturing and Services. The structural shift towards industrial production effected by the Government through Production Linked Incentive (PLI) schemes for various sectors significantly strengthened manufacturing performance, offering timely support as the Services sector navigates an AI-driven hiring transition.

Inflation remained at record low levels during FY2025-26 with annual average estimated to be 2.1%. However, the sudden outbreak of the Middle East conflict in late Q4 spiked crude oil prices much above USD 100/bbl. This combined with the capital outflows led to significant depreciation in the Indian Rupee. While both these factors have moderated due to a tenuous peace, the war's residual impact combined with a sub-normal monsoon forecast due to El Niño conditions, have weighed on the GDP growth projections for FY2026-27. Consequently, the Reserve Bank of India adjusted its FY 2026-27 growth forecast to 6.6% (from 6.9%) with inflation projected at 5.1% In addition, both the Government and the Reserve Bank have adopted various measures related to taxation and deposit schemes to combat currency depreciation and balance equity capital flows thus continuing to maintain the fine macroeconomic balance.



Source: MoSPI June 2026 release, RBI June 2026 Monetary Policy Review

INDUSTRY OVERVIEW

GLOBAL PHARMACEUTICAL INDUSTRY

Market Overview

The global pharmaceutical industry serves as the foundational pillar of modern healthcare and global public health. It has contributed the most in saving countless lives, increase average lifespan and improving quality of life. The pharma industry is now highly industrialized and execution-driven covering the entire lifecycle of therapeutic solutions from early-stage scientific research, drug discovery, clinical testing, quality-controlled manufacturing and secure distribution networks. Global size of the industry was ~ US$ 2 trillion in 2025 and was expected to reach US$ 2.15 trillion in 2026.[1]

The current state of the global pharmaceutical market is characterized by structural portfolio rebalancing and a definitive tilt toward large-molecule biopharmaceuticals vs. small molecules/ conventional drugs. Biologics and biosimilars are projected to claim an impressive 39.09% share of the total global market in 2026.[2] Concurrently, small-molecule chemical entities continue to act as a crucial, lower-cost baseline for corporate cash flows, providing the baseline capital that diversified drugmakers require to fund complex pipelines. The commercial environment has transitioned from discovery-led valuations to execution-driven performance, where long-term success is dictated by manufacturing scale, supply-chain resilience, and rapid speed-to-market.

1 *https://www.fortunebusinessinsights.com/impact-of-covid-19-on-pharmaceuticals-market-102685*

2 *https://www.fortunebusinessinsights.com/impact-of-covid-19-on-pharmaceuticals-market-102685*

OUTLOOK

Data from the Fortune Business Insight's report on the Impact of Covid-19 on Pharmaceutical Market (June 2026 update), indicates that the global pharmaceutical industry is expected to sustain an elevated CAGR of over 8%, and projected to reach US$ 4.04 trillion in size by 2034. This momentum highlights a critical industry transformation: despite navigating a massive patent cliff and intensifying state-backed price controls, the global market is successfully absorbing headwinds due to unprecedented breakthrough innovations in large-molecule biologics, precision oncology, and cardiometabolic therapies. The global industry is poised to see accelerating volume expansion across emerging geographies alongside selective value tightening in Western markets. While net pricing growth in developed economies will experience moderate downward pressure due to payer constraints, the absolute demand for innovative drugs will remain robust.

KEY GROWTH DRIVERS

The global expansion driving incremental revenues for the pharmaceutical industry is being driven in the following areas primarily:

GLP-1 and Obesity Medical Revolution: Cardiometabolic treatments have completely redrawn the industry's growth map. The global obesity medicines market reached $66 billion in list price value in 2025 and is forecast to rise to $92 billion in 2026, before climbing toward a projected window of $105 billion to $200 billion by 2027 and beyond. Innovation in this sector is expanding from basic weight loss to broad comorbidity benefits, including chronic kidney disease, cardiovascular health, and muscle preservation.

Precision Oncology and Targeted Biologics: Oncology continues to dominate as the largest singular therapeutic segment, capturing a 17.62% share of the global market in 2026. Growth within this vertical is propelled by the accelerating clinical adoption of Antibody-Drug Conjugates (ADCs), novel monoclonal antibodies (mAbs), and specialized bispecific therapies.

Innovation in Drug Development: There is surging interest in the next frontier of therapeutics such as mRNA, cell and gene therapies, and personalized medicine.

Demographic Tailwinds: The undeniable economic weight of an aging global population with an enhanced purchasing power is accelerating non-communicable disease (NCD) treatment volumes. Managing chronic conditions is projected to have secure long-term demand across central nervous system (CNS), immunology, and endocrinology segments.

Digital Health Integration: Use of AI and ML in drug discovery and clinical trial digitization, will result in shorter drug development and testing cycle and lower costs, thus boosting financial growth for the sector.

Increased Healthcare Spending by Governments: According to a comprehensive global impact report by WifOR Institute (published for the International Federation of Pharmaceutical Manufacturers & Associations or IFPMA), the public health sector is the primary buyer of the global pharmaceutical industry's outputs, consuming 52.4% of all goods and services. Hence, expansion in public healthcare programs and related spends acts as a catalyst for stable, high-volume growth for the industry.

EMERGING TRENDS

The newer trends that are gaining traction in the industry are as follows:

Biosimilars and Biologics: Accelerated global adoption, growing pipeline and updated regulatory paths that eliminate mandatory Phase 3 trials.

Precision Medicine: Advanced integration of AI, multi-omics, and biomarkers to design highly targeted, personalized patient treatments and commercial scaling of gene-editing tools like CRISPR.

Sustainability: Tightening ESG mandates driving green chemistry, zero-waste manufacturing, and carbon-neutral facilities to secure cross-border market access.

Continuous Manufacturing: Industry is transitioning from the legacy batch production to continuous compression platforms which reduce operational costs by 30% to 50% while automating real-time quality control.

Solubilization Technologies: Commercial deployment of nanoparticulation, advanced solid dispersions and lipid vectors to overcome hydrophobic small molecules have helped optimize drug bioavailability while reducing the dosage size and side effects.

REGIONAL OUTLOOK

The market demand and industry structure of the global market vary significantly by region, as detailed in the matrix below:

Region	Current Size & Outlook[3]	Drivers
North America	Retains absolute global value dominance with an industry size of US$ 895.79 Billion in 2025 and projections to reach US$ 959.4 Billion in 2026; the U.S. five-year growth trajectory continues to outpace the rest of the world combined.	Driven by premium innovative medicine launches, high per-capita healthcare spending, and robust private venture R&D capital.
Latin America, Middle East & Africa	Combined market size of US$ 116.22 Billion in 2025 that would rise to US$ 122.81 Billion in 2026 as per projections.	Enhanced purchasing power, ageing population, improvements in healthcare infrastructure and collaborations between domestic and global players are driving industry expansion.

KEY FOCUS MARKETS

Mexico: The pharmaceutical industry in Mexico is the second-largest market in Latin America (behind Brazil) and ranks among the top 15 global markets. Generating approximately USD 18.2 billion in revenue in 2025, the market is projected to reach USD 35 billion by 2033, expanding at a Compounded Annual Growth Rate (CAGR) of 8.6%. Generics make up over 70% of total prescriptions; however, large-molecule biologics and biosimilars represent the fastest-growing market segment.[4]

Demographic Tailwinds: The undeniable economic weight of an aging global population with an enhanced purchasing power is accelerating non-communicable disease (NCD) treatment volumes. Managing chronic conditions is projected to have secure long-term demand across central nervous system (CNS), immunology, and endocrinology segments.

Mexico's pharmaceutical market requires localized strategies due to administrative backlogs at the regulatory agency, COFEPRIS, and the consolidation of public procurement under state platforms like IMSS-Bienestar (Source: PharmaBoardroom, 2025). Aligning with these dynamics, Caplin's 'Plan Mexico' rewards local presence. Caplin has purchased land in Toluca; landfilling and drainage works are underway, and construction of a localized manufacturing facility is expected to begin by mid-2027. This localization ensures Caplin can compete for tenders restricted to domestic manufacturers.

Chile: The pharmaceutical market in Chile is one of the most developed, highly regulated, and stable markets in Latin America. Generating

3 *https://www.fortunebusinessinsights.com/impact-of-covid-19-on-pharmaceuticals-market-102685*

4 *https://share.google/0gNEadUaoVENRIEfb*

approximately USD 2.7 billion in revenue in 2025, the market is projected to reach USD 3.12 billion by 2028 and expand to USD 5.32 billion by 2035 at a CAGR of 7.89%. Chile boasts the highest healthcare expenditure relative to GDP in Latin America at approximately 9%.[5]

Recent substitution mandates like 'Ley de Fármacos II' require strict ISP bioequivalence and consolidate dispensing power among major pharmacy chains. Consequently, the state procurement agency, CENABAST, has become a vital channel for generic volume. Capitalizing on this, Caplin holds 24 running contracts in Chile expected to contribute USD 9.5 million in FY27. Furthermore, Caplin is aggressively entering the Chilean private market with 35 oral solid dosages and 8 oncology dossiers submitted.

Guatemala: The Guatemalan pharmaceutical market is the largest and most rapidly growing market in Central America. It generated approximately USD 1.45 billion in revenue in 2025, and is projected to reach USD 2.1 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2%. Serving as the geographic gateway to Central America, Guatemala acts as a strategic manufacturing and logistics launchpad for the entire region.[6]

R&D AND REGULATORY LANDSCAPE

The Global R&D and Regulatory environment in 2026 is witnessing major shifts leading to heightened complexity and stringent standards that the industry is expected to manage successfully.

Global Spends: The total global pharmaceutical and biotechnology R&D expenditure was between US$ 250 billion and US$ 300 billion in 2025. The industry is seeing a mixed picture where a good number of large players have pruned underperforming portfolios and restructured them, whereas others are riding high demand areas such as cardiometabolic drugs.

Implementation of the US Inflation Reduction Act (IRA): The first round of Medicare-negotiated drug prices took effect in 2026, altering the long-term net-pricing structures of blockbuster treatments in the United States.

Legislative actions like the U.S. BIOSECURE Act are enforcing strict licensing boundaries on foreign-linked manufacturing partnerships, forcing global pharma companies to build "China+1" geographic redundancy into their supply chains.

Geopolitical Decoupling and Sourcing Reforms: Legislative actions like the U.S. BIOSECURE Act are enforcing strict licensing boundaries on foreign-linked manufacturing partnerships, forcing global pharma companies to build "China+1" geographic redundancy into their supply chains.

CHALLENGES

The diversity of global markets and everchanging environment bring a multifaceted set of challenges for industry participants. The most critical challenges faced by the Global Pharma companies are as follows:

Forced Supply Chain Localization: Global pharmaceutical giants are facing immense pressure to re-shore active ingredient manufacturing due to tariff threats and national security concerns. This forced regionalization is fragmenting the historical low-cost, global supply model.

5 *https://www.linkedin.com/posts/patel-vaibhav-1b1ab0269_chilepharma-drugregistration-marketaccess-share-7457291266750328833-VjGi/*

6 *https://www.statista.com/outlook/hmo/pharmaceuticals/guatemala/?srsltid=AfmBOoqX74nMCqPk0f9PwAyXaT1yB5Ui8WkBmGJZgfsWPHvqMCIHoDz6*

Severe PBM and Payer Concessions: The U.S. market is increasingly witnessing commercial concessions, rebates, and pharmacy benefit manager (PBM) clawbacks.

Escalating Clinical Complexity: The rising baseline complexity of targeted multi-omics, cell therapies, and specialized oncology lines is keeping drug development cost high despite efficiencies derived from AI/ ML usage.

Regulatory Compliance and Cybersecurity: Evolving global regulatory mandates and the escalating necessity to secure sensitive patient data from sophisticated cyber threats take up significant time and resources of the industry.

INDIAN PHARMACEUTICAL INDUSTRY

Market Overview

The Indian pharmaceutical industry has reached a pivotal milestone in its structural growth lifecycle. Long heralded as the "Pharmacy of the World" for its massive volume capacity, the sector is successfully executing a transition from a volume-driven framework to a value-driven scientific ecosystem including complex therapeutics, biosimilars, and integrated supply networks.

According to the Economic Survey 2025-26, the sector recorded a total turnover of ₹4.72 lakh crore (USD 55 billion) in FY 2025, which included exports worth USD 30.5 billion. India maintains its position as the world's 3rd largest pharmaceutical market by volume and ranks 11th in export value globally. Indian products are exported to 191 countries, with over 50% directed to stringent regulatory environments across North America and Europe.[7]

Market intelligence from Mordor Intelligence and industry analysts indicates that the overall Indian pharmaceutical ecosystem was valued at approximately ₹4.97 lakh crore (USD 57.61 billion) in 2025, and is estimated to reach ₹5.20 lakh crore (USD 60.32 billion) in 2026, maintaining a steady expansion rate of 7% to 9% as it scales toward a long-term target of USD 130 billion by 2030.[8]

Key Growth Drivers

The accelerated expansion of India's pharmaceutical capability is powered by a combination of regulatory developments, policy interventions, and demand outlook:

1. **Production-Linked Incentive (PLI) Schemes:** The Government of India's operational PLI scheme (with an outlay of ₹15,000 crore / $2.04 billion running through 2028-29) for Bulk Drugs/ API has successfully catalysed domestic investments in manufacturing.
2. **Massive Infrastructure Funding:** In late 2025, the Ministry of Chemicals and Fertilizers announced a targeted ₹60,000 crore ($7 billion) API-push framework designed to build specialized bulk drug parks, establishing strong state-backed clusters in Gujarat, Andhra Pradesh, and Himachal Pradesh.
3. **Biologics & Biosimilars Push:** In February 2026, the government unveiled the Biopharma Shakti investment initiative that earmarked ₹10,000 crores ($1.08 billion) to build next-generation clinical trial infrastructure, support cell and gene therapy networks, and scale indigenous biologics capabilities.
4. **Quality Standard Overhauls:** The institutionalization of the revised Schedule M guidelines under the Drugs and Cosmetics Act is aligning domestic quality frameworks directly with global regulatory baselines.

EXPORT & GLOBAL INTEGRATION

India's pharmaceutical exports rose by more than 2% year-on-year to hit a record US$ 31.11 billion in FY 2025-26, breaking the previous high of US$ 30.47 billion recorded in FY 2024-25. India fulfils 20% of the global volume demand for Generics and supplies 55-60% of the UNICEF's

7 *https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/mar/doc2026321831401.pdf*

8 *https://www.ibef.org/industry/pharmaceutical-india*

global vaccine procurement.[9] USA remains the largest export market for India and more than 50% of the export volumes are sent to highly regulated western markets. However, the share of alternative emerging destinations such as EU, Brazil, Russia, Francophone Africa, etc. is on a rising trend due to emphasis on diversification away from the USA. Indian pharma players are also moving up and across the value chain by growing their share of the Branded Generics, Biosimilars, and API/Bulk Drug markets.

R&D AND INNOVATION TRENDS

The Indian pharmaceutical industry has over the years shifted away from simple reverse-engineering toward advanced drug discovery models, complex delivery systems, and specialty biopharmaceuticals, and this trend has accelerated in the last few years.

Digitalisation: By integrating Artificial Intelligence and Machine Learning technologies, Indian companies are successfully cutting down baseline drug discovery and clinical trial validation cycle times by up to 20%.

PRIP Scheme: Indian Government has allocated ₹5,000 Crores towards the Promotion of Research and Innovation in Pharma-MedTech (PRIP) scheme to provide state-backed risk capital to fund early- and late-stage R&D in precision medicine, gene therapies, and novel medical devices.

Focus Shift: Capital expenditure across mid-and large-cap firms is heavily favouring biopharmaceuticals, high-barrier and sterile delivery platforms, and inorganic acquisition of product portfolios and proprietary platforms in addition to internal R&D.

OPPORTUNITIES AHEAD

Global Patent Cliff: Between 2026 and 2030, multiple blockbuster biological drugs and small-molecule formulations are set to lose patent exclusivity. The global industry is looking at an exclusivity loss amounting to ~US$ 200 billion by 2030. This offers an enormous multi-billion-dollar opportunity for Indian pharma players.

Sourcing Shift: India's Contract Research, Development, and Manufacturing Organizations (CRDMO) sector is projected to double its market size to US$ 14 billion by 2028 because of the rapid "China+1" diversification wave.

SEGMENT WISE OUTLOOK

Segment	Current Size & Outlook	Drivers
Generics	20% of global supply volume is from India. It is projected to grow at 8-10% in revenue terms.	Evolving product shortages in the US; rising demand for complex generic formulations
API/ Bulk Drugs	Valued at US$ 19.21 Billion in 2025 and expected to touch US$ 20.7 Billion in 2026. Long-term CAGR of 7.8%.[10]	State-backed Bulk Drug Park allocations; implementation of green chemistry protocols
Biosimilars	Valued at US$ 1.29 Billion in 2025 and projections of US$ 1.54 Billion in 2026. Long-term CAGR of 21.3%.[11]	Dominated by Monoclonal Antibodies (mAbs); rapid commercial scale-up of Insulin analogues.
Domestic Formulations	Expected to maintain healthy CAGR of 10% over a 10-year period from ₹ 2,00,000 Crores in 2024.[12]	Volume expansion in chronic therapies (Oncology, Anti-Diabetic, and Cardiac segments).
OTC & Wellness	Expected to grow from ₹47,000 Crores in 2024 to ₹98,000 Cr in 2030, i.e., 13% CAGR.[13]	Driven by a systemic post-pandemic shift toward preventive health.

9 *https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/mar/doc2026321831401.pdf*

10 *https://www.imarcgroup.com/india-active-pharmaceutical-ingredients-market*
11 *https://www.grandviewresearch.com/horizon/outlook/biosimilars-market/india*
12 *https://www.avendus.com/insights/investment-banking/report/indian-domestic-formulations-an-inr-5-5-trillion-market-by-2034*
13 *https://www.ey.com/en_in/newsroom/2026/01/india-s-over-the-counter-drugs-market-set-to-hit-dollor-98-000-crore-by-2030-growing-at-13-percent-cagr-ey-parthenon-report*

CHALLENGES FOR INDIAN PHARMACEUTICAL INDUSTRY

Despite staggering growth over the years, the Indian Pharma industry continues to face significant structural challenges that also offer an opportunity for the players to innovate and differentiate.

Key Starting Material (KSM) Dependency: Indian formulation players continue to depend heavily on imports, primarily from China, for approximately 35% of their total raw material requirements. This could lead to severe margin compression due to price shock in input costs.

Heightened Regulatory Oversight: Compliance remains an active operational risk. The trend of post-pandemic acceleration of physical USFDA plant audits, for e.g., has resulted in delayed product launches and heavy financial cost due to a rise in warning letters and strict import alerts.

Geopolitical & Logistic Vulnerabilities: Ongoing regional wars, particularly in West Asia, continue to trigger severe shipping bottlenecks, erratic container availability, and steep freight rate spikes, impacting export volumes and lengthening global time-to-market metrics.

Pricing Pressures: The Drug Price Control Order (DPCO) framework leaves little pricing headroom for domestic drug manufacturers to address escalating raw material and energy costs and invest in upgraded compliance regimens. Correspondingly, in the export market, intense competition and concentrated buying power of the customers in the biggest export market, USA, has resulted in deflationary pressure on generics pricing.

COMPANY OVERVIEW

Caplin has established itself as an industry benchmark based on its consistent financial high performance across revenue, profit and cash generation. Caplin successfully doubled its revenues to ₹2,300 crores while tripling both its free cash reserves and liquid assets over the last five years. It has maintained a highly resilient, debt-free balance sheet while internally financing its strategic evolution with a continuous, aggressive CAPEX of around ₹900 crores during this period.

From its start as a plain-vanilla generic manufacturer serving frontier markets across Latin America and Francophone Africa, Caplin has undergone a profound strategic transformation. It has evolved into a technology-led, R&D-driven, and vertically integrated pharmaceutical player that offers a highly diversified portfolio of branded generics and difficult-to-manufacture products across 36 therapeutic segments with a presence in more than 23 countries including the core Emerging and new Regulated markets. Its in-house R&D facilities and state-of-the-art manufacturing facilities are certified by US-FDA, INVIMA-Colombia, WHO-GMP, EU-GMP, UAE-MoHAP, ANVISA-Brazil, ISP-Chile and DCGI-India.

Caplin has 5,000+ product registrations and 30,000+ touch points in the Emerging Markets of Latin America, Caribbean and Africa, clearly demonstrating the breadth of its product portfolio and deep distribution strength in these markets. It has particularly strong presence in the Central American countries. Alongside its retail and private brand distribution channels, in key Latin American growth markets such as Mexico and Chile, Caplin is also successfully scaling its footprint by actively securing high-value institutional tender wins. Its business growth in these key markets is supported by a growing portfolio of over 160 product licenses across both countries and a rapidly expanding pipeline for filings. It has also bolstered the product pipeline in Emerging Markets through its “China 2.0” strategy of partnering with Chinese companies that have ANDAs/ MAs approved in US and EU. Caplin’s commitment to Latin American region is further reinforced by targeted local infrastructure investments, including an operational warehouse in Chile and industrial land acquisition in Mexico for localized manufacturing. It is scaling up complex, high-margin delivery platforms, including Ready-to-Use (RTU) bags and specialized Unit Dose Ophthalmics utilizing advanced Blow-Fill-Seal (BFS) technology. This portfolio pivot has established a rapidly expanding footprint in highly regulated spaces, driven by a surging US ANDA pipeline alongside active expansions in Canada, Australia, and Brazil.

Caplin systematically allocates capital toward comprehensive backward integration via advanced API plants, specialized contract research (CRO) setups like Amaris Clinicals. Supported by 5 state-of-the-art R&D centres and owned distribution, Caplin remains structurally insulated from global supply disruptions and perfectly positioned for sustainable global scaling.

FINANCIAL PERFORMANCE DURING THE YEAR

(₹ in Crores)

Metric	FY25	FY26	Growth
Total Revenue	2,034	2,303	13.2%
Revenue from Operations	1,937	2,187	12.9%
Gross Profit	1,167	1,322	13.3%
EBITDA	743	876	17.9%
EBIT	677	803	18.6%
PAT	541	650	20.1%
Cash & Cash Equivalents	1,180	1,471	24.7%
R&D Spend	89	101	13.5%

Caplin maintained its track record of delivering sustained growth across the top line and the bottom line in FY 2025-26. Thus, the charismatic combination of the founder Chairman's guiding vision and 'smartwork' of Caplin's young and dynamic operational leadership team continued to propel Caplin's structural transformation, without compromising on the balance sheet quality and financial performance. Caplin surpassed its previous highest consolidated revenue from operations to touch a new high of ₹ 2,187.19 crore during the year. The margins showed improvement across all profitability metrics in FY 2025-26 with the EBITDA margin jumping 160 basis points from 36.5% to 38.1% and the PAT margin going up to 28.2% from 26.6% in the previous year.

STRATEGIC & OPERATIONAL PARAMETERS

Caplin continued to achieve milestones on its transformational journey by delivering progressing on key strategic parameters.

- Company remained debt-free with ₹ 1,471 Cr cash reserves on its balance sheet.
- Its premiumisation push delivered a 25% revenue share of Branded Generics in FY 2025-26.
- Revenue contribution of the Regulated markets (USA) went up from 18% in FY 2024-25 to 21% in FY 2025-26.
- Tender business (Institutional Channel) is getting increased traction in larger markets like Chile.
- Share of exports from India went up to 76% from 73% in FY 2024-25 and is expected to go up further as full capacity addition comes online.

R&D & MANUFACTURING SCALE-UP (CROSS-GEOGRAPHY IMPACT)

During FY 2025-26, Caplin continued to set newer benchmarks with its R&D and Manufacturing initiatives.

- Imminent launch of a lineup of Branded Pre-Filled Syringe products in LatAm, providing a unique value addition to our growing portfolio.
- Entering highly niche and complex Blow-Fill-Seal (BFS) technology segment, with the first product development nearing completion for Unit Dose Ophthalmics and Sterile Inhalation products, backed by a development pipeline of over 14 products.

- Amaris Clinical (CRO): To cater to growing demands for internal pipeline products BE and Clinical studies, Company plans to take up expansion activities at Amaris Clinical to increase capacity up to 120 Beds.
- API: the API unit at Vizag received its manufacturing license and completed validations for 4 APIs; plans on track to validate 12 more APIs before the end of the calendar year 2026.
- COL Injectable facility at Gummidipoondi for injectables and ophthalmics is scheduled for completion by Q1 FY2027-28.
- Oncology API facility at Thervoy Kandigai is scheduled for completion by Q4 FY2026-27.
- OSD facility at Puducherry is scheduled for completion by Q1 FY2027-28.

CAPLIN STERILES LIMITED (CSL):

CSL continued its journey of growing its share of contribution in the overall growth journey of Caplin. The major developments in CSL, during the year were as under

- 10 new ANDA approvals received in FY26, alongside 10 ANDAs acquired from 3rd party companies.
- Around 15 products in the development pipeline, which are likely to be filed in the US within FY27, predominantly in Pre-Filled Syringes and niche segments.
- Filed 54 products (of which 32 are approved) across multiple Non-US markets (Canada, EU, Australia, Mexico, Brazil, South Africa, Saudi, UAE, etc.), with plans to file 50+ products in these regions over the next 18 months.
- Company expands capacity of IV Bag lines to 3X the current size, since multiple products have been approved in this niche segment.

Caplin maintained its track record of delivering sustained growth across the top line and the bottom line in FY 2025-26. Thus, the charismatic combination of the founder Chairman's guiding vision and 'smartwork' of Caplin's young and dynamic operational leadership team continued to propel Caplin's structural transformation

- Company's unique "Project Visual Integration" has been operational by the fisrt quarter of FY27. This project will ensure complete integration and monitoring of all critical processes, as part of Caplin's continuous push towards Automation and Compliance.

OWN-LABEL FRONT-END IN THE US:

This ambitious strategic move for the regulated markets continued progressing successfully in FY 2025-26.

- CSU launched 30 products and secured critical distribution infrastructure, including weekly ordering cycles with the 'Big 4' US wholesalers and direct supply agreements with over 30 Integrated Delivery Networks (IDNs) and hospital systems.
- Tied up with major wholesalers and 30+ direct buyers (hospital systems).
- Current end users: 14,300 (hospitals, pharmacies, clinics, etc.)

THE STRATEGIC GROWTH INITIATIVES:

Caplin continued its journey of successfully compounding returns while building strategic redundancies in FY 2025-26. It invested in creating new capacities, adding and acquiring newer products, and enhancing product portfolio through R&D. Following is an update on the key projects as at end of FY 2025-26 from Mr. C.C. Paarthipan, Chairman of Caplin Point Laboratories Limited, who said:

"Our Emerging Markets business continues to be a reliable growth engine, driven by deep market presence, expanding product portfolios, and increasing participation in institutional channels. At the same time, we are making meaningful strides in strengthening our footprint in Regulated Markets, particularly in the United States, where Caplin Steriles is gaining scale and depth."

"During the year, we made significant investments in building future capabilities — across manufacturing, automation, compliance strengthening, backward integration, product development, and regulatory filings. Our progress in Oncology, APIs, and complex dosage forms such as Pre-Filled Syringes and Blow-Fill-Seal technology, positions us well for the next phase of growth."

"We are also encouraged by the early success of Caplin Steriles USA, our front-end initiative in the US, which achieved profitability within its first year of operations — an outcome that reflects both execution discipline and the strength of our product selection. This was done without a de-growth in our B2B business, which shows our discipline in capacity utilization and ensuring consistent supply across segments."

"As we look ahead, our focus remains clear: to build a diversified and resilient business across geographies, deepen our presence in complex and differentiated products, and continue investing in quality, compliance, and automation. Initiatives such as our backward integration program, expansion into new technologies, and digital transformation efforts will play a critical role in strengthening our competitive position."

FINANCIAL RATIOS

Below are some of the Key Financial ratios:

Particulars	Consolidated			Standalone		
	FY26	FY25	Variance	FY26	FY25	Variance
Debtor Turnover Ratio (Times)	3.00	3.30	(9.10%)	3.35	4.95	(32.40%)
Inventory Turnover Ratio (Times)	2.26	2.21	2.41%	3.01	3.12	(3.39%)
Current Ratio (Times)	6.70	6.97	(3.93%)	6.77	8.27	(18.15%)
Interest Coverage Ratio (Times)	NA	NA	-	NA	NA	-
Debt Equity Ratio (Times)	NA	NA	-	NA	NA	-
Operating Profit Margin %	34.90%	33.31%	4.78%	54.38%	49.81%	9.18%
Net Profit Margin %	28.22%	26.60%	6.06%	42.47%	38.27%	10.99%
Return on Net Worth %	17.89%	18.75%	(4.54%)	19.34%	38.27%	(49.46%)

Explanation for variance in ratios:
**Primarily attributable to increased sales during the later part of the year coupled with normal credit period available to customers.*
***Increase in foreign exchange translation reserve of Rs. 141.42 Crores, which is part of Net worth, has not been routed through P&L account thereby marginally reducing the Return on Networth year-on-year basis.*

RISK MANAGEMENT

Caplin recognises that effective risk management is a key factor in operating its business successfully. To achieve operational and financial excellence, Caplin's Enterprise Risk Management (ERM) Framework prioritises realising a fine balance between managing risks and exploiting opportunities. The Framework, which is well-established and robust, covers these steps that are performed regularly: **Identify** (recognize and define the risks), **Analyse** (assess impact and probability), **Strategise** (prioritise risks and design approach/es to tackle them), **Address** (implement strategies designed to tackle the risks) and **Monitor & Improve** (review performance and improve the Framework). The feedback loop, and monitoring of significant external developments and internal operational milestones that can impact the risk portfolio, is critical to tackle any new/ emerging threats and note changes in the severity or probability of any existing risk. The ERM framework enables Caplin to navigate complex global environments effectively by keeping a vigilant eye on any changes in its risk profile.

A comprehensive review of the risk management policy is also carried out annually by the Risk Management Committee (RMC; formed by the Board) and the Board of Directors to ensure long-term business continuity. The RMC meets periodically and brings together the expertise of our CFO, Independent Directors, and senior operational executives. In addition, Caplin's senior leadership team actively drives risk governance measures at the corporate, plant and regional levels to enforce standard operating procedures.

Caplin recognizes that structural risks cannot be entirely eliminated, however, it tries to execute comprehensive mitigation measures to minimise the impact of such risks. It adopts four high-level approaches to tackle all risks, which are as follows:

Mitigation: Minimise the threat level by changing workflows or improving physical security/ protection.

Transfer: Offload the financial and operational risks to a third-party.

Avoidance: Drop the high-risk activity in case of very high impact where mitigation and transfer are not feasible.

Acceptance: Live with the risk while setting aside a financial buffer in case of an eventuality and ensure active monitoring.

Below is the updated, summarized account of our key risks and the corresponding mitigation measures.

The feedback loop, and monitoring of significant external developments and internal operational milestones that can impact the risk portfolio, is critical to tackle any new/ emerging threats and note changes in the severity or probability of any existing risk.

STRUCTURAL RISKS & MITIGATION ARCHITECTURE

Area	Category	Impact	Mitigation
Country Risk	Portfolio	Political instability, changes in local regulations, or localized economic crises in core territories could disrupt established revenue flows.	Securing first-mover advantage by pioneering entry into challenging frontier markets across Latin America (LATAM) and Francophone Africa, building a deep, defensive distribution moat. De-risk footprint by expanding its presence in highly regulated and larger economies like USA, Mexico, Chile, Colombia, Brazil, etc, and entering newer markets. 'Stock and Sale' model helps insulate operations by keeping enough inventory close to its end-customer. It also helps minimise sensitivity to trade friction, currency fluctuations and supply disruptions.
Regulatory Risk	Portfolio & Operational	Evolving validation standards or negative audit observations from international regulatory bodies could lead to production halts, import alerts, or delays in product commercialization.	Enforcing an "always-ready" regulatory compliance posture across all manufacturing and R&D facilities (proven by its successful inspection track record with premier global regulators including the USFDA, EU-GMP, ANVISA, and INVIMA). Gaps caught during internal audits trigger immediate, rigorous corrective and preventive actions (CAPA).
Supply Chain & Operational Risks	Operational	Over-reliance on single-source supply (whether raw material or final products) or localized asset constraints could stall order fulfilment and compromise market share.	Fine balancing of the need for speedy and asset-light expansion; supply diversification and in-house control on production through a strategic manufacturing split: 60% in-house production and 40% outsourced volume. Allocated outsourced volume across thoroughly vetted multiple Contract Manufacturing Organizations (CMOs) in India and China. Vertical integration with its own API plants, R&D and distribution.

Area	Category	Impact	Mitigation
Talent Pipeline & Human Capital Attrition Risk	Operational	Loss of specialized scientific talent in research domains or high attrition rates among technical shop-floor personnel could stall R&D pipelines and impair strict GMP compliance.	Investing in specialized on the job technical training to employees, performance-linked incentives, and transparent career progression mapping. Actively recruiting and upskilling rural women work force for core manufacturing and laboratory roles leading to a highly disciplined, resilient, and locally rooted workforce that significantly reduces shop-floor attrition and safeguards technical continuity.
Product Portfolio & Lifecycle Risk	Portfolio & Operational	Lack of new product pipeline and overdependence on a small set of products can lead to attrition in market share. Without swift approvals, the R&D ROI would fall due to cost overruns and obsolete pipelines.	Maintaining a highly disciplined R&D spend, currently at ~ 4.6% of revenue from operations, distributed across 5 independent, state-of-the-art R&D centres. Distributed research focus yielding a robust and diverse product portfolio and future pipeline across 36 distinct therapeutic segments that covers over 65% of the WHO Essential Medicines List. Tactical acquisition of 15 third-party ANDAs taking the cumulative ANDA portfolio to 65 filings, 59 approvals and 55+ in pipeline. Active focus on increasing the base of product registrations leading to a massive portfolio of 5,000+ registrations for 650+ pharmaceutical formulations in the emerging markets. Across non-US regulated zones such as Canada, Australia, Caplin Steriles Limited (CSL) has successfully filed 54 products out of which 32 have been approved. Focus on niche delivery platforms and difficult to manufacture products to get a competitive edge.
Regulated Market Compliance Risk	Portfolio	Entering highly regulated countries like the USA and EU increases the vulnerability to stringent systemic audits.	Maintain an entirely segregated, dedicated manufacturing units and specialized regulatory affairs teams specifically for highly regulated territories. Execute aggressive internal cross-audits and deploy automated data logging systems to match the evolving oversight demands of Western regulatory bodies, keeping Caplin insulated from systemic enforcement actions.

Area	Category	Impact	Mitigation
Data Governance Risk	Operational	Sophisticated cyberattacks, ransomware, or network breaches could compromise proprietary drug formulations, disrupt automated manufacturing lines, or result in data integrity violations.	Implement an enterprise-wide cybersecurity architecture in step with its digital transformation roadmap (includes next-generation firewalls, continuous end-point tracking, multi-factor authentication, and encrypted air-gapped backups across all 5 R&D hubs and operational facilities). Subject systems to routine independent vulnerability assessments to guarantee absolute data security and strict compliance with global digital data storage mandates.
Environmental Impact & ESG Compliance Risk	Operational	Failure to keep pace with changing environmental mandates or global sustainability benchmarks could lead to penalties, operational closures, or institutional investor alienation.	Integrate ESG benchmarks directly into operational protocols. Aggressively control its environmental footprint by integrating green logistics and maximizing energy efficiency across plant sites. On the social front protect community relations through targeted investments in rural healthcare via CSR. Advance corporate governance and social equity by expanding high-value, safe career pathways for the rural workforce.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

Caplin maintains a comprehensive system of internal controls and monitoring procedures tailored to the scope, scale, and operational complexity of its business. This framework establishes robust checks and balances designed to ensure the orderly and efficient conduct of operations, strict policy adherence, and the prevention and detection of administrative errors or fraud. The system ensures that all transactions are accurately authorized, recorded, and reported, while safeguarding corporate assets against loss from unauthorized use or disposal.

Caplin has engaged an independent, professional Internal Audit firm to evaluate its control systems. The Audit Committee reviews and approves annual audit plans derived from systematic internal risk assessments. Audits are conducted on an ongoing basis, and the internal auditors present their findings quarterly to the Audit Committee. Any significant deviations are brought directly to the Committee's notice, allowing for early remedial actions and the swift execution of recommended corrective measures.

The Audit Committee routinely consults with executive management, statutory auditors, and the internal audit team to gauge the strength of the financial controls. The Committee is satisfied with the adequacy and operational effectiveness of these controls and keeps the Board of Directors informed. Caplin mandates technological updates based on periodic reviews to ensure the systems evolve dynamically alongside business environment and growth.

INDUSTRIAL RELATION AND HUMAN RESOURCES

The Industrial Relations scenario continued to be cordial during the year under review. Caplin regards its expanding global workforce of 3,389 employees across manufacturing, R&D, distribution, and corporate functions as its most valuable asset. Caplin's sustained growth is driven by the relentless dedication, passion, and strong sense of ownership displayed by its people.

Caplin maintains a culture of openness, transparency, and a distinct bottom-up approach to its shop-floor decision-making that helps in providing its employees a hospitable and encouraging work environment. This environment fosters a profound pride of association that translates into high engagement levels and a lower employee turnover rate across all operational units.

Talent Acquisition: The Human Resources department has put in place a modernized, long-term talent acquisition strategy to support Caplin's growth that is aligned with its operational expansion. Caplin's streamlined recruitment cycle swiftly onboards specialized professionals in stringent regulatory, advanced R&D, and sterile manufacturing domains. In order to maintain deep market alignment, especially in regulated territories, the front-end teams in the US and Latin American markets continue to be driven heavily by local talent acquisition.

Work Culture: Caplin has expanded its technical and soft-skills training protocols, utilizing the "Caplin Connect" internal digital platform with an objective to cultivate a continuous learning culture. In tandem with Caplin's digital transformation roadmap, targeted upskilling initiatives have actively prepared employees to operate advanced analytical tools, smart manufacturing frameworks, and e-logbook applications, minimizing operational risks and securing internal talent mobility. Caplin focuses on meritocracy and accountability through its existing performance management framework that includes a KPI-linked Variable Pay and Employee Stock Option Plans (ESOPs), thus directly rewarding employees based on corporate success. The founding management team is actively involved in mentoring mid-level managers for leadership roles.

Diversity & Inclusion: Caplin continues to champion social equity and operational excellence by actively recruiting and upskilling women professionals from rural and semi-urban areas near its manufacturing facilities, structurally strengthening shop-floor discipline and data integrity, while improving gender diversity of the workforce. It also delivers social impact through healthcare and employment initiatives, particularly for underserved areas, where their employees need to align with the needs of the communities neighbouring their facilities.

Caplin also prioritises holistic employee well-being through engagement activities that include celebrating cultural festivities, acknowledging big and small team wins, events and involvement of employees in Caplin's CSR initiatives. Through these continuous efforts, Caplin ensures a safe, agile, and empowering environment that positions its human capital for sustained global success.

Caplin maintains a culture of openness, transparency, and a distinct bottom-up approach to its shop-floor decision-making that helps in providing its employees a hospitable and encouraging work environment. This environment fosters a profound pride of association that translates into high engagement levels and a lower employee turnover rate across all operational units.

ADHERENCE TO ACCOUNTING STANDARDS

Caplin continues to adhere to standard accounting policies under the Indian Accounting Standards (Ind AS), as applicable.

CAUTIONARY STATEMENT

Certain statements made in this section describe Caplin's objectives, projections, expectation and estimations which may be 'forward looking statements' within the meaning of applicable securities laws and regulations. Forward–looking statements are based on certain assumptions and expectations of future events. Caplin cannot guarantee that these assumptions and expectations are accurate or will be realised by Caplin. Actual results could differ materially from those expressed in the statements or implied due to the influence of external factors which are beyond the control of Caplin. Caplin assumes no responsibility to publicly amend, modify or revise any forward-looking statements on the basis of any subsequent developments.

CAPLIN POINT®
Laboratories

MANAGEMENT REPORTS

DIRECTORS' REPORT

To the Members,

The Directors present their 35th Annual Report on the business and operations of the Company and the financial statements for the year ended March 31, 2026.

1. FINANCIAL HIGHLIGHTS

₹ in Crores

Financial Results	Standalone		Consolidated	
Particulars	**2025-26**	**2024-25**	**2025-26**	**2024-25**
Revenue from Operations	738.33	752.41	2,187.19	1,937.47
Other Income	195.37	134.59	115.54	96.43
Total Income	**933.70**	**887.00**	**2,302.73**	**2,033.90**
Profit Before Interest, Depreciation and Tax	533.15	466.56	876.39	743.36
Less: Finance cost	0.20	0.12	0.87	0.61
Less : Depreciation and amortization expenses	25.43	24.77	72.77	65.96
Add: Share of Profit in Associate	-	-	0.04	(0.01)
Profit Before Tax	**507.52**	**441.67**	**802.79**	**676.78**
Less: Tax Expenses	110.94	102.18	153.06	135.69
Profit After Tax	**396.58**	**339.49**	**649.73**	**541.09**
Less: Non-controlling Interest	-	-	8.49	4.78
Net profit attributable to the Shareholders of the Company	**396.58**	**339.49**	**641.24**	**536.31**

2. OPERATIONS REVIEW /PERFORMANCE

The Company has, on standalone basis, registered total revenue from operations of ₹738.33 Crores (Total Income ₹933.70 Crores) during the year under review as against ₹ 752.41 Crores (Total Income ₹ 887.00 Crores) in the previous Financial Year. The Profit After Tax was ₹ 396.58 Crores during the year under review as against ₹ 339.49 Crores in the previous Financial Year. The Company has, on consolidated basis, registered total revenue from operations of ₹ 2,187.19 Crores (Total Income ₹ 2,302.73 Crores) during the year under review as against ₹ 1,937.47 Crores (Total Income ₹ 2,033.90 Crores) in the previous Financial Year.

3. MANAGEMENT DISCUSSION & ANALYSIS AND BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT

A separate section on Management Discussion & Analysis, as approved by the Board, which includes details on the state of affairs of the Company along with operational performance / review, forms part of this Report.

The Business Responsibility and Sustainability Report ("BRSR") of the Company for the year ended March 31, 2026, as approved by the Board, is provided in a separate section and forms part of this Report and is also made available on the website of the Company at https:// www.caplinpoint.net/index.php/annual-report/. Limited assurance for BRSR Core was carried out by M/s Alagar & Associates LLP, Practicing Company Secretaries and their report is annexed to and forms part of this report.

4. DIVIDEND

The Board of Directors at their Meeting held on May 14, 2026, declared an Interim Dividend of ₹ 4.00 (200%) per equity share of ₹2/- each, for the Financial Year 2025-26 and it was paid to those shareholders whose name appeared in the Register of Members and beneficial owners as on the record date of May 30, 2026.

Further, at the meeting held on August 12, 2026, the Board had recommended a Final Dividend of ₹ 4.00 (200%) per equity share of ₹ 2 /- each, for the Financial Year 2025-26, subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM). If approved, the total dividend for the Financial Year 2025-26 would amount to ₹ 8/- per equity share (400 %) of ₹ 2/- each.

In compliance with Regulation 43A of the Listing Regulations, the Dividend Distribution Policy is uploaded on the Company's website at https://www.caplinpoint.net/wp-content/uploads/2021/07/Dividend_Distribution_Policy.pdf

5. TRANSFER TO RESERVES

The Board of Directors have decided to retain the entire amount of profits for the Financial Year 2025-26 in profit and loss account.

6. SUBSIDIARIES/ASSOCIATES

During the year, Caplin Point Far East Limited, a material subsidiary of the Company, acquired Neoethicals Chile SpA by purchasing of all its Equity shares. Neoethicals Chile SpA is engaged in the business of pharmaceutical marketing and distribution in Chile. The investment was made to establish Neoethicals Chile SpA as the Company's front-end entity for the direct sales, marketing, and distribution of its pharmaceutical products in Chile and to support its long-term growth plans in the Chilean market. Further, in another key market of Mexico, Caplin Point Far East Limited acquired Triwin Pharma S.A. DE C.V., pursuant to a Share Purchase Agreement executed on June 3, 2025. This investment will establish Triwin as the Company's front-end entity in Mexico which will facilitate local presence and participation in government tenders. To strengthen the capability to supply affordable medicines with high quality, during the year Triwin Pharma acquired 5.5 acres of land in Mexico for establishing a pharmaceutical manufacturing facility.

As of the year end, the Company has Five (5) Subsidiaries and Nine (9) Step down Subsidiaries. Nuevos Eticos Neo Ethicals S.A – Guatemala, Caplin Steriles Limited, Caplin Point Far East Limited, Hong Kong and Neoethicals S.A - Nicaragua are the material subsidiaries of the Company for the Financial Year 2025-26. Based on the parameters of the current financial year, Neoethicals S.A- Nicaragua shall not be a material Subsidiary for the Financial Year 2026-27.

Pursuant to Section 129(3) of the Act, 2013, a statement containing the salient features of the financial statements of subsidiaries in the prescribed Form AOC-1 is annexed as **Annexure - I** to this Report.

7. CONSOLIDATED FINANCIAL STATEMENTS

The Consolidated Financial Statements prepared in accordance with the Indian Accounting Standards, are attached to this report. The Consolidated Financial Statements along with relevant documents and separate audited Financial Statements in respect of the subsidiaries are available on the website of the Company.

8. DEPOSITS

The Company did not accept any deposits from the public within the meaning of Chapter V of the Act, 2013, read with the Companies (Acceptance of Deposits) Rules, 2014 for the year ended March 31, 2026.

9. SHARE CAPITAL

The authorized share capital of the Company as on March 31, 2026, stood at ₹ 17,00,00,000/- consisting of 8,50,00,000 equity shares of ₹2/- each. The Subscribed and Paid-up share capital as on March 31, 2026, stood at ₹ 15,20,23,392/- consisting of 7,60,11,696 equity shares of ₹2/- each.

There was no change in Authorized, Subscribed and Paid-up Share capital of the Company during the Financial Year.

10. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186 OF THE ACT, 2013

Particulars of loans, guarantees and investments as on March 31, 2026, are given in Note No. 3, 4 and 8 to the Standalone Financial Statements.

11. NUMBER OF MEETINGS OF THE BOARD

The Board of Directors of the Company met 5 (five) times during the year under review. The dates of the Board meeting and the attendance of the Directors at the said meetings are provided in the Corporate Governance Report, which forms part of this Report.

12. DIRECTORS AND KEY MANAGERIAL PERSONNEL

a. Directors

As on March 31, 2026, Board comprised of Nine (9) Directors, out of which Five (5) are Independent Directors (including an Independent Woman Director), a Managing Director and Three (3) Promoter Directors. As part of the Company's succession planning to ensure orderly leadership transition, Mr. Ashok Partheeban (DIN: 02507261) and Mr. Vivek Partheeban (DIN: 02507289) were appointed as Non-Executive Directors and Vice Chairmen of the Company with effect from November 5, 2025. Ms. Susan Mathew (DIN: 00517738) was inducted as Independent Director on the Board with effect from January 31, 2026 and Dr. K C John (DIN: 01067374) was inducted as Independent Director with effect from November 5, 2025. Dr. K C John (DIN: 01067374) returns to the Board as Independent Director after completing the mandatory cooling off period of three years after his previous stint as Independent Director of the Company. All their appointments were approved by the shareholders through Postal Ballot on January 31, 2026. Dr. C K Gariyali (DIN: 08711546) ceased to be an Independent Director with effect from the close of business hours on March 3, 2026, as she had served the maximum tenure permitted for an Independent Director.

Mr. C C Paarthipan (DIN: 01218784) serves as the Promoter Director who is also the Non- Executive - Chairman of the Company. Dr. Sridhar Ganesan (DIN: 06819026) is the Managing Director. Dr. R Nagendran (DIN: 08943531), Mr. S Deenadayalan (DIN: 01951620), Ms. Susan Mathew (DIN: 00517738), Dr. K C John (DIN: 01067374) and Mr. R Vijayaraghavan (DIN: 00026763) are the Independent Directors on the Board. Mr. Ashok Partheeban (DIN: 02507261) and Mr. Vivek Partheeban (DIN: 02507289) serve as Non-Executive Directors and Vice Chairmen.

At the meeting held on August 12, 2026, the Nomination and Remuneration Committee and the Board had recommended the elevation of Mr D Muralidharan, Chief Financial Officer (DIN: 08301904) as a Whole Time Director which is being placed for approval of the shareholders at the forthcoming Annual General Meeting. Details and justification for this elevation is given as part of the Corporate Governance Report and the Notice of the Annual General Meeting, which forms part of this report.

b. Company Secretary and Compliance Officer

Mr. Venkatram G is the Company Secretary & Compliance Officer of the Company.

c. Retirement by rotation

Pursuant to Section 152 (6) of the Companies Act, 2013, Dr. Sridhar Ganesan (DIN: 06819026), Managing Director, retires by rotation and being eligible offers himself for re-appointment.

d. Key Managerial Personnel (KMP)

Dr. Sridhar Ganesan, Managing Director, Mr. D Muralidharan, Chief Financial Officer and Mr. Venkatram G, General Counsel & Company Secretary are the KMPs of the Company.

13. DECLARATION BY INDEPENDENT DIRECTORS

All the Independent Directors have declared that they meet the criteria of independence as provided under the Companies Act 2013 and Listing Regulations and the Board confirms that they fulfil the conditions specified under the Act and the Listing Regulations and are independent of the management. Further, each Independent Director has affirmed compliance to the Code of Conduct for Independent Directors as prescribed in Schedule IV of the Act.

In terms of Rule 8(5)(iiia) of the Companies (Accounts) Rules, 2014, the Board, after undertaking due assessment of the veracity of the declarations submitted by the Independent Directors, is of the opinion that the Independent Directors of the Company are persons of integrity and possess the requisite qualifications, experience, expertise and proficiency, fulfil the conditions specified in the Act and the Rules made thereunder as well as the Listing Regulations, and are independent of the management of the Company.

14. CRITERIA FOR APPOINTMENT OF DIRECTORS AND REMUNERATION POLICY

The Company's selection process of the Directors involves the Nomination and Remuneration Committee identifying the persons of integrity who bring in a mix of expertise in varied fields, experience and leadership qualities as per the Board Diversity policy and also ensures positive attributes, independence, age and other criteria as laid down under the Act, Listing Regulations or other applicable laws.

Details of Remuneration and the policy on Remuneration of Directors, Key Managerial Personnel and Senior Management Personnel is provided as part of the Corporate Governance report and the policy is available at https://www.caplinpoint.net/wp-content/uploads/2021/07/Nomination-and-Remuneration-Policy.pdf

15. ANNUAL EVALUATION OF THE BOARD, ITS COMMITTEES AND INDIVIDUAL DIRECTORS

The Board of Directors has carried out annual evaluation of its own performance, the Directors Individually, as well as the evaluation of the working of its committees. The Independent Directors at their separate meeting held on March 31, 2026, have also evaluated the performance of the other Non-Independent Directors. The manner in which the evaluation was carried out has been explained in the Corporate Governance Report, which forms part of this report.

16. BOARD COMMITTEES

The Company has formed all the statutory Committees, namely, the Audit Committee, the Nomination and Remuneration Committee, the Corporate Social Responsibility Committee, the Stakeholders' Relationship Committee and the Risk Management Committee. During the year, the Board has re-constituted the Nomination and Remuneration Committee and Risk Management Committee. At the meeting held on August 12, 2026, the Board had expanded the mandate of the Corporate Social Responsibility Committee to include oversight of the ESG initiatives and renamed the Committee as CSR and Sustainability Committee with the Chairperson being Dr. R Nagendran (DIN: 08943531) who has rich expertise and experience on sustainability and policy advisory.

Detailed information about all the Committees and relevant information for the year are given in the Corporate Governance Report.

There have been no instances where the Board did not accept the recommendations of its committees including the Audit Committee.

17. DIRECTORS RESPONSIBILITY STATEMENT

The Directors confirm that:

a. In the preparation of the annual accounts, the applicable accounting standards (IND AS) had been followed along with proper explanation relating to material departures;

b. The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2026 and of the profit of the Company for that period;

c. The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d. The Directors had prepared the annual accounts on a "going concern" basis;

e. The Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively; and

f. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

18. STATUTORY COMPLIANCE

The Company has successfully deployed a comprehensive, enterprise-wide digital compliance management system, which is fully operational across all modules. To foster a robust culture of accountability, functional and site leadership periodically certify and report on compliance statuses within their respective domains. The efficacy of this framework is continuously evaluated through rigorous internal compliance and internal audit programs. Remediation strategies and action plans are systematically tracked, with material observations escalated to the Audit Committee and the Board of Directors for strategic oversight. Furthermore, to ensure stringent governance, the Secretarial Auditors review the adequacy and operational efficacy of the compliance management system, providing an additional layer of external assurance regarding regulatory adherence.

19. MATERIAL CHANGES AND COMMITMENTS, IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY

There were no material changes and commitments, affecting the financial position of the Company, which have occurred between the end of the Financial Year of the Company to which the financial statements relate and the date of the report.

20. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

Particulars of conservation of energy, technology absorption, foreign exchange earnings and outgo, as on March 31, 2026, are given as **Annexure - II** to this Directors' Report.

21. CORPORATE SOCIAL RESPONSIBILITY (CSR)

The Company, through the Caplin Point Meenakshi CSR Trust ("CSR Trust") has established and operationalized the Caplin Point Meenakshi Hospital. The outpatient and diagnostic section (including pharmacy) is operating in full swing, except for certain diagnostic services like Mammogram, which requires specific licensing from regulatory authorities. The Hospital has submitted the application for obtaining the relevant regulatory approval, which is expected to be obtained during the year 2026-27 after which the Hospital can offer full integrated and advanced diagnostic services along with consultation and treatment.Further, the Company and the CSR Trust are exploring future CSR initiatives including undertaking activities in the field of education, comprising support to Schools and construction of college, with particular focus on programmes in Pharmacy, reflecting the Company's commitment to creating a lasting social impact in the areas of health and education.

Disclosure under the Companies (Corporate Social Responsibility Policy) Rules, 2014 is annexed as **Annexure - III** to this report.

22. INTERNAL FINANCIAL CONTROLS

The Company has established adequate internal controls framework comprising of policies, procedures, and mechanisms surrounding operational efficiency, minimizing risks, and supporting decision-making and accountability. Details in respect of adequacy of internal financial controls concerning the financial statements are stated in the Management Discussion and Analysis section, which forms part of this Report.

23. VIGIL MECHANISM

The Company is committed to ethical conduct of business and towards this had empowered the employees and other stakeholders to report any unethical practices without fear of any repercussion. The details of the Whistle Blower Policy and the mechanism are given in the Corporate Governance Report, which forms part of this report.

24. AUDITORS

a. Statutory auditors

The Audit Committee and the Board, at their meeting held on August 07, 2023 had recommended and the Shareholders at their 32^{nd} AGM held on September 21, 2023, had approved the appointment of M/s Brahmayya & Co, Chartered Accountants, (Firm Registration No. 000511S) Chennai, as Statutory Auditors of the Company to hold office from the conclusion of 32^{nd} AGM till the conclusion of 37^{th} AGM.

The Auditor's Report for the Financial Year 2025-26 has been issued with an unmodified opinion and the same is enclosed as part of the financial statements.

b. Secretarial auditors

The Shareholders, based on the recommendation of the Board, had appointed M/s. Alagar and Associates LLP as the Secretarial Auditors of the Company for a period of 5 years from financial year 2025-26 till 2029-30. The Secretarial Audit Report for the Financial Year 2025-26, issued by M/s. Alagar and Associates LLP, is attached as **Annexure - IV** to this Report. The Secretarial Audit Report does not contain any qualification, reservation or other remarks.

Pursuant to Regulation 24A of Listing Regulations, the company shall annex with its Annual Report the Secretarial Audit Report of its material unlisted subsidiary incorporated in India. Caplin Steriles Limited being a material Indian unlisted subsidiary of the Company, the Secretarial Audit Report is annexed as **Annexure - IV-A** to this Director's Report.

c. Internal auditors

Based on the recommendation of the Audit Committee, the Board of Directors re-appointed M/s. TBL & Associates as the Internal Auditors of the Company for the Financial Year 2025-26. The internal audit for the year was successfully executed in strict adherence to the comprehensive, risk-based audit plan and scope approved by the Audit Committee.

25. REPORTING OF FRAUDS BY AUDITORS

The Statutory Auditors, Internal Auditors and the Secretarial Auditors have not reported any incident of fraud to the Audit Committee during the year under review.

26. CORPORATE GOVERNANCE

Pursuant to Regulation 34 of Listing Regulations, a Report on Corporate Governance is given separately which forms part of this Report.

27. ANNUAL RETURN

The Annual Return in Form MGT-7 for FY 2024-25 is uploaded on the website of the Company and can be accessed at https://www.caplinpoint.net/wp-content/uploads/2022/06/Annual-Return.pdf

28. RISK MANAGEMENT

The Company has constituted a Risk Management Committee in accordance with Regulation 21 of the Listing Regulations to drive strategic risk mitigation and organizational resilience. During the financial year, the Committee's composition was strengthened with the induction of Dr. K C John (Independent Director) and Mr. Vivek Partheeban (Vice Chairman). By expanding the RMC to five (5) members, the Board has prioritized an optimal compositional balance. This carefully structured blend of Independent and Non-Independent Directors, alongside the Managing Director and senior executives, empowers the Committee to deliver independent, balanced, and highly effective enterprise risk management.

The details of this Committee and its terms of reference are set out in Corporate Governance Report, which forms part of this Report.

29. EMPLOYEE STOCK OPTION PLAN

The Company recognizes equity-based compensation as a cornerstone of its total rewards and human capital strategy. By aligning the interests of our workforce with those of our shareholders, our stock option schemes are designed to reward meaningful contributions, attract high-caliber talent, retain critical capabilities, and foster sustainable, long-term wealth creation for employees across the Company and its subsidiaries.

Currently, the Company administers three active schemes: the Caplin Point Employee Stock Option Plan – 2015, the Caplin Point Employee Stock Option Plan – 2017, and the Caplin Point Laboratories Limited Employees Stock Option Plan – 2021. As of March 31, 2026, a total of 226,969 options remain outstanding across these schemes.

To synchronize our talent retention strategies with the Company's growth trajectory, the Nomination and Remuneration Committee (NRC) approved a two-year deferment of the vesting dates for 79,935 options. This strategic realignment is tied to the Company's ongoing capital expansion initiatives, which are scheduled for completion over the next two years and are projected to significantly drive future profitability.

All schemes are administered in strict compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The statutory disclosures mandated under the SBEB Regulations, alongside the Secretarial Auditor's certificate confirming compliant implementation, are hosted on the Company's website at https://www.caplinpoint.net/index.php/annual-report/.

30. EMPLOYEES RELATED DISCLOSURES

The statements required under Section 197 of the Act, 2013 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, forms part of **Annexure - V** to this Report.

31. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

The Company adheres to a rigorous governance framework for Related Party Transactions (RPTs) to ensure they are executed on an arm's length basis and in the ordinary course of business. All RPTs are subject to prior approval from the Audit Committee. Transactions falling outside the ordinary course of business or not on an arm's length basis necessitate Board approval, and all material RPTs are escalated for shareholder approval. To streamline routine operations, the Audit Committee grants prior annual omnibus approval for foreseeable, repetitive transactions and conducts quarterly reviews to monitor their nature, value, and terms. In exceptional circumstances where prior approval is not administratively feasible, such transactions are placed before the Audit Committee for ratification within three months, in alignment with statutory provisions.

Detailed financial disclosures regarding RPTs are provided in Note No. 42 to the Standalone Financial Statements, and the particulars of specific arrangements in Form AOC-2 are enclosed as **Annexure-VI** to this Report. The Company's comprehensive Related Party Transaction Policy is accessible at https://www.caplinpoint.net/wp-content/uploads/2021/07/Related-Party-Transaction-Policy-1.pdf.

32. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS

There are no significant and material orders passed by the Regulators or Courts or Tribunals which would impact the going concern status of the Company.

33. DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT THE WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

Pursuant to the provisions of Sexual Harassment of Women at the Workplace (Prevention, Prohibition and Redressal) Act, 2013, the Company has put in place a Policy on Prevention of Sexual Harassment at Workplace and Internal Complaints Committees (ICC) has been set up to redress complaints. There were no complaints relating to sexual harassment, pending at the beginning of Financial Year, received during the year and pending at the end of the Financial Year 2025-26.

34. INVESTOR EDUCATION AND PROTECTION FUND

During the year under review, the Company has credited 3,09,948 unclaimed equity shares of ₹ 2/- each to IEPF pertaining to those shareholders who have not encashed/claimed their dividends for a period of seven consecutive years. The voting rights on the shares outstanding in the IEPF Authority as on March 31, 2026, shall remain frozen till the rightful owner of such shares claims the shares.

Further, the unpaid or unclaimed dividend for the Financial Year 2018-19 (final) has to be transferred to IEPF. Members who have not yet encashed or claimed the dividends that are yet to be transferred to the IEPF, are requested to refer to the Corporate Governance Report.

35. OTHER DISCLOSURES

a) There has been no change in the nature of business of the Company during the year under review.

b) Pursuant to Section 197 (14) of the Companies Act, 2013, the Managing Director of the Company did not receive any remuneration or commission from any of its subsidiaries.

c) The Company maintains cost records as per Companies (Cost Records and Audit) Rules, 2014.

d) The Board confirms the compliance with the provisions of the Secretarial Standards notified by the Institute of Company Secretaries of India.

e) There were no applications made or any proceedings pending under the Insolvency and Bankruptcy Code, 2016.

f) There was no instance of any one-time settlement or any requirement of a valuation for any loan from the banks or financial institutions during the year.

g) The Company has complied with the provisions of the Maternity Benefit Act, 1961, including all applicable amendments and rules framed thereunder.

36. ACKNOWLEDGEMENT

The Board of Directors wishes to place on record its sincere appreciation to the customers, suppliers, business partners and shareholders for their support. The Directors would like to thank the Bankers and financial Institutions as well. The Directors would take this opportunity to appreciate and sincerely acknowledge the dedication and hard work of the employees for the growth of the Company.

For and on behalf of the Board of Directors

Place: Chennai **C C Paarthipan**
Date: August 12, 2026 **Chairman**

Annexure - I

FORM AOC-1

(Pursuant to first Proviso to Sub-Section (3) of Section 129, of the Act, 2013 read with Rule 5 of Companies (Accounts) Rules, 2014)

STATEMENT CONTAINING SALIENT FEATURES OF THE FINANCIAL STATEMENT OF SUBSIDIARIES / ASSOCIATE COMPANIES / JOINT VENTURES

PART "A": SUBSIDIARIES

(Amount in ₹)

S. No.	Particulars	Details				
1	Name of the subsidiary	Caplin Steriles Limited (Consolidated) **	Argus Salud Pharma LLP	Caplin Point Far East Limited– Hong Kong (Consolidated) ***	Caplin Point (S) Pte. Ltd Singapore	Caplin One Labs Limited
2	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable
3	Date of Acquisition	December 12, 2018	April 13, 2010	May 13, 2014	October 4,2019	June 2, 2021
4	Reporting currency and Exchange rate as on the last date of the relevant Financial Year in the case of foreign subsidiaries	Not Applicable	Not applicable	Closing Rate 1 USD = ₹ 94.65 Average rate 1 USD = ₹ 88.36^	Closing Rate 1 USD = ₹ 94.65 Average rate 1 USD = ₹ 88.36^	Not Applicable
5	Share capital	1,79,95,70,886	99,10,000	92,14,90,951	37,69,726	90,00,00,000
6	Reserves & surplus	2,09,63,08,098	1,22,53,266	13,07,47,66,433	(16,40,285)	(14,85,56,930)
7	Total assets	7,39,29,26,403	7,36,45,919	16,95,61,78,649	33,27,705	4,97,24,34,936
8	Total Liabilities	3,49,70,47,420	5,14,82,654	2,84,02,62,216	2,35,489	4,22,09,92,290
9	Investments #	1,83,34,961	-	-	-	-
10	Turnover^	4,53,39,99,173	6,57,63,472	12,74,03,81,611	-	32,93,15,820
11	Profit before taxation^	73,82,59,310	1,88,27,168	2,94,86,04,479	1,82,022	(19,08,64,000)
12	Provision for taxation^	18,86,34,274	65,78,965	25,86,47,569	16,082	(3,23,97,705)
13	Profit after taxation^	54,96,25,036	1,22,48,203	2,68,99,56,911	1,65,940	(15,84,66,295)
14	Proposed Dividend	-	-	-	-	-
15	% of shareholding	99.999%	99.90%	100%	100%	100%

Notes:

*Indian Rupee equivalent of the foreign currency translated as per Closing rate as mentioned in Sl No.4 above

^ Indian Rupee equivalent of the foreign currency translated as per average rate as mentioned in Sl No.4 above.

Investments other than in subsidiary companies

** For the FY 2025-26, the financials of Caplin Steriles USA Inc has been consolidated with the Financial Statements of the company

***Represents details as per Consolidated Financial Statements of Caplin Point Far East Limited which includes the financial statements of its subsidiaries Caplin Point El Salvador, S.A. De C.V., Drogueria Saimed de Honduras S. A, Neoethicals CIA.LTDA - Ecuador, Neo Ethicals S.A - Nicaragua, Nuevos Eticos Neo Ethicals S.A – Guatemala, Caplin Point Laboratories Colombia SAS, Neoethicals Chile SpA and Triwin Pharma S.A DE C.V Mexico

1. Name of subsidiaries which are yet to commence commercial operations: Caplin Point (S) Pte. Ltd.
2. Name of subsidiaries which have been liquidated or sold during the year: NIL

PART "B": ASSOCIATES AND JOINT VENTURES

(Amount in ₹)

S. No.	Name of associates/Joint ventures	Latest audited balance sheet Date	Date on which the Joint venture/ Associate was acquired	Shares of Associate/Joint ventures held by the company on the year end			Description of how there is significant influence	Reason Why the Joint venture/ Associate is not consolidated	Net worth attributable To shareholding as per latest audited balance sheet	Profit / Loss for the year	
				No. of Shares	Amount of Investment In Associates/Joint Venture	Extent of Holding %				I. Considered in Consolidation	ii. Not Considered in Consolidation
1	Sunsole Solar Private Limited	31.03.2026	09.03.2022	1,75,000	1,40,00,000	28.01%	The Company's Subsidiary, Caplin Steriles Limited holds more than 20% of the equity share capital of the said Company.	Not applicable	1,77,27,961	3,94,381	-

Notes:

1. Name of associates or joint ventures which are yet to commence commercial operations: NIL
2. Name of associates or joint ventures which have been liquidated or have ceased to be associate or joint venture during the year: NIL

For and on behalf of the Board of Directors

C C Paarthipan
Chairman
DIN:01218784

Dr. Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Venkatram G
General Counsel & Company Secretary
Membership No: A23989

Place: Chennai
Date: August 12, 2026

Annexure - II

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO

(A) CONSERVATION OF ENERGY

1.	**The steps taken or impact on conservation of energy**	Power consumption for FY26 was 1,19,71,316 units as against 1,21,67,530 units in FY25. The unit consumption has decreased by 1.61% YOY. The Company has undertaken various energy conservation measures, including centralized energy monitoring, granular energy metering, optimization of HVAC and chiller operations, and installation of energy-efficient systems such as VFDs and timers. Renewable energy adoption has also been promoted through solar water heaters and solar lighting. Further, condensate recovery and optimized equipment operating schedules have helped reduce energy consumption and improve operational efficiency. These initiatives collectively contribute to reducing energy wastage, improving resource efficiency and lowering the environmental impact of operations.
2.	**The steps taken by the company for utilizing alternate sources of energy**	The Company, through its subsidiary, Caplin Steriles Limited, continues to procure solar power in sizeable quantum and enhance clean energy adoption in its operations through Sunsole Solar Private Limited and Thangamman Renewable Energy Private Limited. On a Standalone basis, the Company has plans to transition majorly to renewable energy in the form of establishment of a captive solar power unit in Puducherry in the near term. At Consolidated level, 36.65% of the total energy consumption of the group is now sourced through solar power. In addition to the above, the Board, had set targets to increase renewable energy consumption to 35% across the Company and Caplin One Labs Limited by the Financial Year 2030. The consumption of renewable energy had increased from 2,90,845 units to 5,28,675 units during the financial year.
3.	**The capital investment on energy conservation equipment**	Details of Capital Investment in energy conservation equipment is given as part of the Business Responsibility and Sustainability Report in Principle No. 2, Question No. 1.

(in ₹)

Power and Fuel Consumption	Year ended March 31, 2026	Year ended March 31, 2025
Electricity		
Purchased units	1,11,39,050.00	1,15,57,414.00
Total amount paid	10,16,58,618.00	10,09,18,348.00
Rate per unit	9.13	8.73
Own generation by		
Diesel Generator (units)	3,03,590.00	3,19,271.00
Amount paid	83,05,103.00	87,13,741.00
Rate per unit	27.36	27.29

(in ₹)

Power and Fuel Consumption	Year ended March 31, 2026	Year ended March 31, 2025
Third party		
Third party (units)	5,28,675.00	2,90,845.00
Amount paid	26,70,684.00	14,47,792.00
Rate per unit	5.05	4.98
Others		
Diesel Consumed for Boiler (in Litres)	-	-
Total Amount paid	-	-
Rate per Litre	-	-
Furnace Oil Consumed for Boiler (in Litres)	-	-
Total Amount paid	-	-
Rate per Litre	-	-
Light Diesel Oil Consumed for Boiler(in Litres)	5,63,779.00	6,94,706.00
Total Amount paid	3,45,46,437.00	4,27,38,123.00
Rate per Litre	61.30	61.52

(B) TECHNOLOGY ABSORPTION

i. Efforts made towards technology absorption

a. Inclusion of latest technological developments in new product initiatives like peptides, biosimilars etc

b. Quality Improvement projects for major products

c. FR & D efforts in conducting trials, stabilization of process and optimization of process

d. Laying emphasis on innovation and continuous product improvements to widen the range of products / applications

e. Formulation development and analytical development of injectable and ophthalmic

f. Support to QC in transferring the analytical methods

g. Support to regulatory department in compiling documents required for dossier submission

h. The Company also lays emphasis on adopting the latest technology into its operations to ensure quality of products, energy efficiency and health & safety to the workers.

i. Development of new technology platforms (Bead Mill and Blow-Fill-Seal [BFS]) for complex ophthalmic, otic, and inhalation products, including suspensions, emulsions, and solutions. These initiatives focus on expanding advanced drug delivery capabilities and strengthening the product development portfolio.

ii. Benefits derived as a result of R& D

Provides Company an opportunity to widen the range and application of products. Continuous process improvements resulting in optimization of products and cost reduction

iii. Imported Technology (Imported during the Last three years reckoned from the beginning of the financial year)

a.	Details of technology imported:	NIL
b.	The year of import:	Not applicable
c.	Whether the technology been fully absorbed:	Not applicable
d.	If not fully absorbed, areas where absorption has not taken place and the reasons thereof:	Not applicable

iv. Expenditure incurred on Research and Development

The Company has incurred an expenditure of ₹ 56.11 Crores towards Research and Development ₹ 37.74 Crores of Revenue Expenditure and ₹ 18.37 Crores of Capital Expenditure

(C) FOREIGN EXCHANGE EARNINGS AND OUTGO

(₹ in Crores)

Foreign exchange earned	708.06
Foreign exchange used	27.11

For and on behalf of the Board of Directors

Place: Chennai
Date: August 12, 2026

C C Paarthipan
Chairman

Annexure - III

ANNUAL REPORT ON CSR ACTIVITIES FOR THE FINANCIAL YEAR 2025-26

(Pursuant to Section 135 of the Act, 2013 and Companies (Corporate Social Responsibility) Rules, 2014, as amended)

1. Brief outline on CSR Policy of the Company and its CSR activities

At Caplin, Corporate Social Responsibility (CSR) is an integral component of our strategic and operational model. Beyond traditional philanthropy, our CSR framework aligns directly with global Environmental, Social, and Governance (ESG) principles—ensuring that long-term social value is weighed alongside financial metrics in every strategic and operational decision. Demonstrating this commitment, the Board is reconstituting and expanding the mandate of its CSR Committee into a dedicated **CSR and Sustainability Committee** to oversee both CSR projects and support the Company's long-term sustainability objectives. Caplin intentionally directs resources toward high-impact, non-commercial initiatives that advance societal well-being and operationalize our core motto: delivering affordable, high-quality healthcare solutions to underserved communities at the bottom of the pyramid.

A key component of this outlay includes ongoing funding through Caplin Point Meenakshi CSR Trust (**"Trust"**) towards operating the **Caplin Point Meenakshi Hospital ("Hospital")** which provides free diagnostic services and treatment to underprivileged individuals**.** The said Hospital has been constructed on the land that was taken on long-term lease from Caplin Point Laboratories Limited by the Trust at a very nominal cost. The Hospital's outpatient, pharmacy, and diagnostic sections are operating in full swing to provide accessible healthcare to all in Gummidipoondi and surrounding areas, with applications submitted for regulatory approval for remaining advanced diagnostics (such as Mammography) which are expected to be received in 2026-27.

In addition to the Hospital, at the meeting held on May 14, 2026, the Committee had proposed to identify and support educational institutions like schools and colleges and had decided to reallocate a portion of the CSR budget towards identifying and supporting such educational institutions through capital expenditure, infrastructure, and learning resources.

With initiatives like the above and with enhanced corpus that is expected to be available for CSR purposes due to the Company's Subsidiaries getting covered under the mandatory CSR provisions, the company intends to make CSR a key business process for sustainable development at group level which will help in developing a strong social license to operate.

2. Composition of CSR Committee

S. No.	Name of Director	Designation / Nature of Directorship	No. of meetings of CSR Committee held during the year	No. of meetings of CSR Committee attended during the year
1.	Mr. C C Paarthipan*	Chairman / Non- Executive Director	4	4
2.	Dr. Sridhar Ganesan	Member/ Managing Director		4
3.	Mr. S Deenadayalan	Member / Independent Director		4

*The Committee was renamed as "CSR and Sustainability Committee" and Dr. R Nagendran was designated as the Chairman of the Committee with effect from August 12, 2026. Mr. C C Paarthipan continues to be the member of the Committee

3. Web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company:

S. No.	Particulars	Weblink
1.	CSR Committee	https://www.caplinpoint.net/wp-content/uploads/2021/11/Composition-of-Board-and-Committees.pdf
2.	CSR Policy	https://www.caplinpoint.net/wp-content/uploads/2021/07/Corporate-Social-Responsibility-Policy.pdf
3.	CSR Projects	https://www.caplinpoint.net/index.php/sustainability/csr-key-projects/

4. **Provide the executive summary along with web-link(s) of Impact Assessment of CSR Projects carried out in pursuance of sub-rule (3) of rule 8, if applicable:** Not Applicable

5. a. Average net profit of the company as per sub-section (5) of section 135: ₹ 367.96 Crores

   b. Two percent of average net profit of the company as per sub-section (5) of section 135: ₹ 7.36 Crores

   c. Surplus arising out of the CSR Projects or programmes or activities of the previous Financial Years: ₹ 0.29 Crores (the Surplus represents the interest earned on Deposits of CSR funds pending utilization for CSR purposes)

   d. Amount required to be set-off for the Financial Year, if any: NIL

   e. Total CSR obligation for the Financial Year [(b)+(c) -(d)]: ₹ 7.65 Crores

6. a. Amount spent on CSR Projects (both Ongoing Project and other than Ongoing Project): During the year ₹ 0.43 Crores was spent towards other than Ongoing Projects and ₹ 3.93 crores was spent towards ongoing projects from the CSR amounts earmarked for financial Year 2023-24.Further, interest earned on fixed deposits amounting to ₹ 0.18 Crore was spent towards CSR activities over and above the CSR obligation for FY 2024–25.

   b. Amount spent in Administrative overheads: ₹ 0.05 crores

   c. Amount spent on Impact Assessment, if applicable: Not Applicable

   d. Total amount spent for the Financial Year [(a)+(b)+(c)]: ₹ 4.59 Crores

7. a. CSR amount spent or unspent for the Financial Year

(₹ in Crores)

Total Amount Spent for the Financial Year.	Total Amount transferred to Unspent CSR Account as per sub-section (6) of section 135.		Amount transferred to any fund specified under Schedule VII as per second proviso to sub-section (5) of section 135.		
	Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
0.43	7.22*	April 29, 2026	Not Applicable		

*The total amount of ₹7.22 crores includes ₹0.26 crores of interest on Fixed deposits pertaining to respective years unspent CSR Account and hence only ₹6.96 crores was transferred to unspent CSR account "Caplin point Laboratories Limited unspent CSR Account FY 2025-26" on April 29, 2026.

   b. Excess amount for set-off, if any: Not Applicable

   c. Details of Unspent Corporate Social Responsibility amount for the preceding three Financial Years

(₹ in Crores)

Sl. No.	Preceding Financial Year(s)	Amount transferred to Unspent CSR Account under sub-section (6) of section 135	Balance Amount in Unspent CSR Account under sub-section (6) of section 135	Amount Spent in the Financial Year	Amount transferred to a Fund as specified under Schedule VII as per second proviso to sub-section (5) of section 135, if any		Amount remaining to be spent in succeeding Financial Years	Deficiency, if any
					Amount	Date of Transfer		
1	2024-25	5.71	5.71#	0.18*	NIL	NIL	5.71	NIL
2	2023-24	4.35	3.98	3.98	NIL	NIL	NIL	NIL
3	2022-23	4.50	NIL	NIL	NIL	NIL	NIL	NIL

During the year Company has transferred ₹ 1.00 crores to Caplin Point Meenakshi CSR Trust, however it is unspent as on March 31, 2026.

* The amount of ₹ 0.18 crores represents interest earned on fixed deposits, which was spent for CSR activities, in addition to the CSR obligation of ₹ 5.71 crores.

8. Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the financial year: Yes

Sl. No.	Short particulars of the property or asset(s) [including complete address and location of the property]	Date of creation	Pin code of the property or asset(s)	Amount of CSR amount spent	Details of entity / Authority / beneficiary of the registered owner	CSR Registration Number, if applicable
1	Infrastructure upgradation of road components at Chinnapuliyur village - Gummidipoondi	19-08-2025	601 201	₹ 0.20 crore	NA [Direct implementation by the Company]	Not-Applicable
2	Capital Asset created through Construction of Caplin Point Meenakshi Hospital at No. 19, Chinnapuliyur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Tamil Nadu – 601 201.	09-05-2025	601 201	The project is an ongoing project undertaken by the Company. The total expenditure incurred on the project amounts to ₹ 6.27 Crore, of which ₹ 1.10 Crore was incurred during FY 2025–26 and capitalised upon completion of the building during the year. The balance expenditure of ₹ 5.17 Crore represents expenditure incurred in previous years towards the Construction	Caplin Point Meenakshi CSR Trust 3rd Floor, Ashvich Towers, Developed Plot Industrial Estate, Perungudi	CSR00023499.
3	Medical Equipments at Caplin Point Meenakshi Hospital 1. **Diagnostic & Imaging Equipment:** Scan Machine, X-Ray Machine, ECG Machine, ABG Machine, Electrolyte Analyzer, Urine Analyzer and Biochemistry Analyzers for diagnosis and clinical testing. 2. **Critical Care Equipment:** Ventilators, Defibrillators, Multi-Para Monitors, BiPAP Machines and Crash Carts for emergency and intensive care 3. **Operation Theatre Equipment:** OT Tables, OT Lights, OT Pendant, OT Control Panel, Anesthesia Machine, Scrub Station and Fumigators for surgical procedures. 4. **Patient Care Equipment:** ICU Cots, Fowlers Cots, Examination Couches, Patient Writing Boards, Blood Collection Chairs and Emergency Trolleys for patient care and support 5. **Specialized & Support Equipment:** Hemodialysis Machine, Autoclave, Clinical Equipment, X-Ray Film Viewer, X-Ray Lobby and other medical equipment for specialized treatment, sterilization and hospital operations.	09-05-2025	601 201	The medical equipment was acquired as part of the ongoing hospital project undertaken by the Company. The total expenditure of ₹ 3.69 Crore incurred towards medical equipment was capitalised during FY 2025–26, of which ₹ 0.43 Crore was incurred during the year. The balance expenditure of ₹ 3.26 Crore was incurred in previous years towards the ongoing project	Caplin Point Meenakshi CSR Trust 3rd Floor, Ashvich Towers, Developed Plot Industrial Estate, Perungudi	CSR00023499.

Sl. No.	Short particulars of the property or asset(s) [including complete address and location of the property]	Date of creation	Pin code of the property or asset(s)	Amount of CSR amount spent	Details of entity / Authority / beneficiary of the registered owner	CSR Registration Number, if applicable
4	Electrical and other equipments at Caplin Point Meenakshi Hospital 1. **Power & Electrical Systems:** Diesel Generator, 500 KVA Transformer, LV Systems, UPS and electrical fittings for uninterrupted and safe power distribution. 2. **HVAC & Climate Control:** AHU, cassette and split AC units, ICU HVAC systems and dehumidifiers for ventilation, cooling and humidity control. 3. **Water & Utility Systems:** Pumps, pipeline fittings and STP Plant with accessories for water distribution, wastewater treatment and utility management. 4. **Safety & Infrastructure:** Fire Hydrant Systems, Fire Extinguishers, Lift, Gate Shutters and Sign Boards for fire safety, accessibility and building operations. 5. **Other Operational Equipment:** Digital multifunction devices, barcode printers, refrigerators and related accessories for administrative and operational requirements.	09-05-2025	601201	The electrical and other equipment was acquired as part of the ongoing hospital project undertaken by the Company. The total expenditure of ₹ 4.55 Crore incurred towards Electrical equipment was capitalised during FY 2025–26, of which ₹ 0.51 Crore was incurred during the year. The balance expenditure of ₹ 4.04 Crores was incurred in previous years towards the ongoing project.	Caplin Point Meenakshi CSR Trust 3rd Floor, Ashvich Towers, Developed Plot Industrial Estate, Perungudi	CSR00023499.

9. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per sub-section (5) of section 135.

The company has identified certain on-going projects for which the amount has been earmarked, the spending will be ensured within the statutorily available time line.

For and on behalf of the Board of Directors

Place: Chennai
Date: August 12, 2026

R. Nagendran
Chairman of CSR Committee
DIN:08943531

Dr. Sridhar Ganesan
Managing Director
DIN: 06819026

Annexure - IV

FORM NO. MR-3
SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
Caplin Point Laboratories Limited

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Caplin Point Laboratories Limited** (hereinafter called "**the Company**"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we hereby report that in our opinion, the Company has, during the Audit Period covering the Financial Year ended March 31, 2026 (**"Audit Period"**) complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the Financial Year ended March 31, 2026, according to the provisions of:

1. The Companies Act, 2013 ('Act') and the rules made thereunder, as amended from time to time including Secretarial Standards issued by Institute of Company Secretaries of India ('ICSI') as mandated by the Companies Act,2013
2. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made thereunder;
3. The Depositories Act, 1996 and the Regulations and Byelaws framed thereunder;
4. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment and Overseas Direct Investment and External Commercial Borrowings
5. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'), as amended from time to time:-
   (i) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
   (ii) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
   (iii) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 **(there were no events requiring compliance during the Audit Period)**
   (iv) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
   (v) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act, 2013 and dealing with client
   (vi) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
   (vii) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021 **(there were no events requiring compliance during the Audit Period)**
   (viii) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 **(there were no events requiring compliance during the Audit Period)**

(ix) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 **(there were no events requiring compliance during the Audit Period)**

6. Based on the information received and representation made by the Company, other than general laws like fiscal, labour laws, environmental laws and all other laws, rules, regulations and guidelines which are generally applicable, the following Laws/Acts are also, interalia, applicable to the Company

   (i) Air (Prevention & Control of Pollution) Act, 1981

   (ii) Water (Prevention & Control of Pollution) Act, 1974

   (iii) Environment Protection Act, 1986

   (iv) Drugs and Cosmetics Act, 1940

   (v) The Boilers Act, 2025

   (vi) Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016

During the audit period, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that the Board of Directors of the Company is duly constituted with proper balance of Executive Director, Non- Executive Directors, Independent Directors and Women Director. The changes in the composition of the Board of Directors that took place during the audit period were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings. Agenda and detailed notes on agenda were sent to them at least seven days in advance or as the case may be, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

As per the minutes, the decisions at the Board Meetings were taken unanimously and there was no instance of dissent by any director during the audit period.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period, there were no specific events/actions having a major bearing on the company's affairs in pursuance of the above referred laws, rules, regulations, guidelines and standards.

For Alagar & Associates LLP
(Formerly known as M. Alagar & Associates)
Company Secretaries
Firm Registration No : L2025TN019200
Peer Review Certificate No: 6814/2025

M. Alagar
Designated Partner
FCS No: 7488/ CoP No: 8196
UDIN: F007488H001087798

Place: Chennai
Date: August 12, 2026

This report is to be read with our letter of even date which is annexed as **Annexure I** and forms an integral part of this report.

ANNEXURE - I

To,
The Members,
Caplin Point Laboratories Limited

Our report is to be read along with this letter

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our Audit.

2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.

3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

4. Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.

5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.

6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For Alagar & Associates LLP
(Formerly known as M. Alagar & Associates)
Company Secretaries
Firm Registration No : L2025TN019200
Peer Review Certificate No: 6814/2025

M. Alagar
Designated Partner
FCS No: 7488/ CoP No: 8196
UDIN: F007488H001087798

Place: Chennai
Date: August 12, 2026

Annexure - IV-A

FORM NO. MR-3
SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
Caplin Steriles Limited

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Caplin Steriles Limited** (hereinafter called "**the Company"**). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we hereby report that in our opinion, the Company has, during the Audit Period covering the Financial Year ended March 31, 2026 ("Audit Period") complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the Financial Year ended March 31, 2026, according to the provisions of:

1. The Companies Act, 2013 ('Act') and the rules made thereunder, as amended from time to time including Secretarial Standards issued by Institute of Company Secretaries of India ('ICSI') as mandated by the Companies Act,2013;

2. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made thereunder;- **Not Applicable to the Company**

3. The Depositories Act, 1996 and the Regulations and Byelaws framed thereunder

4. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment and Overseas Direct Investment and External Commercial Borrowings

5. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'): **Not Applicable to the Company**

   (i) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

   (ii) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

   (iii) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;

   (iv) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;

   (v) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act, 2013 and dealing with client.

   (vi) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;

   (vii) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021;

   (viii) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018;

   (ix) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021.

6. Based on the information received and representation made by the Company, other than general laws like fiscal, labour laws,

environmental laws and all other laws, rules, regulations and guidelines which are generally applicable, the following Laws/Acts are also, interalia, applicable to the Company:

(i) Air (Prevention & Control of Pollution) Act, 1981

(ii) Water (Prevention & Control of Pollution) Act, 1974

(iii) Environment Protection Act, 1986

(iv) Drugs and Cosmetics Act, 1940

(v) The Boilers Act, 2025

(vi) Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016

During the audit period, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that the Board of Directors of the Company is duly constituted. The changes in the composition of the Board of Directors that took place during the audit period were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent to them at least seven days in advance or as the case may be, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

As per the minutes, the decisions at the Board Meetings were taken unanimously and there was no instance of dissent by any director during the audit period.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period, there were no specific events/actions having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines and standards.

For Alagar & Associates LLP
(Formerly known as M. Alagar & Associates)
Company Secretaries
Firm Registration No : L2025TN019200
Peer Review Certificate No: 6814/2025

M. Alagar
Designated Partner
FCS No: 7488/ CoP No: 8196
UDIN: F007488H001071531

Place: Chennai
Date: August 10, 2026

This report is to be read with our letter of even date which is annexed as **Annexure I** and forms an integral part of this report.

ANNEXURE - I

To,
The Members,
Caplin Steriles Limited

Our report is to be read along with this letter

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our Audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management representation about the compliance of Laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For Alagar & Associates LLP
(Formerly known as M. Alagar & Associates)
Company Secretaries
Firm Registration No : L2025TN019200
Peer Review Certificate No: 6814/2025

M. Alagar
Designated Partner
FCS No: 7488/ CoP No: 8196
UDIN: F007488H001071531

Place: Chennai
Date: August 10, 2026

Annexure - V

PARTICULARS OF EMPLOYEE RELATED DISCLOSURES

Pursuant to Section 197 of the Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

i. The ratio of the remuneration of each director to the median remuneration of the employees of the company as on March 31, 2026 and the percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary in the financial year:

S.No	Name of the Director/KMP	Designation	Ratio to Median in Remuneration	% of increase in Remuneration
1	Mr. C C Paarthipan	Chairman	0.00 Times	NIL
2	Dr. Sridhar Ganesan	Managing Director	12.40 Times	NIL
3	Mr. D Muralidharan	Chief Financial Officer	13.54 Times	10.64%
4	Mr. Venkatram G	General Counsel & Company Secretary	11.94 Times	26.26%

Dr. K C John, Ms. Susan Mathew, Dr C K Gariyali, Mr S Deenadayalan, Mr. R Vijayaraghavan and Dr. R Nagendran were paid only sitting fees for attending the Board/ Committee Meetings.

Mr. Ashok Partheeban and Mr. Vivek Partheeban, in their capacity as, Non-Executive Directors, were not paid any remuneration by the Company during the year.

ii. The percentage increase in the median remuneration of employees in the financial year: 11.45%

iii. Number of Permanent employees in the rolls of the Company as on March 31, 2026: 1024

iv. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:

In the Financial Year 2025-26 there is an average increase of 13.87% in the remuneration of all the employees other than the managerial personnel and Percentage increase in the Managerial Remuneration is Nil

v. Affirmation that the remuneration is as per the remuneration policy of the Company:

The Company affirms remuneration is as per the remuneration policy of the Company

vi. Names of the top ten employees in terms of remuneration drawn:

S. No	Employee Name	Gross Salary (₹ in Crores)	Perquisites (₹ in Cores)	EPF Employer Contribution (₹ in Crores)	Total (₹ in Crores)	Designation	Qualification	Experience (No. of years) (Overall experience including Caplin)	Date of commencement of employment	Age (yrs)	Last employment held by such employee before joining the company (with Designation)	Percentage of Equity Shares held	whether any such employee is a relative of any director or manager of the company and if so, name of such director or manager
1	Neelakandan K	0.88	0.05	0.07	0.99	President - API R&D	Ph D	23	May 13, 2019	45	Emcure Pharmaceutical / General Manager	0.01%	No
2	Muralidharan D	0.55	0.00	0.05	0.60	Chief Financial Officer	B Com, ACS, CMA	49	February 19, 2016	70	Merck Specialities Pvt Ltd/ Chief Commercial Head	0.03%	No
3	Dr. Sridhar Ganesan	0.53	0.00	0.04	0.57	Managing Director	B Pharm, M S, Doct of HMD	47	August 25, 2014	71	National pharmaceutical/ CEO	0.13%	No
4	Venkatram G	0.47	0.00	0.04	0.51	General Counsel & Company Secretary	B. Com, MBA, ACS, LLB	22	June 01, 2022	43	India Nippon Electricals ltd / Company Secretary, Compliance & Legal Head	0.00%	No
5	Sivakumar Balasubramanian	0.45	0.04	0.00	0.49	Plant Head	M B A	21	March 18, 2005	45	-	0.33%	No
6	Vinayak Dinkar Kadam	0.44	0.00	0.03	0.47	Associate Vice President – FR&D	M.Pharm, Phd.	22	June 23,2025	46	Lupin/ Principal Scientist	0.00%	No
7	Yewale Bhushan Ravindra	0.37	0.00	0.00	0.37	General Manager - Strategic Sourcing	PGD Packaging	16	August 02,2021	39	Aurabindho/ Manager	0.00%	No
8	Umapathy V	0.29	0.03	0.02	0.34	General Manager	Ph D	37.5	May 09, 2005	60	Vel's College of Science / Associate professor	0.01%	No
9	Raghavan C	0.31	0.00	0.00	0.31	Senior General Manager	B Pharm	26	June 05,2013	47	Bafna pharmaceuticals/ Assistant General Manager	-	No
10	Dinesh R	0.30	0.00	0.00	0.30	Senior General Manager	M BA	22	December 01,2010	44	TCS eserve/ Deputy Manager	0.01%	No

vii. Employed throughout the Financial Year, was in receipt of remuneration for that year which, in the aggregate, was not less than one crore and two lakh rupees: NIL

viii. Employed for a part of the Financial Year, was in receipt of remuneration for any part of that year, at a rate which, in the aggregate, was not less than eight lakh and fifty thousand rupees per month: NIL

ix. Employed throughout the Financial Year or part thereof, was in receipt of remuneration in that year which, in the aggregate, or as the case may be, at a rate which, in the aggregate, is in excess of that drawn by the managing director or whole-time director or manager and holds by himself or along with his spouse and dependent children, not less than two percent of the equity shares of the company: NIL

x. The percentage of equity shares held by the employee in the company and whether any such employee is a relative of any director or manager of the company and if so, name of such director or manager: NIL

For and on behalf of the Board of Directors

Place: Chennai
Date: August 12, 2026

C C Paarthipan
Chairman

Annexure - VI

AOC – 2

(Pursuant to Section 134 (3) (h) of the Act, 2013 read with Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contract / arrangements entered in to by the Company with the related parties referred to in sub-Section 188 (1) of the Act, 2013 including certain arm's length transactions under third proviso thereto.

1 Details of contracts or arrangements or transactions not at arm's length basis

There were no contracts or arrangements or transactions entered in to by the Company during the year ended March 31, 2026 which were not at arm's length basis.

2 Details of material contracts or arrangement or transactions at arm's length basis:

Sl. No	Name of the Related party and relationship	Durations	Salient terms	Date approved by Board / Audit Committee	Nature of Transactions	Amount (in ₹ Crores)
1	Nuevos Eticos Neoethicals S.A-Guatemala, Step down Subsidiary	01.04.2025 to 31.03.2026	The salient terms are as per the shareholders' approval accorded on September 29, 2022	February 07, 2025	Sale of goods	219.06

For and on behalf of the Board of Directors

Place: Chennai
Date: August 12, 2026

C C Paarthipan
Chairman

CORPORATE GOVERNANCE REPORT

1. COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE

Caplin Point Laboratories Limited ("Caplin") is built on a foundation of robust corporate governance, emphasizing transparency, excellence, accountability, and the protection of stakeholder interests as a continuous and ongoing process. Committed to upholding the highest ethical, moral, and legal standards, Caplin's objective is to move beyond simple compliance and ensure robust governance by embedding global best practices into our core operations.

To maximize sustainable value for all stakeholders, our governance philosophy is driven by three interconnected frameworks:

- **Holistic Value Creation:** We recognize that long-term success requires balancing financial growth with ethical business practices. Our governance framework is designed to protect shareholder interests while proactively addressing the needs of our employees, supply chain partners, and local communities.
- **Commitment to ESG:** Environmental, Social, and Governance (ESG) principles are integrated directly into our operational DNA. We prioritize responsible environmental stewardship in our manufacturing processes, drive social equity through dedicated employee well-being and community initiatives, and maintain rigorous internal controls to ensure transparent governance.
- **Incorporating Elements of Integrated Reporting:** To provide a more comprehensive view of our performance, we are actively adopting key elements of the Integrated Reporting framework into our disclosures. We are presenting our financial metrics alongside our relevant ESG achievements and sustainability goals. This approach offers stakeholders a transparent understanding of how Caplin creates, preserves, and delivers value over the short, medium, and long term.

2. BOARD OF DIRECTORS

i. Succession Planning

In terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("SEBI Listing Regulations") the Board of Directors, periodically reviews succession plans for the Board and Senior Management to ensure orderly leadership transition and long-term continuity of governance.

As a part of this, and in recognition of their long-standing contribution to the Company's operations and their readiness to assume greater governance responsibility, the Board approved the appointment of Mr. Ashok Partheeban (DIN: 02507261) and Mr. Vivek Partheeban (DIN: 02507289) as Non-Executive Directors and Vice-Chairmen of the Company with effect from November 5, 2025, subsequently approved by the shareholders through postal ballot on January 31, 2026.

This step forms part of the Company's broader succession framework anchored around the founding leadership of Mr. C.C. Paarthipan, Chairman, and is intended to build institutional continuity in Board-level oversight while the Company's day-to-day executive management continues to be led by the Managing Director and the professional management team.

ii. Composition and category of Board of Directors

As on March 31, 2026, Board comprised of Nine (9) Directors out of which five (5) are Independent Directors (including an Independent Woman Director), a Managing Director and three (3) Non-Independent Non-Executive Directors.

Composition of Independent & Non-Independent Directors



Mr. C. C. Paarthipan serves as the Chairman and Non-Executive Director of the Company. Mr. Ashok Partheeban and Mr. Vivek

Partheeban serve as the Vice-Chairmen and Non-executive Directors of the Company. Mr. C. C. Paarthipan, Mr. Ashok Partheeban and Mr. Vivek Partheeban are the Promoter Directors.

Dr. Sridhar Ganesan is the Managing Director of the Company.

Dr. C K Gariyali (DIN: 08711546) ceased to be an Independent Director and member of Nomination and Remuneration Committee with effect from March 03, 2026, as she had served the maximum tenure permitted for an Independent Director. To meet the requirement of Board Composition under the Companies Act, 2013 and SEBI Listing Regulations, the shareholders had approved the appointment of Ms. Susan Mathew (DIN: 00517738) as an Independent Director for a term of five years at the postal ballot held on January 31, 2026. Requisite approvals were taken from the shareholders in the said Postal Ballot for continuation of appointment on crossing seventy-five years of age. Further, the shareholders, through the same Postal Ballot concluded on January 31, 2026, approved the appointment of Mr. Ashok Partheeban (DIN: 02507261), Mr. Vivek Partheeban (DIN: 02507289) as Non-executive Non-Independent Directors of the Company, and Dr. K. C. John (DIN: 01067374) as Independent Director of the Company. Requisite approvals were taken from the shareholders in the said Postal Ballot for continuation of appointment of Dr. K C John on crossing seventy-five years of age.

Dr. Sridhar Ganesan (DIN: 06819026), retires by rotation and being eligible offers himself for re-appointment.

Further, the Nomination and Remuneration committee and the Board, at their respective meetings held on August 12, 2026, considered and approved the following;

1. Re-appointment of Dr. Sridhar Ganesan as the Managing Director for a period of 2 years with effect from August 25, 2026, to August 24, 2028.
2. Continuation of Mr. C. C. Paarthipan as the Chairman and Non-Executive, Non-Independent Director beyond seventy five years of age.
3. Appointment of Mr. D Muralidharan as a Whole Time Director of the Company for a period of 2 years with effect from August 12, 2026, to August 11, 2028.

The requisite shareholder approvals for the above appointments are being sought at the AGM, and the relevant resolutions form part of the Notice convening the AGM.

The Composition of the Board is in conformity with the requirement of Regulation 17 of the SEBI Listing Regulations and the Companies Act, 2013. In the opinion of the Board, all the Independent Directors have confirmed that they meet the “Independence Criteria” as mentioned under Section 149 of the Companies Act, 2013 and Regulation 16 (1)(b) of SEBI Listing Regulations. Every Independent Director, at the first meeting of the Board in which he/she participates as a Director and thereafter at the first meeting of the Board in every Financial Year, gives a declaration under Section 149(7) of the Companies Act, 2013 that he/she meets the criteria of independence as required under Section 149(6) of the Companies Act, 2013.

As required under Regulation 16 of the SEBI Listing Regulations, it is also ensured that Independent Directors do not hold Non-Independent Directorship position in another company, where any Non- Independent Director of the Company is an Independent Director.

iii. Board Meetings

During the year, meetings of the Board and its Committees were convened through video conferencing as well as in physical mode at the Registered Office of the Company. Further, the information as mentioned in Part A of Schedule II of the SEBI Listing Regulations, has been placed before the Board for its consideration. The Board periodically reviews the compliance reports of all Laws applicable to the Company, the Company’s strategic direction, management policies, performance objectives and effectiveness of Corporate Governance practices.

As a matter of good governance practice, all Board meetings are called by proper notice along with structured agenda papers which are backed by comprehensive background information of the business transaction. The Board has complete unrestricted access to all the information concerning the Company.

During the Financial Year under review, the Board of Directors met five times (i.e.) May 15, 2025, August 7, 2025, November 5, 2025, December 29, 2025, and February 5, 2026.

The maximum time gap between two meetings did not exceed 120 days. The necessary quorum was present for all the meetings.

Besides, the Independent Directors held a separate meeting on March 31, 2026, through video conferencing, in compliance with the provisions of the Companies Act, 2013 and Regulation 25(3) of the SEBI Listing Regulations. All the Independent Directors, except Ms. Susan Mathew, were present at the meeting.

The composition of the Board, attendance of the Directors at the Board Meetings held during the year under review and at the last AGM, number of directorships, memberships/ chairmanships of the Board and Committees of public Companies are as under:

Name of the Director & DIN	Category	No. of Board meetings attended in the year	Attendance at the previous AGM (22.09.2025)	Directorships in other Public Limited Companies	Committee Position(s) in Public Limited Companies (Including Caplin Point Laboratories Limited)		Directorship(s) in other Listed Companies
					Chairman	Member	
Mr. C C Paarthipan DIN: 01218784	Non-Executive Non-Independent Director, Promoter Chairman	5	Yes	2	0	0	-
Mr. Ashok Partheeban DIN: 02507261	Non-Executive Non-Independent Director Vice-Chairman	1	NA	0	0	0	-
Mr. Vivek Partheeban DIN: 02507289	Non-Executive Non-Independent Director Vice-Chairman	2	NA	2	0	1	-
Dr. Sridhar Ganesan DIN: 06819026	Managing Director	5	Yes	2	0	2	-
Mr. R Vijayaraghavan DIN: 00026763	Independent Director	5	Yes	4	3	7	1. Sundram Fasteners Limited 2. The United Nilgiri Tea Estates Company Limited
*Dr. C K Gariyali DIN: 08711546	Independent Director	4	Yes	1	0	1	-
Ms. Susan Mathew DIN: 00517738	Independent Director	1	NA	1	0	1	-
Mr. S Deenadayalan DIN: 01951620	Independent Director	5	Yes	1	1	2	-
Dr. R Nagendran DIN: 08943531	Independent Director	5	Yes	1	0	2	-
Dr. K C John DIN: 01067374	Independent Director	2	NA	1	1	1	-

Notes: -

- *Dr. C K Gariyali completed her term of office as an Independent Director with effect from the close of business hours of March 03, 2026.

- As required under Regulation 17A of the SEBI Listing Regulations, none of the Directors, including Independent Directors hold Directorship in more than 7 (seven) listed companies across the Directorships held including that of Caplin Point Laboratories Limited.
- None of the Directors is a member in more than 10 (ten) Committees, nor a Chairman in more than 5 (five) committees across all companies in which he/she was a Director, including those held in Caplin Point Laboratories Limited. For the purpose of considering the limit of the committees in which a Director can serve, all public limited companies, whether listed or not, have been included and all other companies including private limited companies, foreign companies and companies under Section 8 of the Companies Act, 2013, have been excluded.
- Only Audit Committee and Stakeholders' Relationship Committee are considered for the purpose of reckoning committee positions.
- Mr. C C Paarthipan, Mr. Ashok Partheeban and Mr. Vivek Partheeban are related to each other. Mr. C C Paarthipan is the father of Mr. Ashok Partheeban. and Mr. Vivek Partheeban

iv. Familiarization Programme for Independent Directors

In line with the provisions of the Companies Act, 2013, and the SEBI Listing Regulations, Caplin Point has a structured familiarization program to empower Independent Directors with a thorough understanding of the company and its operating environment. This initiative is designed to ensure that the directors are equipped to contribute effectively to board discussions and decision-making. The familiarization program is a continuous process that includes both formal induction for new directors and ongoing engagement for all Independent Directors.

Throughout the year, Independent Directors are regularly apprised of critical information through presentations by the senior management team. These updates cover a range of topics including business performance, risk management frameworks, internal control over financial reporting, and the broader industry landscape. Directors are also regularly informed of changes in relevant statutory and regulatory frameworks and are consulted in their areas of expertise to provide strategic insights. The program also includes visits to the company's manufacturing and research facilities to provide a first-hand understanding of operations. The details of familiarization programme are provided at https://www.caplinpoint.net/wp-content/uploads/2021/07/Familiarization-Programme-310326-1.pdf. Further, the Independent Directors were involved and consulted in the areas of their expertise whenever there was a requirement, which also provided insights into the business of the Company.

v. Key Skills, Expertise and Competencies of the Board

The Board comprises of ideal mix of Directors who have expertise in varied fields to bring divergent thinking to Board room deliberations. These Directors are nominated based on well-defined selection criteria. The Nomination and Remuneration Committee considers, inter alia, key skills, qualifications, expertise and competencies, whilst recommending to the Board the candidature for appointment of Director. The Board of Directors have, based on the recommendations of the Nomination and Remuneration Committee, identified the following core key skills/expertise/competencies of Directors as required in the context of business of the Company for its effective functioning which are currently possessed by the Board Members.

Matrix highlighting core skills/expertise/competencies of the Board of Directors

Name of the Director	Financial	Governance	People management and Leadership	Industry Knowledge	Strategic Planning	Risk Management
Mr. C C Paarthipan	√	√	√	√	√	√
Mr. Ashok Partheeban	√	√	√	√	√	
Mr. Vivek Partheeban	√	√	√	√	√	√
Dr. Sridhar Ganesan	√	√	√	√	√	√
Mr. R. Vijayaraghavan	√	√	√		√	√
Dr. R Nagendran	√	√	√		√	
Mr. S Deenadayalan	√	√	√		√	√
Ms. Susan Mathew	√	√	√		√	
Dr. K C John	√	√	√	√	√	√

a. **Financial:** Basic understanding of financial management, financial statements, financial controls and experience in accounting principles, auditing and reporting.

b. **Governance:** Ensuring adherence to the Corporate Governance Principles, Company's Codes and Policies, Statutory compliance, protecting and enhancing stakeholders' value and driving corporate ethics and values, ability to understand, assess and manage risk.

c. **People management and Leadership:** Effective management of business operations, ability to guide on complex business decisions, anticipate changes, setting priorities, aligning resources towards achieving goals, expertise in developing talent, succession planning, furthering representation and diversity.

d. **Industry Knowledge:** Working knowledge in Pharma and allied Industries.

e. **Strategic planning:** Good business instincts and acumen, ability to provide guidance and active participation in complex decision making, set strategic priorities and focus energy & resources towards achieving goals.

f. **Risk Management:** Knowledge and expertise of risk management, risk framework, adequacy and efficiency of controls, mitigation of risks etc.

3. COMMITTEES

A. Audit Committee

a. Terms of Reference

The Audit Committee's terms of reference is in accordance with the provisions of the SEBI Listing Regulations and the Companies Act 2013. The Committee acts as a link between the Management, the Statutory Auditors, Internal Auditors and the Board. The Committee, inter alia, performs the following functions:

- Recommending the appointment, remuneration and term of appointment of Statutory Auditors of the Company and approval for availing any other services;
- Reviewing and monitoring the Auditor's independence and performance and effectiveness of audit process;
- Examining the annual financial statements and auditor's report thereon before submission to the Board for approval;
- Overseeing the Company's financial reporting process and disclosure of financial information to ensure that the financial statements are correct, sufficient and credible;
- Reviewing Management Discussion and Analysis of Financial condition and results of operations;
- Scrutinizing the inter-corporate loans and investments;
- Reviewing, approving or subsequently modifying any Related Party Transactions in accordance with the Related Party Transaction Policy of the Company;
- Reviewing with the Management, performance of Statutory Auditors and Internal Auditors, adequacy of internal control systems;
- Reviewing the adequacy of internal audit function and discussing with Internal Auditors any significant finding and follow-up thereon;
- Evaluating internal financial controls and risk management systems, reviewing the functioning of the whistle blower mechanism;
- Reviewing the valuation of undertakings or assets of the Company, wherever it is necessary;
- Reviewing the utilization of loans and/ or advances from/ investment, by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments as on the date of coming into force of this provision;
- Any other functions as may be decided by the Board from time to time.

b. Composition

The composition of the Committee is given below:

Name of the Members	Category
Mr. R. Vijayaraghavan	Chairman, Independent Director
Dr. Sridhar Ganesan	Member, Managing Director
Mr. S Deenadayalan	Member, Independent Director
Dr. R Nagendran	Member, Independent Director

c. Meetings

The Audit Committee met four times during the year on May 15, 2025, August 7, 2025, November 5, 2025 and February 5, 2026.

The maximum time gap between two meetings did not exceed 120 days.

Name of the Members	No. of meetings attended
Mr. R. Vijayaraghavan	4
Dr. Sridhar Ganesan	4
Mr. S Deenadayalan	4
Dr. R Nagendran	4

Mr. R. Vijayaraghavan, the Chairman of the Audit Committee was present at the AGM held on September 22, 2025. The Company Secretary of the Company acts as the Secretary to the Committee.

The Committee invites the Statutory Auditors and the Internal Auditors for discussions at the meeting. Chief Financial Officer is a permanent invitee at the Committee meetings. Members of Senior Management team also attend the meetings depending on the agenda.

B. Nomination and Remuneration Committee

a. Terms of Reference

The Nomination and Remuneration Committee's terms of reference is in accordance with the provisions of the SEBI Listing Regulations and the Companies Act 2013. The Committee, inter alia, performs the following functions:

- Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to, the remuneration of the directors, key managerial personnel and other employees;
- Evaluating the balance of skills, knowledge and experience required on the Board. Based on this evaluation, the Committee shall prepare a description of the role and capabilities required of an Independent Director. The person recommended by the Committee to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:

  i. use the services of external agencies, if required;

  ii. consider candidates from a wide range of backgrounds, having due regard to diversity; and

  iii. consider the time commitments of the candidates.
- Formulation of criteria for evaluation of performance of independent directors and the board of directors;
- Devising a policy on diversity of board of directors;
- Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the board of directors their appointment and removal;
- Recommend whether to extend or continue the term of appointment of an independent director, on the basis of the report of performance evaluation of independent directors;
- Recommend to the board, all remuneration, in whatever form, payable to senior management.

The Committee also acts as the Compensation Committee for administration of all the ESOP Schemes of the Company.

b. Composition

The composition of the Committee is given below:

Name of the Members	Category
Mr. S Deenadayalan	Chairman, Independent Director
Mr. C C Paarthipan	Member, Non -Executive Non-Independent Director
Dr. C K Gariyali*	Member, Independent Director
Dr. K C John#	Member, Independent Director

* Ceased to be a member with effect from March 3, 2026

Appointed as a member with effect from March 3, 2026

c. Meetings

The Nomination and Remuneration Committee met four times during the year on May 15, 2025, August 7, 2025, November 5, 2025, and December 29, 2025.

Name of the Members	No. of meetings Attended
Mr. S Deenadayalan	4
Mr. C C Paarthipan	4
Dr. C K Gariyali	4
Dr. K C John	Not Applicable

Mr. S Deenadayalan, the Chairman of the Nomination and Remuneration Committee was present at the AGM held on September 22, 2025. Company Secretary of the Company acts as the Secretary to the Committee.

d. Annual Performance Evaluation

The Board has carried out the annual performance evaluation as per the following process:

Process

Pre-meeting

- The Company Secretary circulated the evaluation forms reflecting the rating criteria along with the rating scale as specified in the Nomination and Remuneration Policy to all the Directors.
- The note detailing the process of evaluation was circulated to all the Directors.

Independent Director ("ID") Meeting held on March 31, 2026

- IDs reviewed the performance of all the Directors, the Board and Committees.
- The IDs elected a lead Independent Director to summarize the deliberations and communicate the summary along with the ratings to the Chairman in case of individual Directors and to the Board/Nomination Remuneration Committee in case of Board/Committee evaluation.
- Meeting of IDs was conducted electronically without the presence of executive management.

Board / Nomination and Remuneration Committee Meeting

- Chairman considered the individual Director's evaluation and discussed the same with individual Directors.
- The lead Independent Director apprised the Nomination and Remuneration Committee and the Board about the rating summary for Board and Committee.
- The Chairman took note of the suggestions and proposed an implementation plan.

The performance evaluation process comprises three components each of them having its own parameters as below:

Parameters

Evaluation of the Board as a whole

- Strategy
- Performance Management & Succession Plans
- Execution, Investments, M&A and Financial Controls
- Talent Management
- Risk Management
- Corporate Governance & Compliance
- Review of Information
- Monitoring of Committees
- Overall

Evaluation of the Committees of the Board

- Functions and Duties
- Management Relations
- Effectiveness of Meetings
- Overall

Evaluation of the Individual Directors (including Independent Directors and Chairman)

- Attendance and preparation for meetings, communication of opinions and concerns, etc.
- Strategic and functional abilities
- Ethics and values
- Team player
- Self-development
- Additional parameters for Independent Directors and Chairman

e. Remuneration Policy

The Remuneration Policy of the Company is designed and framed to attract, motivate and retain available talents. The policy reflects the Company's objectives for good corporate governance as well as sustained long-term value creation for shareholders.

When determining the remuneration policy and arrangements for Executive Directors/ KMPs, the Nomination & Remuneration Committee considers pay, other employee retention benefits such as ESOP etc, and employment conditions with peers / elsewhere in the competitive market to ensure that pay structures are appropriately aligned and that levels of remuneration remain appropriate in the context of the business.

With respect to Senior Management Personnel, the remuneration package shall be fixed based on the recommendation of the Human Resources department based on internal parity and market conditions for the said Senior Management role. However, the Committee will ensure that the remuneration is reasonable and sufficient to attract, retain and motivate the person to ensure the quality required for the concerned Senior Management position.

The remuneration paid to Managing Director as mentioned in this report has been approved by the Board and shareholders. No remuneration, other than sitting fees for attending the Board/ Committee meetings were paid to the non-Executive Directors.

The remuneration policy has been uploaded on the website of the Company at https://www.caplinpoint.net/wp-content/uploads/2021/07/Nomination-and-Remuneration-Policy.pdf

f. Details of Remuneration Paid to Non-Executive Directors for the Financial Year ended March 31, 2026: -

Name of Director	Remuneration (in ₹)	Commission and Performance linked Incentive (in ₹)	Sitting Fees Amount (in ₹)	Total Amount (in ₹)	No. of shares held
Mr. C C Paarthipan	-	-	-	-	1,41,67,192
Mr. Ashok Partheeban	-	-	-	-	90,50,000
Mr. Vivek Partheeban	*12,49,000	-	-	12,49,000	90,09,371
Mr. R. Vijayaraghavan	-	-	4,25,000	4,25,000	-
Dr. C K Gariyali	-	-	3,00,000	3,00,000	-
Mr. S Deenadayalan	-	-	6,75,000	6,75,000	70
Dr. R Nagendran	-	-	4,00,000	4,00,000	-
Ms. Susan Mathew	-	-	50,000	50,000	-
Dr. K C John	-	-	1,50,000	1,50,000	-

* Mr. Vivek Partheeban was the Chief Operating officer of the Company till November 5, 2025. The Remuneration was paid to him in his capacity as a Chief Operating Officer. He is not entitled to any remuneration from the Company in his capacity as a Non-Executive Director.

g. Details of remuneration paid to Managing Director for the Financial Year Ended March 31, 2026: -

Name of Director	Gross ₹ in Crores	Contribution to PF ₹ in Crores	Total ₹ in Crores	No. of Shares held
Dr. Sridhar Ganesan	0.53	0.04	0.57	98,750

Further, Dr. Sridhar Ganesan was granted 12,000 stock options on May 16, 2024 which shall vest as per the terms and conditions approved by the Nomination and Remuneration committee and the ESOP Scheme. There is no severance fees payable to the Managing Director. The Notice period is bound by the contract of employment.

C. Stakeholders Relationship Committee

a. Terms of Reference

The Stakeholders Relationship Committee's terms of reference is in accordance with the provisions of the SEBI Listing Regulations and the Companies Act 2013. The Committee, inter alia, reviews the mechanism of redressal of grievances of the securities holders, service level of Registrar and Transfer Agents and deals with other matters concerning securities holders including dividend.

b. Composition

The composition of the Committee is given below:

Name of the Members	Category
Mr. S Deenadayalan	Chairman, Independent Director
Mr. R Vijayaraghavan	Member, Independent Director
Dr. Sridhar Ganesan	Member, Managing Director

c. Meetings

The Committee met once during the year on February 5, 2026.

Name of the Members	No. of meetings attended
Mr. S Deenadayalan	1
Mr. R Vijayaraghavan	1
Dr. Sridhar Ganesan	1

Mr. S Deenadayalan, Chairman of the Stakeholders Relationship Committee was present at the AGM held on September 22, 2025. The Company Secretary of the Company acts as the Secretary to the Committee.

The status of Investor Complaints during the year ended March 31, 2026, is as under:

Particulars	No. of Complaints
Complaints as on April 1, 2025	3
Complaints received during the year	51
Complaints resolved during the year	45
Complaints pending as on March 31, 2026	9

D. Risk Management Committee

a. Terms of Reference

The Risk Management Committee's terms of reference is in accordance with the provisions of the SEBI Listing Regulations and the Companies Act 2013. The brief description of the terms of reference of the Committee, inter-alia, are given below: -

- ► To formulate a detailed risk management policy which shall include:

  i. A framework for identification of internal and external risks specifically faced by the listed entity, including financial, operational, sectoral, sustainability (particularly, ESG related risks), information, cyber security risks or any other risk as may be determined by the Committee.

ii. Measures for risk mitigation including systems and processes for internal control of identified risks.

iii. Business continuity plan

- To ensure that appropriate methodology, processes and systems are in place to monitor and evaluate risks associated with the business of the Company;
- To monitor and oversee implementation of the risk management policy, including evaluating the adequacy of risk management systems;
- To periodically review the risk management policy, at least once in two years, including by considering the changing industry dynamics and evolving complexity;
- To keep the board of directors informed about the nature and content of its discussions, recommendations and actions to be taken;
- The appointment, removal and terms of remuneration of the Chief Risk Officer (if any) shall be subject to review by the Risk Management Committee.

b. Composition

The composition of the Risk Management Committee is given below:

Name of the Members	Category
Mr. S Deenadayalan	Chairman, Independent Director
Dr. Sridhar Ganesan	Member, Managing Director
Mr. D Muralidharan	Member, Chief Financial Officer
Mr. Vivek Partheeban*	Member, Non -Executive Non-Independent Director
Dr. K C John*	Member, Independent Director

* Appointed as members with effect from March 3, 2026

c. Meetings

The Risk Management Committee met twice during the year on August 7, 2025, and February 5, 2026.

Name of the Members	No. of meetings attended
Mr. S Deenadayalan	2
Dr. Sridhar Ganesan	2
Mr. D Muralidharan	2
Mr. Vivek Partheeban	Not Applicable
Dr. K C John	Not Applicable

The Company Secretary of the Company acts as the Secretary to the Committee.

The Chairman of the Committee apprises the Board about the most significant risks along with the status of action taken by the Management for mitigating such risks and the effectiveness of the Enterprise Risk Management Framework. Details of Risk Management measures taken by the Company have been provided in the Management Discussion and Analysis Report which is attached to the Board's Report.

E. Corporate Social Responsibility Committee

a. Terms of Reference

The Company has constituted a Corporate Social Responsibility ("CSR") Committee pursuant to the provisions of Section 135 of the Companies Act, 2013, read with Companies (Corporate Social Responsibility) Rules, 2014. The responsibilities of CSR committee include:

- Approving the CSR budget, taking into account the required spending under the Act as well as the Surplus arising out of any CSR project that needs to be ploughed back, unspent amount carried forward as well as excess spending of the previous Financial Year, if any;

Approving the following:

- List of CSR projects for the entirety of CSR budget
- Duration of each of the CSR projects and approving converting a single year project into multi-year (Ongoing) project along with proper justification

- The selection of implementing agency(ies), if any, on the basis of track record and other criteria such as local credibility, local knowledge, domain expertise, local institutional relationships and their approach to sustainability.
- Formulating and recommending to the Board, an Annual Action Plan, at the same meeting for approving the CSR budget, comprising the following:
  - i. the list of CSR projects that are approved to be undertaken in areas or subjects specified in Schedule VII of the Act;
  - ii. the manner of execution of such projects;
  - iii. the modalities of utilisation of funds and implementation schedules for the projects;
  - iv. monitoring and reporting mechanism for the projects; and
  - v. details of need and impact assessment, if any, for the projects undertaken by the company
- Making recommendations to the Board about any changes required in the annual action plan along with justifications;
- Instituting a transparent monitoring mechanism for the implementation of the Projects along with specifying the documentation standards required from the implementation agencies/ in house CSR personnel to enable certification of amount spent to the Board by the Committee and the Chief Financial Officer.

b. Composition

The composition of the Corporate Social Responsibility Committee is given below:

Name of the Members	Category
Mr. C C Paarthipan	Chairman, Non- Executive Director
Mr. S Deenadayalan	Member, Independent Director
Dr. Sridhar Ganesan	Member, Managing Director

c. Meetings

The Corporate Social Responsibility Committee met four times during the year on May 15, 2025, August 7, 2025, November 5, 2025, and February 5, 2026.

Name of the Members	No. of meetings attended
Mr. C C Paarthipan	4
Dr. Sridhar Ganesan	4
Mr. S Deenadayalan	4

The Company Secretary acts as the Secretary to the Committee.

The CSR Report as required under the Companies Act, 2013 for the year ended March 31, 2026, is attached as Annexure - III to the Board's Report.

4. PARTICULARS OF SENIOR MANAGEMENT PERSONNEL AS ON MARCH 31, 2026

i. Anto Vijinth V, Functional Head -HO, HR & Admin

ii. Dinesh R, Functional Head - HO, Production Planning & Inventory Control

iii. Dr Gunasakaran S, President, Caplin Steriles USA Inc.,

iv. Muralidharan D, Chief Financial Officer, Finance & Accounts

v. Dr Neelakandan K, Vice President, R&D (API), Hyderabad

vi. Sivakumar Balasubramanian, Plant Head, Puducherry

vii. Dr Umapathy V, General Manager, Regulatory Affairs

viii. Venkatram G, General Counsel & Company Secretary

ix. Dr. Vinayak Dinkar Kadam, Associate Vice President – FR&D, Ticel Biopark.

Mr. Thiagaraja Manikandan, Chief Transformation & Digital Officer, ceased to be associated with the company w.e.f April 21, 2025, Mr. Umesh Setty V, Senior Vice President, R&D (Formulations), ceased to be associated with the company w.e.f May 07, 2025, Mr. Paul Premchand J, Vice President, Corporate Affairs, ceased to be associated with the company w.e.f. July 18, 2025 and Mr. Vivek Partheeban, Chief Operating Officer, relinquished his position of Chief Operating Officer consequent to his appointment as a Director and Vice-Chairman of the Company w.e.f. November 05, 2025. Dr. Vinayak Dinkar Kadam, Associate Vice President, was designated as a Senior Management Personnel of the Company w.e.f June 27, 2025, consequent to his appointment as Associate Vice President – FR&D.

5. EMPLOYEE STOCK OPTION

Detailed information about Employee Stock Option is available at https://www.caplinpoint.net/index.php/shareholder-information/

6. GENERAL BODY MEETINGS

I. Annual General Meeting

Details of AGM held during last three years and the special resolution(s) passed thereat, are as follows:

Year	Date	Time	Location	Special resolutions passed
2025	22-09-2025 (34th AGM)	10.00 AM	Through Video Conferencing ("VC").	Nil
2024	30-09-2024 (33rd AGM)	10.00 AM	Through Video Conferencing ("VC").	1. Re-appointment of Dr Sridhar Ganesan as the Managing Director of the Company 2. Appointment of Mr R Vijayaraghavan as an Independent Director of the Company
2023	21-09-2023 (32nd AGM)	10.00 AM	Through Video Conferencing ("VC").	1. Re-appointment of Dr C K Gariyali as an Independent Director

II. Postal Ballot

The Postal Ballot was conducted in accordance with the provisions contained in Section 110 and other applicable provisions of the Companies Act, 2013, read with Rule 22 of the Companies (Management and Administration) Rules, 2014. The Shareholders were provided with the facility to vote through e-voting for the postal ballot. The postal ballot notice was sent to shareholders as per the permitted mode wherever applicable. The Company also published a notice in the newspapers in accordance with the requirement under the Companies Act, 2013. Shareholders holding equity shares as on the cut-off date casted their votes through e-voting for Postal Ballot during the voting period fixed for this purpose. After completion of scrutiny of votes, the scrutinizer submitted his report to the Chairman and the results of voting by Postal Ballot were announced within 2 working days of the conclusion of the voting period. The results were also displayed on the website of the Company at https://www.caplinpoint.net/index.php/shareholder-information/ and communicated to the Stock Exchanges and Depositories.

Following are the details of the postal ballot and the special resolutions passed therein:

Date of Postal Ballot Notice: December 29, 2025

Voting period: January 02, 2026 (9.00 A.M.) to January 31, 2026 (5.00 P.M.)

Date of Declaration of Results: February 03, 2026

Person who conducted the Postal Ballot: M/s. Alagar & Associates LLP (Firm Registration No. L2025TN019200), was appointed as the scrutinizer to scrutinize the e-voting in connection with postal ballot.

Details of voting:

Resolution	No. of votes polled	Votes cast in Favour		Votes cast Against	
		No. of Votes	% of Votes	No. of Votes	% of Votes
Appointment of Dr. K C John (DIN: 01067374) as Non-Executive Independent Director of the Company for a term of five years.	59555850	57596642	96.71	1959208	3.29
Appointment of Mrs. Susan Mathew (DIN: 00517738) as Non-Executive Independent Director of the Company for a term of five years.	59555850	59527312	99.95	28538	0.05

At present, there are no other special resolutions proposed to be conducted through postal ballot.

7. MEANS OF COMMUNICATIONS

i. Results

Quarterly financial results are announced within 45 (forty-five) days from the end of the quarter and annual audited results are announced within 60 (sixty) days from the end of the Financial Year as per the Regulation 33 of the Listing Regulations and are published in the newspapers in accordance with Regulation 47 of the Listing Regulations.

Financial results are announced to stock exchanges within 30 (thirty) minutes from the closure of the Board meeting at which these are considered and approved.

Quarterly, half- yearly and annual financial results are published in the Financial Express and Maalai Malar. These financial results are also hosted on the website of the Company. The Financial results are published in the newspaper along with the Quick Response code ("QR Code"), enabling stakeholders to directly access the financial results uploaded on the website.

ii. Website & ESG Profile

The Company maintains a fully functional, regularly updated "Investors" section on its website https://www.caplinpoint.net/index.php/investors-2/ in compliance with Regulation 46 of the Listing Regulations, displaying details of interest to various stakeholders, including statutory filings, financial results, annual reports, corporate governance policies, shareholding patterns, and press releases.

The Company has also integrated a dedicated, interactive **'Real-time ESG Disclosure Platform'** on its website. This portal provides transparent access to the Company's Environmental, Social, and Governance (ESG) framework, Business Responsibility and Sustainability Report (BRSR), sustainability metrics, CSR initiatives, and key disclosures mapped across global standards.

iii. Presentations to Institutional Investors / Analysts & Facility Visits

Detailed presentations are made to institutional investors and analysts on a quarterly basis, and the same are hosted on the website of the Company prior to or during the earnings call. In compliance with SEBI Regulations, audio/video recordings of all analyst/investor calls are posted on the website within 24 hours (or before the next trading day), and complete transcripts are uploaded within 5 (five) working days from the conclusion of the call.

To provide institutional investors and analysts with a deeper operational perspective, the Company selectively organizes plant visits, R&D center tours, and facility walk-throughs, subject to operational safety protocols and non-disclosure of Unpublished Price Sensitive Information (UPSI).

8. GENERAL INFORMATION TO THE SHAREHOLDERS

Day, Date, Time & Venue of Annual General Meeting	Friday, September 25, 2026, at 10:00 AM through VC/OAVM
Dividend Payment Date	Final Dividend as recommended by the Board of Directors, if approved at the meeting, will be paid as per the Statutory timelines
Financial Year	April 1 to March 31
Listing of Equity Shares:-	**BSE Limited ("BSE")** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 **National Stock Exchange of India Ltd. ("NSE")** Exchange Plaza, C-1, Block G, Bandra Kurla Complex Bandra (E), Mumbai - 400 051
Trading symbol	**NSE**: **CAPLIPOINT** **BSE**: **524742**

ISIN number in National Securities Depository Limited (NSDL) and the Central Depository Services (India) Limited (CDSL)	INE475E01026
Outstanding GDRs/ADRs/ not issued Warrants or any Convertible instruments	Not Issued
Listing Fees	Annual listing fee for the Financial Year 2025-26 paid to all the Stock Exchanges.
Depository Fees	Annual custody fee for the Financial Year 2025-26 paid to the Depositories.
Dematerialization of shares	As on March 31, 2026, 99.21% of the Company's shares were held in dematerialized form.

Particulars	No. of Shares	%
Physical (A)	6,02,125	0.79
NSDL	6,90,57,550	90.85
CDSL	63,52,021	8.36
Demat (B)	7,54,09,571	99.21
Total (A+B)	**7,60,11,696**	**100**
Registrar and Share Transfer Agents	Integrated Registry Management Services Private Limited, II Floor, "Kences Towers" No.1 Ramakrishna Street, North Usman Road T Nagar, Chennai - 600 017, Phone: 044 - 28140801 – 803, Fax: 044 –28142479	
Share Transfer System	In terms of Regulation 40(1) of SEBI Listing Regulations, as amended, securities can be transferred only in dematerialized form. Members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Transfers of equity shares in electronic form are effected through the depositories with no involvement of the Company.	
Outstanding GDRs / ADRs / Warrants / any other Convertible Instruments	The Company does not have any outstanding GDRs / ADRs / Warrants / Any other Convertible Instruments as on March 31, 2026.	
Commodity Price Risk or Foreign exchange Risk and hedging activities	**1. Commodity Price Risk and hedging** The Company's operating activity involves purchase of Active Pharmaceutical Ingredients (API) and other direct materials, whose prices are exposed to the risk of fluctuation over short period of time. The commodity price risk exposure is evaluated and managed through procurement and other related operating policies. As on 31 March 2026 the Company had not entered into any material derivative contracts to hedge exposure to fluctuations in commodity prices. Accordingly, the disclosures as required under SEBI Master circular dated January 30, 2026, is not applicable to the Company. **2. Foreign exchange Risk and hedging** The Company is exposed to currency risk on account of its export and import of pharmaceuticals and import of raw material, capital goods, etc. The functional currency of the Company is Indian Rupee, whereas majority of its export and imports are settled through USD. The Company does not use any derivative to manage exchange risk since certain degree of a natural hedge is available in the form of foreign currency realised from exports are paid against imports.	

DISTRIBUTION OF SHAREHOLDING AS ON MARCH 31, 2026



9. DISTRIBUTION OF SHAREHOLDING AS ON MARCH 31, 2026 (BASED ON FOLIO)

Category	No. of Folios	Shares	%
Promoter and Promoter group	7	5,36,42,353	70.57
Individuals	90,939	1,11,66,336	14.69
Foreign Portfolio Investors	141	46,73,413	6.15

Category	No. of Folios	Shares	%
IEPF	1	23,09,652	3.04
Body Corporates	471	7,80,359	1.03
NRI- Repatriable	2,570	9,38,698	1.23
Mutual Fund	46	15,34,682	2.02
Unclaimed Suspense A/C	2	65,815	0.09
Limited Liability Partner	86	3,82,884	0.50
HUF	1,248	3,16,657	0.42
Trust	7	8,797	0.01
NRI- Non Repatriable	569	99,376	0.13
Alternative Investment Fund	10	83,366	0.11
Bank	2	3,550	0.00
Insurance Company-LIC	1	5,758	0.01
Total	**96,100**	**7,60,11,696**	**100.00**

10. DISTRIBUTION SCHEDULE AS ON MARCH 31, 2026 (BASED ON PAN)

S. No	Category of Shares	No. of Holders	% to Holders	No. of Shares	% to Capital
1	Up to 500	90,535	96.42	48,17,065	6.34
2	501 - 1000	1,663	1.77	12,85,635	1.69
3	1001 - 2000	872	0.93	12,72,566	1.67
4	2001 - 3000	279	0.30	6,90,051	0.91
5	3001 - 4000	114	0.12	4,00,377	0.53
6	4001 - 5000	96	0.10	4,49,124	0.59
7	5001 - 10000	151	0.16	10,72,612	1.41
8	Above 10001	186	0.20	6,60,24,266	86.86
	Total	**93,896**	**100.00**	**7,60,11,696**	**100.00**

11. UNCLAIMED DIVIDEND AS ON MARCH 31, 2026

As per Section 124(6) of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules") as amended from time to time, all the shares in respect of which dividend has remained unpaid / unclaimed for seven consecutive years or more are required to be transferred electronically to the Demat Account opened in the name of IEPF Authority by the Ministry of Corporate Affairs.

In case the dividends are not claimed within the due date(s), necessary steps will be initiated by the Company to transfer shares held by the members to IEPF. Please note that no claim shall lie against the Company in respect of the shares so transferred to IEPF.

As required under the said provisions, all subsequent corporate benefits that accrue in relation to the above shares will also be credited to the said IEPF Account. In the event of transfer of shares and the unclaimed dividends to IEPF, Members are entitled to claim the same from IEPF by submitting an online application in the prescribed Form IEPF-5 available on the website www.iepf.gov.in and sending a physical copy of the same duly signed.

The following are the details of unclaimed dividend as on March 31, 2026

Financial Year	Due date for claim by shareholders	Due date for transfer to IEPF	(Amount in ₹)
2018-2019	19.10.2026	17.11.2026	31,33,180.60
2019-20 (Interim)	10.04.2027	09.05.2027	34,08,111.00
2019-20 (Final)	04.11.2027	03.12.2027	5,37,294.60
2020-21 (Interim)	12.06.2028	11.07.2028	16,47,722.00
2020-21 (Final)	04.11.2028	03.12.2028	15,65,303.50
2021-22 (Interim)	18.06.2029	17.07.2029	19,17,950.00
2021-22 (Final)	11.09.2029	10.10.2029	17,76,909.00
2022-23 (Interim)	03.07.2030	01.08.2030	15,96,739.00
2022-23 (Final)	11.11.2030	10.12.2030	22,77,881.00
2023-24 (Interim)	22.06.2031	21.07.2031	25,56,415.50
2023-24 (Final)	06.11.2031	05.12.2031	23,26,956.00
2024-25 (Interim)	21.06.2032	20.07.2032	24,64,866.00
2024-25 (Final)	29.10.2032	27.11.2032	23,02,315.00

12. PLANT LOCATIONS

a) Factories

Puducherry
85/3, Suthukeny Village, Mannadipet Commune Panchayat, Puducherry – 605 502.

Visakhapatnam
Plot No. 28 I & 28 H, APIIC, AP-SEZ, Denotified Area, Rambilli Mandal, Atchutapuram, Visakhapatnam – 531 011

b) Research & Development Units of the Company

Amaris Clinical CRO	Hyderabad R&D	TICEL Park R&D	Perungudi R&D
Plot No.44, 8th Avenue, Domestic Tariff Area, Mahindra World City, Chengalpattu Taluk, Chengalpattu - 603 004	No. 95&96, 4th Floor, Road No. 9, ALEAP Industrial Estates, Gajularamaram Village, Qutubullapur Mandal, Hyderabad, Telangana – 500090	Module no. 307, 308 and 408, 3rd Floor, Ticel Park, Phase II, CSIR Road, Taramani, Chennai - 600113	Ashvich Towers, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai - 600 096

c) **Address for Correspondence**

Registrar and Transfer Agents (Issues relating to shares, dividends and Annual Reports)	Integrated Registry Management Services Private Limited Unit: Caplin Point Laboratories Ltd II Floor, "Kences Towers" No.1 Ramakrishna, Street North Usman Road, T Nagar, Chennai - 600 017 Phone: 044 - 28140801 - 803 Fax: 044 - 28142479 E-mail: csdstd@integratedindia.in
For any other general matters or in case of any difficulties / grievances	Company Secretary & Compliance Officer Caplin Point Laboratories Limited "Ashvich Towers" 3rd Floor, No.3, Developed, Plots Industrial Estates, Perungudi, Chennai- 600 096 Phone: 044 2496 8000 Website: www.caplinpoint.net E-mail: investor@caplinpoint.net

13. OTHER DISCLOSURES

i. Related Party Transactions

There were no materially significant related party transactions made by the Company with its Promoters, their subsidiaries, Directors or Management or relatives etc. that may have potential conflict with the interests of the Company at large. All the related party transactions are at arm's length basis and were approved by the Audit Committee. Those transactions that are not in the normal course of business are approved by the Board in addition to Audit Committee and, if material, are taken to shareholders for approval. The details of related party transactions along with the Loans and advances in the nature of loans to firms/companies in which Directors are interested, is provided in Notes to accounts (Refer Note No. 42 to the Standalone Financial Statements). The Board of Directors amended the Policy on Related Party Transactions at its meeting held on February 5, 2026. The updated Policy is available on the Company's website at https://www.caplinpoint.net/wp-content/uploads/2021/07/Related-Party-Transaction-Policy-1.pdf

ii. Prevention of insider trading and code of corporate disclosure practices:

Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the Company has adopted a Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives, as well as a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI), which includes the Policy for Determination of Legitimate Purpose.

The Company Secretary serves as the Compliance Officer for monitoring adherence to the Regulations. The Board of Directors amended the Policy on Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information at its meeting held on May 14, 2026. The updated policy has been intimated to the Stock Exchanges and is accessible on the Company's website at: https://www.caplinpoint.net/wp-content/uploads/2021/07/code_of_fair_disclosure.pdf.

iii. Details of Non-compliance

The Company has complied with various rules and regulations prescribed by the Stock Exchanges, Securities and Exchange Board of India or any other statutory authority relating to the capital markets during the last 3 years. No penalties or strictures have been imposed by them on the Company. The Company further confirms that during the year, no material non-compliance was reported.

iv. Vigil Mechanism / Whistle Blower Policy

The Company had created a dedicated email ID and had established an Ethics Committee for addressing instances of violation of Code of Conduct & Business Ethics and also to address complaints received through the Whistle-blower mechanism on a timely manner. In exceptional cases, the Chairman of the Audit Committee can be approached. The Vigil Mechanism / Whistle Blower Policy, inter-alia, enables the following: -

- Provides a platform and mechanism for the Employees, Directors and Third parties to voice genuine concerns or grievances about unprofessional conduct without fear of reprisal.
- It provides an environment that promotes responsible and protected whistle blowing. It reminds Employees, Directors and Third parties about their duty to report any suspected violation of any law that applies to the Company and any suspected violation of the Company's Code of Conduct or Ethics Policy and other policies.
- Above all, it is a dynamic source of information about what may go wrong at various levels within the Company, which will help the Company in realigning various processes and to take corrective actions as part of good governance practice.

The Company hereby affirms that no Directors/Employees/ Third-parties have been denied access to the Chairman of the Audit Committee. The whistle blower policy is hosted on the website of the Company at https://www.caplinpoint.net/wp-content/uploads/2021/07/Whistle-Blower-Policy-Vigil-Mechanism.pdf

v. Compliance with Mandatory Requirements

The Company has complied with all the mandatory requirements specified in Regulations 17 to 27 and clauses (b) to (i) of sub – regulation (2) of Regulation 46 of the SEBI Listing Regulations.

vi. Policy on Material Subsidiaries

The Company has formulated a Policy on Material Subsidiary as required under SEBI Listing Regulations. The Board of Directors at their meeting held on May 14, 2026, had amended the policy on Material Subsidiary and the updated policy is hosted on the website of the Company at https://www.caplinpoint.net/wp-content/uploads/2021/07/Material-Subsidiary-Policy-1.pdf.

vii. Utilization of Funds

The Company has not raised any funds through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A) of the SEBI Listing Regulations.

viii. Certificate on Non-Disqualification of Directors

The Company has obtained a certificate from Alagar & Associates LLP, (Formerly known as M/s. M. Alagar & Associates) Company Secretaries, Chennai, Secretarial Auditor of the Company, confirming that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as Directors of the Company by SEBI/ Ministry of Corporate Affairs or any such Statutory Authority.

ix. Recommendations by the Committees

During the year under review, the Board of Directors had accepted all recommendations of the Committees of the Board of Directors, which are mandatorily required to be given.

x. Total Fees paid to Statutory Auditors

During the Financial Year 2025-26, total fees for all services paid by the Company to M/s. Brahmayya & Co, Chartered Accountants, Chennai, Statutory Auditors and all the entities forming part of the same network, aggregate to Rs. 0.18 Crores for Statutory Audit, Rs. 0.045 Crores for Tax Audit purposes, Rs. 0.03 Crores for Other Certifications and 0.01 Crores for reimbursement of expenses.

xi. Sexual Harassment at Workplace

During the year under review, the Company has not received any complaints in terms of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

xii. Details of material subsidiaries

Caplin Steriles Limited, Caplin Point Far East Limited, Hongkong, Nuevos Eticos Neo Ethicals S.A – Guatemala and Neo Ethicals S.A. Nicaragua are the material subsidiaries of the company as on March 31, 2026. Following data is given with respect to the material subsidiaries:

Name of Subsidiary	Date & Place of incorporation	Name of Statutory Auditor	Date of appointment of Statutory Auditor
Caplin Steriles Limited	December 12, 2018, India	MSKA & Associates LLP	July 12, 2021
Caplin Point Far East Limited, Hongkong	May 13, 2014 Hongkong, China	C&N Certified Public Accountants	February 03, 2016
Nuevos Eticos Neo Ethicals S.A – Guatemala	November 16, 2004 Guatemala	UHY Pérez & Co.	March 31, 2020
Neo Ethicals S.A. Nicaragua	June 6, 2008, Nicaragua	UHY Pérez & Co.,	April 22, 2019

xiii. Compliance on Corporate Governance Report

The Corporate Governance Report of the Company for the Financial Year 2025 – 26 is in compliance with the applicable requirements of SEBI Listing Regulations. The certificate confirming compliance with the requirements of Corporate Governance, issued by M/s. Alagar & Associates LLP, forms part of this Annual Report.

xiv. CEO/ CFO Certification

The Managing Director and the CFO of the Company have certified to the Board of Directors, inter-alia, the accuracy of financial statements and adequacy of internal controls for the financial reporting as required under Regulation 17(8) of the SEBI Listing Regulations for the Financial Year ended March 31, 2026.

xv. Code of Conduct

The Company has received confirmations from the Board and the Senior Management personnel regarding their adherence to the Code of Conduct. The Annual Report of the Company contains a certificate by the Managing Director, on the compliance declarations received from Board of Directors and Senior Management. The Code has been hosted on the Company's website at https://www.caplinpoint.net/wp-content/uploads/2021/07/Code-of-Conduct-Business-Ethics.pdf

14. NON-MANDATORY REQUIREMENTS

i. The Company maintains an office for the Non-Executive Chairman of the Company at the Company's expense and bears the expenses incurred in performance of his duties.

ii. The auditors' report on financial statements of the Company is unqualified.

iii. The Chairman and the Managing Director are separate persons. Further the Chairman is a non-executive Director who is not related to the Managing Director.

iv. The internal auditors of the Company make presentations to the Audit Committee on their reports on a regular basis.

15. UNCLAIMED SUSPENSE ACCOUNT

Details	Number of Members	Number of equity shares
Aggregate number of shareholders and the outstanding shares in the suspense account lying at the beginning of the year (01-04-2025) (A)	151	366515
No. of Shares transferred to IEPF Account (B)	20	277000
Number of shareholders who approached listed entity for transfer of shares from suspense account during the year	26	26000
Number of shareholders to whom shares were transferred from suspense account during the year (C)	23	24200
Number of Shares Transferred to Suspense Escrow Demat Account (D)	1	500
Aggregate number of shareholders and the outstanding shares in the suspense account lying at the end of the year (31-03-2026) (A-B-C+D)	109	65815

DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL WITH THE COMPANY'S CODE OF CONDUCT

This is to confirm that for the Financial Year ended March 31, 2026 all members of the Board and the Senior Management Personnel have affirmed in writing their adherence to the Code of Conduct adopted by the Company.

FOR CAPLIN POINT LABORATORIES LIMITED

Dr. Sridhar Ganesan
Managing Director
DIN: 06819026

Place: Chennai
Date: August 12, 2026

COMPLIANCE CERTIFICATE ON CORPORATE GOVERNANCE

(Pursuant to Regulation 34(3) and Schedule V Para E of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Members
Caplin Point Laboratories Limited

We have examined all relevant records of **Caplin Point Laboratories Limited ("the Company")** for the purpose of certifying compliance of the conditions of Corporate Governance under Regulation 17 to 27 and clauses (b) to (i) of regulation 46(2) and para C and D of Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (**"SEBI LODR"**) for the financial year ended March 31, 2026. We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of certification.

The compliance of conditions of Corporate Governance is the responsibility of the management. Our examination was limited to procedures and implementation thereof adopted by the company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the Financial Statements of the company.

On the basis of our examination of the records produced, explanations and information furnished, we certify that the Company has complied with all the mandatory conditions of Corporate Governance as stipulated in the SEBI (LODR).

We further state that such compliance is neither an assurance as to the future viability of the company nor the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For Alagar & Associates LLP
(Formerly known as M. Alagar & Associates)
Company Secretaries
Firm Registration No: L2025TN019200
Peer Review Certificate No: 6814/2025

M. Alagar
Designated Partner
FCS No: 7488; CoP No. 8196
UDIN: F007488H001087666

Place: Chennai
Date: August 12, 2026

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

[Pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To
The Members
Caplin Point Laboratories Limited

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Caplin Point Laboratories Limited** having CIN: L24231TN1990PLC019053 and having Registered Office at Ashvich Towers, 3rd Floor, No.3, Developed Plots, Industrial Estates, Perungudi, Chennai - 600096, Tamil Nadu (hereinafter referred to as '**the Company**'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, we hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on March 31, 2026 have been debarred or disqualified from being appointed or continuing as Directors of Companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority.

SL.NO	NAME OF DIRECTOR	DIN	DESIGNATION	DATE OF APPOINTMENT/RE-APPOINTMENT
1.	Mr. Paarthipan Chingelput Chellappan	01218784	Chairperson (Non-Executive and Non-Independent and Promoter Director)	01/10/1993
2.	Mr. Ashok Partheeban	02507261	Non Executive , Non-Independent Director	05/11/2025
3.	Mr. Vivek Partheeban	02507289	Non Executive , Non-Independent Director	05/11/2025
4.	Dr. Sridhar Ganesan	06819026	Managing Director	12/02/2014 (Re-appointed on August 25, 2024)
5.	Mr. S. Deenadayalan	01951620	Independent Director	29/09/2022
6.	*Dr. Gariyali Chanderkanta	08711546	Independent Director	04/03/2020 (Re-appointed on March 04, 2023)
7.	Dr. R. Nagendran	08943531	Independent Director	29/09/2022
8	Mr.Ranganathan Vijayaraghavan	00026763	Independent Director	30/09/2024
9	Dr. K C John	01067374	Independent Director	05/11/2025
10.	Ms. Susan mathew	00517738	Independent Director	31/01/2026

***Dr. Gariyali Chanderkanta (DIN: 08711546) ceased to be an Independent Director with effect from March 03,2026 upon completion of her second term from March 04,2023 to March 03,2026.**

Ensuring the eligibility of the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion based on our verification of registers, records and disclosures. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Alagar & Associates LLP
(Formerly known as M. Alagar & Associates)
Company Secretaries
Firm's Registration No: L2025TN019200
Peer Review Certificate No: 6814/2025

M. Alagar
Designated Partner
FCS No: 7488; CoP No: 8196
UDIN: F007488H001087688

Place: Chennai
Date: August 12, 2026

BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT

SECTION A: GENERAL DISCLOSURES

I. Details of the listed entity

1. **Corporate Identity Number (CIN) of the Listed Entity** - L24231TN1990PLC019053
2. **Name of the Listed Entity** – Caplin Point Laboratories Limited
3. **Year of incorporation** - 1990
4. **Registered office address** – Ashvich Towers, 3rd Floor, No.3, Developed Plots, Industrial Estate, Perungudi, Chennai, Tamil Nadu 600096
5. **Corporate address**- Ashvich Towers, 3rd Floor, No.3, Developed Plots, Industrial Estate, Perungudi, Chennai, Tamil Nadu 600096
6. **E-mail** – compliance.officer@caplinpoint.net
7. **Telephone** - +91 04424968000
8. **Website** - www.caplinpoint.net
9. **Financial year for which reporting is being done** – April 01, 2025 to March 31, 2026
10. **Name of the Stock Exchange(s) where shares are listed :**

Name of the Exchange	Stock Code
BSE Ltd.	524742
National Stock Exchange of India Ltd.	CAPLIPOINT

11. **Paid-up Capital** – ₹ 15,20,23,392 /-
12. **Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report** –

    Mr Venkatram G, General Counsel & Company Secretary, Tel No. 044 24968000, Email: compliance.officer@caplinpoint.net.

13. **Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together)**. – The Company has considered all units of Caplin Point Laboratories Limited (CPL) and its subsidiaries, namely Caplin Steriles Limited (CSL) and Caplin One Labs Limited (COL). The overseas Subsidiaries are not considered for the purpose of this report since they are involved only in marketing the products in respective countries of operation and hence the Company had determined they are not material for the purpose of this report.
14. **Name of assessment or assurance provider** – In line with the applicable provisions and guidance issued by the SEBI on the assurance of BRSR Core disclosures, the Company has undertaken an independent assurance of the applicable core indicators included in this report. The assurance engagement has been carried out by M/s Alagar & Associates LLP.

15. **Type of assessment or assurance obtained** –The Company has obtained limited assurance on its BRSR Core disclosures, based on the procedures performed in accordance with the applicable guidelines prescribed by SEBI.

II. Products/services

16. **Details of business activities (accounting for 90% of the turnover):**

S. No.	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1	Manufacturing and sale of pharmaceuticals	Pharmaceuticals and finished dose formulation	100%

17. **Products/Services sold by the entity** (accounting for 90% of the entity's Turnover):

S. No.	Product/ Service	NIC Code	% of Turnover contributed
1.	Pharmaceuticals and finished dose formulation	21002	100%

III. Operations

18. **Number of locations where plants and/or operations/offices of the entity are situated:**

Location	Number of plants	Number of offices	Total
National	4 Manufacturing Units and 5 R&D Centres	1 Corporate Office	10
International	The Company's overseas subsidiaries and overseas offices are not considered for the purpose of this reporting.		

Registered Office of the Company

- Ashvich Tower, 3rd Floor, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai-600096, Tamil Nadu.

Manufacturing Units

- Caplin Point Laboratories Limited (CPL): No. 85/3, Suthukeny Village, Mannadipet Commune Panchayat, Puducherry 605502.
- Caplin Steriles Limited (CSL): No. 895 & 897, Sirupuzhalpettai, Gummidipoondi Taluk, Thiruvallur, Tamil Nadu 601201.
- Caplin One Labs Limited (COL): G44, G45, G46 in SIDCO Industrial Estate, Kakkalur, Thiruvallur, Tamil Nadu 602003.
- Caplin Point Laboratories Limited (CPL): Plot No. 28H & 28I. AP-SEZ, Denotified Area, Achutapuram Rambilli Mandal, Anakapalli District -531011.

R & D Units

- CPL (Amaris Clinical CRO): No. 44, 8th Avenue, Domestic Tariff Area, Mahindra World City, Chengalpattu Taluk, Tamil Nadu – 603004.
- CPL Hyderabad R&D): No. 95&96, 4th Floor, Road No. 9, ALEAP Industrial Estates, Gajularamaram Village, Qutubullapur Mandal, Hyderabad, Telangana – 500090.
- CPL (TICEL Park R&D): Module No. 307 & 308, & 408, 3rd Floor, TICEL Park, Phase II, CSIR Road, Taramani, Chennai, Tamil Nadu - 600113.

- CPL (Perungudi R&D): Ashvich Tower, No. 3 Developed Plots Industrial Estate, Perungudi, Chennai, Tamil Nadu - 600096.
- CSL (Perungudi R&D): Ashvich Towers, No. 3 Developed Plots Industrial Estate, Perungudi, Chennai, Tamil Nadu - 600096.

19. **Markets served by the entity:**

a. Number of locations

Locations	Number
National (No. of States & UTs)	The Company's products are not marketed in India
International (No. of Countries)	57[1]

[1]The list of countries includes countries where Company is in the process of registering its products.

b. What is the contribution of exports as a percentage of the total turnover of the entity?

100% of the products are meant for export market.

c. A brief on types of customers:

Through its subsidiaries in Hong Kong, Guatemala, Ecuador, El Salvador, Nicaragua, Honduras, and Colombia, Chile and Mexico, CPL uses a distinctive business strategy to deliver its goods directly to government, retailers and wholesalers. CPL uses its channel partner to market its goods in Africa. The items are exported by CPL to various subsidiaries and channel partners, who then supply them in their respective markets. CSL exports its goods to consumers in regulated markets, such as the US, Canada, Australia, and others, as well as through Caplin Steriles USA Inc., a direct subsidiary in the US. COL primarily serves the markets that CPL serves.

IV. Employees

20. **Details as at the end of Financial Year:**

a. Employees and workers (including differently abled):

S. No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B/A)	No. (C)	% (C/A)
EMPLOYEES[1]						
1.	Permanent (D)[2]	2249	1504	67%	745	33%
2.	Other than Permanent (E)	628	241	38%	387	62%
3.	**Total employees (D + E)**	**2877**	**1745**	**61%**	**1132**	**39%**
WORKERS						
4.	Permanent (F)	1950	1225	63%	725	37%
5.	Other than Permanent (G)	628	241	38%	387	62%
6.	**Total workers (F + G)**	**2578**	**1466**	**57%**	**1112**	**43%**

[1] The count of employees given in this table (for both permanent and other than permanent employees) includes the count of workers (both permanent and other than permanent workers) in line with the definition of the respective terms under Industrial Relations Code 2020. Contract workers are considered under other than permanent category of employees and workers.

[2]The Company engages trainees on the same terms as permanent employees of the Company. Hence, they are not considered for the purpose of calculation under Other than permanent employees' category.

b. Differently abled Employees and workers:

S. No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B/A)	No. (C)	% (C/A)
DIFFERENTLY ABLED EMPLOYEES						
1.	Permanent (D)	Nil	Nil	Nil	Nil	Nil
2.	Other than Permanent (E)	Nil	Nil	Nil	Nil	Nil
3.	**Total differently abled employees (D + E)**	**Nil**	**Nil**	**Nil**	**Nil**	**Nil**
DIFFERENTLY ABLED WORKERS						
4.	Permanent (F)[1]	2	2	100%	Nil	Nil
5.	Other than permanent (G)	Nil	Nil	Nil	Nil	Nil
6.	**Total differently abled workers (F + G)**	**2**	**2**	**100%**	**Nil**	**Nil**

[1] Shows the count of workers as per Industrial Relations Code, 2020.

21. Participation/Inclusion/Representation of women

	Total (A)	No. and percentage of Females	
		No. (B)	% (B / A)
Board of Directors[1]	24	3	12.50%
Key Management Personnel[2]	11	3	27.27%

[1]Director holding common directorship in CPL, CSL and COL are counted thrice for the purpose of this report. For the purpose of determining the number of Directors, all Directors who were appointed or ceased to hold office during FY 2025-26 have been considered.

[2]In case a KMP is occupying that position in more than one Company, the same is counted more than once. For the purpose of determining the number of KMP, all KMPs who were appointed or ceased to hold office during FY 2025-26 have been considered.

22. Turnover rate for permanent employees and workers

(*Disclosure trends for the past 3 years*)

	FY 2025-26			FY 2024-25			FY 2023-24		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees[1]	37.43%	35.70%	36.93%	34.95%	23.50%	32.52%	27.9 %	22.7%	26.9%
Permanent Workers	-	-	-	-	-	-	-	-	-

[1]The Turnover rate of the permanent employees includes the turnover rate of permanent workers since the definition of employees under Industrial relations code 2020 includes those covered under the definition of workers.

V. Holding, Subsidiary and Associate Companies (including joint ventures)

23. (a) Names of holding / subsidiary / associate companies / joint ventures

S. No.	Names of Holding / Subsidiary / Associate companies / Joint Ventures (A)[1]	Indicate whether holding/ Subsidiary/ Associate/ Joint Venture	% of shares held by listed entity / subsidiaries	Does the entity indicated at Column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1.	Caplin Steriles Limited	Subsidiary	99.999%	Yes
2.	Caplin One Labs Limited	Wholly owned Subsidiary	100%	Yes
3.	Argus Salud Pharma LLP	Subsidiary (LLP)	99.90%	No
4.	Caplin Point Far East Limited	Wholly owned Subsidiary	100%	No
5.	Caplin Point (S) Pte Ltd	Wholly owned Subsidiary	100%	No
6.	Caplin Point Laboratories Colombia SAS	Step down subsidiary	100%	No
7.	Caplin Point El Salvador, S.A. DE C.V.	Step down subsidiary	100%	No
8.	Drogueria Saimed de Honduras S.A	Step down subsidiary	100%	No
9.	Neoethicals CIA. LTDA Ecuador	Step down subsidiary	100%	No
10.	Neo Ethicals S.A. Nicaragua	Step down subsidiary	100%	No
11.	Nuevos Eticos Neo Ethicals S.A. Guatemala	Step down subsidiary	69%	No
12.	Sunsole Solar Private Limited	Associate of Caplin Steriles Limited	28.01%	No
13.	Caplin Steriles USA Inc.	Step down subsidiary	100%	No
14	Neoethicals Chile SpA	Step down subsidiary	100%	No
15	Triwin Pharma S.A DE C.V, Mexico	Step down subsidiary	100%	No

[1]All the step down subsidiaries except Caplin Steriles USA Inc. are the subsidiaries of Caplin Point Far East Limited – Hong Kong. Caplin Steriles USA Inc. is a subsidiary of Caplin Steriles Limited. Neoethicals Chile SpA, Chile and Triwin Pharma S.A DE C.V, Mexico were the two Subsidiaries acquired through Caplin Point Far East Limited – Hong Kong during the financial year.

VI. CSR Details

24. Whether CSR is applicable as per section 135 of Companies Act, 2013[1]: Yes

(₹ in Crores)

Company	CSR Applicable (Sec 135)	Turnover	Net Worth	Net Profit
Caplin Point Laboratories Limited	Yes	752.41	1700.93	444.53
Caplin Steriles Limited	Yes	365.77	343.43	65.90
Caplin One Labs Limited	Yes	34.65	74.60	8.11

[1]The figures in this table pertains to the year 2024-25 to highlight the applicability of CSR provisions in 2025-26.

VII. Transparency and Disclosures Compliances

25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/No) (If Yes, then provide web-link for grievance redress policy)[4]	FY 2025-26			FY 2024-25		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	Yes	Nil	Nil	Nil	Nil	Nil	Nil
Investors (other than shareholders)	Yes	Nil	Nil	Nil	Nil	Nil	Nil
Shareholders[1]	Yes	51	9[3]	Nil	16	3	Nil
Employees and workers[2]	Yes	48	10	Nil	55	12	Nil
Customers	Yes	78	1	Nil	46	Nil	Nil
Value Chain Partners	Yes	Nil	Nil	Nil	Nil	Nil	Nil
Other	Yes	Nil	Nil	Nil	Nil	Nil	Nil

[1]The Company follows the regulations and circulars issued by SEBI with respect to addressing of investor complaints and there is no specific policy in this regard.The Company has appointed M/s. Integrated Registry Management Services Private Limited to receive and dispose of complaints from shareholders in a time bound manner.

[2]The complaints from employees and workers mainly pertain to Health & Safety (received through Safety Committee meetings), Working Conditions and terms of employment related issues which were taken up and closed on timely manner. One case pertains to ongoing litigation by/ or against employees/ workers in judicial/ quasi-judicial forums. Most of the complaints were actually suggestions for improvements which were taken up and resolved. Complaints which are pending as of the close of Financial Year has been resolved subsequently.

[3]The complaints by shareholders which is shown as pending at the end of FY 25-26 were subsequently resolved in Q1 FY 2026-2027.

[4]Some of the policies are internal in nature and hence has not been posted in the website though it provides for effective redressal of the relevant complaints. Policies that are available for external stakeholders are given in the Company's website at https://www.caplinpoint.net/index.php/corporate-governance/.

26. **Overview of the entity's material responsible business conduct issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with its financial implications**

S. No.	Material issue identified	Indicate whether Risk or Opportunity (R/O)	Rationale for identifying the Risk / Opportunity	In case of Risk, approach to adapt or mitigate	Financial implications of the Risk or Opportunity (Indicate Positive or Negative implications)
1	Access and Affordability	Opportunity	The cornerstone of the Company's business model differentiation has been taking medicines closer to the end Consumers who are underserved. This approach has led to the sustained growth of revenues and bottom line while also ensuring that the masses are served well with affordable medicines. As we expand into more geographies, achieving the same degree of closeness to end Consumers that we were able to achieve in our present markets will present a significant opportunity for sustained business growth while also ensuring that our core value remains intact - addressing the needs of the all in newer markets.	NA	Positive.
2	Diversity & inclusion	Opportunity	Promoting a diverse workforce enhances organizational resilience while creating an atmosphere of fairness towards underrepresented sections of the society. Towards this, the Company had recognized the importance of ensuring significant representation to women in the workforce and ensuring that they are upskilled and properly equipped in performing various roles in our Company. Also, since majority of these women are from the local area of operations, their representation promotes diversity and inclusion in our Company.	NA	Positive.

S. No.	Material issue identified	Indicate whether Risk or Opportunity (R/O)	Rationale for identifying the Risk / Opportunity	In case of Risk, approach to adapt or mitigate	Financial implications of the Risk or Opportunity (Indicate Positive or Negative implications)
3	Social License to Operate	Opportunity	The growing footprint of the group in terms of projects under development in various locations across Tamil Nadu, Andhra Pradesh and Puducherry presents a significant opportunity to engage with the local stakeholders and ensure that their voices are heard and their concerns are incorporated into the Company's strategic planning. Some of the projects that involves stricter compliances under the environmental norms requires incorporating environmental best practices as well as ensuring that the Company treats the local community and other stakeholders fairly. Acceptance of the local community enables creation of shared value by fostering equity, health, education and sustainability.	NA	Positive.
4	Regulatory compliances	Risk	With the expanding presence of our business, the responsibility to ensure compliance with the applicable laws, that are both specific to the pharmaceutical sector as well as the general laws applicable to any business, assumes utmost significance. Newer requirements of the geographies where we are venturing combined with the various local statutory requirements presents a key risk where any non-compliance would result in significant penalties as well as reputation loss for the Company.	The Company implements measures to both adapt and mitigate risks arising due to evolving Compliance requirements. Adapting is done by evaluating the specific actions to be taken by the Company to comply with the requirements including change in business processes, upgrading/ modifying operating procedures to meet compliance requirements and evaluating Compliance risks as part of the Risk Management process of the Company. Mitigating involves a strategy of identifying	Negative. No such instance has occurred in the reporting year.

S. No.	Material issue identified	Indicate whether Risk or Opportunity (R/O)	Rationale for identifying the Risk / Opportunity	In case of Risk, approach to adapt or mitigate	Financial implications of the Risk or Opportunity (Indicate Positive or Negative implications)
				all applicable Acts, utilising technology for managing and reporting compliances, obtaining assurance of compliance through internal sources like internal compliance audits/ verifications and external sources like Internal Audit verifications, drawing down an action plan for remedying non-compliances and escalating significant instances of non-compliances to appropriate levels for remedial action.	
			Newer requirements of the geographies where we are venturing combined with the various local statutory requirements presents a key risk where any deviance results in significant penalties as well as reputation loss for the Company.	Adapting is done by evaluating the specific actions to be taken by the Company to comply with the requirements including change in business processes, upgrading/ modifying operating procedures to meet compliance requirements and evaluating Compliance risks as part of the Risk Management process of the Company. Mitigating involves a strategy of identifying all applicable Acts, utilising technology for managing and reporting compliances, obtaining assurance of compliance through internal sources like internal compliance audits/ verifications and external sources like Internal Audit verifications, drawing down an action plan for remedying non- compliances and escalating significant instances of non- compliances to appropriate levels for remedial action.	

S. No.	Material issue identified	Indicate whether Risk or Opportunity (R/O)	Rationale for identifying the Risk / Opportunity	In case of Risk, approach to adapt or mitigate	Financial implications of the Risk or Opportunity (Indicate Positive or Negative implications)
5	Supply chain management	Risk	Due to the nature of business, Company needs to engage with diverse range of value chain partners. To ensure, that those who form the part of the value chain are in line with the manufacturing standards, environmental goals and sustainability objectives of the Company is a complex task. But, the risk of deviation in any part of the value chain will have significant impact on both the sustainability and business performance of the Company.	The Company follows a strategy of contractually enforcing key sustainability goals through its sourcing contracts with the value chain partners and also by way of reference to the code of business ethics in the purchase orders issued to vendors. The Company is also subject to similar covenants in contracts with its Customers in regulated markets which specify explicit measures to be taken to comply with the environmental goals and sustainability objectives. These covenants are tracked for performance to avoid breach.	Negative. No such instance has occurred in the reporting year.
6	Energy management	Opportunity	Renewable energy usage results in meeting the sustainability objectives of the Company by reducing the Company's carbon footprint. It also results in tangible financial benefits like cost saving.	NA	Positive.
7	Product quality and safety	Risk	The growing mix of branded generics and other products that bear the registered trademarks of Caplin combined with the geographical expansion of our business presents a significant risk of proliferation of counterfeit products. This not only erodes the brand value of the products but also presents significant public health risk.	The Company is actively pursuing a multi-pronged strategy of registering the key trademarks in the respective countries where there are plans to expand the business, combined with active market surveillance and taking stringent legal measures wherever counterfeiting is identified.	Negative. No such instance has occurred in the reporting year.

SECTION B: MANAGEMENT AND PROCESS DISCLOSURES

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements.

Disclosure Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
Policy and management processes									
1. a. Whether your entity's policy/ policies cover each principle and its core elements of the NGRBCs. (Yes/No)	Y	Y	Y	Y	Y	Y	Y	Y	Y
b. Has the policy been approved by the Board? (Yes/No)	Y	Y	Y	Y	Y	Y	Y	Y	Y
c. Web Link of the Policies, if available	All the policies that were approved by the Board are available on the Company's Website https://www.caplinpoint.net/index.php/corporate-governance/. The same set of policies apply for the Subsidiaries of the Company.								

Sr. No.	Name of policy	Link to Policy	Which Principles each policies goes into
1	Corporate Social Responsibility Policy and CSR and Sustainability Charter	https://www.caplinpoint.net/wp-content/uploads/2021/07/Corporate-Social-Responsibility-Policy.pdf https://www.caplinpoint.net/wp-content/uploads/2021/07/CSR-and-Sustainability-Committee-charter.pdf	P1, P8
2	Environment, Health & Safety Policy	https://www.caplinpoint.net/wp-content/uploads/2021/07/Environment-Health-Safety-Policy.pdf	P2, P6
3	Equal Opportunity Policy	https://www.caplinpoint.net/wp-content/uploads/2021/07/EQUAL-OPPORTUNITY-POLICY.pdf	P3, P5
4	Human Rights Policy	https://www.caplinpoint.net/wp-content/uploads/2021/07/HUMAN-RIGHTS-POLICY.pdf	P3, P5
5	Personal Data Protection & Privacy Policy	https://www.caplinpoint.net/wp-content/uploads/2021/07/PERSONAL-DATA-PROTECTION-AND-PRIVACY-POLICY-2.pdf	P9
6	Criteria for Making Payment to Non-Executive Director	https://www.caplinpoint.net/wp-content/uploads/2021/07/CMP.pdf	P1
7	IT Security Policy & Process	Available Internally	P9
8	Related Party Transaction Policy	https://www.caplinpoint.net/wp-content/uploads/2021/07/Related-Party-Transaction-Policy-1.pdf	P1, P7
9	Familiarization Programme for Independent Directors	https://www.caplinpoint.net/wp-content/uploads/2021/07/Familiarization-Programme-310326-1.pdf	P1

Sr. No.	Name of policy	Link to Policy	Which Principles each policies goes into
10	Whistle Blower Policy (Vigil Mechanism)	https://www.caplinpoint.net/wp-content/uploads/2021/07/Whistle-Blower-Policy-Vigil-Mechanism.pdf	P1, P5
11	Code of Conduct & Business Ethics	https://www.caplinpoint.net/wp-content/uploads/2021/07/Code-of-Conduct-Business-Ethics.pdf	P1, P3, P7
12	Nomination and Remuneration Policy	https://www.caplinpoint.net/wp-content/uploads/2021/07/Nomination-and-Remuneration-Policy.pdf	P1, P5
13	Fair Disclosure of Unpublished Price Sensitive Information	https://www.caplinpoint.net/wp-content/uploads/2021/07/code_of_fair_disclosure.pdf	P1
14	Dividend Distribution Policy	https://www.caplinpoint.net/wp-content/uploads/2021/07/Dividend_Distribution_Policy.pdf	P1, P4
15	Policy on Material Subsidiary	https://www.caplinpoint.net/wp-content/uploads/2021/07/Material-Subsidiary-Policy-1.pdf	P1
16	Policy on Preservation of Records / Archival Policy	https://www.caplinpoint.net/wp-content/uploads/2021/07/Preservation_of_Record_and_Archival_policy.pdf	P1, P9
17	Policy for Determination of Materiality of Events	https://www.caplinpoint.net/wp-content/uploads/2021/07/Policy-on-Determination-of-Materiality-of-events.pdf	P1

Disclosure Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
2. Whether the entity has translated the policy into procedures. (Yes / No)	Y	Y	Y	Y	Y	Y	Y	Y	Y
3. Do the enlisted policies extend to your value chain partners? (Yes/No)	Yes. The Company's Code of Conduct and Business Ethics is shared with value chain partners as part of the onboarding process. The applicable requirements are communicated to value chain partners at the time of onboarding.								
4. Name of the national and international codes/ certifications/labels/ standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustea) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.	➢ WHO Good Manufacturing Practice (GMP) – **Caplin Steriles Limited /Caplin Point Laboratories Ltd/Caplin One Labs Limited** ➢ US FDA GMP - **Caplin Steriles Limited/Amaris clinical CRO (a division of Caplin Point Laboratories Limited)** ➢ ISO 9001:2015 Quality Management System certificate- **Amaris clinical CRO (a division of Caplin Point Laboratories Limited)** ➢ Philippines FDA - **Caplin Steriles Limited/ Caplin Point Laboratories Limited** ➢ Accredited for BA/BE study by CDSCO (Central Drugs Standard Control Organization) India – **Amaris Clinical CRO (A division of Caplin Point Laboratories Limited)**								

Disclosure Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
	➢ ISP Chile - **Amaris Clinical CRO (A division of Caplin Point Laboratories Limited), Caplin Point Laboratories Limited** ➢ ANVISA Brazil - **Caplin Steriles Limited, Amaris Clinical CRO (A division of Caplin Point Laboratories Limited)** ➢ INVIMA Colombia - **Caplin Steriles Limited / Caplin Point Laboratories Limited/ Caplin One Labs Limited** ➢ Main Pharmaceutical Inspectorate (GIF), Poland - **Caplin Steriles Limited** ➢ United Arab Emirates (UAE) MoHAP - **Caplin Steriles Limited** ➢ Saudi Food & Drug Authority (SFDA), Saudi Arabia - **Caplin Steriles Limited** ➢ DSIR - **Amaris Clinical CRO (A division of Caplin Point Laboratories Limited), Caplin Steriles Limited, Caplin Point Laboratories Limited**								
5. Specific commitments, goals and targets set by the entity with defined timelines, if any.	The Company has fixed the following targets for 2026-2027 and beyond: ➢ Solar energy to constitute 35% of the energy mix across CPL and COL units by FY 2029-30 and 50% of CPL, CSL and COL units by 2030-31. ➢ Ensuring Zero liquid Discharge across all units of CPL and CSL by FY 2028-29 and ensuring all upcoming projects to be fully ZLD compliant. ➢ Achievement of zero landfill of hazardous waste across all existing units by FY 2026-27 and ensuring 100% of hazardous waste generated is either recycled or sent to Alternative Fuel and Raw Material Facilities (AFRF) for all the units of CPL, CSL and COL by FY 2028-29. ➢ Ensuring the implementation of ISO 14001 (Environmental Management System) and ISO 45001 (Occupational Health and Safety Management System) certifications across all units of CPL, CSL and COL by FY 2028-29. ➢ Prioritizing women empowerment by enhancing female workforce participation to 35% in all the units of COL and CPL by FY 2027-28, and to 45% taken together across all the units of CPL, CSL and COL by FY 2028-29. ➢ Fully operationalizing all the services at Caplin Point Meenakshi Hospital by 2027-28 and increasing the number of beneficiaries by incremental 20% each year by conducting a minimum of four medical camps annually. ➢ Integration of value chain partners into the groups ESG framework by introducing annual ESG questionnaires for top ten supply chain partners by FY 2026-27 and ensuring coverage of supply chain partners constituting 80% of procurement value by FY 2028-29. **Note:** The above targets have been approved by the Company for the next financial year.								

Disclosure Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
6. Performance of the entity against specific commitments, goals and targets along-with reasons in case the same are not met.	➢ The Company consumed 1,15,10,433 KWh of renewable power, representing up to 36.65% of operations and avoiding 8,368 Metric Tonnes of CO2 emissions. ➢ A total of 46,464.46 KL of freshwater was conserved. ➢ The Company successfully recycled and reused 52.39% of its water in FY26. ➢ One key manufacturing unit currently operates with Zero Liquid Discharge capabilities. ➢ Hazardous waste sent to landfill was restricted to 0.19%, with 94.58% diverted to recycling or Alternate Fuel Recovery. ➢ Through circularity efforts, 80.35% of waste was disposed of to minimize overall landfill impact. ➢ Women represented 33.13% of the Indian workforce, 46% of the global workforce, 62% of the contract workforce, and 20.88% within R&D units. ➢ Total Corporate Social Responsibility (CSR) spending reached ₹ 4.70 Crores. ➢ All employees (100%) completed web-based Code of Conduct sensitization training. ➢ Direct CSR initiatives supported 1,156 beneficiaries, and 3,080 patients were served through the CSR hospital-cum-diagnostic center. ➢ A total of 23 contract manufacturers were covered under ESG covenants and assessed for ESG performance.								

Governance, leadership and oversight

7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements

Our growth trajectory remains closely aligned with sustainable operating practices and community welfare, reflecting our commitment to integrating environmental stewardship, social responsibility, and ethical governance into every operational and strategic aspect. On the social front, healthcare accessibility continues to be a core mission. Following the completion of our state-of-the-art Hospital-cum-Diagnostic Center at Gummidipoondi, Tamil Nadu, the facility fully commenced operations under the aegis of the Caplin Point Meenakshi CSR Trust, delivering high-quality diagnostic and medical care to underserved rural communities. Furthermore, we actively support this mission by supplying affordable generics to underserved populations.

Our workforce remains our most critical execution pillar. Through our digital platform, we target to have targeted upskilling programs to prepare our technical teams for automated, digital shop-floor operations. We continue to advance social equity and operational discipline by actively recruiting and upskilling rural women professionals for core manufacturing and laboratory roles, which has helped us build a resilient workforce.

Environmentally, we recognize our responsibility toward planet protection by proactively reducing emissions and waste while conserving water. We have expanded our renewable energy utilization to reduce reliance on traditional grid power, and we have incorporated high-efficiency multi-effect evaporators to maximize internal wastewater recycling. To ensure rigorous and transparent disclosure of these continuous efforts to all stakeholders, our ESG platform actively tracks over 400 key performance indicators across more than 35 frameworks, reinforcing our dedication to sustainable, shared progress.

Disclosure Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
The Company also recognizes the need to involve its value chain partners in its sustainability efforts. It plans to cover its top ten supply chain partners through annual ESG questionnaires within FY 2026-27 and evaluate suppliers representing 80% of procurement based on their ESG performance by FY 2028-29. The Company will continue to monitor progress against these targets and address challenges as they arise.									
8. Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies).	Name: Dr Sridhar Ganesan, Managing Director								
9. Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No). If yes, provide details.	At the Meeting held on August 12, 2026, the Board has expanded the role of CSR Committee to include oversight of sustainability initiatives of the Company and has renamed the committee as CSR and sustainability Committee. This Committee will be chaired by Dr. R. Nagendran, Independent Director who is an expert in environmental management, sustainability and policy advisory. He has served as the expert member of the National Green Tribunal. The Board has also approved the CSR and Sustainability Charter, which sets out the responsibilities of the Committee in relation to sustainability matters, in addition to its CSR responsibilities. The Charter is available on the Company's website at https://www.caplinpoint.net/wp-content/uploads/2021/07/CSR-and-Sustainability-Committee-charter.pdf								

Details of Review of NGRBCs by the Company:

Subject for Review	Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee									Frequency(Annually/ Half yearly/ Quarterly/ Any other – please specify)								
	P1	P2	P3	P4	P5	P6	P7	P8	P9	P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action	The Company undertakes review of performance against the applicable policies through the Board of Directors and relevant committees, as applicable. Such reviews are undertaken periodically and as required, based on the nature of the policy and matters arising.																	
Compliance with statutory requirements of relevance to the principles, and, rectification of any non-compliances	The Company fully complies with all the statutory rules and regulations applicable to it.																	
10. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If yes, provide name of the agency.	No. However, The Internal And Secretarial Auditors Of The Company Assess/ Evaluate Adherence To The Compliances Applicable Under Various Statutes As Well The Company's policies approved by the Board and the findings are reported to the Audit committee/Board.																	

11. If answer to question (1) above is "No" i.e. not all Principles are covered by a policy, reasons to be stated:

Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
The entity does not consider the Principles material to its business (Yes/No)	-	-	-	-	-	-	-	-	-
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)	-	-	-	-	-	-	-	-	-
The entity does not have the financial or/human and technical resources available for the task (Yes/No)	-	-	-	-	-	-	-	-	-
It is planned to be done in the next financial year (Yes/No)	-	-	-	-	-	-	-	-	-
Any other reason (please specify)	NA								

SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE

PRINCIPLE 1: Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.

Essential Indicators

1. Percentage coverage by training and awareness programmes on any of the Principles during the financial year:

Segment	Total Number of Training and Awareness Programmes held[1]	Topics/ Principles covered under the training and its impact	% age of persons in respective Category covered by the awareness Programmes
Board of Directors	➢ The Independent Directors are familiarised with the Company's organisational structure, functioning of various divisions, market position and industry, internal control processes and governance mechanisms at the time of their appointment – 100%. ➢ The Company also provides regular updates to the Independent Directors on amendments to applicable regulations, including corporate laws, environmental regulations, labour laws and other relevant statutes- 100%.		
Key Managerial Personnel	➢ As part of the Board processes described above, all Key Managerial Personnel of the Company were provided training on the policies relevant to sustainability and social responsibility- 100%.		
Employees other than BoD and KMPs	1,070	During the year, employees and workers underwent training across various areas, including workplace safety, emergency preparedness, environmental management, technical operations, regulatory compliance and ethical conduct.	100%

Segment	Total Number of Training and Awareness Programmes held[1]	Topics/ Principles covered under the training and its impact	% age of persons in respective Category covered by the awareness Programmes
Workers	1,070	These included induction and awareness sessions, fire safety and first aid training, chemical handling and hazardous waste management, equipment operation protocols, and Standard Operating Procedures for handling specialised pharmaceutical products.	100%

[1]Both employees and workers were provided wide-ranging training in areas which will enhance health & safety and sustainable practices. The training programs considered include training based on online modules which employees were required to go through and confirm.

2. **Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year** (basis the materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website)

Monetary					
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (In INR)	Brief of the Case	Has an Appeal been preferred? (Yes/No)
Penalty/ Fine	Nil	Nil	Nil	Nil	Nil
Settlement	Nil	Nil	Nil	Nil	Nil
Compounding fee	Nil	Nil	Nil	Nil	Nil
Non-Monetary					
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (In INR)	Brief of the Case	Has an Appeal been preferred? (Yes/No)
Imprisonment	Nil	Nil	Nil	Nil	Nil
Punishment	Nil	Nil	Nil	Nil	Nil

3. **Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed.**

Case Details	Name of the regulatory/enforcement agencies/judicial institutions
Not Applicable	

4. **Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web-link to the policy.**

The Company does not have a separate Anti-Corruption and Anti-Bribery Policy. However, the Code of Conduct and Business Ethics and the Whistle-Blower Policy cover the key processes relating to prevention and reporting of corruption and bribery. The Company does not permit any form of corruption, bribery or kickbacks, whether undertaken directly by employees or through consultants or other third parties. The Code of Conduct prohibits bribery, kickbacks, inappropriate gifts and hospitality, political contributions and any other undue monetary or non-monetary advantage intended to influence a person for personal or financial gain. Any request for illegal gratification by a public official is required to be reported to the Managing Director and Vice Chairman for appropriate action under applicable laws. The same policy is applicable for all its Subsidiaries located in India. More details about the policy can be had from the link https://www.caplinpoint.net/wp-content/uploads/2021/07/Code-of-Conduct-Business-Ethics.pdf

5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:

	FY 2025-26	FY 2024-25
Directors	Nil	Nil
KMPs	Nil	Nil
Employees	Nil	Nil
Workers	Nil	Nil

6. Details of complaints with regard to conflict of interest:

	FY 2025-26		FY 2024-25	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of conflict of interest of the Directors	The Company did not receive any complaints in relation to conflict of interest.			
Number of complaints received in relation to issues of Conflict of Interest of the KMPs				

7. Provide details of any corrective action taken or underway on issues related to fines / penalties/ action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.

Since there were no complaints in relation to conflict of interest or corruption, corrective action does not arise.

8. Number of days of accounts payables ((Accounts payable *365) / Cost of goods/services procured) in the following format:

	FY 2025-26[1]	FY 2024-25
Number of days of accounts payables	120	96

[1]Only input materials excluding capex are considered.

9. Open-ness of Business

Provide details of concentration of purchases and sales with trading houses, dealers and related parties along-with loans and advances & investments, with related parties, in the following format:

Parameters	Metrics	FY 2025-26	FY 2024-25
Concentration of Purchases	a. **Purchases from Trading houses as % of total purchases**	7.87%	9.33 %
	b. **Number of trading houses where purchases and made from**	250	263
	c. **Purchases from top 10 trading houses as % of total purchases from trading houses**	40.32%	34.29%
Concentration of Sales	a. **Sales to dealers/distributors as % of total sales[1]**	100%	100%
	b. **Number of dealers/distributors to whom sales are made**	75	65
	c. **Sales to top 10 dealers/distributors as % of total sales to dealers/distributors**	75.25%	74.68%

Parameters	Metrics	FY 2025-26	FY 2024-25
Share of RPTs in	a. **Purchases (Purchases with related parties/Total Purchases)**	0.49%	0.06%
	b. **Sales (Sales to related parties/Total Sales)**	34.65%	40.63%
	c. **Loans & advances (Loans & advances given to related parties/Total loans & advances)**	98.36%	97.70%
	d. **Investments (Investments in related parties/Total Investments made)**	24.11%	30.28%

[1]The entire sales by CPL, CSL, COL were done on B2B basis thorough overseas distribution entities (which includes subsidiaries).

Leadership Indicators

1. **Awareness programmes conducted for value chain partners on any of the Principles during the financial year:**

Total number of awareness programmes held	Topic/principles covered under the training	%age of value chain partners covered (by value of business done with such partners) under the awareness programmes
The Company has not conducted any awareness programmes for its value chain partners during the reporting period. However, the need for such initiatives will be assessed and undertaken in the future, as necessary.		

2. **Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No). If Yes, provide details of the same.**

Yes. The Company has instituted a structured framework to identify, disclose and manage actual or potential conflicts of interest involving members of the Board, anchored in its Code of Conduct and Business Ethics ("**Code**") and reinforced by its Whistle Blower Policy (Vigil Mechanism).

Under the Code, Directors are required to act in the best interests of the Company at all times and to avoid situations where a personal, financial or family interest could interfere with objective decision-making. Specifically, the Code requires that:

- Any Director proposing to take up gainful employment, a directorship, or an advisory/consultancy role in an unrelated entity obtains prior written approval, renewable annually;
- Where a Director (or a Director's family member) has an interest in a prospective or existing business relationship, such interest is disclosed, the concerned Director abstains from influencing or participating in the related decision-making, and adequate safeguards and documentation are maintained to evidence that the transaction was evaluated fairly and on merit;
- No Director holds a "significant financial interest" — i.e., ownership exceeding 1% of equity, or an investment representing more than 5% of the Director's total assets — in any material customer, supplier or competitor of the Company, without prior approval of the Board/Audit Committee.

In keeping with corporate governance requirements under the Companies Act, 2013, Directors also make an annual disclosure of their concern or interest in other companies, bodies corporate, firms or associations of individuals at the first Board meeting of each financial year and are required to promptly update this disclosure whenever there is any change, ensuring the Board and Audit Committee remain apprised of potential conflicts on a continuing basis. Directors additionally affirm their compliance with the Code annually to the Board.

The Whistle Blower Policy supplements this framework by providing Directors, employees and third parties a confidential channel — including anonymous reporting for employees — to raise concerns regarding undisclosed interests or other unethical conduct involving a Board member, with protection against victimisation. Such complaints are investigated by the Ethics Committee (or escalated to the Chairman of the Audit Committee, where warranted), and any Ethics Committee member is excluded from deliberations concerning their own conduct. Any deviation from the Code by a Board member is determined by the Board of Directors and may attract appropriate disciplinary or other action.

The Code of Conduct and Business Ethics is publicly accessible at: http://caplinpoint.net/wp-content/uploads/2021/07/Code-of-Conduct-Business-Ethics.pdf

PRINCIPLE 2: Businesses should provide goods and services in a manner that is sustainable and safe

Essential Indicators

1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.

	FY 2025-26	FY 2024-25	Details of Improvements in environmental and social impacts
R&D	100%[1]	100%[2]	1. **SCIEX Triple Quad™ 6500+ TQMS System:** Reduces solvent consumption and hazardous chemical waste through efficient analytical workflows. It also minimizes energy consumption and personnel exposure to toxic solvents. 2. **Gas Chromatography (GC) Systems:** Helps monitor VOC and solvent emissions, reduces hazardous solvent waste through precise analysis, and supports drug purity and quality. 3. **Thermo Dionex Ion Chromatography System:** Minimizes chemical waste and repeat testing through precise ion quantification, while supporting water quality compliance and laboratory safety. 4. **Lab Link Water Purification System:** Reduces water and chemical consumption through efficient purification and recycling, minimizes hazardous waste, and provides ultrapure water for pharmaceutical testing. 5. **New Technology Platforms:** Our R&D enables development of complex ophthalmic, otic and inhalation products (suspensions, emulsions and inhalation solutions). In addition our R&D efforts results in reduction of material and packaging waste, minimizes contamination risk, and eliminates or reduces the need for preservatives — lowering the environmental footprint of manufacturing while improving energy efficiency. By enabling in-house development of complex generics for respiratory, ophthalmic and otic therapies, this technology also widens access to affordable, high-quality medicines for patients (social impact) and supports improved health & safety standards for workers engaged in manufacturing operations.
Capex	23.49%	1.13%	1. **Clean room panels:** Reduce product wastes, promotes energy efficiency by preventing contamination related batch failures, ensure hygienic workplace and product safety. 2. **Purified Water Generation System:** a. Minimizes chemical usage in treatment reducing hazardous effluent discharge b. Prevents contaminated water release into environment ensuring ecological safety c. Ensures ultrapure water supply critical for safe pharmaceutical manufacturing 3. **30 TR Chiller:** a. Minimizes refrigerant emissions and greenhouse gas impact on environment b. Ensures product integrity and stability during temperature-sensitive manufacturing c. Reduces carbon footprint through energy-efficient compressor and cooling systems. 4. **Solar Power Unit (Uthiramerur):** Captive solar power generation facility established to reduce reliance on grid electricity and overall electricity consumption. 5. **EV vehicles:** Purchased to reduce reliance on fossil fuels and promote the use of cleaner, more sustainable transportation.

[1&2] 100% of the R&D expense is treated as having societal impact since the Company's business model entirely targets people at the bottom of the pyramid

2. a. Does the entity have procedures in place for sustainable sourcing? (Yes/No)

Yes, the Company has procedures in place for sustainable sourcing.

b. If yes, what percentage of inputs were sourced sustainably?

The Company has a process of contractual enforcement of sustainability principles with key vendors so that the inputs sourced by the Company are manufactured by those key vendors adhering to sustainability principles which includes the following:

- Compliance with all Statutory norms labour, health, safety, environment and ethical standards.
- Zero tolerance towards corruption, fraud, bribery and other unethical conduct.
- Prohibition of Child Labour and protection of human rights.
- Equal opportunities and no discrimination on the basis of gender, race, age, caste etc.
- Protection of environment.
- Safe and healthy workplace.
- The Company uses recyclable packaging materials for all finished products intended for export. This includes the use of paper-based cardboard for secondary packaging and recyclable materials such as aluminum blisters and PET bottles for primary packaging. This reduces the environmental footprint of the Company's exported products and aligns with its commitment to sustainable packaging.
- The Company has procedures in place to promote sustainable sourcing and reduce the environmental impact of its procurement and logistics activities. As part of this approach, the Company consolidates dispatches geographically and/or vendor-wise, wherever feasible, to reduce the number of shipments and associated carbon emissions.

3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.

Since exports account for the entire turnover of the Company and are undertaken through overseas subsidiaries that are not covered under the current BRSR reporting scope, specific measures relating to plastic and medical/hazardous waste generated from such exports cannot be provided. For waste generated and disposed of within India, the Company follows the following practices:

Hazardous waste is disposed of through authorised disposal facilities under long-term agreements.

E-waste is sent to authorised e-waste recyclers. As the quantity generated is not significant, disposal is carried out through authorised vendors on a case-to-case basis rather than through long-term agreements.

Bio-medical waste, which forms a significant part of the waste generated, is disposed of through authorised recyclers under long-term agreements.

Plastic waste is disposed of through recyclers who also handle hazardous and other types of waste.

4. Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same.

Yes. The major source of plastic waste generation for the Company is through export of items and so EPR is not relevant for those wastes. The Company has obtained EPR registration under the new guidelines issued by the Ministry of Environment on Extended Producer Responsibility for

Plastic Waste. The Company is an importer of goods/ materials which contain plastic components/ wrapped in plastic materials and also for the negligible quantity of plastic wastes that is disposed locally. COL is currently working on getting EPR Registration.

Leadership Indicators

1. **Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)? If yes, provide details in the following format?**

NIC Code	Name of Product/ Service	% of total Turnover Contributed	Boundary for which the Life Cycle Perspective / Assessment was conducted	Whether conducted by independent external agency (Yes/No)	Results communicated in public domain (Yes/No) If yes, provide the web-link.
The Company has not conducted LCA in the reporting year.					

2. **If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same.**

Name of Product/ Service	Description of the risk/ concern	Action Taken
	Not Applicable	

3. **Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry).**

Indicate input material	Recycled or re-used input material to total material	
	FY 2025-26	FY 2024-25
The percentage of recycled or reused input material could not be quantified for the respective financial years.		

4. **Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely disposed, as per the following format:**

	FY 2025-26			FY 2024-25		
	Re-Used	Recycled	Safely Disposed	Re-Used	Recycled	Safely Disposed
Plastics (including packaging)	27.34 Metric Tonnes of plastic waste have been recycled.			37.55 Metric Tonnes of plastic waste have been recycled.		
E-waste						
Hazardous Waste						
Other waste						

5. **Reclaimed products and their packaging materials (as percentage of products sold) for each product category**

Indicate product category	Reclaimed products and their packaging materials (as percentage of products sold) for each product category
NIL	

PRINCIPLE 3: Businesses should respect and promote the well-being of all employees, including those in their value chains

Essential Indicators

The Company undertakes a range of employee welfare measures aimed at ensuring the physical, financial and professional well-being of its workforce. These include subsidised canteen and food facilities, staff insurance coverage, employee transportation, and skill/training programs, in addition to other staff welfare initiatives, as reflected in the welfare spend disclosed below.

As part of its focus on employee health, the Company has also tied up with a leading Hospital in Chennai to provide health check-up kits to its regular employees at subsidised rates, enabling access to preventive healthcare and regular health monitoring.

These initiatives collectively reflect the Company's continued commitment to employee welfare, and the associated welfare spend constitutes a consistent proportion of the Company's revenue from operations year-on-year.

1. a. Details of measures for the well-being of employees:

Category	% of employees covered by										
	Total (A)	Health Insurance		Accident Insurance		Maternity Benefits		Paternity Benefits		Day Care Facilities	
		No. (B)	%(B/A)	No. (C)	% (C/A)	No. (D)	%(D/A)	No. (E)	%(E/A)	No. (F)	% (F/A)
Permanent Employees											
Male	1504	1504	100%	1504	100%	0	0	0	0	517	34.38%
Female	745	745	100%	745	100%	745	100%	0	0	457	61.34%
Total	**2249**	**2249**	**100%**	**2249**	**100%**	**745**	**33.13%**	**0**	**0**	**974**	**43.31%**
Other than Permanent Employees[1]											
Male	241	241	100%	241	100%	0	0	0	0	54	22.41%
Female	387	387	100%	387	100%	387	100%	0	0	42	10.85%
Total	**628**	**628**	**100%**	**628**	**100%**	**387**	**61.62%**	**0**	**0**	**96**	**15.29%**

[1]The health insurance, accident insurance, and maternity benefits for non-permanent employees are covered under the ESI scheme provided by the respective contractors and hence they are treated as covered under the respective benefits.

b. Details of measures for the well-being of workers:

Category	% of workers covered by										
	Total (A)	Health Insurance		Accident Insurance		Maternity Benefits		Paternity Benefits		Day Care Facilities	
		No. (B)	%(B/A)	No. (C)	%(C/A)	No. (D)	%(D/A)	No. (E)	%(E/A)	No. (F)	% (F/A)
Permanent Workers											
Male	1225	1225	100%	1225	100%	0	0	0	0	455	37.14%
Female	725	725	100%	725	100%	725	100%	0	0	455	62.76%
Total	**1950**	**1950**	**100%**	**1950**	**100%**	**725**	**37.18%**	**0**	**0**	**910**	**46.67%**

Category	% of workers covered by										
	Total (A)	Health Insurance		Accident Insurance		Maternity Benefits		Paternity Benefits		Day Care Facilities	
		No. (B)	%(B/A)	No. (C)	%(C/A)	No. (D)	%(D/A)	No. (E)	%(E/A)	No. (F)	% (F/A)
Other than Permanent workers[1]											
Male	241	241	100%	241	100%	0	0	0	0	54	22.41%
Female	387	387	100%	387	100%	387	100%	0	0	42	10.85%
Total	**628**	**628**	**100%**	**628**	**100%**	**387**	**61.62%**	**0**	**0**	**96**	**15.29%**

[1]The health insurance, accident insurance, and maternity benefits for non-permanent workers are covered under the ESI scheme provided by the respective contractors and hence they are treated as covered under the respective benefits.

c. **Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format:**

	FY 2025-26	FY 2024-25
Cost incurred on well-being measures as a % of total revenue of the company	0.77%	0.75%

2. **Details of retirement benefits, for Current Financial Year and Previous Financial Year.**

Benefits	FY 2025-26[1]			FY 2024-25		
	No. of employees covered as a % of total employees	No. of workers covered as a % of total employees	Deducted and deposited with the authority (Y/N/N.A.)	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)
PF	100%	100%	Y	99.91%	100%	Y
Gratuity	100%	100%	Y	100%	100%	Y
ESI	35%	41%	Y	33.82%	40.14%	Y

[1]The count of employees given in this table includes the count of workers in line with the definition of the respective terms under Industrial Relations Code 2020. Only Direct employees & workers have been considered for the purpose of this table.

3. **Accessibility of workplaces**

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.

The Company is committed to providing adequate facilities and infrastructure to enable persons with disabilities to perform their duties efficiently within the organization. Our physical infrastructure — including buildings, furniture, and other facilities and services across our premises/campus — is designed to align with the accessibility standards prescribed under the Harmonized Guidelines and Space Standards for Barrier Free Built Environment for Persons with Disabilities and Elderly Persons, 2016, as well as the National Building Code, 2016. The Accessibility requirements are reviewed at every stage of construction, whether a facility is newly built, renovated, leased or rented. Additionally, employees facing accessibility-related concerns can raise them through a dedicated reporting mechanism to the HR Head/Managing Director, ensuring they receive appropriate support.

4. Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy.

Yes. The Company has an Equal Opportunity Policy framed in accordance with the Rights of Persons with Disabilities Act, 2016 and the rules framed thereunder. The Policy applies to persons with disabilities across employment-related matters, including recruitment, training, working conditions, employee benefits and career advancement. It also provides for reasonable accommodation, accessible facilities and a grievance redressal mechanism. The policy is publicly accessible at: https://www.caplinpoint.net/wp-content/uploads/2021/07/EQUAL-OPPORTUNITY-POLICY.pdf

5. Return to work and Retention rates of permanent employees and workers that took Parental leave.

Gender	Permanent Employees		Permanent Workers	
	Return to work	Retention Rate[1]	Return to work	Retention Rate
Male	NA	NA	NA	NA
Female	100 %	NA	100%	90.91%
Total	**100 %**	**NA**	**100%**	**90.91%**

[1]While calculating the retention rate for the year, the Company has considered those women employees/ workers who joined back in the year 2024- 25 after their maternity leave and have completed one year of service during the year 2025-26. The count of employees given in this table (for both permanent and other than permanent employees) includes the count of workers (both permanent and other than permanent workers) in line with the definition of the respective terms under Industrial Relations Code 2020.

6. Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? If yes, give details of the mechanism in brief.

<table>
<tr><th></th><th>Yes/No (If Yes, then give details of the mechanism in brief)</th></tr>
<tr><td>Permanent Workers</td><td rowspan="4">Yes. The Company has established mechanisms for employees and workers to raise and address grievances. These include:
➢ The Company maintains a portal containing the applicable Codes and Policies for employees and third parties, along with guidance on the grievance redressal process and the procedure for raising grievances.
➢ Health and Safety Committees have been constituted at the units, with representation from employees and workers. The Committees conduct regular meetings and inspections to identify unsafe or unhealthy working conditions and address grievances within defined timelines. Grievances and the corresponding action plans are recorded in the Committee minutes/reports.
➢ Internal Complaints Committees have been constituted at all units under the Prevention of Sexual Harassment Policy to address grievances raised by women employees, and can be reached at posh@caplinpoint.net.
➢ The Company's whistle-blower policy covers all employees and workers (including contractual/fixed term and casual) of the Company, whether engaged on part time or full time basis. Under the whistle-blower policy, a dedicated Ethics Committee looks into all complaints and grievances of employees/ workers with regard to any violation of the Company's policies, codes and statutes applicable to its operations. A dedicated e-mail ID ethics@caplinpoint.net/ ethics@caplinsteriles.net has been created to receive and address all grievances and complaints.</td></tr>
<tr><td>Other than Permanent Workers</td></tr>
<tr><td>Permanent Employees</td></tr>
<tr><td>Other than Permanent Employees</td></tr>
</table>

7. Membership of employees and worker in association(s) or Unions recognized by the listed entity:

Category	FY 2025-26			FY 2024-25		
	Total employees / workers in respective category (A)	No. of employees / Workers in respective category, who are part of association or Union (B)	% (B / A)	Total employees / workers in respective category (C)	No. of employees/ workers in respective category, who are part of Union or Associations (D)	% (D / C)
Total Permanent Employees	Nil	Nil	Nil	Nil	Nil	Nil
Male	Nil	Nil	Nil	Nil	Nil	Nil
Female	Nil	Nil	Nil	Nil	Nil	Nil
Total Permanent Workers	Nil	Nil	Nil	Nil	Nil	Nil
Male	Nil	Nil	Nil	Nil	Nil	Nil
Female	Nil	Nil	Nil	Nil	Nil	Nil

8. Details of training given to employees and workers:

Category	FY 2025-26[1]					FY 2024-25				
	Total (A)[2]	On Health and Safety Measures		On skill Upgradation		Total (D)	On Health and Safety Measures		On skill Upgradation	
		No. (B)	% (B/A)	No. (C)	% (C/A)		No. (E)	% (E/D)	No. (F)	% (F/D)
Employees										
Male	1504	767	51.00%	767	51.00%	1637	1237	75.57%	1237	75.57%
Female	745	533	71.54%	533	71.54%	518	475	91.69%	475	91.69%
Total	**2249**	**1300**	**57.80%**	**1300**	**57.80%**	**2155**	**1712**	**79.44%**	**1712**	**79.44%**
Workers										
Male	1225	512	41.80%	512	41.80%	1316	1110	84.35%	1110	84.35%
Female	725	654	90.21%	654	90.21%	495	466	94.14%	466	94.14%
Total	**1950**	**1166**	**59.79%**	**1166**	**59.79%**	**1811**	**1576**	**87.02%**	**1576**	**87.02%**

[1]The count of employees given in this table includes the count of workers in line with the definition of the respective terms under Industrial Relations Code 2020.

[2]Only direct employees & workers have been considered.

9. Details of performance and career development reviews of employees and worker:

Category	FY 2025-26[1]			FY 2024-25		
	Total (A)	No. (B)	% (B/A)	Total (C)	No. (D)	% (D/C)
Employees						
Male	1504	1504	100%	1637	1637	100%
Female	745	745	100%	518	518	100%
Total	**2249**	**2249**	**100%**	**2155**	**2155**	**100%**
Workers						
Male	1225	1225	100%	1316	1316	100%
Female	725	725	100%	495	495	100%
Total	**1950**	**1950**	**100%**	**1811**	**1811**	**100%**

[1]Only direct employees & workers are considered. Also, the performance evaluation cycle of the Company commences from October of each year and applicable only to those who have joined to the month of June of that year. The count of employees given in this table includes the count of workers in line with the definition of the respective terms under Industrial Relations Code 2020.

10. Health and safety management system:

a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, the coverage such system?

Yes. The Company has implemented occupational health and safety management system across its facilities. Our Environment, Health and Safety policy applies to all R&D Units and Manufacturing units.

Manufacturing Units have implemented unit specific EHS policy which is aligned with the operations and processes of the unit and in line with Occupational Health & Safety objectives. All the Manufacturing units have Health & safety Committees that prioritize the resolution of any grievances and implementation of any suggestions regarding health & safety. The Committee encourages the employees & workers to come forward and record their grievances and suggestions in a fear-free atmosphere. The Company has robust fire safety and detection system to address fire risks and in case of any fire incident, the same shall be notified immediately through SMS to the supervisors concerned. All the units are equipped with fire hydrants, automatic sprinkler systems and centralized fire alarm and public addressing systems. Our Health and safety management system comprises of the following -

i. Written Instructions and safe work procedures:

In all our manufacturing units, EHS policy and procedures have been placed in designated areas in both local language and in English for providing clear safety instructions to the employees.

ii. Trainings

Employees on all levels receive appropriate safety trainings and necessary refresher trainings. Some of the trainings conducted are:

- Earthing Essentials to Safeguard Electrical Hazards on Machineries
- Health and Safety Awareness Training in the Laboratory

- Behaviour Based Safety & Safety Awareness Training
- Implementation of 5S Methodology in Workplace
- External First Aid
- External Fire Fighting Training
- Handling and Maintenance of Fire Extinguishers
- Usage and Maintenance of Emergency Eye Wash Station
- Safety Awareness Training on Behaviour Based Safety
- General Awareness Training on Chemical Handling
- General Safety Awareness Training on Material Handling
- Accident / Incident / Near-Miss Investigation Report
- Lock Out and Tag Out
- Handling of Hazardous and Bio-Medical Waste Management
- Chemical Spillage Response Procedure
- Emergency Response and Preparedness Training
- Personal Protective Equipment training
- Chemical Safety Module training
- Environment, Health and Safety (EHS) Module training
- Fire Alarm Response Module training

iii. Identifying hazards and managing risk

iv. Health and safety committee meetings

v. Emergency preparedness drills- the Company has site- specific emergency response plan policy that outlines the responsibilities of

vi. ERT members in case of fires, chemical spills, power outages

vii. Inspection of premises, equipment, workplaces & work practices

viii. Comprehensive maintenance contracts for all emergency systems like fire protection system

b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

- The Company aims to maintain a safe and healthy workplace by identifying workplace hazards, assessing the associated risks and reviewing the effectiveness of the measures in place. Risk assessments for routine activities across R&D and manufacturing operations, including laboratory and process-related hazards, are carried out periodically and before undertaking any new activity. These assessments include:

- Qualitative risk assessment – (QCERA) Qualitative Chemical Exposure Risk Assessment
- Quantitative risk assessment – (HIRA) Hazard Identification Risk Assessment
- Safety inspection and walkthrough observations of the site including corrective and preventive actions identification
- Comparing and updating SOPs (Standard Operating Procedures) as per the safety standards
- Internal Audits
- Safety Committee meetings
- Availability of Material Safety Data Sheet

c. Whether you have processes for workers to report the work-related hazards and to remove themselves from such risks. (Y/N)

Yes. The Company has implemented mechanisms across all units for reporting and investigating incidents and near-miss incidents, along with appropriate corrective measures. Employees are provided periodic training on emergency preparedness and evacuation procedures. Personal protective equipment and emergency contact details are also made available to employees.

d. Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? (Yes/ No)

The Company currently provides non-occupational medical and healthcare services to employees and workers through tie-ups with hospitals and clinical laboratories, enabling them to undergo periodic health check-ups.

11. Details of safety related incidents, in the following format:

Safety Incident/Number	Category	FY 2025-26[2]	FY 2024-25
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)[1]	**Employees**	Nil	Nil
	Workers	0.51	0.15
Total recordable work-related injuries	**Employees**	Nil	Nil
	Workers	1	8
No. of fatalities	**Employees**	Nil	Nil
	Workers	Nil	Nil
High consequence work-related injury or ill-health (excluding fatalities)	**Employees**	Nil	Nil
	Workers	Nil	Nil

[1] There was only one injury recorded during the FY 25-26 involving lost time.

[2]For the purpose of calculating the LTIFR, the total man-hours have been calculated based on the actual working hours of employees at the respective unit.

12. Describe the measures taken by the entity to ensure a safe and healthy workplace.

The Company has established mechanisms to maintain a safe and healthy working environment for its employees. The EHS Policy has been implemented in line with the Company's business objectives and compliance requirements. The measures undertaken by the Company to ensure health and safety at the workplace include:

- Permit to work system: In manufacturing units, permit-to work system is used to ensure that work is done safely and efficiently. Permits for work execution are prepared by an authorized person (both the issuer and the receiver). Based on safety officer clearance, the work shall be initiated in the work place.

- Qualitative risk assessment – (QCERA) Qualitative Chemical Exposure Risk Assessment.
- Quantitative risk assessment – (HIRA) Hazard Identification Risk Assessment.
- Environment Monitoring and Display boards at place to monitor the emissions, discharge and waste generation.
- Standard operating Procedures.
- Elaborate change management process.
- Safety Committee meetings.
- Pre-start up safety review.
- Safety inductions before commencement of new activity.
- Process specific trainings.
- The Company conducts National Safety Day programs to promote awareness about workplace safety.
- The Company provides Personal protective equipment to protect the employees from various exposures.
- The Company actively introduces various new technologies to avoid or minimize the exposure of employees to harmful chemicals/processes.

13. Number of Complaints on the following made by employees and workers:

	FY 2025-26			FY 2024-25		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending Resolution at the end of year	Remarks
Working Conditions [1]	47	9	NIL	53	10	NIL
Health & Safety	0	0	NIL	0	0	NIL

[1]The above Complaints were collected during the course of Safety and other Committee meetings where the employees/ workers participate. Many of the complaints were actually suggestions for improvements which were taken up and resolved.

14. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)[1]
Health and safety practices	100%
Working Conditions	100%

[1] Assessments were carried out by statutory authorities as a part of their regular site visits and also by internal auditors who regularly cover compliance with statutory requirements as part of their audit.

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.

Incident management and reporting systems have been adopted by manufacturing units. All incidents are investigated properly to ascertain the root reasons and trainings are provided to employees/ workers for remediating the fundamental causes to prevent recurrence of occurrences. The same applies to near misses, where there are procedures to highlight, investigate and remedy. Workplace is inspected, initially and periodically, to find any new or repeated dangers. Furthermore, there are frequent trainings on safety and control methods on new or recurrent hazards. Sign boards and other devices are used throughout the units to provide adequate information about safe workplace.

Leadership Indicators

1. Does the entity extend any life insurance or any compensatory package in the event of death of (A) Employees (Y/N) (B) Workers (Y/N).

Yes. The Company provides death-related financial protection to both employees and workers through the Employee Deposit Linked Insurance (EDLI) Scheme. Further, the Company has also obtained the LIC Group Gratuity Scheme, along with gratuity benefits, as applicable.

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners-

The Company has instituted the following measures to monitor and ensure compliance by its contractors:

i. **Contractual safeguards:** Contractor/vendor agreements contain explicit clauses mandating compliance with Provident Fund (PF), Employees' State Insurance (ESI), Gratuity, Minimum Wages, and Bonus Act requirements, along with indemnification clauses in the event of non-compliance by the contractor.

ii. **Pre-onboarding verification:** As part of the empanelment process, contractors are required to furnish valid PF/ESI registration numbers, labour licenses, and other relevant statutory registrations prior to being onboarded.

iii. **Monthly documentary verification:** The Company collects challans on a monthly basis evidencing actual payment/deposit of PF, ESI, Gratuity and Bonus in respect of the contract labour engaged, to confirm that statutory dues deducted from wages have been duly remitted to the respective authorities.

iv. **Consequence management:** In the event a contractor fails to deposit the statutory dues, payments due to such contractor are withheld by the Company until compliance is demonstrated, thereby ensuring timely remittance of dues to the workers' accounts.

3. Provide the number of employees / workers having suffered high consequence work- related injury / ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:

	Total no. of affected employees/ workers		No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY 2025-26	FY 2024-25	FY 2025-26	FY 2024-25
Employees	Nil	Nil	Nil	Nil
Workers	Nil	Nil	Nil	Nil

4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/ No)- No.

The Company currently does not provide transition assistance programmes.

5. **Details on assessment of value chain partners:**

	% of value chain partners (by value of business done with such partners) that were assessed
Health and safety practices	**NIL**
Working Conditions	**NIL**

6. **Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners.**

Not applicable, as the Company did not conduct any assessment of its value chain partners during the reporting year.

PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders

Essential Indicators

1. **Describe the processes for identifying key stakeholder groups of the entity.**

Company deals with a diverse spectrum of stakeholders in its day to day activities. The Stakeholder engagement also assists in managing risks and opportunities in corporate operations. The primary stakeholders recognised by the Company, based on the risks and opportunities they provide to the Company are: Employees, Investors, Vendors, Patients, Regulators and Local Communities.

2. **List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.**

Stakeholder Group	Whether identified as vulnerable & Marginalized Group (Yes/No)	Channel of communication	Frequency of Engagement (Annually/Half Yearly / Quarterly/ others)	Purpose and Scope of engagement including key topics and concerns raised during such engagement
Employees	No	Through regular meetings, dedicated employee portal, projects or operations reviews; one-on-one discussions,video/audio conferences; and counselling. Supplemented by training & upskilling programs, stock-based reward systems, recognition events, and occupational safety protocols.	Annually and need based.	Career management and growth prospects, learning opportunities, compensation structure, building a safety culture and inculcating healthy & safe work practices. Additional focus on overall safety and wellbeing, upskilling and growth, leadership development, and recognition/reward.

Stakeholder Group	Whether identified as vulnerable & Marginalized Group (Yes/No)	Channel of communication	Frequency of Engagement (Annually/Half Yearly / Quarterly/ others)	Purpose and Scope of engagement including key topics and concerns raised during such engagement
Shareholders/ investors	No	Through Annual Report, Company website, Press Releases, interviews by Key Managerial Personnel, Investor Presentations, earnings calls, and arranged plant visits for analysts/investors. Also includes Annual General Meetings, BSE/NSE filings, and the ESG Portal.	Quarterly and annually.	Financial & operational performance, business sustainability, strategy, updates on key projects, communicating growth plans, and understanding shareholder expectations. Focuses on reporting and disclosures, dividend policies, strategic direction, capital allocation, and securing funds while promoting strong governance.
Regulators/ Policy Makers	No	Through audits, filing of statutory records, and participation in consultative processes. Includes ANDA filings, inspections, quality/regulatory submissions, PHARMEXCIL engagement, DSIR recognition, and participation in State government industrial incentive schemes.	Quarterly, Half-yearly, Annually and need based.	Ensure 100% compliance to all laws and participation in policy-making initiatives to drive cross-industry sustainability. Key topics include proactive compliance, quality system maintenance, multi-regulator strategy, automation and digital compliance, export promotion, R&D policy, and industrial development.
Vendors (Suppliers and Contract Manufacturers)	No	Through site inspections/ visits, mails & calls.	Annually and need based.	Building stronger partnerships, driving sustainability in the value chain, ensuring product quality, ethical conduct, and fair business practices. Focus areas include supply chain quality, business continuity, and enabling high-quality, consistent supplies.

Stakeholder Group	Whether identified as vulnerable & Marginalized Group (Yes/No)	Channel of communication	Frequency of Engagement (Annually/Half Yearly / Quarterly/ others)	Purpose and Scope of engagement including key topics and concerns raised during such engagement
Customers	Yes	Through direct presence in markets, distributors, representatives, and pharmacists. Includes in-country subsidiaries, tender participation, robust distribution networks, regulatory interactions, and sponsoring local healthcare initiatives.	Regular.	Reaching bottom-of-the-pyramid customers with quality products at affordable costs with better availability. Expanding access to affordable medicines, ensuring reliable uninterrupted supplies, managing tender relationships, B2B/B2C engagement, and product launches.
Local Communities	Yes	Through community interactions. Supported by the CSR Trust, hospital engagement, scholarships, and access to medicines programs.	Annually and need based.	Ascertaining impactful projects for CSR initiatives. Fostering rural healthcare, education, diversity and inclusion, social impact, and overall community well-being for positive social and environmental outcomes.

Leadership Indicators

1. **Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.**

   Caplin recognizes stakeholder consultation as an integral part of its governance framework for addressing economic, environmental, and social matters. The Company regularly engages with various government departments and ministries through structured consultative mechanisms, including interactions with industry facilitation cells operating under government aegis. These engagements enable the Company to share on-ground feedback relevant to ease of doing business, regulatory simplification, and policy strengthening, while also keeping it abreast of emerging regulatory and policy developments affecting the pharmaceutical sector. Such consultations are undertaken by relevant functional and senior management teams who are closest to these stakeholder relationships, and material feedback, concerns, and outcomes arising from these interactions are periodically are reviewed by the senior management and relevant action plans are placed before the board.

2. **Whether stakeholder consultation is used to support the identification and management of environmental, and social topics (Yes / No). If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into policies and activities of the entity.**

   Yes. Stakeholder consultation is used by the Company to support the identification and management of environmental and social topics relevant to its business and communities. As part of its CSR initiatives, the Company regularly interacts with patients visiting Caplin Point Meenakshi Hospital and gathers structured feedback on the quality, adequacy, and accessibility of healthcare services offered. This ongoing feedback mechanism helps the Company identify gaps and unmet needs within the local community it serves. Basis such inputs received from patients, the Company is progressively expanding and enhancing the range of medical services offered at Caplin Point Meenakshi Hospital, thereby improving healthcare access and outcomes for the local population. This reflects the Company's approach of using stakeholder feedback as a direct input into shaping its social initiatives and CSR activities on an ongoing basis

3. Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized stakeholder groups.

Refer the response given under Question 2 above.

PRINCIPLE 5: Businesses should respect and promote human rights

Essential Indicators

1. Employees and workers who have been provided training on human rights issues and policy (ies) of the entity, in the following format:

Category	FY 2025-26[1&2]			FY 2024-25		
	Total (A)	No. employees / workers Covered (B)	% (B / A)	Total (C)	No. employees / workers Covered (D)	% (D / C)
Employees						
Permanent	2249	2249	100%	2155	2155	100%
Other than permanent	628	628	100%	783	783	100%
Total Employees	**2249**	**2249**	**100%**	**2938**	**2938**	**100%**
Workers						
Permanent	1950	1950	100%	1811	1811	100%
Other than permanent	628	628	100%	783	783	100%
Total Workers	**2578**	**2578**	**100%**	**2594**	**2594**	**100%**

[1]The Company has provided training to its employees and workers on prevention of sexual harassment during the year. In addition, as part of the induction program for new joiners, the Company provides a comprehensive overview of the human rights policy and awareness of human rights issues and how to avoid them. The Company also regularly communicates with the employees on human rights issues like ensuring equality, avoiding child labour by posting the relevant policies in the website and in other conspicuous places etc.

[2]The count of employees given in this table (for both permanent and other than permanent employees) includes the count of workers (both permanent and other than permanent workers) in line with the definition of the respective terms under Industrial Relations Code 2020.

2. **Details of minimum wages paid to employees and workers, in the following format:**

Category	FY 2025-26[1]					FY 2024-25				
	Total (A)	Equal to Minimum Wage		More than Minimum Wage		Total (D)	Equal to Minimum Wage		More than Minimum Wage	
		No. (B)	% (B / A)	No. (C)	% (C / A)		No. (E)	% (E / D)	No. (F)	% (F / D)
Employees										
Permanent Employees	**2249**	**2249**	**100%**	**0**	**0**	**2155**	**0**	**0**	**2155**	**100%**
Male	1504	1504	100%	0	0	1637	0	0	1637	100%
Female	745	745	100%	0	0	518	0	0	518	100%
Other than Permanent employees	**628**	**628**	**100%**	**0**	**0**	**738**	**0**	**0**	**738**	**100%**
Male	241	241	100%	0	0	375	0	0	375	100%
Female	387	387	100%	0	0	408	0	0	408	100%
Workers										
Permanent Workers	**1950**	**1950**	**100%**	**0**	**0**	**1811**	**0**	**0**	**1811**	**100%**
Male	1225	1225	100%	0	0	1316	0	0	1316	100%
Female	725	725	100%	0	0	495	0	0	495	100%
Other than Permanent Workers	**628**	**628**	**100%**	**0**	**0**	**738**	**0**	**0**	**738**	**100%**
Male	241	241	100%	0	0	375	0	0	375	100%
Female	387	387	100%	0	0	408	0	0	408	100%

[1]The count of the employees given in this table (for both permanent and other than permanent employees) includes the count of workers for both permanent and other than permanent workers) in line with the definition of the respective terms under Industrial Relations Code 2020.

3. **Details of remuneration/salary/wages, in the following format:**

a. **Median remuneration/wages:**

	Male		Female	
	Number	Median remuneration/ salary/ wages of respective category	Number	Median remuneration/ salary/ wages of respective category
Board of Directors (BoD)[1]	0	0	0	0
Key Managerial Personnel[3]	7	59,74,248	2	8,00,004
Employees other than BoD and KMP	275	12,63,822	20	6,46,782
Workers[2]	1225	3,80,232	723	2,40,696

1. All non-executive directors are paid only sitting fees. MD/WTD has been considered as part of KMP.
2. Only permanent workers have been considered for the purpose of calculation median remuneration/salary/wages.
3. In case a KMP is occupying that position in more than one Company, the same is counted more than once. For the Purpose of calculating the median remuneration we have considered the remuneration of Key Managerial Personnel (KMP) who were holding office as on March 31,2026, in their respective capacities.

4. **Gross wages paid to females as % of total wages paid by the entity, in the following format:**

	FY 2025-26	FY 2024-25
Gross wages paid to females as % of total wages[1]	15.62%	13%

[1] Only Permanent employees and permanent workers data has been taken in to consideration for calculating the data for this table.

5. **Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)**

Yes. The Company effectively addresses and resolves a broad spectrum of concerns and issues raised by its employees and workers.

6. **Describe the internal mechanisms in place to redress grievances related to human rights issues**

The Company has constituted an Ethics Committee comprising of the following officials:

i. Managing Director

ii. Vice chairman

iii. Chief Financial Officer

iv. General Counsel & Company Secretary

v. Head - Human Resources

The Ethics Committee has the following role in respect of any human rights violation issues reported to it:

i. Conduct the enquiry in a fair and unbiased manner.

ii. Ensure complete fact-finding.

iii. Maintain strict confidentiality.

iv. Decide on the outcome of the investigation, whether an unethical activity has been committed and if so by whom.

v. Decide on the appropriate course of action - suggested disciplinary action, including dismissal, and preventive measures.

vi. Minute Committee deliberations and document the final report.

vii. Submit a report to the Audit Committee regarding the effective functioning of the Whistle-blower mechanism, at such intervals as the Committee may specify which shall not be more than six months.

Apart from the Ethics Committee, the Company also has Internal Complaints Committee for addressing Sexual Harassment issues as per statutory procedure.

7. Number of Complaints on the following made by employees and workers:

	FY 2025-26			FY 2024-25		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Sexual Harassment	Nil	Nil	Nil	Nil	Nil	Nil
Discrimination at workplace	Nil	Nil	Nil	Nil	Nil	Nil
Child Labour	Nil	Nil	Nil	Nil	Nil	Nil
Forced Labour/Involuntary Labour	Nil	Nil	Nil	Nil	Nil	Nil
Wages	Nil	Nil	Nil	Nil	Nil	Nil
Other human rights related issues	Nil	Nil	Nil	Nil	Nil	Nil

8. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

	FY 2025-26	FY 2024-25
Total Complaints reported under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	Nil	Nil
Complaints on POSH as a % of female employees / workers	Nil	Nil
Complaints on POSH upheld	Nil	Nil

9. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases

The Company has a standard procedure for safeguarding whistle blower from discrimination and harassment. No action by way of discrimination, harassment, victimisation, suspension, reduction or discontinuation or any other unfair employment practice like threat or intimidation or termination or suspension of service, disciplinary action, transfer, demotion, refusal of promotion or the like shall be adopted against any employee or third-party on account of his or her making such Complaint. Complainants shall be protected.

10. Do human rights requirements form part of your business agreements and contracts?

Yes. The Company has incorporated human rights provisions into key agreements with its vendors and suppliers. The Company is also subject to various ESG requirements under the contracts entered into with its customers.

11. Assessments for the year:

	% of your plants and Offices that were assessed (by entity or statutory authorities or third parties)
Child Labour	100%
Forced/involuntary labour	100%
Sexual Harassment	100%
Discrimination at workplace	100%

	% of your plants and Offices that were assessed (by entity or statutory authorities or third parties)
Wages	100%
Others- **1. Health and safety** **2. Working Conditions**	100%

12. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 10 above.

No incidents of this nature were identified during the reporting year.

Leadership Indicators

1. **Details of a business process being modified / introduced as a result of addressing human rights grievances/ complaints:** During the reporting period, the Company did not receive any specific complaints from its employees or workers pertaining to human rights matters. Consequently, no business process was modified or newly introduced during the year specifically in response to human rights grievances or complaints.

2. **Details of the scope and coverage of any Human rights due diligence conducted.**

   No specific due diligence were conducted.

3. **Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?**

   Yes. The Company is committed to providing adequate facilities and infrastructure to enable persons with disabilities to perform their duties efficiently within the organisation. Our physical infrastructure — including buildings, furniture, and other facilities and services across our premises/ campus — is designed to align with the accessibility standards prescribed under the Harmonized Guidelines and Space Standards for Barrier Free Built Environment for Persons with Disabilities and Elderly Persons, 2016, as well as the National Building Code, 2016. The Accessibility requirements are reviewed at every stage of construction, whether a facility is newly built, renovated, leased or rented. Additionally, employees facing accessibility-related concerns can raise them through a dedicated reporting mechanism to the HR Head/Managing Director, ensuring they receive appropriate support.

4. **Details on assessment of value chain partners:**

	% of value chain partners (by value of business done with such partners) that were assessed[1]
Sexual Harassment	0%
Discrimination at workplace	
Child Labour	
Forced Labour / Involuntary Labour	
Wages	
Others- Please specify	

[1]The Company has not conducted any assessment for its value chain partners during the reporting period. However, such assessments will be undertaken in the future, as necessary.

5. **Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 4 above.**

As the Company has not yet undertaken an assessment of its value chain partners, no situations requiring corrective actions have arisen during the reporting period.

PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment

Essential Indicators[1]

1. **Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:**

Parameter	FY 2025-26 (In Gigajoules[2])	FY 2024-25 (In Gigajoules)
From renewable sources		
Total electricity consumption (A)	41,437.56	41,554.53
Total fuel consumption (B)	43,065.32	47,216.50
Energy consumption through other sources (C)	-	-
Total Energy consumption from renewable sources (A+B+C)	84,502.88	88,771.03
From non-renewable sources		
Total electricity consumption (D)	70,355.33	68,178.55
Total fuel consumption (E)	42,676.24	43,397.19
Energy consumption through other sources (F)	-	-
Total Energy consumption from non-renewable sources (D+E+F)	1,13,031.58	1,11,575.74
Total energy consumed (A+B+C+D+E+F)	1,97,534.46	2,00,346.76
Energy intensity per rupee of turnover (Total energy consumption/ Revenue from Operations) – GJ/Rupees	0.0000009	0.0000104
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) **(**Total energy consumed / Revenue from operations adjusted for PPP**) – GJ/USD**	0.000018	0.000215
Energy intensity in terms of physical output[3] - GJ/MT	237.73	213.00
Energy intensity – GJ/employee	68.66	68.19

[1]For FY 2025–26, CPL (Vizag) unit has been included in the reporting boundary. It was not included in the reporting boundary for FY 2024–25.

[2]Energy consumption for FY 2025-26 has been reported in Gigajoules (GJ). To ensure consistency and comparability, the corresponding FY 2024-25 figures — previously reported in Megajoules (MJ) in the earlier BRSR — have been restated in GJ for the current reporting period. This change is limited to the unit of measurement and does not impact the underlying energy consumption data.

[3]For calculating energy intensity in terms of physical output, the FY 2024–25 calculation includes electricity and fuel consumption and the corresponding physical output of both CPL Puducherry Unit and COL. The output of injectables and syrups has been excluded from the calculation, as their units of measurement are not comparable with those of the other production outputs.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

There hasn't been an external review or analysis conducted to assess various aspects of our operations, performance, or compliance with standards or regulations.

2. **Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any**

No, The facilities are not covered under the Perform, Achieve and Trade (PAT) Scheme initiated by the Government of India.

3. **Provide details of the following disclosures related to water, in the following format:**

Parameter	FY 2025-26	FY 2024-25
Water withdrawal by source (in kilolitres)		
(i) Surface water	-	-
(ii) Groundwater	50,155.48	41,761.35
(iii) Third party water	28,079.74	13,355.03
(iv) Seawater / desalinated water	-	-
(v) Others	-	-
Total Volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)	**78,235.22**	**55,116.38**
Total volume of water consumption (in kilolitres)	**46,464.46**	**22,797.88**
Water intensity per rupee of turnover (Water consumed / Revenue from operations)**- KL/Rupees**	0.00000021	0.0000012
Water Intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)- (Total water consumption / Revenue from operations adjusted for PPP)- KL/USD	0.0000043	0.000025
Water intensity in terms of physical output - KL/MT	55.92	24.24
Water intensity KL/Employee	16.15	7.76

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

There hasn't been an external review or analysis conducted to assess various aspects of our operations, performance, or compliance with standards or regulations.

4. Provide the following details related to water discharged

Parameter	FY 2025-26	FY 2024-25
Water discharge by destination and level of treatment (in kilolitres)		
(i) To Surface water		
- **No treatment**	-	-
- **With treatment – please specify level of treatment**	-	-
(ii) To Groundwater		
- **No treatment**	-	-
- **With treatment – please specify level of treatment**	-	-
(iii) To Seawater		
- **No treatment**	-	-
- **With treatment – please specify level of treatment**	-	-
(iv) Sent to third-parties		
- **No treatment**	2,048.00	489.00
- **With treatment – Primary and Secondary Treatment**	2,495.48	2,688.00
(v) Others - Gardening, Toilet Flushing and Ticel Bio park common facility		
- **No treatment**	2,780.00	2,920.00
- **With treatment – Primary, Secondary and Tertiary treatment**	24,342.67	26,138.50
Total water discharged (in kilolitres)	31,666.15	32,235.50

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

There hasn't been an external review or analysis conducted to assess various aspects of our operations, performance, or compliance with standards or regulations.

5. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.

Yes. The entity has implemented a Zero Liquid Discharge (ZLD) mechanism at COL with a treatment capacity of 125 KLD. The ZLD system is designed to minimize freshwater consumption and eliminate the discharge of treated waste water outside the facility by enabling treatment, recovery, recycling and reuse of wastewater generated from the operations.

At COL, the wastewater generated from various process activities is initially routed to the Effluent Treatment Plant (ETP) for treatment. The treated effluent is subsequently fed into a three-stage Reverse Osmosis (RO) system for further treatment and water recovery. The permeate generated from the first-stage RO is reused within the facility, including for cooling tower applications. The reject from RO-1 is further treated through RO-2, and the reject from RO-2 is subsequently processed through RO-3 to maximize water recovery. The final reject from the RO system is sent to a forced evaporator, where water is evaporated and recovered, while the residual salts are collected and handed over to an authorized hazardous waste management vendor. The recovered salts are further utilized for conversion into alternative fuel for cement plants. Sludge generated from the primary settling process is also sent to the authorized vendor for conversion into alternative fuel, while sludge from the secondary settling process is utilized as bio-manure for gardening within the premises. This integrated treatment and recovery system enables the facility to operate on a closed-loop basis and prevents the discharge of liquid effluent into the environment.

At the other facilities, ZLD has not yet been fully implemented, although wastewater management and reuse systems are in place. At CPL – Puducherry, process effluent and sewage are treated through an on-site 60 KLD ETP and 40 KLD STP, respectively. The treated effluent undergoes physical, chemical and biological treatment, followed by filtration and RO treatment. The recovered water is reused for gardening, utility and flushing purposes. The facility is in the process of implementing ZLD in the near future.

Similarly, CSL – Thiruvallur currently does not have a ZLD system but is in the process of implementing ZLD during FY 2026–27. The facility treats its effluent through multi-stage ETP processes comprising primary chemical treatment, secondary biological treatment and tertiary filtration/ disinfection. Treated effluent is reused for gardening, while sludge generated from the activated sludge process is utilized as manure for gardening. The treated effluent is also monitored to ensure compliance with the applicable Tamil Nadu Pollution Control Board (TNPCB) disposal standards.

For the CPL and CSL Head Offices and R&D Centres at Perungudi, a common treatment facility comprising a 2 KLD ETP and 20 KLD STP is operated. The ETP incorporates flocculation, primary and secondary settling, biological treatment and filtration through pressure sand and activated carbon filters. Treated water is reused for gardening and toilet flushing. The STP uses a Fluidised Bio Reactor-based treatment process, followed by filtration and disinfection, with treated water reused for gardening, floor washing and flushing. The generated bio-sludge is utilized as manure.

At the CPL R&D Centre in Hyderabad, ZLD has not been implemented. Liquid waste is collected in dedicated 10 KL effluent storage tanks and subsequently managed through authorized tanker arrangements. The pH of the effluent is checked prior to transfer and, where required, adjusted to the acceptable range. Domestic wastewater is currently discharged through the existing drainage system.

At the CPL Chengalpattu-Amaris CRO, trade effluent generated from the bio-analytical laboratory is collected and stored in a designated solvent waste storage area. The effluent undergoes primary chemical treatment involving pH adjustment, coagulation and flocculation, followed by solar evaporation in concrete solar beds. While this system supports treatment and evaporation of the generated trade effluent, the facility does not currently operate a formal ZLD system.

The CPL R&D Centre at TICEL Biopark utilizes the common wastewater treatment facility operated by TICEL Biopark for the building. CPL Vizag unit currently does not have a ZLD mechanism.

Overall, while ZLD has been fully implemented at COL, the remaining facilities are at different stages of wastewater treatment, reuse and ZLD implementation. The entity is progressively strengthening its water management practices, with CPL – Puducherry and CSL – Thiruvallur specifically working towards implementation of ZLD, with CSL – Thiruvallur targeting implementation in FY 2026–27.

6. Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:

Parameter	Unit	FY 2025-26[1]	FY 2024-25
NOx	mg/Nm3	2,466.85	3,940.31
SOx	mg/Nm3	353.30	457.23
Particulate matter (PM)	mg/Nm3	311.24	734.97
Persistent organic pollutants (POP)	-	-	-
Volatile organic compounds (VOC)	-	-	-
Hazardous air pollutants (HAP)	-	-	-
Others – CO	mg/Nm3	1,520.62	2,221.04
Others – NMHC	mg/Nm3	13.00	72.50
Others – HCl	mg/Nm3	15.74	-

[1] The reduction in air emissions during FY 2025–26 was primarily attributable to the lower operating hours of Diesel Generator (DG) sets during the reporting period. The reduced utilisation of DG sets resulted in lower consumption of diesel fuel and consequently reduced emissions generated from their operation.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

The external assessment in CPL Puducherry was conducted by Chennai Metex Lab Pvt. Ltd. In CPL R & D unit (Hyderabad), the assessment was carried out by Global Enviro Labs, which is certified by MOEF&CC and NABL. For the sites in Amaris, COL, CPL and CSL – Perungudi R&D Centres and Offices and CSL, EHS 360 Labs Pvt. Ltd. performed the independent assessment.

7. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:

Parameter	Unit	FY 2025-26	FY 2024-25
Total Scope 1 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)[1]	*Metric tonnes of CO2 equivalent*	3,524.56	3,588.82
Total Scope 2 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	*Metric tonnes of CO2 equivalent*	13,875.64	13,768.28
Biogenic Emissions from Biobriquettes	*Metric tonnes of CO2 equivalent*	63,564.42	69,691.55
Total Scope 1 and Scope 2 emissions per rupee of turnover (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations)	Metric tonnes of CO2 equivalent/Rupee	0.00000008	0.0000009
Total Scope 1 and Scope 2 emissions per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations adjusted for PPP)	Metric tonnes of CO2 equivalent/USD	0.0000016	0.000019
Total Scope 1 and Scope 2 emissions intensity in terms of physical output	Metric tonnes of CO2 equivalent/MT	20.94	18.45
Total Scope 1 and Scope 2 emission intensity	Metric tonnes of CO2 equivalent/Employee	6.05	5.91

[1]For calculating Scope 1 and Scope 2 emissions intensity in terms of physical output, the FY 2024–25 calculation includes emissions and corresponding physical output from both CPL Puducherry Unit and COL. The output of injectables and syrups has been excluded from the calculation, as their units of measurement are not comparable with those of the other physical outputs.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

There hasn't been an external review or analysis conducted to assess various aspects of our operations, performance, or compliance with standards or regulations.

8. Does the entity have any project related to reducing Green House Gas emission? If yes, then provide details.

Yes. The entity has undertaken and implemented multiple initiatives across its manufacturing facilities, R&D centres and offices to reduce energy consumption, improve operational efficiency, increase the use of renewable energy and consequently reduce its Scope 1 and Scope 2 GHG emissions. Key initiatives implemented across the facilities are summarized below:

CPL – Puducherry: The Company has undertaken several energy-efficiency and resource-conservation initiatives at its manufacturing facility. A Condensate Recovery System (CRS) has been installed to recover and reuse unused steam condensate as boiler feedwater, which is expected to reduce boiler fuel consumption by approximately 5%, thereby reducing associated Scope 1 emissions. Chiller operations have also been optimized by reducing daytime operating capacity from approximately 990 TR to 865 TR, with one 125 TR chiller being switched off whenever process cooling requirements permit. This optimization is supported by condenser and evaporator water balancing and alignment of AHU operation with actual process requirements. In addition, two of the four chillers are equipped with Variable Frequency Drives (VFDs), enabling compressor speed to be adjusted according to cooling demand and potentially reducing compressor energy consumption by approximately 10%, subject to operating conditions.

The facility has further optimized HVAC set points and AHU operating schedules based on production shift timings to minimize idle operation and unnecessary electricity consumption. Timers have been installed for external lighting systems to automatically control operating hours. The Company has also installed a 100-litre solar water heater and eight solar lights, thereby supporting the use of renewable energy. Further, R22 refrigerant used in HVAC and cold-storage systems is being progressively replaced with more environmentally preferable alternatives, reducing the environmental impacts associated with high-GWP and ozone-depleting refrigerants. Employee awareness initiatives, including energy-saving notices, have also been undertaken to encourage responsible energy consumption. Tree plantation and sapling distribution activities have additionally been undertaken to support green-belt development. Collectively, these measures contribute to improving energy efficiency and reducing the facility's GHG emissions footprint.

CSL – Thiruvallur: As part of its GHG emission reduction initiatives, the Company replaced four petrol-engine cars with electric vehicles (EVs) during FY 2025–26. The Company has further planned to replace the remaining nine petrol/diesel-powered cars with EVs during FY 2026–27. Upon completion, the Company's car fleet is expected to comprise only electric vehicles. This transition is expected to reduce direct Scope 1 emissions associated with company-owned vehicles by eliminating the consumption of petrol and diesel for these vehicles.

CPL and CSL – Perungudi R&D Centres and Offices: The Company has implemented a combination of energy-management and resource-efficiency measures. A Centralized Control and Monitoring (CCM) system has been deployed to automate energy management and prevent unnecessary operation of air-conditioning systems, thereby reducing electricity consumption and associated Scope 2 emissions. Dedicated energy sub-meters have also been installed across production facilities to enable real-time monitoring of electricity consumption, identify energy-intensive operations and facilitate timely corrective actions to minimize energy wastage.

The Company has additionally undertaken water conservation measures, including reuse of RO reject water for restroom flushing, installation of water-efficient push-type faucets and reuse of treated effluent for landscape irrigation. While primarily intended to conserve water, these measures also have an indirect GHG reduction benefit by reducing the energy requirements associated with water pumping, treatment and freshwater consumption.

COL- Kakkalur – OSD Manufacturing Facility: During FY 2025–26, the Company implemented an AHU power conservation initiative in its Oral Solid Dosage manufacturing operations, aligned with the principles of WHO TRS 1010, Annex 2. Following power shutdown and environmental recovery validation studies, AHUs are now programmed to switch on approximately 180 minutes before the commencement of manufacturing activities, rather than operating continuously during non-operational hours. Validation studies confirmed that the required environmental parameters, including temperature, relative humidity and viable and non-viable particulate levels, could be restored within this period, supported by a risk assessment.

As a result, 16 out of 20 AHUs at the facility are switched off during non-operational hours, while four AHUs continue to operate continuously for critical areas such as product storage, warehouse and logistics areas. The initiative is estimated to save approximately 2,200–2,500 kWh of electricity per day, with an average estimated saving of approximately 2,350 kWh/day. At an assumed electricity cost of ₹ 10.60/kWh, this corresponds to estimated electricity cost savings of approximately ₹ 7.47 lakh per month. The reduction in electricity consumption also contributes to a corresponding reduction in the facility's Scope 2 GHG emissions.

Overall, these initiatives demonstrate the Company's continued efforts towards GHG emission reduction through energy efficiency, electrification of vehicles, renewable energy adoption, optimization of HVAC systems, improved energy monitoring, resource recovery and reduction in unnecessary electricity consumption.

9. Provide details related to waste management by the entity, in the following format:

Parameter	FY 2025-26	FY 2024-25[2]
Total Waste generated (in metric tonnes)		
Plastic waste (A)	28.36	41.51
E-waste (B)	1.90	1.06
Bio-medical waste (C)	69.05	50.84
Construction and demolition waste (D)	-	-
Battery waste (E)	0.04	-
Radioactive waste (F)	-	-
Other Hazardous waste (G)		
35.3. Category (Chemical Sludge)	6.33	6.06
28.4. Category (Off- specification Products)	4.22	4.95
28.5. Category	0.05	0.08
28.6 Category	1.02	0.79
28.1 Category	59.57	55.17
28.3 Category	-	0.42
33.2 Category	0.54	0.43
33.1 Category	3.28	3.19
5.1 Category	0.60	0.52
Used or spent oil Used or spent oil	1.82	0.69
Date Expired Products	0.10	0.11
Spent solvent	6.30	1.48
Charcoal	0.16	0.10
Borosilicate waste	0.12	-
Organic Waste	0.002	-
Other Non-hazardous waste generated (H). **Please specify, if any. (Break-up by composition i.e. by materials relevant to the sector)**		
Paper & Carton waste	117.51	124.07
Metal waste	37.63	26.23

Parameter	FY 2025-26	FY 2024-25[2]
Fire wood waste	18.24	17.12
Aluminium waste	-	2.01
Copper waste	0.97	0.21
Cloth waste	0.01	0.55
Rubber waste	1.87	2.12
Thermacol waste	0.01	0.54
Others (Glass Bottles, Silicon Tubes etc.)	14.36	10.71
Total (A+B + C + D + E + F + G + H)	**374.07**	**350.97**
Waste intensity per rupee of turnover (Total waste generated / Revenue from operations) MT/ Rupee	0.0000000017	0.00000002
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)- MT/USD (Total waste generated / Revenue from operations adjusted for PPP)	0.000000035	0.00000038
Waste intensity in terms of physical output	0.45	0.14
Waste intensity (optional) - the relevant metric may be selected by the entity- MT/employee	0.13	0.12
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)		
Category of waste- Plastic, E-waste, Hazardous and Non-Hazardous waste		
(i) Recycled -Used oil, spent solvent, plastic waste, E-waste, Category 5.1, Category 33.1 and Category 28.6, Carton Boxes	53.81	60.15
(ii) Re-used	-	-
(iii) Other recovery operations	-	-
Total	**53.81**	**60.15**
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)		
Category of waste- Plastic, Biomedical waste, Hazardous waste, Non-Hazardous waste		
(i) Incineration – Biomedical waste, Date expired products	66.17	50.56
(ii) Landfilling – Chemical sludge, Biomedical waste	2.77	0.38
(iii) Other disposal operations- Disposed to Alternate fuel resources facility (AFRF) for pre-processing and to use the same in cement industry. Chemical sludge and off specified products	72.90	68.18
(iv) Other disposal operations[1] - Disposal to third party (Plastic, Non-Hazardous, E-waste and Battery waste)	174.04	171.52
Total	**315.88**	**290.65**

[1]The total quantity of waste disposed of and reclaimed does not reconcile with the total waste generated, as certain waste generated at the CPL Vizag unit facility remained undisposed as of FY 2025–26. Additionally, only a portion of the biomedical waste generated was incinerated during the reporting period.

[2] The e-waste generated at Perungudi during FY 2024-25 remained undisposed as at the end of the reporting period. It was subsequently disposed of in the following period, resulting in a variance between the total waste generated and the sum of waste disposed off/reclaimed for FY 2024-25.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

As of the reporting period, there has been no independent external review or analysis assessing our operations, performance, or compliance with relevant standards or regulations.

10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

The Company has established comprehensive waste management practices across its manufacturing units, R&D centres and office facilities to ensure the segregation, safe storage, handling, treatment, recycling, recovery and disposal of waste in accordance with applicable environmental regulations and requirements of the respective regulatory authorities, including the CPCB, SPCBs and TNPCB. Hazardous and other regulated wastes are managed through authorized vendors, recyclers and treatment facilities, as applicable.

At CPL – Puducherry, solid, hazardous and other wastes generated from operations are segregated at source and stored in designated areas prior to being handed over to authorized vendors for recycling, recovery, treatment or disposal. The Company maintains valid authorizations for the handling and disposal of hazardous and biomedical waste. Various waste streams, including e-waste, hazardous waste under Categories 5.1, 33.1 and 28.6, plastic waste, corrugated boxes, waste paper and metal scrap, are channelized to authorized recyclers/vendors to promote resource recovery and minimize waste sent for final disposal. The facility also operates an ETP and STP for treatment of process effluent and sewage prior to reuse/disposal, thereby minimizing the environmental impact associated with waste water generation.

At CSL – Thiruvallur, non-hazardous waste is segregated at source and handed over to appropriate vendors for safe disposal. Hazardous waste is segregated and stored in designated hazardous waste storage areas and subsequently transferred to authorized vendors for recycling, recovery, treatment or co-processing, depending on the nature and characteristics of the waste. Used/spent oil is sent to authorized recyclers, spent solvents are recovered/recycled, while off-specification and expired products, chemical sludge and other suitable hazardous waste streams are routed through authorized Alternate Fuel Resource Facilities (AFRFs) for pre-processing and subsequent co-processing in cement manufacturing. Wherever technically feasible, the Company has prioritized recycling, recovery and resource utilization over conventional disposal routes such as landfilling and incineration. Further, sludge generated from the STP is dewatered and naturally dried in designated sludge drying beds and, after adequate drying, is utilized as manure for gardening and landscaping within the premises.

At the CPL and CSL R&D facility – Perungudi, the operation and maintenance of the ETP and STP are managed by an authorized third-party O&M vendor. Sludge generated from the treatment processes is collected and removed by the vendor and disposed of through authorized recyclers. Hazardous waste routed through the AFRF process undergoes consignment-wise sampling and analysis, segregation, labelling and designated storage, followed by appropriate pre-processing such as blending, drying and mechanical processing based on its characteristics. The processed material is subsequently supplied to cement manufacturing units for co-processing as an alternative fuel and/or raw material, thereby facilitating resource recovery and reducing dependence on conventional disposal methods.

At Amaris Clinical – CRO- Chengalpattu sewage is conveyed directly to the Common STP operated by Mahindra World City, with sludge management undertaken by the STP operator in accordance with applicable regulatory requirements.

Strategy for Reduction and Management of Hazardous and Toxic Chemicals

The Company adopts a source-control and responsible chemical management approach, with emphasis on minimizing the environmental impact associated with hazardous and toxic substances throughout their use and disposal. This includes appropriate segregation and storage of hazardous materials, controlled handling, treatment and channelization of hazardous waste to authorized recyclers or treatment facilities, and recovery of materials wherever feasible.

As part of this approach, the Company is progressively replacing R22 refrigerant used in HVAC and cold-storage systems at CPL – Puducherry with more environmentally preferable alternatives. This phased replacement is intended to reduce reliance on refrigerants with high global warming potential and ozone-depleting properties. In addition, spent solvents are routed for recovery/recycling, while suitable hazardous waste streams are directed to AFRFs for pre-processing and subsequent co-processing in cement manufacturing, thereby converting waste into useful alternative fuel/raw material.

Overall, the Company's waste management strategy focuses on the 3R principles of reduction, recovery and recycling, supported by source segregation, controlled storage, authorized transportation and disposal, resource recovery, co-processing and progressive substitution of environmentally harmful substances. These practices collectively help reduce the generation and environmental impact of hazardous and toxic waste while ensuring compliance with applicable regulatory requirements.

11. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required, please specify details in the following format:

S. No.	Location of operations/ offices	Types of operations	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
The Company refrains from conducting its operations in ecologically sensitive regions.			

12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

Name and brief details of project	EIA Notification No.	Date	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
During the current reporting period, the entity did not undertake any Environmental Impact Assessments (EIA) for its projects.					

13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, and Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:

Serial Number	Specify the law / regulation / guidelines which was not complied with	Provide details of the non-compliance	Any fines / penalties / action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any action
There were no material non-compliances reported in the current reporting period. Hence, the Company adheres to all relevant environmental laws and regulations.				

Leadership Indicators

1. Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):

For each facility / plant located in areas of water stress, provide the following information:

(i) **Name of the area**

(ii) **Nature of operations**

(iii) **Water withdrawal, consumption and discharge in the following format:**

Parameter	FY 2025-26	FY 2024-25
Water withdrawal by source (in kilolitres)		
(i) Surface water	Our plants are situated in regions where water stress is not a concern. This deliberate choice of locations is part of our commitment to responsible resource management, ensuring that our operations have minimal impact on water-stressed areas.	
(ii) Groundwater		
(iii) Third party water		
(iv) Seawater / desalinated water		
(v) Others		
Total volume of water withdrawal (in kilolitres)		
Total volume of water consumption (in kilolitres)		
Water intensity per rupee of turnover (Water consumed / turnover)		
Water intensity (optional) **– the relevant metric may be selected by the entity**		
Water discharge by destination and level of treatment (in kilolitres)		
(i) Into Surface water		
- **No treatment**		
- **With treatment – please specify level of treatment**		
(ii) Into Groundwater		
- **No treatment**		
- **With treatment – please specify level of treatment**		
(iii) Into Seawater		
- **No treatment**		
- **With treatment – please specify level of treatment**		
(iv) Sent to third-parties		
- **No treatment**		
- **With treatment – please specify level of treatment**		
(v) Others		
- **No treatment**		
- **With treatment – please specify level of treatment**		
Total water discharged (in kilolitres)		

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

To date, there has been no independent external review or analysis assessing our operations, performance, or compliance with relevant standards or regulations.

2. **Please provide details of total Scope 3 emissions & its intensity, in the following format:**

For FY 25-26, Scope 3 emissions have been calculated based on Category 5 – Waste Generated in Operations, considering the applicable waste generation and corresponding disposal, treatment, or reclamation methods. For certain waste streams managed through third-party vendors, the specific treatment or disposal methodologies were not available at the time of assessment. Accordingly, emission factors could not be reliably assigned to these waste streams. The Company is in the process of strengthening data collection and coordination with its waste management partners to enable more comprehensive Scope 3 emissions assessment in the forthcoming reporting periods.

Parameter	Unit	FY 2025-26	FY 2024-25
Total Scope 3 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available) – Limited	**Metric tonnes of CO2 equivalent**	58.57	The Company has not yet assessed the categories applicable under Scope 3 emissions. However, it is undertaking the necessary measures to assess and quantify the relevant Scope 3 emission categories in the forthcoming years.
Total Scope 3 emissions per rupee of turnover	**Metric tonnes of CO2 equivalent/Rs**	0.00000000027	
Total Scope 3 emission intensity	**Metric tonnes of CO2 equivalent/Employee**	0.02	

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

There has not been an external review or analysis conducted to assess various aspects of our operations, performance, or compliance with standards or regulations.

3. **With respect to the ecologically sensitive areas reported at Question 11 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities.**

The Company refrains from conducting its operations in environmentally fragile or ecologically sensitive regions. This strategic decision underscores the company's commitment to responsible business practices and environmental stewardship, avoiding potential harm to delicate ecosystems. By deliberately choosing locations that are not ecologically sensitive, the company aims to minimize its environmental impact and contribute to the preservation of biodiversity and natural habitats.

4. **If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:**

Sr. No.	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative
1.	Waste Segregation, Storage and Responsible Disposal	The entity has established systems for source segregation, safe storage, handling, transportation, treatment, recycling, recovery and disposal of waste generated across its manufacturing facilities, R&D centres and offices. Hazardous and other regulated waste is stored in designated areas and handed over only to authorized vendors, recyclers and treatment facilities in accordance with applicable CPCB, SPCB and TNPCB requirements. The Company also maintains applicable authorizations for handling and disposal of hazardous and biomedical waste. At CSL – Thiruvallur, non-hazardous waste is segregated at source and handed over to appropriate vendors, while hazardous waste is managed through authorized agencies based on the nature and characteristics of the waste.	Ensures safe and compliant management of waste while minimizing risks to human health and the environment. Source segregation also facilitates recycling, recovery and appropriate treatment of different waste streams.
2.	Recycling and Resource Recovery of Waste	The Company prioritizes recycling, recovery and resource utilization over conventional disposal wherever technically feasible. At CPL – Puducherry, e-waste, plastic waste, corrugated boxes, waste paper, metal scrap and hazardous waste categories such as 5.1, 33.1 and 28.6 are channelized to authorized recyclers/vendors. At CSL – Thiruvallur, used/spent oil is sent to authorized recyclers for recycling and spent solvents are sent for recovery/recycling. These practices are supplemented by controlled storage and documentation prior to transfer to authorized agencies.	Reduces the quantity of waste requiring final disposal, promotes recovery of valuable materials and supports the principles of circularity and resource efficiency.
3.	Hazardous Waste Co-processing through AFRF	At CSL – Thiruvallur and other applicable facilities, suitable hazardous waste streams, including off-specification products, date-expired products and chemical sludge, are routed to an authorized Alternate Fuel Resource Facility (AFRF) for pre-processing. The waste undergoes consignment-wise sampling and analysis, segregation, labelling, storage and appropriate processing, including blending, drying and mechanical processing depending on its characteristics. The processed material is subsequently supplied to cement manufacturing units for co-processing as alternative fuel and/or raw material.	Diverts suitable hazardous waste from conventional disposal routes such as landfilling and incineration, while enabling resource recovery and substitution of conventional fuels/raw materials in cement manufacturing.

Sr. No.	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative
4.	ETP and STP Wastewater Management	The Company operates Effluent Treatment Plants (ETPs) and Sewage Treatment Plants (STPs) at applicable manufacturing and office facilities. At CPL – Puducherry, process effluent and sewage are treated through on-site ETP and STP systems prior to reuse/ disposal. At CPL and CSL – Perungudi, the ETP/STP operations are managed by a third-party O&M vendor. At CPL – Chengalpattu/ Amaris, sewage is conveyed to the Common STP operated by Mahindra World City.	Ensures that wastewater generated from operations is appropriately treated prior to reuse or disposal, thereby minimizing the potential environmental impact of liquid effluents and supporting responsible water management.
5.	Reduction and Substitution of Environmentally Harmful Chemicals – Refrigerants	As part of its efforts to reduce the environmental impact associated with hazardous and environmentally harmful substances, R22 refrigerant used in HVAC and cold-storage systems at CPL – Puducherry is being progressively replaced with more environmentally preferable alternatives. The replacement is being undertaken in a phased manner to reduce dependence on refrigerants with high global warming potential and ozone-depleting properties.	Reduces the environmental impact associated with the use and potential release of high-GWP and ozone-depleting refrigerants and supports the transition towards more environmentally preferable alternatives.
6.	Condensate Recovery System (CRS) – CPL Puducherry	A Condensate Recovery System (CRS) has been installed at the CPL – Puducherry manufacturing facility to recover unused steam condensate and reuse it as boiler feedwater. This reduces the requirement for fresh water and the energy required for heating boiler feedwater, thereby improving overall boiler efficiency.	The initiative is expected to reduce boiler fuel consumption by approximately 5%, thereby contributing to a reduction in associated Scope 1 GHG emissions and improving energy and resource efficiency.
7.	HVAC and AHU Optimization – CPL Puducherry	HVAC set points and AHU operating schedules have been optimized based on production shift timings and actual process requirements. This enables HVAC equipment to operate only when required and minimizes idle running hours during non-operational periods.	Reduces unnecessary electricity consumption from HVAC and AHU systems and contributes to improved operational energy efficiency and reduction in associated Scope 2 GHG emissions.
8.	Variable Frequency Drives (VFDs) for Chillers – CPL Puducherry	Two of the four chillers at CPL – Puducherry are equipped with Variable Frequency Drives (VFDs) for compressor operation. The VFDs enable compressor speed to be varied in line with actual cooling demand, thereby avoiding unnecessary energy consumption associated with fixed-speed operation, particularly under part-load conditions.	The initiative is expected to reduce compressor energy consumption by approximately 10%, subject to actual load conditions and operating hours, thereby contributing to lower electricity consumption and Scope 2 GHG emissions.

Sr. No.	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative
9.	Renewable Energy Adoption – CPL Puducherry	A 100-litre solar water heater and eight 18-watt solar lights have been installed within the factory premises. These systems utilize solar energy for water heating and lighting applications, thereby reducing dependence on conventional electricity.	Supports renewable energy adoption and reduces electricity consumption from conventional sources, contributing to a reduction in the facility's Scope 2 GHG emissions.
10.	Electrification of Company Vehicle Fleet – CSL Thiruvallur	During FY 2025–26, the Company replaced four petrol-engine cars with electric vehicles (EVs) as part of its initiative to reduce fossil-fuel consumption associated with company-owned vehicles. The Company has further planned to replace the remaining nine petrol/diesel-powered cars with EVs during FY 2026–27. Upon completion, the Company's car fleet is expected to comprise only electric vehicles.	The transition to EVs is expected to eliminate direct petrol and diesel consumption from company-owned cars, thereby reducing associated Scope 1 GHG emissions and supporting the Company's vehicle fleet decarbonization efforts.
11.	Centralized Control and Monitoring (CCM) System – Perungudi	A Centralized Control and Monitoring (CCM) system has been deployed across the CPL and CSL Perungudi R&D centres and offices to automate energy management. The system helps prevent unnecessary operation of air-conditioning systems by aligning their operation with actual occupancy and operational requirements.	Reduces unnecessary electricity consumption from air-conditioning systems and contributes to a reduction in associated Scope 2 GHG emissions.
12.	Water-efficient Fixtures – Perungudi	Water-saving push-type faucets have been installed at the facilities to reduce unnecessary water consumption during daily operations.	Reduces water consumption and the associated energy requirements for water supply and pumping, thereby providing an indirect contribution to the Company's resource-efficiency and GHG reduction objectives.
13.	AHU Power Conservation Initiative – COL OSD Manufacturing Facility	During FY 2025–26, COL implemented an AHU power conservation initiative at its Oral Solid Dosage (OSD) manufacturing facility, aligned with the principles of WHO TRS 1010, Annex 2. Following power shutdown and environmental recovery validation studies, AHUs are programmed to switch on approximately 180 minutes before the commencement of manufacturing activities, rather than operating continuously during non-operational hours. Environmental parameters, including temperature, relative humidity and viable and non-viable particulate levels, were validated to ensure recovery within the 180-minute period, supported by a comprehensive risk assessment.	Out of 20 AHUs, 16 are switched off during non-operational hours, while four continue to operate continuously for critical areas such as product storage and warehouse/logistics areas. The initiative is estimated to save approximately 2,200–2,500 kWh/day, with average savings of approximately 2,350 kWh/day.

Sr. No.	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative
14.	Energy Awareness and Green-belt Development – CPL Puducherry	Energy-saving notice boards have been installed in non-operational areas to create awareness among employees and encourage responsible energy consumption. In addition, tree plantation and sapling distribution activities have been undertaken for employees and workers, including initiatives associated with World Environment Day, to support green-belt development within and around the facility.	Promotes energy-conscious behaviour among employees and supports the development of green areas within and around the facility, complementing the Company's broader environmental sustainability initiatives.
15.	Chiller Capacity Optimization – CPL Puducherry	Daytime chiller operations have been optimized by reducing the operating capacity from approximately 990 TR to 865 TR. One 125 TR chiller is switched off whenever process cooling requirements permit. The optimization is supported by condenser and evaporator water balancing and alignment of AHU operation with actual process requirements to avoid excess cooling capacity and unnecessary energy consumption.	Reduces unnecessary electricity consumption associated with chiller operations and consequently contributes to a reduction in Scope 2 GHG emissions and improvement in energy efficiency.

5. Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web link

The disaster management strategy of the company is deeply rooted in comprehensive policies that emphasize risk assessment, incident management, and compliance. The Incident Management Policy outlines structured procedures for addressing and mitigating the impact of unexpected events, ensuring swift response and recovery efforts across departments. Employees are required to be fully acquainted with these provisions, confirming their understanding and adherence through formal declarations. Additionally, the Risk Assessment and Treatment Policy provides a framework for identifying, evaluating, and treating risks to minimize potential disruptions. This approach ensures that the company not only reacts effectively to incidents but also proactively manages risks, fostering a resilient organizational environment. Employees affirm their compliance with these policies, demonstrating their commitment to uphold the company's standards in disaster preparedness and response.

6. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard?

The Company has not undertaken any mitigation or adaptation measures as of yet.

7. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.

NIL

8. How many Green Credits have been generated or procured:

a. By the listed entity: Nil

b. By the top ten (in terms of value of purchases and sales, respectively) value chain partners: Nil

PRINCIPLE 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

Essential Indicators

1. a) Number of affiliations with trade and industry chambers/ associations.

The Company is member of total 9 trade and industry chambers/ associations

b) List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to.

S. No	Name of the trade and industry chambers/ associations	Reach of trade and industry chambers/ associations (State/National)
1	Indian Drug Manufacturers Association	National
2	Pharmaceuticals Manufacturers Association of Tamil Nadu	State
3	Pharmaceutical Export Promotion Council	National
4	Federation of Indian Export Organisations	National
5	Confederation of Indian Industry	National
6	PDMA – Pondicherry Drug Manufacturers Association	State
7	Hindustan Chamber of Commerce	National
8	Tamil Nadu Chamber of Commerce	State
9	Federation of Indian Chambers of Commerce	National

2. Provide details of corrective action taken or underway on any issues related to anticompetitive conduct by the entity, based on adverse orders from regulatory authorities

Name of authority	Brief of the case	Corrective action taken
No such instance during the Financial Year		

Leadership Indicators

1. Details of public policy positions advocated by the entity:

Sr. No	Public policy advocated	Method resorted for such advocacy	Whether information available in public domain? (Yes/No)	Frequency of Review by Board (Annually/ Half yearly/ Quarterly / Others – please specify)	Web Link, If available
Caplin advocates public policy positions relating to ease of doing business, simplification of regulatory and compliance procedures, and strengthening of the policy framework governing the pharmaceutical sector, through its engagement with trade and industry bodies. These advocacy efforts are undertaken by relevant functional and senior management teams who are closest to these stakeholder relationships, with the objective of contributing constructively to policy development that supports innovation, industry growth, and improved patient access to affordable medicines. Outcomes and feedback arising from such engagements are periodically reviewed by senior management, and relevant action plans are placed before the Board.					

PRINCIPLE 8: Businesses should promote inclusive growth and equitable development

Essential Indicators

1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.

Name and Brief details of project	SIA Notification No.	Date of notification	Whether conducted by independent external agency (Yes/No)	Results communicated in public domain (Yes/No)	Relevant Web Link
Not Applicable					

2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:

S. No	Name of Project for which R&R is ongoing	State	District	No. of Project Affected Families (PAFs)	% of PAFs covered by R&R	Amounts paid to PAFs in the FY (in INR)
Not Applicable						

3. Describe the mechanisms to receive and redress grievances of the community.

The Company interacts with local community on a regular basis through formal and informal communication channels.

4. Percentage of input material (inputs to total inputs by value) sourced from suppliers:

	FY 2025-26	FY 2024-25
Directly sourced from MSMEs/ small producers[1]	6.16%	4.92%
Directly from within India	81.84%	84.46%

[1]The company has excluded capex from input material.

5. Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost

Location	FY 2025-26	FY 2024-25
Rural	22.59%	60%
Semi-Urban	41.52%	4%
Urban	No Unit in urban	No Unit in urban
Metropolitan	35.89%	36%

Leadership Indicators

1. Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments (Reference: Question 1 of Essential Indicators above):

Details of negative social impact identified	Corrective action taken
NIL	

2. Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies:

S. No	State	Aspirational District	Amount spent (In INR)
NIL			

3. (a) Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized /vulnerable groups? (Yes/No)

No. The Company does not have a preferential procurement policy providing preference to suppliers comprising marginalized or vulnerable groups. The Company may evaluate the need for such measures as part of its procurement practices and stakeholder considerations, as appropriate

(b) From which marginalized /vulnerable groups do you procure?

Not applicable, as the Company does not procure from marginalized or vulnerable groups.

(c) What percentage of total procurement (by value) does it constitute?

Not applicable

4. Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge:

S.No	Intellectual Property based on traditional knowledge	Owned/ Acquired (Yes/No)	Benefit shared (Yes / No)	Basis of calculating benefit share
Not Applicable				

5. Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes wherein usage of traditional knowledge is involved.

Name of authority	Brief of the case	Corrective Action taken
Not Applicable		

6. Details of beneficiaries of CSR Projects:

S. No	CSR Project	No. of persons benefitted from CSR projects	% of beneficiaries from vulnerable and marginalized groups
1	We have taken up CSR activity directly by actively supporting development of school infrastructure, sponsoring student's education and supporting school events etc.	1,156	100%
2	CSR activities carried through Caplin Point Meenakshi Trust	3,080	100%

PRINCIPLE 9: Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators

1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback.

In markets such as Latin America, the Company mainly exports its pharmaceutical products to its Subsidiaries operating across the region, which in FY26 served a distribution network of over 30,000 touchpoints, up from ~22,000 in FY25. In certain countries, the Company also works through several front-end and channel partners. In both arrangements, the teams at the Subsidiaries are responsible for receiving consumer grievances and complaints and sharing them with the Company for prompt resolution. The Company follows established policies and procedures for addressing such complaints within defined timelines.

In regulated markets, consumer complaints are received and addressed in accordance with the contractual terms agreed with the respective front-end partners. Following the establishment of Caplin Steriles USA Inc. as a front-end entity in the United States, the entity engages with healthcare service providers and end consumers — including hospitals, pharmacies, and clinics, which grew from 5,610 in FY25 to 14,300 in FY26 — to monitor and address complaints.

Standard Operating Procedures have also been established for managing market complaints in regulated markets, with the Quality Assurance, Regulatory Affairs, and external Pharmacovigilance teams involved in the process.

The Quality Assurance department oversees the complaint handling process, including receipt and recording of complaints, initiation of investigations, constitution of cross-functional teams, completion of investigations and communication with relevant stakeholders, wherever required under customer quality agreements. The department is also responsible for implementing corrective and preventive measures, communicating the outcome to complainants and maintaining product complaint records.

Complaints concerning Adverse Drug Reactions / Adverse Drug Events are investigated by the external Pharmacovigilance team, which submits the investigation findings to the Head of Regulatory Affairs. Customer support or external pharmacovigilance services may also be engaged for such investigations.

The Pharmacovigilance team's scope includes the following Individual Case Safety Reporting (ICSR) activities:

- **Literature screening**
- **Case processing services**, including:
  - Triage, case processing, quality review, medical review and expedited reporting
  - Literature searches, analysis and reporting of literature cases
- **Aggregate reporting**, including Development Safety Update Reports (DSURs), Quarterly Periodic Adverse Drug Experience Reports (PADERs), and Periodic Safety Update Reports (PSURs) / Periodic Benefit Risk Evaluation Reports (PBRERs)
- **Clinical Overviews (COs)**
- **Signal management and preparation of signal reports**
- **Risk management reports**
- **Call centre management support**

The Regulatory Affairs department evaluates complaints from a regulatory perspective and is responsible for issuing field alerts or notifying the relevant health authorities / qualified persons in cases involving critical failures in the complaint handling process.

2. Turnover of products and/ services as a percentage of turnover from all products/service that carry information about:

	As a percentage to total turnover
Environmental and social parameters relevant to the product	NA
Safe and responsible usage	100%
Recycling and/or safe disposal	NA

3. Number of consumer complaints in respect of the following:

	FY 2025-26		Remarks	FY 2024-25		Remarks
	Received during the Year	Pending resolution at end of year		Received during the Year	Pending resolution at end of year	
Data Privacy	Nil	Nil	Nil	Nil	Nil	Nil
Advertising	Nil	Nil	Nil	Nil	Nil	Nil
Cyber-security	Nil	Nil	Nil	Nil	Nil	Nil
Delivery of essential services	Nil	Nil	Nil	Nil	Nil	Nil
Restrictive Trade Practices	Nil	Nil	Nil	Nil	Nil	Nil
Unfair Trade Practices	Nil	Nil	Nil	Nil	Nil	Nil
Other – Customer / Market complaints	78	1	Nil	46	Nil	Nil

4. Details of instances of product recalls on account of safety issues:

	Number	Reasons for recall
Voluntary recalls	0	0
Forced recalls	0	0

5. Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a web-link of the policy.

The Company has a Personal Data Protection and Privacy Policy that provides a framework for managing data privacy and related cybersecurity risks. The Policy is available on the Company's website under the Corporate Governance section. Pursuant to the Digital Personal Data Protection (DPDP) Act, 2023 and the rules notified thereunder, the Company is in the process of revising this framework to align with the requirements of the Act, and expects to achieve full compliance as per the timelines provided under the DPDP Act, 2023.

6. **Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services.**

   There were no other instances of product recalls, quality issues, or privacy or cybersecurity breaches requiring corrective action as at the end of the financial year. Further, no penalties were imposed or regulatory actions were taken in relation to the safety of the Company's products or services. Corrective measures were undertaken for the reported product recall to prevent recurrence.

7. **Provide the following information relating to data breaches:**

   a. **Number of instances of data breaches**

      0

   b. **Percentage of data breaches involving personally identifiable information of customers**

      0

   c. **Impact, if any, of the data breaches**

      Nil

Leadership Indicators

1. **Channels / platforms where information on products and services of the entity can be accessed (provide web link, if available).**

   The Company's products and services information is disseminated through multiple channels appropriate to the regulatory environment in which it operates. For operations in highly regulated markets such as the United States, product information — including safety, composition, and quality parameters — is made accessible through publicly maintained regulatory and institutional platforms, namely:

   - DailyMed and the FDA National Drug Code (NDC) Directory, for clinical safety and product composition details.
   - The FDA Orange Book and recognized global pharmaceutical data repositories such as PharmaCompass, for product quality track record and therapeutic compliance parameters.

   In addition, product and service information is available on the Company's website: https://www.caplin-us.com/our-products/

   The Company is also in the process of developing a dedicated B2B ordering portal to further enhance accessibility of product information and streamline institutional ordering for its US operations.

2. **Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.**

   The entity provides relevant information to consumers to support the safe and responsible use of its products. This includes directions for use, ingredients, warnings, precautions and other relevant product information on the product packaging. Where applicable, additional information is provided through pamphlets/leaflets accompanying the product packaging.

3. **Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.**

   The Company informs consumers of any disruption or risk of discontinuation of essential products through multiple channels, including social media platforms, newspaper notifications, and the Company's official website.

4. **Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable) If yes, provide details in brief.**

   Yes. In addition to displaying mandatory product details and manufacturer address on product labels in a legible format, as required under applicable regulatory requirements, the Company also publishes comprehensive product information on its website: **https://www.caplin-us.com/our-products/**, making it accessible to a wider base of institutional and clinical stakeholders beyond the regulatory minimum.

5. **Did your entity carry out any survey with regard to consumer satisfaction relating to the major products / services of the entity, significant locations of operation of the entity or the entity as a whole? (Yes/No)**

   Yes. The Company, through its foreign subsidiaries and various distribution channels, conducts customer satisfaction surveys to gather feedback on its products and services and to assess customer expectations and satisfaction levels.

INDEPENDENT PRACTITIONER'S LIMITED ASSURANCE REPORT

To
The Board of Directors,
Caplin Point Laboratories Limited.

Assurance Report on Sustainability disclosures in the Business Responsibility and Sustainability Reporting (BRSR) Core format.

Caplin Point Laboratories Limited (CIN: L24231TN1990PLC019053), hereinafter referred to as " Caplin Point" or "the Company") engaged M/s Alagar & Associates LLP, ('A&A' or 'us' or 'we') vide engagement letter dated July 1, 2026 to undertake an independent assurance engagement in respect of the agreed Sustainability Information specified below (the "Identified Sustainability Information" or "BRSR Core indicators") included in the Company's Business Responsibility and Sustainability Report (hereinafter referred to as 'BRSR') for Financial Year (FY) 2025-26.

This engagement was conducted by a multidisciplinary team including assurance practitioners, environmental engineers and specialists.

Identified Sustainability Information

Our scope of Limited Assurance consists of the BRSR Core indicators listed in the **Annexure I** to our report.

Our Limited Assurance engagement was with respect to the year ended March 31, 2026 information only unless otherwise stated and we have not performed any procedures with respect to earlier periods or any other elements included in the BRSR and, therefore, do not express any opinion thereon.

Reporting criteria

The Criteria used by the Company to prepare the Identified Sustainability Information is as under:

- Regulation 34(2)(f) of the Securities and Exchange Board of India (the "SEBI") (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended;
- Business Responsibility and Sustainability Reporting Requirements for listed entities per Master Circular No. HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026 (the "SEBI Master Circular") and
- Industry Standards on Reporting of BRSR Core as per SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2024/177 dated December 20, 2024

Assurance Methodology / Standard

We conducted our engagement in accordance with the Standard on Sustainability Assurance Engagements (SSAE) 3000, "Assurance Engagements on Sustainability Information", and Standard on Assurance Engagements (SAE) 3410 "Assurance Engagements on Greenhouse Gas Statements" (together the "Standards"), both issued by the Sustainability Reporting Standards Board (the "SRSB") of the Institute of Chartered Accountants of India (ICAI).

Management's Responsibility

The Company's management is responsible for selecting or establishing suitable criteria for preparing the Sustainability Information, taking into account applicable laws and regulations, if any, related to reporting on the Sustainability Information, Identification of key aspects, engagement with stakeholders, content, preparation and presentation of the Identified Sustainability Information in accordance with the Criteria. This responsibility includes design, implementation and maintenance of internal control relevant to the preparation of the BRSR and the measurement of Identified Sustainability Information, which is free from material misstatement, whether due to fraud or error.

Our Independence and Quality Control

We have maintained our independence and confirm that we have met the requirements of the SEBI Master Circular, its clarifications thereto and have the required competencies and experience to conduct this assurance engagement. We confirm that we are independent of the Company and its group entities and have maintained our independence throughout the engagement.

We maintain a system of quality control designed to provide assurance that our engagements are performed in accordance with applicable professional standards, regulatory requirements and relevant ethical requirements, and that the assurance reports issued by us are appropriate in the circumstances.

The engagement was subject to appropriate quality control procedures, including engagement planning, review of significant judgements, evaluation of the sufficiency and appropriateness of evidence obtained, and review of the final assurance report prior to its issuance.

Our Responsibility

Our responsibility is to express a Limited Assurance opinion on the Identified Sustainability Information listed in **Annexure I** based on the procedures we have performed and evidence we have obtained.

Basis for our conclusion

The procedures we performed were based on our professional judgment and included inquiries, observation of processes performed, inspection of documents, evaluating the appropriateness of quantification methods and reporting policies, analytical procedures and agreeing or reconciling with underlying records.

Given the circumstances of the engagement, in performing the procedures listed above, we:

- Obtained an understanding of the Identified Sustainability Information and related disclosures;
- Obtained an understanding of the assessment criteria and their suitability for the evaluation and/or measurements of the Identified Sustainability Information;
- Made inquiries of Company's management, including Environment Health and Safety team, finance team, compliance team, human resources team amongst others and those with the responsibility for preparation of the Report;
- Obtained an understanding and performed an evaluation of the design of the key systems, processes and controls for recording, processing and reporting on the Identified Sustainability Information at the corporate office and at plants on a sample basis. This included evaluating the design of those controls relevant to the engagement and determining whether they have been implemented by performing procedures in addition to inquiry of the personnel responsible for the Identified Sustainability Information;

- Undertook 4 site visits covering the Head Office, R&D units, Manufacturing plants at Puducherry, Gummidipoondi and a Clinical Research site in Chengalpet. The locations were selected based on their significance to the environmental disclosures, relative size of their workforce and the overall footprint;
- Applied analytical procedures as appropriate and recalculated the information covered by limited assurance based on the criteria;
- Reviewed the Company's process for collating the sustainability information through agreeing or reconciling the Identified Sustainability Information with the underlying records on a sample basis;

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our limited assurance conclusion.

Inherent Limitations

Our assurance engagement assume that the data and information provided by the Company to us as part of our review have been provided in good faith, is true, complete, sufficient, authentic and is free from material misstatements. The assurance scope has the following limitations:

- The assurance engagement considers a **±5% tolerance level** in relation to potential estimation and measurement errors or omissions.
- We have not been involved in evaluation or assessment of any financial data/performance of the company. Our opinion on specific BRSR Core indicators relies on the third party audited financial reports of the Company. We do not take any responsibility of the financial data reported in the audited financial reports of the Company.
- The scope of our assurance engagement is restricted to data and information pertaining to the defined reporting period. Information, events, or data relating to periods outside the reporting period have not been considered as part of this engagement.
- Our assurance does not extend to statements or disclosures that express opinions, claims, beliefs, aspirations, expectations, objectives, or future intentions of the Company.

Other information

The Company's management is responsible for the other information. Our opinion on the Identified Sustainability Information does not cover the other information and we do not express any form of assurance thereon.

In connection with our assurance engagement of the Identified Sustainability Information, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Identified Sustainability Information or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Limited Assurance Opinion

On the basis of the assessment undertaken at the Limited level of Assurance, nothing has come to our attention to suggest that the BRSR Core Key Performance Indicators (KPIs) under 9 ESG attributes (as listed in Annexure I of this statement) do not adhere to the reporting requirements outlined in Industry Standard on Reporting of BRSR Core.

Our Conclusion

The Company has undertaken considerable efforts to ensure the consistency and reliability of the data presented in this Report. The Company may continue to strengthen its data collection and collation processes to further enhance the robustness and quality of its disclosures.

Restriction on Distribution and Use

Our Limited Assurance report has been prepared and addressed to the Board of Directors of Caplin Point at the request of the Company solely, to assist the Company in reporting on Company's sustainability performance and activities. To the fullest extent permitted by law, M/s Alagar & Associates LLP, does not assume responsibility to anyone other than the Company. Our Limited Assurance Report (Deliverables) should not be used for any other purpose or by any person other than the addressees of our report (Deliverables). We neither accept nor assume any duty of care or liability for any other purpose or to any other party to whom our report (Deliverables) is shown or into whose hands it may come without our prior consent in writing.

For Alagar& Associates, LLP
(Formerly known as M. Alagar & Associates)
Practicing Company Secretaries
Peer Review Certificate No: 6814/2025
Firm Registration No: L2025TN019200

M Alagar
Designated Partner
Membership No: F7488 CoP No: 8196
UDIN: F007488H001088755

Place: Chennai
Date: August 12, 2026

ANNEXURE - I

BRSR CORE ATTRIBUTES – LIMITED ASSURANCE FOR FY 2025-26

Principle	Attribute/Area	Parameter/Metric
Principle 1 – E8	Fairness in Engaging with Customers and Suppliers	Number of days of accounts payable
Principle 1 –E9	Openness of business	Concentration of purchases & sales done with trading houses, dealers, and related parties Loans and advances & investments with related parties
Principle 3 – E1 c	Enhancing Employee Wellbeing and Safety	Spending on measures towards well-being of employees and workers – cost incurred as a % of total revenue of the company
Principle 3 – E11		Details of safety-related incidents for employees and workers (including contract-workforce e.g. workers in the company's construction sites)
Principle 5 – E3 b	Enabling Gender Diversity in Business	Gross wages paid to females as % of wages paid
Principle 5 – E7		Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013
Principle 6 – E1	Energy Footprint	Total energy consumption
		Percentage of energy consumed from renewable sources
		Energy intensity
Principle 6 – E3	Water Footprint	Total water consumption
		Water consumption intensity
Principle 6 – E4	Water Footprint	Water discharge by destination and levels of Treatment
Principle 6 – E7	GHG Footprint	Total Scope 1 emissions
		Total Scope 2 emissions
		GHG Emission Intensity (Scope 1+2)
Principle 6 – E9	Embracing circularity – details related to waste management by the entity	Details of total waste generated (in each category)
		Waste Intensity
		Each category of waste generated, total waste recovered through recycling, re-using or other recovery operations
		For each category of waste generated, total waste disposed by nature of disposal method
Principle 8 – E4	Enabling Inclusive Development	Input material sourced from following sources as % of total purchases – Directly sourced from MSMEs/ small producers and from within India
Principle 8 – E5		Job creation in smaller towns – Wages paid to persons employed in smaller towns (permanent or non-permanent /on contract) as % of total wage cost
Principle 9 – E7	Fairness in Engaging with Customers and Suppliers	Instances involving loss / breach of data of customers as a percentage of total data breaches or cyber security events

CAPLIN POINT®
Laboratories

STANDALONE FINANCIAL STATEMENTS

INDEPENDENT AUDITOR'S REPORT

To
The Members of
Caplin Point Laboratories Limited,

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying Standalone Financial Statements of Caplin Point Laboratories Limited ("the Company"), which comprise the Standalone Balance Sheet as at March 31, 2026, the Standalone Statement of Profit and Loss (including Other Comprehensive Income), the Standalone Statement of Changes in Equity and the Standalone Statement of Cash Flows for the year then ended, and notes to the Standalone Financial Statements, including a summary of material accounting policies and other explanatory information (hereinafter referred to as "the Standalone Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone Financial Statements give the information required by the Companies Act, 2013, as amended, ("the Act") in the manner so required and give a true and fair view in conformity with accounting principles generally accepted in India including the Indian Accounting Standards prescribed under section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS") of the state of affairs of the Company as at March 31, 2026, of its profit (including other comprehensive income), of its changes in equity and of its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Standalone Financial Statements in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Standalone Financial Statements.

Key Audit Matters

Key Audit Matters are those matters that, in our professional judgement, were of the most significance in our audit of the Standalone Financial Statements of the financial year ended March 31, 2026. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the following matters as Key Audit Matters to be communicated in our report:

Key Audit Matter	Auditor's Response
Accuracy and completeness of disclosure of related party transactions and compliance with the provisions of Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI (LODR) 2015'). (Refer Note No. 42 to the Standalone Financial Statements)	Our audit approach include: • We obtained an understanding, evaluated the design and tested operating effectiveness of the controls related to capturing of related party transactions and management's process of ensuring all transactions and balances with related parties have been disclosed in the standalone Ind AS financial statements. • We obtained an understanding of the Company's policies and procedures in respect of evaluating arms-length pricing and approval process by the audit committee and the board of directors.

Key Audit Matter	Auditor's Response
	• We agreed the amounts disclosed with underlying documentation and read relevant agreements, evaluation of arms-length by management, on a sample basis, as part of our evaluation of the disclosure. • We assessed management evaluation of compliance with the provisions of Section 177 and Section 188 of the Companies Act 2013 and SEBI (LODR) 2015. • We evaluated the disclosures through reading of statutory information, books and records and other documents obtained during the course of our audit.
The company carries significant inventory in both the Manufacturing as well as in trading divisions. The relevant Inventory management, including stock verification procedures at periodical intervals and valuation of inventories considering the specific life cycle of the products are underlying key factors in determining the appropriateness of value of inventories. As per the company's accounting policies, inventories are measured at the lower of cost or net realizable value. Considering the volume and complexity of the inventory verification process and the associated valuation, inventories are considered as a key audit matter. (Refer Note No. 1B(g) & 7 to the Standalone Financial Statements).	Our audit approach include: • We have assessed the carrying value of inventories, including costing and provisions for obsolescence and net realisable value. • The existence of inventories has been tested through our attendance at year-end inventory stocktakes. Observing physical inventories assisted with our valuation assessment as we were able to identify quality issues if any, validate expiry dates of products. • We assessed the appropriateness of the determination of inventory cost by assessing the accuracy of the standard costing used by the Company and assessing the recognition of variances from standard costs. • We assessed whether inventory is recognised at the lower of cost or net realisable value at period end by comparing the inventory value measured at cost to audit evidence supporting net realisable value such as the current selling price of the products and achieved margins. • We assessed whether the provisions for obsolescence calculated by the Company reflect known quality issues if any, and commercial considerations including product expiration, market demand, manufacturing plans, as well as their compliance with Ind AS 2 and consistent application from prior periods.
As per the principles of Revenue recognition set out in the Accounting Standards involves certain key judgments relating to the identification of distinct performance obligations, determination of transaction price of the identified performance obligations, the appropriateness of the basis used to measure revenue recognised over a period. Additionally, the revenue accounting standard contains disclosures that involve collation of information in respect of disaggregated revenue and periods over which the remaining performance obligations will be satisfied subsequent to the balance sheet date. (Refer Note No. 1B(n), 25 to the Standalone Financial Statements).	Our audit approach includes: • Testing the design and operating effectiveness of the internal controls associated with contracts with customers. • Analysing contracts with customers from selected samples. • Analysing invoices with customers from selected samples. • Testing of the approval mechanism, access and change controls associated with the price. • Reviewing the report of Internal Auditors. • Performance of analytical procedures for reasonableness of the estimates.

Other Information

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Company's Annual Report but does not include the Standalone Financial Statements, Consolidated Financial Statements and our auditor's report thereon.

Our opinion on the Standalone Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Standalone Financial Statements, our responsibility is to read the other information and in doing so, consider whether other information is materially inconsistent with Standalone Financial Statements, or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report the fact. We have nothing to report in this regard.

Management's Responsibilities for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Ind AS specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

(a) Identify and assess the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

(b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system with reference to Standalone Financial Statements in place and the operating effectiveness of such controls.

(c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

(d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

(e) Evaluate the overall presentation, structure and content of the Standalone Financial Statements, including the disclosures, and whether the Standalone Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatement in the Standalone Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of the work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Standalone Financial Statements of the financial year ended March 31, 2026 and are therefore Key Audit Matters. We describe these matters in our auditor's reports unless law or regulations precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order.

2. As required by Section 143(3) of the Act, we report to the extent applicable that:

   (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Standalone Financial Statements.

   (b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid Standalone Financial Statements have been kept by the Company so far as it appears from our examination of those books except for the matters stated in the paragraph 3(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014, as amended.

   (c) The standalone balance sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone statement of cash flow dealt with by this report are in agreement with the books of accounts.

   (d) In our opinion, the aforesaid Standalone Financial Statements comply with the Accounting Standards specified under Section

133 of the Act, read with the Companies (Indian Accounting Standard) Rules, 2015, as amended.

(e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

(f) The modifications relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 2(b) above on reporting under section 143(3)(b) of the Act and paragraph 3(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014, as amended.

(g) With respect to the adequacy of the internal financial controls with reference to Standalone Financial Statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B" to this report.

(h) In our opinion, the managerial remuneration for the year ended March 31, 2026 has been paid/provided by the Company to its directors in accordance with the provisions of section 197 read with Schedule V to the Act;

3. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:

(a) The Company has disclosed the impact of pending litigations on its financial position in its Standalone Financial Statements. Refer Note No. 36 to the Standalone Financial Statements.

(b) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

(c) There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

(d) (i) The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(ii) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(iii) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii), contain any material misstatement.

(e) According to the information and explanations given to us, the final dividend paid by the Company during the year in respect of the same declared for the previous year is in accordance with Section 123 of the Act to the extent it applies to payment of dividend.

The interim dividend declared and paid by the Company during the year and until the date of this audit report is in accordance with Section 123 of the Act.

(f) Based on our examination which included test checks, except for the instances mentioned below, the Company has used accounting softwares for maintaining its books of account, which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the respective softwares.

The feature of recording audit trail (edit log) facility was not enabled at the database level to log any direct data changes for the accounting softwares used for maintaining the books of account relating to payroll and the accounting software used for maintaining ledgers.

Further, the audit trail (edit log) facility was enabled and operated throughout the year for the respective accounting softwares and we did not come across any instance of the audit trail feature being tampered with.

The audit trail has been preserved by the Company as per the statutory requirements for record retention.

For **Brahmayya & Co.**
Chartered Accountants
Firm Registration No: 000511S

N. Sri Krishna
Partner
Membership No: 026575
UDIN: 26026575AJPKHH5642

Place: Chennai
Date: May 14, 2026

Annexure A to the Independent Auditor's Report

The "**Annexure A**" referred to in Clause 1 of "**Report on Other Legal and Regulatory Requirements**" Paragraph of the Independent Auditor's Report of even date to the members of **Caplin Point Laboratories Limited ("the Company")** on the Standalone Financial Statements as on and for the year ended March 31, 2026.

i) a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property Plant and Equipment and relevant details of Right of Use Assets.

(B) The Company has maintained proper records showing full particulars of intangible assets.

b) We are informed that a test of physical verification of Property, Plant and Equipment and Right of Use assets was carried out by the management at reasonable intervals and no material discrepancies were noticed. In our opinion, the frequency of verification of these assets is reasonable having regards to the size of the Company and nature of its assets.

c) The title deeds of all the immovable properties (other than properties, where the Company is the lessee and the lease agreements are duly executed in favour of the Company), as disclosed in the Standalone Financial Statements, are held in the name of the Company, except for a land and factory building purchased by the Company for Rs. 17.38 Crores during the Financial Year 2020-2021 through e-auction from Punjab National Bank under the SARFAESI Act, 2002 and rules thereof, for which the transfer of title is in progress.

(₹ in Crores)

Description of property	Gross Carrying Value	Held in the name of	Whether promoter, director or their relative or employee	Period held by promoter, director or their relative or employee	Reason for not being held in the name of the company
Factory Land and Factory Building at SIDCO, Kakkalur, Tamilnadu	₹ 17.38 Crores	TANSIDCO	No	Not Applicable	The Transfer of Title Deeds is in progress

d) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has not revalued its Property, Plant and Equipment (including right of use assets) and intangible assets during the year ended March 31, 2026.

e) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, there are no proceedings initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transaction Act, 1988 and rules made thereunder.

ii) (a) The management has conducted physical verification of inventory at reasonable interval during the year and no discrepancies were noticed for any class of inventory.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks on the basis of security of current assets. In our opinion, the quarterly statements filed by the Company with such banks are in agreement with the books of account of the Company.

iii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has provided loans and advances during the year to following entities:

(₹ in Crores)

Particulars of Loans	Amount
Aggregate amount during the year ended March 31, 2026	
A. Subsidiaries (Refer Note No. 4 & 12 to the Standalone Financial Statement)	22.04
B. Others (Employee Loan)	0.27

Particulars of Loans	Amount
Balance outstanding as at balance sheet date March 31, 2026	
A. Subsidiaries (Refer Note No. 4 & 12 to the Standalone Financial Statement)	267.84
B. Others (Employee Loan)	0.08

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, in our opinion the investments made and the terms and conditions of the grant of loans and staff advances during the year are, prima facie, not prejudicial to the interest of the Company.

(c) According to the information and explanation given to us, schedule of payment of Interest and repayment of principal has been stipulated and receipts have been regular. Further, the Company has provided loan to its employees during the year as per the Company's policy and receipts are generally regular.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, there is no overdue amount.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, there are no loan or staff advances granted that has fallen due during the year, which has been renewed or extended or fresh loans granted to settle the overdue of existing loans given to same parties.

(f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted any loans or staff advances during the year either repayable on demand or without specifying any terms or period of repayment.

iv) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has complied with the provisions of section 185 and section 186 of the Act to the extent applicable with respect to grant of loans, security, guarantee given, and investments made.

v) According to the information and explanations given to us, and based on our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of sections 73 to 76 of the Companies Act and the rules made thereunder and no order has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any other tribunal, therefore the provisions of clause (v) of paragraph 3 of the order are not applicable to the Company.

vi) We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under Section 148 of the Act and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. We have not, however made a detailed examination of the same.

vii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, in our opinion, the Company is regular in depositing the undisputed statutory dues including Provident Fund, Employee's State Insurance, Income Tax, Service Tax, Excise Duty, Value Added Tax, Goods and Service Tax, Duty of Customs, Cess, and Other Statutory Dues with the appropriate authorities. There are no outstanding undisputed statutory dues on the last day of financial year concerned for a period of more than 6 month from the date they become payable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, the particulars of dues of Income Tax or Sales Tax or Service Tax or Excise Duty or Value Added Tax or Goods and Services Tax or Cess or Stamp Duty as at March 31, 2026 which have not been deposited on account of any dispute are as under:

(₹ in Crores)

Name of Statute	Nature of dues	Amount of Claim	Periods to which amount relates	Forum where dispute is pending
The Income Tax Act, 1961	Income Tax	0.64	AY 2018-2019	The Commissioner of Income Tax (Appeals)

viii) According to the information and explanations given to us, and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

ix) (a) According to information and explanation given to us, the company has not availed loans or other borrowings from any lender during the financial year under audit and hence reporting under clause 3(ix)(a) of the order is not applicable to the Company.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority or other lender.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, the Company has not obtained term loans during the year. Accordingly, clause 3(ix)(c) of the Order is not applicable to the Company.

(d) According to the information and explanations given to us, and on an overall examination of the standalone financial statements of the company, in our opinion, no funds raised on short term basis have been utilized for long term purposes. Accordingly, clause 3(ix)(d) of the Order is not applicable to the Company.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, carried out in accordance with the generally accepted auditing practices in India, in our opinion, that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries or associate.

(f) According to the information and explanations given to us and on the basis of our examination of records of the Company, carried out in accordance with the generally accepted auditing practices in India, in our opinion, the Company has not raised loans during the year on the pledge of securities held in its subsidiaries or associate as defined under the Act. Accordingly, the provisions of clause (ix)(f) of paragraph 3 of the Order are not applicable.

x) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, the Company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, the provisions of clause (x)(b) of paragraph 3 of the Order are not applicable to the Company.

xi) (a) During the course of our examination of the books and records of the Company and according to the information and explanation given to us, we have neither come across any instance of material fraud by the Company or on the Company, noticed or reported during the year, nor have we been informed of any such cases by the management during the course of our audit.

(b) No report under Section 143 (12) of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies

(Audit and Auditors) Rules, 2014, as amended, with the Central Government.

(c) According to the information and explanations given to us provided by the management of the Company, the Company has not received any whistle blower complaints during the year. Accordingly, provision of clause (xi)(c) of paragraph 3 of the Order is not applicable.

xii) In our opinion and according to the information and explanations given to us and based on our examination of records of the Company, carried out in accordance with the generally accepted auditing practices in India, the Company is not a Nidhi Company. Accordingly, the provision of clause (xii)(a), (xii)(b) and (xii)(c) of the paragraph 3 of the Order is not applicable to the company.

xiii) According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties, prima facie are in compliance with the provisions of sections 177 and 188 of the Act, where applicable, and details of such transactions have been disclosed in the Standalone Financial Statements as required by the applicable Ind AS.

xiv) (a) According to the information and explanations given to us and based on our examination of the records of the Company, carried out in accordance with the generally accepted auditing practices in India, the Company has an internal audit system that commensurate with the size and nature of its business.

(b) We have considered, the internal audit reports for the year under audit, issued to the Company.

xv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause (xv) of the paragraph 3 of the Order are not applicable to the company.

xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934, accordingly, the provisions of clause (xvi) (a) of the paragraph 3 of the Order are not applicable to the Company.

(b) The Company has not conducted non-banking financial/housing finance activities during the year. Accordingly, the provisions of clause (xvi)(b) of the paragraph 3 of the Order are not applicable to the Company.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, the provisions of clause (xvi)(c) of the paragraph 3 of Order are not applicable to the Company.

(d) According to the information and explanations provided to us during the course of audit, the Group does not have any CIC. Accordingly, the provisions of clause (xvi)(d) of the paragraph 3 of Order are not applicable to the Company.

xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.

xviii) There has been no resignation of the statutory auditors during the year. Accordingly, the provisions of clause (xviii) of the paragraph 3 of Order are not applicable to the Company.

xix) According to the information and explanations given to us and on the basis of the financial ratios (Refer Note 44 to the Standalone Financial Statements), ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the standalone financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

xx) (a) According to the information and explanations given to us and on the basis of verification of books and records, the Company is not required to transfer unspent CSR expenses to Specified Fund under Section 135(5) of the Act. Hence, the provision of clause (xx)(a) of the paragraph 3 of Order is not applicable to the Company.

(b) According to the information and explanations given to us and on the basis of verification of books and records, in compliance with Section 135(6) of the Act, the Company has transferred unspent amount of Rs. 7.22 crores to a special account, within a period of thirty days from the end of the financial year.

For **Brahmayya & Co.**
Chartered Accountants
Firm Registration No: 000511S

N. Sri Krishna
Partner
Membership No: 026575
UDIN: 26026575AJPKHH5642

Place: Chennai
Date: May 14, 2026

Annexure B to the Independent Auditor's Report

The **Annexure B,** referred to in Clause 2(g) of "**Report on Other Legal and Regulatory Requirements"** Paragraph of the Independent Auditor's Report of even date to the members of **Caplin Point Laboratories Limited** on the Standalone Financial Statements as of and for the year ended March 31, 2026.

Report on the Internal Financial Controls with reference to Standalone financial statements under Clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls with reference to Standalone Financial Statements of Caplin Point Laboratories Limited ("the Company") as of March 31, 2026 in conjunction with our audit of the Standalone Financial Statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Board of Directors is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Acts.

Auditors' Responsibility for Internal Financial Controls

Our responsibility is to express an opinion on the Company's internal financial controls with reference to Standalone Financial Statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ("the Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to Standalone Financial Statements.

Meaning of Internal Financial Controls Over Financial Reporting

A Company's internal financial control with reference to Standalone Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Standalone Financial Statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial controls over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Standalone Financial Statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the Standalone Financial Statements.

Inherent Limitations of Internal Financial Controls with reference to Standalone Financial Statements

Because of the inherent limitations of internal financial controls with reference to Standalone Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls with reference to Standalone Financial Statements were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

For **Brahmayya & Co.**
Chartered Accountants
Firm Registration No: 000511S

N. Sri Krishna
Partner
Membership No: 026575
UDIN: 26026575AJPKHH5642

Place: Chennai
Date: May 14, 2026

CAPLIN POINT®
Laboratories

STANDALONE BALANCE SHEET

AS AT MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Notes	As at March 31, 2026	As at March 31, 2025
ASSETS			
(1) Non-Current Assets			
(a) Property, plant and equipment	2A	219.68	201.59
(b) Capital work-in-progress	2B	9.39	20.64
(c) Intangible assets	2C	1.24	2.10
(d) Right of Use Assets	2D	2.00	1.57
(e) Financial assets			
(i) Investments	3	704.73	491.11
(ii) Loans	4	267.54	245.80
(iii) Other Financial Assets	5	18.04	18.81
(f) Income tax assets (Net)		2.82	2.90
(g) Other Non-current Assets	6	10.42	4.27
Total-Non current assets		**1,235.86**	**988.79**
(2) Current Assets			
(a) Inventories	7	85.66	66.26
(b) Financial assets			
(i) Investments	8	342.51	311.33
(ii) Trade receivables	9	265.96	175.33
(iii) Cash and cash equivalents	10	44.09	99.64
(iv) Bank balances other than (iii) above	11	161.99	115.07
(v) Other Financial Assets	12	39.42	25.92
(c) Other current assets	13	36.25	32.14
Total-Current assets		**975.88**	**825.69**
Total		**2,211.74**	**1,814.48**
EQUITY AND LIABILITIES			
(1) Equity			
(a) Equity share capital	14	15.20	15.20
(b) Other equity	15	2,035.30	1,685.73
Total-Equity		**2,050.50**	**1,700.93**
(2) Liabilities			
(A) Non-Current Liabilities			
(a) Financial liabilities			
(i) Lease Liabilities	16	1.34	1.13
(b) Deferred tax liabilities (Net)	17	10.67	9.25
(c) Other non current liabilities	18	2.85	2.47
(d) Provisions	19	2.21	0.85
Total-Non current liabilities		**17.07**	**13.70**
(B) Current Liabilities			
(a) Financial liabilities			
(i) Trade payables			
(a) total outstanding dues of micro and small enterprises	20	4.46	1.78
(b) total outstanding dues other than micro and small enterprises	20	88.56	59.18
(ii) Lease Liabilities	21	0.85	0.53
(iii) Other financial Liabilities	22	19.77	16.50
(b) Provisions	23	9.10	10.68
(c) Other Current liabilities	24	21.43	11.18
Total-Current liabilities		**144.17**	**99.85**
Total		**2,211.74**	**1,814.48**

The accompanying notes are an integral part of the Standalone financial statements

As per our report of even date attached

For **Brahmayya & Co**
Chartered Accountants
Firm Registration No : 000511S

N. Sri Krishna
Partner
ICAI Membership No. 026575

Place : Chennai
Date : May 14, 2026

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Venkatram G
General Counsel & Company Secretary
M. No. A23989

Place : Chennai
Date : May 14, 2026

STANDALONE STATEMENT OF PROFIT AND LOSS

FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Notes	For the Year ended March 31, 2026	For the Year ended March 31, 2025
I. INCOME			
(a) Revenue from Operations	25	738.33	752.41
(b) Other income	26	195.37	134.59
Total Income		**933.70**	**887.00**
II. EXPENSES			
(a) Cost of Materials Consumed	27	158.82	136.64
(b) Purchases of Stock-in-Trade		82.51	77.17
(c) Changes in inventories of Finished Goods,Work-in-progress and Stock-in-Trade	28	(12.37)	24.36
(d) Employee benefits expense	29	47.72	52.13
(e) Finance costs	30	0.20	0.12
(f) Depreciation and Amortisation Expenses	31	25.43	24.77
(g) Research and Development Expenses	32	37.74	39.82
(h) Other expenses	33	86.13	90.32
Total Expenses		**426.18**	**445.33**
III. Profit before Exceptional items and tax (I-II)		**507.52**	**441.67**
IV. Exceptional Items		**-**	**-**
V. Profit Before Tax (III-IV)		**507.52**	**441.67**
VI. Tax Expense (Net)			
• Current Tax		109.49	102.90
• Deferred tax (Benefits)/Charge		1.45	(0.72)
Total Tax Expense		**110.94**	**102.18**
VII. Profit for the Year (V-VI)		**396.58**	**339.49**
VIII. Other Comprehensive Income Items that will not be reclassified to profit or loss:			
(i) Remeasurement of Defined Benefit Plans		(0.09)	(0.13)
(ii) Income tax relating to these items		0.02	0.03
Other Comprehensive income/(loss) (net of tax)		**(0.07)**	**(0.10)**
IX. Total Comprehensive Income for the Year (VII+VIII)		**396.51**	**339.39**
Earnings Per Equity Share (Nominal value per share ₹ 2/-)	34		
Basic (in ₹)		**52.17**	**44.67**
Diluted (in ₹)		**52.02**	**44.47**

The accompanying notes are an integral part of the Standalone financial statements

As per our report of even date attached

For **Brahmayya & Co**
Chartered Accountants
Firm Registration No : 000511S

N. Sri Krishna
Partner
ICAI Membership No. 026575

Place : Chennai
Date : May 14, 2026

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Venkatram G
General Counsel & Company Secretary
M. No. A23989

Place : Chennai
Date : May 14, 2026

STANDALONE STATEMENT OF CASH FLOWS

For the Year ended March 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
A. Cash Flow from Operating Activities		
Profit before tax	**507.52**	**441.67**
Adjustments for:		
Depreciation and amortisation expense	25.43	24.77
Finance costs	0.20	0.12
Government grant	(0.64)	(0.71)
(Profit)/Loss on sale/disposal of property, plant and equipment	4.14	3.91
Employee stock option scheme expense	(1.38)	6.46
Net unrealised foreign exchange fluctuation loss (gain)	(14.85)	(3.46)
Fair Value (Gain)/Loss on financial instruments through profit or loss	(1.85)	(1.11)
Realised gain on financial assets	(15.05)	(3.48)
Dividend income	(62.30)	(35.53)
Interest income	(77.51)	(75.44)
Operating Profit before working capital changes	**363.71**	**357.20**
Adjustments for :		
(Increase)/Decrease in inventories	(19.40)	19.99
(Increase)/Decrease in trade receivables	(76.03)	(44.62)
(Increase)/Decrease in other assets	(4.11)	(11.33)
(Increase)/Decrease in other financial assets	(0.34)	(0.78)
Increase/(Decrease) in trade payables, other liabilities & provisions	49.06	(20.75)
Cash generated from operations	**312.89**	**299.71**
Income tax Paid	(109.41)	(103.84)
Net Cash inflow/(outflow) from operating activities	**203.48**	**195.87**
B. Cash Flow from Investing Activities		
Sale/(Purchase) of investments	(226.90)	(210.26)
Investment in bank deposits & inter corporate deposits	(1.85)	(7.15)
Investment in subsidiaries	(16.00)	(4.00)
Loan repayment by/(given to) subsidiary (net)	(21.74)	16.20
(Increase)/decrease in other bank balances	(46.67)	20.10
Sale/(purchase) of property, plant and equipment (including CWIP)	(44.63)	(56.56)
Interest received	66.97	62.46
Dividend received	62.30	35.53
Realised gain on financial assets	15.05	3.48
Net Cash inflow/(outflow) from investing activities	**(213.47)**	**(140.20)**
C. Cash Flow from Financing Activities		
Proceeds from exercise of employee stock options*	-	0.01
Interest paid (Including interest on Lease liability)	(0.20)	(0.12)
Dividend paid	(45.61)	(37.99)
Net Cash inflow/(outflow) from Financing activities	**(45.81)**	**(38.10)**
Net increase/(decrease) in cash and cash equivalents during the period D=(A+B+C)	**(55.80)**	**17.57**
Cash and cash equivalents as at the beginning of the period (E)	**99.64**	**80.64**

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Effect of exchange rate changes on cash and cash equivalents (F)	0.25	1.43
Cash and cash equivalents as at the end of the period (G=D+E+F)	**44.09**	**99.64**
Less: Bank Balance in Unspent CSR Account (H)	7.00	5.71
Net cash and cash equivalents as at the end of the period (I=G-H)	**37.09**	**93.93**

Notes:

* Proceeds from exercise of employee stock options amounting to Nil (PY: ₹ 1,39,900) for Nil (PY: 69,950) equity shares exercised during the year ended 31st March 2026 and 31st March 2025 respectively.

The above standalone statement of cash flows has been prepared under the "Indirect method" as set out in Ind AS 7, 'Statement of Cash Flows'.

a) Reconciliation of Cash And Cash Equivalents:

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Cash and cash equivalents as per balance sheet	44.09	99.64
Total cash and cash equivalents as per balance sheet	**44.09**	**99.64**
Less: Bank & other balances in unspent CSR account	7.00	5.71
Total cash and cash equivalents as per the statement of cash flows	**37.09**	**93.93**

b) Cash & Cash Equivalents does not include following:

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Investments in mutual funds	89.73	96.45
Investments in corporate bonds & debentures - non current investments	463.79	184.39
Investments in corporate bonds, debentures & commercial papers - current investments	162.78	199.88
Bank deposits with more than 1 year maturity (other financial asset- non current)	9.01	7.16
Inter corporate deposits- other financial assets (current & non current)	100.00	105.00
Other bank balances	154.54	112.57
Total	**979.85**	**705.45**

The accompanying notes are an integral part of the Standalone financial statements

As per our report of even date attached

For **Brahmayya & Co**
Chartered Accountants
Firm Registration No : 000511S

N. Sri Krishna
Partner
ICAI Membership No. 026575

Place : Chennai
Date : May 14, 2026

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Venkatram G
General Counsel & Company Secretary
M. No. A23989

Place : Chennai
Date : May 14, 2026

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED MARCH 31, 2026

A. EQUITY SHARE CAPITAL (Refer Note 14)

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of Equity Shares of ₹ 2/- each	AMOUNT	No. of Equity Shares of ₹ 2/- each	AMOUNT
Balance at the beginning of the reporting period	7,60,11,696	15.20	7,59,41,746	15.19
Changes in equity share capital due to prior period errors	-	-	-	-
Issue of equity shares during the year	-	-	69,950	0.01
Balance at the end of the reporting period	**7,60,11,696**	**15.20**	**7,60,11,696**	**15.20**

B. OTHER EQUITY (Refer Note 15)

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Reserves and Surplus						Total Other Equity
	Capital Reserve	Securities Premium Reserve	General Reserve	Employee Stock Option Outstanding (Net)	Other Comprehensive Income	Retained Earnings	
Balance as at 31 March 2024	**0.41**	**15.41**	**11.29**	**14.22**	**0.14**	**1,333.49**	**1,374.96**
Changes due to prior period errors	-	-	-	-	-	-	-
Total Comprehensive Income for the year	-	-	-	-	(0.10)	339.49	339.39
Additions/(deductions) during the year :							
Final dividend on equity shares for FY 23-24	-	-	-	-	-	(19.00)	(19.00)
Interim dividend on equity shares for FY 23-24	-	-	-	-	-	(18.99)	(18.99)
Exercise of employee stock option	-	3.95	-	(3.95)	-	-	-
Share-based payment expenses (Net)	-	-	-	6.46	-	-	6.46
Amortised during the year in cost of investment in subsidiary	-	-	-	2.91	-	-	2.91
Balance as at 31 March 2025	**0.41**	**19.36**	**11.29**	**19.64**	**0.04**	**1,634.99**	**1,685.73**
Changes due to prior period errors	-	-	-	-	-	-	-
Total Comprehensive Income for the year	-	-	-	-	(0.07)	396.58	396.51
Additions/(deductions) during the year :							
Final dividend on equity shares for FY 24-25	-	-	-	-	-	(22.80)	(22.80)
Interim dividend on equity shares for FY 24-25	-	-	-	-	-	(22.81)	(22.81)
Exercise of employee stock option	-	-	-	-	-	-	-
Share- based payment expenses (Net)	-	-	-	(1.38)	-	-	(1.38)
Amortised during the year in cost of investment in subsidiary	-	-	-	0.05	-	-	0.05
Balance as at 31 March 2026	**0.41**	**19.36**	**11.29**	**18.31**	**(0.03)**	**1,985.96**	**2,035.30**

The accompanying notes are an integral part of the Standalone financial statements

As per our report of even date attached

For **Brahmayya & Co**
Chartered Accountants
Firm Registration No : 000511S

N. Sri Krishna
Partner
ICAI Membership No. 026575

Place : Chennai
Date : May 14, 2026

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Venkatram G
General Counsel & Company Secretary
M. No. A23989

Place : Chennai
Date : May 14, 2026

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE : 1 MATERIAL ACCOUNTING POLICIES AND KEY ACCOUNTING ESTIMATES AND JUDGEMENTS

1A. Company Overview:

Caplin Point Laboratories Limited ("Caplin Point" or "the Company") incorporated in 1990, headquartered and having its registered office in Chennai, Tamil Nadu, India. The Company is into the business of pharmaceuticals - producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas markets. The Company's principal research and development facilities are located in Tamil Nadu, India; its principal manufacturing facility is located in Puducherry, India. The Company's shares are listed on the Bombay Stock Exchange and the National Stock Exchange in India.

1B. MATERIAL ACCOUNTING POLICIES AND KEY ACCOUNTING ESTIMATES AND JUDGEMENTS:

a) Basis of accounting and preparation of Financial Statements:

i) Statement of Compliance

These financial statements of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified under section 133 of the Companies Act, 2013 ('the Act') read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended and other relevant provisions of the Act and accounting principles generally accepted in India.

ii) Basis of Preparation

The financial statements have been prepared on accrual and going concern basis. Accounting Policies have been consistently applied except where a newly issued Accounting Standard is initially adopted or a revision to an existing Accounting Standard requires a change in the accounting policy hitherto in use.

All assets and liabilities have been classified as current or non-current as per company's normal operating cycle as per paragraph 66 and 69 of Ind AS 1 and other criteria as set out in the Division II of Schedule III to the Companies Act, 2013.

Based on the nature of products and the time between acquisition of assets for processing and their realization in cash and cash equivalents the Company has ascertained its normal operating cycle as twelve months for the purpose of current/non-current classification of assets and liabilities.

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a noncash nature, any deferrals or accruals of past or future operating cash receipts or payments and items of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated. Cash and cash equivalents for the purpose of the statement of cash flows comprise cash and cash on deposit with banks and financial institutions. The Company considers all highly liquid investments with a remaining maturity at the date of purchase of three months or less and that are readily convertible to known amounts of cash to be cash equivalent.

These financial statements are prepared under the historical cost convention except in case of certain class of financial assets/liabilities, share based payments and net liability for defined benefit plan that are measured at fair value.

The Company has decided to round off the figures to the nearest Crores.

These financial statements were authorized for issue by the Company's Board of Directors on May 14, 2026.

iii) Functional and Presentation Currency

These financial statements are presented in Indian rupees, which is the functional currency of the Company. All financial information presented in Indian rupees (₹) has been rounded off to the nearest crores, except otherwise indicated.

iv) Use of Estimates and Judgments

The preparation of the Financial Statements in conformity with Ind AS requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the Financial Statements are prudent and reasonable.

Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known/ materialize. Estimates and underlying assumptions are reviewed on an ongoing basis.

Information about critical judgments in applying accounting policies, as well as estimates and assumptions that have the most significant effect to the carrying amounts of assets and liabilities within the next financial year, are included in the accounting policies, given as under:

- Measurement of defined benefit obligations
- Measurement and likelihood of occurrence of provisions and contingencies
- Recognition of deferred tax assets
- Useful lives of property, plant, equipment and Intangibles
- Impairment of Assets
- Impairment of financial assets

b) Property, Plant and Equipment:

i) Recognition and Measurement

Property, plant and equipment are stated at their cost of acquisition/installation/construction net of accumulated depreciation, and impairment losses, if any, except freehold land which is carried at cost less impairment losses. Subsequent expenditures are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major improvement is performed, its cost is recognized in the carrying amount of the Property, plant and equipment as a replacement if the recognition criteria are satisfied. All other repairs and maintenance are charged to the statement of profit and loss during the reporting period in which they are incurred. The present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset if the recognition criteria for provisions are met.

Spares which meet the definition of property, plant and equipment are capitalized as on the date of acquisition. The corresponding old spares are decapitalized on such date with consequent impact in the statement of profit and loss.

Property, plant and equipment not ready for their intended use as on the balance sheet date are disclosed as "Capital work-in-progress". Such items are classified to the appropriate category of property, plant and equipment when completed and ready for their intended use. Advances given towards acquisition/construction of property, plant and equipment outstanding at each balance sheet date are disclosed as Capital Advances under "Other non-current assets".

An item of property, plant and equipment and any significant part thereof is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss in "other income/(expenses)" when the asset is derecognized.

ii) Depreciation

Depreciation is provided as per the useful life of assets which are determined based on technical parameters/assessment. Depreciation on tangible assets is provided on a straight line method over the estimated useful lives of the assets.

Estimated useful lives of the assets, are as follows:

Asset Category	Estimated useful life (Years)
Factory Building	30
Building other than factory building	20-60
Plant & Machinery	5-15
Furniture & Fixtures	5-10
Office Equipment	5
Computers	2-6
Electrical Fittings and installation	10
Motor Vehicles	5-10

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed during each financial year and adjusted prospectively, if appropriate.

Depreciation on additions is provided on a pro-rata basis for the number of days they are available for use. Depreciation on sale/disposal of assets is provided pro-rata basis up to the date of sale/disposal.

An asset purchased where the actual cost individually does not exceed ₹ 10,000 is depreciated at the rate of 100%.

c) Intangible Assets:

i) Recognition and Measurement

Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any. Expenditure on research and development eligible for capitalization are carried as Intangible assets under development where such assets are not yet ready for their intended use.

An intangible asset is derecognized on disposal, or when no future economic benefits are expected from its use or disposal. Gains or losses arising from derecognition of an intangible asset, if any, are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

(ii) Subsequent Expenditure

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

(iii)Amortization

Intangible assets are amortized over their estimated useful life on Straight Line Method as follows:

Asset Category	Estimated useful life
Computer software & licenses	6 Years or useful life whichever is lower

The estimated useful lives of intangible assets and the amortization period are reviewed at the end of each financial year and the amortization method is revised to reflect the changed pattern, if any.

d) Leases

The Company assesses whether a contract is or contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

i) Company as Lessee

At the date of commencement of the lease, the Company recognizes a right-of-use asset and a corresponding lease liability for all lease arrangements in which it is a lessee, except for short-term leases and leases of low value assets.

The right-of-use assets are initially recognized at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses, if any. Right-of-use assets are depreciated from the commencement date on a straight line basis over the shorter of the lease term and useful life of the underlying asset. The Right-of-use assets is also subject to impairment. Right-of-use assets are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable.

The lease liability is initially measured at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates. The Company uses the incremental borrowing rate as the discount rate.

The Company applies the short-term lease recognition exemption to its short-term leases (i.e., those leases that have a lease term of 12 months or less from the commencement date). It also applies the lease of low value assets recognition exemption to leases that are considered of low value (range different for different class of assets). Lease payments on short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term.

ii) Company as Lessor

Leases for which the Company is a lessor are classified as either finance or operating leases. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the lease is classified as a finance lease. All other leases are classified as operating leases.

In respect of assets provided on finance leases, amounts due from lessees are recorded as receivables at the amount of the Company's net investment in the leases. Finance lease income is allocated to accounting periods to reflect a constant periodic rate of return on the Company's net investment outstanding in respect of the leases. In respect of assets given on operating lease, lease rentals are accounted in the Statement of Profit and Loss, on accrual basis in accordance with the respective lease agreements.

e) Impairment of Assets:

Intangible assets and property, plant and equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the Cash Generating Unit (CGU) to which the asset belongs.

If such assets are considered to be impaired, the impairment to be recognized in the Statement of Profit and Loss is measured by the amount by which the carrying value of the assets exceeds the estimated recoverable amount of the asset. An impairment loss is reversed in the Statement of Profit and Loss if there has been a change in the estimates used to determine the recoverable amount. The carrying amount of the asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

f) Research and Development:

Revenue expenditure pertaining to research is charged to the Statement of Profit and Loss. Development costs of products are also charged to the Statement of Profit and Loss in the year in which they are incurred. Fixed assets utilized for research and development are capitalized and depreciated in accordance with the policies stated for Tangible Fixed Assets and Intangible Assets. Expenditure on in-licensed development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalized, if the cost can be reliably measured, the product or process is technically and commercially feasible and the Company has sufficient resources to complete the development and to use and sell the asset.

g) Inventories

Inventories are valued at lower of cost or net realizable value. Cost is determined as follows;

i) Raw materials, Stores and Spares and Packing materials

Cost includes purchase price, other costs incurred in bringing the inventories to their present location and condition, and taxes for which credit is not available. Cost is determined on Weighted Average basis.

ii) Work-in-progress and Finished goods

Cost includes direct materials and labour and a proportion of manufacturing overheads based on normal operating capacity, but excluding borrowing costs. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale. The Company reviews its inventory regularly to assess any risk of items becoming slow-moving, obsolete, or otherwise non-saleable. This assessment is based on several practical considerations, including shelf life remaining, changes in market demand, regulatory status, pricing trends, and ageing of inventory. Where applicable, adjustments are made to inventory values through appropriate provisions, ensuring they reflect current realities and past trends in product movement and usability.

h) Government Grants and Assistance

Grants from the Government are recognized when the Company will comply with all the conditions attached to them and there is a reasonable assurance that the grant will be received and all attaching conditions will be complied with.

Government grants relating to an asset are initially recognized as deferred income and subsequently recognized in the Statement of Profit and Loss as other income on a systematic basis over the useful life of the asset.

i) Borrowing Costs

Borrowing cost directly attributable to acquisition and construction of assets that necessarily take substantial period of time to get ready for their intended use or sale are capitalised as part of the cost of such assets up to the date when such assets are ready for intended use or sale. All other borrowing costs are expensed in the period in which they occur. Borrowing cost consists of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

j) Fair Value Measurement

The Company measures some of its financial instruments at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

i. Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities.

(All amounts are in ₹ Crores unless otherwise stated)

ii. Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.

iii. Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

k) Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets and financial liabilities are initially measured at fair value.

Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through the statement of profit and loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition.

Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through the statement of profit and loss are recognized immediately in the statement of profit and loss.

I. Financial Assets

The Company's Financial Assets mainly comprise of;

► Current financial assets mainly consist of trade receivables, investments in liquid mutual funds, Cash and Bank balances, Fixed deposits with banks and financial institutions, and other current receivables.

► Non-current financial assets mainly consist of financial investments in equity, fixed deposits and non-current deposits.

Initial Recognition and measurement of Financial Assets

The Company recognizes a financial asset when it becomes party to the contractual provisions of the instrument. All financial assets are recognized initially at fair value, plus in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. However, trade receivables that do not contain a significant financing component are measured at transaction price. All regular purchases or sales of financial assets are recognized and derecognized on a trade date basis, i.e. the date that the Company commits to purchase or sell the asset.

Subsequent Measurement of Financial Assets

For purposes of subsequent measurement, financial assets are classified in the following categories:

i) Financial Assets at Amortized Cost;

A Financial asset is measured at the amortised cost if both the following conditions are met:

■ The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and

■ Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

Financial assets at amortized cost category is the most relevant to the Company. It comprises of current financial assets such as trade receivables, cash and bank balances, fixed deposits with bank and financial institutions, other current receivables and non-current financial assets such as non-current receivables and deposits.

After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate (EIR) method. The EIR amortization is included in other income in the statement of profit and loss. The losses arising from impairment, if any are recognized in the statement of profit and loss.

ii) Financial Assets at Fair Value through Profit and Loss

All equity investments in scope of Ind AS 109 "Financial Instruments" are measured at FVTPL with all changes in fair value recognized in the statement of profit and loss. The Company has designated its investments in equity instruments as FVTPL category.

iii) Financial Assets at Fair Value through Other Comprehensive Income

The Company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Company has not designated investments in any equity instruments as FVTOCI.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of group of similar financial assets) is primarily derecognized (i.e. removed from the Company's balance sheet) when:

i) The rights to receive cash flows from the asset have expired, or

ii) The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either:

- the Company has transferred substantially all the risks and rewards of the asset, or
- the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

Impairment of financial assets

In accordance with Ind AS 109, the Company applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss on the following financial assets:

i) Trade Receivables

ii) Other financial assets that are measured at amortized cost.

In case of trade receivables, the Company follows a simplified approach wherein an amount equal to lifetime ECL is measured and recognized as loss allowance.

In case of other assets (as listed in ii above), the Company determines if there has been a significant increase in credit risk of the financial asset since initial recognition. If the credit risk of such assets has not increased significantly, an amount equal to 12-month ECL is measured and recognized as a loss allowance. However, if credit risk has increased significantly, an amount equal to lifetime ECL is measured and recognized as a loss allowance.

II. Financial Liabilities and Equity Instruments

i) Financial Liabilities

The Company's Financial Liabilities mainly comprise of Current financial liabilities mainly consist of trade payables and liability for capital expenditure

Initial Recognition and measurement of Financial Liabilities

The Company recognizes a financial liability in its balance sheet when it becomes party to the contractual provisions of the instrument. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

Financial liabilities are initially recognized and measured at amortized cost.

Subsequent Measurement of Financial Liabilities at Amortized Cost

The carrying amounts of financial liabilities that are subsequently measured at amortized cost are determined based on the effective interest rate method. Interest expense that is not capitalized as part of cost of an asset is included in the 'Finance costs' line item. The effective interest rate method is a method used to calculate the amortized cost of a financial liability and to allocate interest expense over the relevant period.

Derecognition of Financial Liability

A financial liability is derecognized when the obligation under the liability is discharged, cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of profit and loss.

ii) Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all its liabilities. Equity instruments issued by the company are recognised at the proceeds received, net of direct issue costs.

Debt and equity instruments issued by the Company are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

III. Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously.

l) Foreign Currency Transactions

Transactions in foreign currencies are translated into the functional currency of the Company at the exchange rates prevailing on the dates of the transactions or an average rate if the average rate approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Nonmonetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined.

Non-monetary assets and liabilities that are measured based on historical cost in a foreign currency are translated at the exchange rate on the date of the original transaction. Exchange differences arising on settlement of such transactions and on translation of monetary items are recognized in the Statement of Profit and Loss.

m) Provisions, Contingent Liabilities and Contingent Assets

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows (representing the best estimate of the expenditure required to settle the present obligation at the balance sheet date) at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as finance cost. Expected future operating losses are not provided for.

A contract is considered onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognizes any impairment loss on the assets associated with that contract.

Contingent liabilities and contingent assets are not recognized in the financial statements. Contingent liabilities are disclosed in the financial statements unless the possibility of any outflow in settlement is remote. Contingent assets are disclosed in the financial statements where an inflow of economic benefit is probable.

n) Revenue Recognition

Revenue from contracts with customers is recognized when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Revenue is recognized only to the extent that it is highly probable a significant reversal will not occur.

i) Sale of Goods

Revenue from the sale of goods is recognized when delivery has taken place, control of the goods has been transferred to the customer, and there are no longer any unfulfilled obligations. The customer obtains control of the goods when the significant risks and reward of products sold are transferred according to the specific delivery terms agreed upon with the customer.

Revenue towards satisfaction of a performance obligation is measured at the transaction price (net of variable consideration) allocated to that performance obligation, received or receivable, after deduction of any discounts, price concessions, volume rebates and any taxes or duties collected on behalf of the government such as goods and services tax, etc. Accumulated experience is used to estimate the provision for such discounts, price concessions and rebates.

In determining the transaction price, the Company considers the effects of variable consideration, the existence of significant financing components, noncash consideration, and consideration payable to the customer (if any). The Company estimates variable consideration at contract inception until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

ii) Service Income

Revenue from services rendered is recognized in the statement of profit or loss as the underlying services are performed. Upfront payments received under these arrangements are recognized as revenue upon satisfaction of performance obligations.

iii) Interest and Dividend Income

Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Dividend income is recognized when right to receive is established (provided that it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably).

o) Export Incentive

Export incentives comprise of Duty draw back and RODTEP (Remission of Duties or Taxes on Export Products Scheme) scrips.

Duty drawback and RODTEP is recognised as income when the right to receive credit as per the terms of the scheme is established in respect of the exports entitled for this benefit made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds. RODTEP scrips are freely transferable and can be utilised for the payment of customs duty.

p) Employee Benefits

i) Short term employee benefits

Short term employee benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized as an expense at the undiscounted amount in the statement of profit and loss of the year in which the related service is rendered.

Accumulated compensated absences, which are expected to be availed or encashed within 12 months from the end of the year are treated as short-term employee benefits. The obligation towards the same is measured at the expected cost of accumulating compensated absences as the additional amount expected to be paid is as a result of the unused entitlement as at the year end.

ii) Post-Employment Benefits:

► *Defined contribution plans*

Employee benefits in the form of contribution to Provident Fund managed by Government Authorities, Employees State Insurance Corporation and Labour Welfare Fund are considered as defined contribution plans and the same are charged to the statement of profit and loss for the year in which the employee renders the related service.

► *Defined benefit plans*

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan.

❖ *Gratuity*

The Company's gratuity benefit scheme is a defined benefit plan. The Company's net obligation in respect of defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. Obligation under the gratuity scheme is covered under a Scheme of Life Insurance Corporation of India (LIC) and contributions in respect of such scheme are recognized in the statement of profit or loss.

The calculation of defined benefit obligation is performed annually by a qualified actuary using the projected unit credit method.

Remeasurement of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized in OCI. The Company determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in the statement of profit or loss.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognized immediately in Statement of Profit and Loss. The Company recognizes gains and losses on the settlement of a defined benefit plan when the settlement occurs.

❖ *Compensated absences:*

Accumulated compensated absences, which are expected to be availed or encashed beyond 12 months from the end of the year are treated as other long term employee benefits. The Company's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. Actuarial losses/gains are recognized in the statement of profit and loss in the year in which they arise.

q) Share based Payments

The Company operates Employee Stock Option Plans (ESOP's) for its employees and for the employees of its Subsidiaries.

ESOP's: The grant date fair value of options, using Black Scholes model granted to the Company's employees is recognized as an employee expense and those granted to the Subsidiary Company employees are recognized under "Investment made in Subsidiary" for the value of shares of Grant after reducing the Exercise price, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the options. The expense is recorded for each separately vesting portion of the award as if the award was, in substance, multiple awards. The increase in equity recognized in connection with share based payment transaction is presented as a separate component in equity under "Employee Stock Options Outstanding Reserve". The amount recognized as an expense/Investment made in Subsidiary, is adjusted to reflect the actual number of stock options that vest.

The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and Company's best estimate of the number of equity instruments that will ultimately vest. In case of forfeiture/lapse of stock option, which is not vested/not exercised, the amortized portion is reversed by credit to employee compensation expense/Investment made in Subsidiary, as appropriate.

r) Taxation

Tax expense comprises current income tax and deferred income tax and includes any adjustments related to past periods in current and/or deferred tax adjustments that may become necessary due to certain developments or reviews during the relevant period.

i) Current Tax

Current income tax is measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognized amounts and there is an intention to settle the asset and the liability on a net basis.

ii) Deferred Tax

Deferred income tax is recognized using the balance sheet approach. Deferred income tax assets and liabilities are recognized for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount.

Deferred income tax liabilities are recognized for all taxable temporary differences. Deferred income tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be released simultaneously.

s) Earnings Per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

Diluted earnings per share are computed by dividing the profit after tax as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on conversion of all dilutive potential equity shares.

t) Operating Segments

Operating segments are reported in the manner consistent with the internal reporting to the chief operating decision maker (CODM). An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company's other components, and for which discrete financial information is available. All operating segments' operating results are reviewed regularly by the Company's board of directors to make decisions about resources to be allocated to the segments and assess their performance.

The Company is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and therefore, has only one reportable segment in accordance with Ind AS 108 "Operating Segments". Hence no separate segment reporting is applicable to the company.

u) Dividends to Shareholders

The Company recognises Final dividend to the shareholders as a liability in the period in which the dividends are approved by the shareholders. Any Interim Dividend paid is recognised based on the approval by the Board of Directors.

v) Recent Accounting Pronouncements

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time.

Ind AS 21 - The Effects of Changes in Foreign Exchange Rates:

In May 2025, MCA notified amendments to Ind AS 21 - The Effects of Changes in Foreign Exchange Rates, applicable w.e.f. April 1, 2025. The amendment specifies the exchange rate to use in reporting foreign currency transactions when exchangeability between two currencies is temporarily lacking. The Group has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

In August 2025, MCA notified the following amendments to:

1) **Ind AS 1, Presentation of Financial Statements, applicable w.e.f. April 1, 2025 –** The amendment relates to classification of liabilities as current or non-current and non-current liabilities with covenants. In the context of classifying a liability as current, it removes the requirement of existence of a right to defer settlement for at least 12 months after the reporting date and instead requires that the said right should exist on the reporting date and have substance.

   The amendment also introduces guidance on classification of liabilities with covenants. The Group has no impact of these amendments in its classification criteria of current and noncurrent liabilities.

2) **Ind AS 7, Statement of Cash Flows and Ind AS 107, Financial Instruments:** Disclosures, applicable w.e.f. April 1, 2025 – The amendment in Ind AS 7 requires to inform users of financial statements of the existence of supplier finance arrangements and explain the nature of the arrangements, the carrying amount of liabilities and the range of payment due dates. Ind AS 107 has been amended to add supplier finance arrangements as a factor that may cause concentration of liquidity risk. The Group has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

3) **Ind AS 12, International Tax Reform – Piller Two Model Rules**

   The amendments provide a temporary mandatory relief from deferred tax accounting for top-up tax and disclose that they have applied the relief. This relief is immediate and applies retrospectively. The Group has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE : 2A - PROPERTY, PLANT & EQUIPMENT

Particulars	Gross block				Accumulated Depreciation				Net Block	
	As at 01-04-2025	Additions during the year	Deletions during the year	As at 31-03-2026	As at 01-04-2025	Additions during the year	Deletions during the year	As at 31-03-2026	As at 31-03-2026	As at 31-03-2025
Tangible Assets										
Land (i)	34.74	0.60	0.02	35.32	-	-	-	-	35.32	34.74
Leasehold Land (ii)	14.04	-	-	14.04	0.68	0.14	-	0.82	13.22	13.36
Factory Buildings (i)	80.80	4.78	0.02	85.56	16.01	2.76	-	18.77	66.79	64.79
Buildings - Others	9.41	-	-	9.41	1.45	0.16	-	1.61	7.80	7.96
Plant & Machinery (iii)	109.33	16.61	4.39	121.55	63.48	10.17	0.43	73.22	48.33	45.85
Air Conditioner	5.89	1.02	-	6.91	2.05	0.50	-	2.55	4.36	3.84
Furniture & Fixtures	19.00	1.14	0.06	20.08	12.34	1.63	-	13.97	6.11	6.66
Office Equipment	7.14	1.18	0.07	8.25	6.32	0.46	0.07	6.71	1.54	0.82
Computers	7.44	1.18	0.04	8.58	6.95	0.44	0.03	7.36	1.22	0.49
Electrical Fittings	13.12	0.54	0.05	13.61	9.31	1.12	0.01	10.42	3.19	3.81
Motor Vehicles	9.65	2.24	-	11.89	5.02	1.24	-	6.26	5.63	4.63
Tools & Spares	0.48	-	-	0.48	0.48	-	-	0.48	-	-
Lab Equipment (iii)	58.80	16.94	0.67	75.07	44.16	5.04	0.30	48.90	26.17	14.64
Total Tangible Assets	**369.84**	**46.23**	**5.32**	**410.75**	**168.25**	**23.66**	**0.84**	**191.07**	**219.68**	**201.59**

Note:

(i) The title deeds of immovable properties included in Property, Plant & Equipment are held in the name of the Company, except for a land and building for ₹ 17.38 Crores purchased by the Company during the financial year 2020-21 through e-auction from Punjab National Bank under the SARFAESI Act, 2002 and rules thereof, for which the transfer of title is in progress.

(ii) In respect of immovable properties taken on lease and disclosed as property, plant and equipment in the financial statements, the lease agreements are in the name of the Company.

(iii) Gross Block for 31st March 2026 includes ₹ 8.26 Crores (PY: ₹ 7.24 Crores) of government grant in the nature of waiver of duty on purchase of plant and machinery & lab equipment. Accumulated Depreciation for Plant & Machinery as at 31st March 2026 includes ₹ 5.41 Crores (PY: ₹ 4.77 Crores) on such government grant.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Gross block				Accumulated Depreciation				Net Block	
	As at 01-04-2024	Additions during the year	Deletions during the year	As at 31-03-2025	As at 01-04-2024	Additions during the year	Deletions during the year	As at 31-03-2025	As at 31-03-2025	As at 31-03-2024
Tangible Assets										
Land (i)	18.95	15.81	0.02	34.74	-	-	-	-	34.74	18.95
Leasehold Land (ii)	14.04	-	-	14.04	0.54	0.14	-	0.68	13.36	13.50
Factory Buildings (i)	77.49	3.32	0.01	80.80	13.44	2.58	0.01	16.01	64.79	64.05
Buildings - Others	5.87	3.54	-	9.41	1.32	0.13	-	1.45	7.96	4.55
Plant & Machinery (iii)	86.39	28.22	5.28	109.33	53.52	10.28	0.32	63.48	45.85	32.87
Air Conditioner	3.36	2.53	-	5.89	1.70	0.35	-	2.05	3.84	1.66
Furniture & Fixtures	18.13	0.87	-	19.00	10.78	1.56	-	12.34	6.66	7.35
Office Equipment	7.16	0.04	0.06	7.14	5.93	0.45	0.06	6.32	0.82	1.23
Computers	7.08	0.36	-	7.44	6.64	0.31	-	6.95	0.49	0.44
Electrical Fittings	12.83	0.29	-	13.12	8.15	1.16	-	9.31	3.81	4.68
Motor Vehicles	8.07	2.09	0.51	9.65	4.35	1.16	0.49	5.02	4.63	3.72
Tools & Spares	0.48	-	-	0.48	0.48	-	-	0.48	-	-
Lab Equipment (iii)	48.31	10.52	0.03	58.80	39.54	4.64	0.02	44.16	14.64	8.77
Total Tangible Assets	**308.16**	**67.59**	**5.91**	**369.84**	**146.39**	**22.76**	**0.90**	**168.25**	**201.59**	**161.77**

Note:

(i) The title deeds of immovable properties included in Property, Plant & Equipment are held in the name of the Company, except for a land and building for ₹ 17.38 Crores purchased by the Company during the financial year 2020-21 through e-auction from Punjab National Bank under the SARFAESI Act, 2002 and rules thereof, for which the transfer of title is in progress.

(ii) In respect of immovable properties taken on lease and disclosed as property, plant and equipment in the financial statements, the lease agreements are in the name of the Company.

(iii) Gross Block for 31st March 2025 includes ₹ 7.24 Crores (PY: ₹ 6.76 Crores) of government grant in the nature of waiver of duty on purchase of plant and machinery & lab equipment. Accumulated Depreciation for Plant & Machinery as at 31st March 2025 includes ₹ 4.77 Crores (PY: ₹ 4.06 Crores) on such government grant.

NOTE : 2B - CAPITAL WORK IN PROGRESS

Ageing for capital work-in-progress as at March 31, 2026

Particulars	Amount in Capital Work-in-Progress for a period of				Total
	< 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in Progress	3.95	5.44	-	-	9.39
Projects temporarily suspended	-	-	-	-	-

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Ageing for capital work-in-progress as at March 31, 2025

Particulars	Amount in Capital Work-in-Progress for a period of				Total
	< 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in Progress	20.42	0.22	-	-	20.64
Projects temporarily suspended	-	-	-	-	-

NOTE : 2C INTANGIBLE ASSETS

Particulars	Gross block				Accumulated Depreciation				Net Block	
	As at 01-04-2025	Additions during the year	Deletions during the year	As at 31-03-2026	As at 01-04-2025	Additions during the year	Deletions during the year	As at 31-03-2026	As at 31-03-2026	As at 31-03-2025
Computer Software	8.50	0.04	-	8.54	6.40	0.90	-	7.30	1.24	2.10
Total Intangible Assets	**8.50**	**0.04**	**-**	**8.54**	**6.40**	**0.90**	**-**	**7.30**	**1.24**	**2.10**

Particulars	Gross block				Accumulated Depreciation				Net Block	
	As at 01-04-2024	Additions during the year	Deletions during the year	As at 31-03-2025	As at 01-04-2024	Additions during the year	Deletions during the year	As at 31-03-2025	As at 31-03-2025	As at 31-03-2024
Computer Software	8.49	0.01	-	8.50	5.32	1.08	-	6.40	2.10	3.17
Total Intangible Assets	**8.49**	**0.01**	**-**	**8.50**	**5.32**	**1.08**	**-**	**6.40**	**2.10**	**3.17**

NOTE : 2D RIGHT OF USE (ROU) ASSETS

Particulars	Gross block				Accumulated Depreciation				Net Block	
	As at 01-04-2025	Additions during the year	Deletions during the year	As at 31-03-2026	As at 01-04-2025	Additions during the year	Deletions during the year	As at 31-03-2026	As at 31-03-2026	As at 31-03-2025
ROU Assets	3.07	1.30	1.42	2.95	1.50	0.87	1.42	0.95	2.00	1.57
Total ROU Assets	**3.07**	**1.30**	**1.42**	**2.95**	**1.50**	**0.87**	**1.42**	**0.95**	**2.00**	**1.57**

Particulars	Gross block				Accumulated Depreciation				Net Block	
	As at 01-04-2024	Additions during the year	Deletions during the year	As at 31-03-2025	As at 01-04-2024	Additions during the year	Deletions during the year	As at 31-03-2025	As at 31-03-2025	As at 31-03-2024
ROU Assets	1.80	1.65	0.38	3.07	0.95	0.93	0.38	1.50	1.57	0.85
Total ROU Assets	**1.80**	**1.65**	**0.38**	**3.07**	**0.95**	**0.93**	**0.38**	**1.50**	**1.57**	**0.85**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 3: NON CURRENT INVESTMENTS

Particulars		As at March 31, 2026	As at March 31, 2025
A.	**Fully paid Ordinary Equity shares in Subsidiaries/Share in LLP - Unquoted - at cost**		
	8,57,97,957 (8,57,97,957) Caplin Point Far East Limited, (Hong Kong) of HKD 1/- each (i)	0.08	0.08
	Argus Salud Pharma LLP 99.90% (99.90%) of capital contribution and 99.90% (99.90%) share of profit	0.99	0.99
	10,53,74,113 (10,53,74,113) equity shares of Caplin Steriles Limited of ₹ 10/- each fully paid up (ii)	141.36	141.51
	50,000 (50,000) Equity Shares in Caplin Point (S) Pte Ltd of USD 1/- each	0.38	0.38
	9,00,00,000 (7,40,00,000) Equity Shares in Caplin One Labs Limited of ₹ 10/- each fully paid up (iii)	90.44	74.24
	Total (A)	**233.25**	**217.20**

(i) The company has received 8,57,09,957 Bonus shares of Caplin Point Far East Limited (Hong Kong) of face value HKD 1/- each at nil value during the previous year ended 31st March 2025.

(ii) The ESOPs issued/reversed by the Company to the employees of Caplin Steriles Limited amounting to ₹ (0.15) Cr (PY: ₹ 2.68 Cr) is considered as part of its cost of investment.

(iii) The company has invested in 1,60,00,000 (PY : 40,00,000) equity shares of Caplin One Labs Limited at Face Value of ₹ 10 each, during the year. Further, the ESOP's issued by the Company to the employees of Caplin One Labs Limited amounted to ₹ 0.20 Cr (PY: ₹ 0.24 Cr) and the same is considered as part of its cost of investment.

Particulars		As at March 31, 2026	As at March 31, 2025
B.	**Fully paid Ordinary/Equity shares - Quoted - fair value through profit or loss account**		
	26,800 (26,800) shares of CSB Bank Limited of ₹ 10/- each fully paid up	0.91	0.81
	4,400 (4,400) shares of Karnataka Bank Limited of ₹10/- each fully paid up	0.10	0.08
	4,800 (4,800) shares of Indian Overseas Bank of ₹ 10/- each fully paid up	0.02	0.02
	700 (700) shares of Bank of India of ₹ 10/- each fully paid up	0.01	0.01
	Total (B)	**1.04**	**0.92**
C.	**Investments in Security Bonds - carried at amortised cost**		
	Investment in Corporate Bonds - Refer Note 8 (ii)	2.00	2.00
	Investment in Debentures - Refer Note 8(iii)	458.44	180.99
	Total (C)	**460.44**	**182.99**
D.	**Investment in Corporate Deposits**	10.00	90.00
	Total (D)	**10.00**	**90.00**
	Total (A+B+C+D)	**704.73**	**491.11**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 4: LOANS

Particulars	As at March 31, 2026	As at March 31, 2025
Unsecured, considered good		
Loan to Subsidiary	267.54	245.80
Total	**267.54**	**245.80**
*** Break up:**		
Loans considered good - Secured	-	-
Loans considered good - Unsecured	267.54	245.80
Loans which have significant increase in credit risk	-	-
Loans - credit impaired	-	-
Total	**267.54**	**245.80**
Less: Allowance for doubtful Loans	-	-
Total Loans	**267.54**	**245.80**

Terms of Borrowings

(i) Unsecured loan to related party consists of loan to subsidiary company amounting to ₹ 267.54 Crores (March 31, 2025: ₹ 245.80 Crores) towards capex projects.

(ii) Interest rate for the loan is currently 11.00 % p.a. (PY : 10.75% p.a.) (SBI's one year MCLR + 2% Risk premium), payable with monthly rests, from the date of first disbursement.

(iii) The principal is repayable over a period of 5 years after completion of the moratorium period.

NOTE 5: OTHER FINANCIAL ASSETS

Particulars	As at March 31, 2026	As at March 31, 2025
Electricity deposit (unsecured & considered good)	2.65	2.37
Security deposit (unsecured & considered good)	1.55	1.79
Bank deposits with more than 12 months maturity	9.01	7.16
Interest Accrued on Investments (unsecured & considered good)	4.83	7.49
Total	**18.04**	**18.81**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 6: OTHER NON CURRENT ASSETS

Particulars	As at March 31, 2026	As at March 31, 2025
Capital Advances (unsecured & considered good)	10.42	4.27
Total	**10.42**	**4.27**

NOTE 7: INVENTORIES

Particulars	As at March 31, 2026	As at March 31, 2025
Raw materials	21.42	19.19
Packing materials	10.43	5.91
Work-in-progress	6.61	4.23
Stock in trade	10.51	9.34
Finished goods	35.75	26.93
Stores and spares	0.94	0.66
Total	**85.66**	**66.26**

NOTE 8: CURRENT INVESTMENTS

Particulars	As at March 31, 2026	As at March 31, 2025
Investments in mutual funds - fair value through profit or loss (i)	89.73	96.45
Investments in debentures (iii) - carried at amortised cost	153.52	199.88
Investments in commercial paper (iv) - carried at amortised cost	9.26	-
Investment in corporate deposits - carried at amortised cost	90.00	15.00
Total	**342.51**	**311.33**

(i) Investment in Mutual Funds

Particulars	As at March 31, 2026		As at March 31, 2025	
	Units	Amount ₹ in Crores	Units	Amount ₹ in Crores
Aditya Birla Sun Life CRISIL IBX Financial Services 3 to 6 months Debt Index Fund - Direct Growth	99,77,102	10.90	99,77,102	10.21
Aditya Birla Sun Life CRISIL IBX Financial Services 3 to 6 months Debt Index Fund - Regular Growth	30,69,968	3.35	1,00,44,052	10.27
Aditya Birla Sun Life CRISIL IBX Financial Services 9 to 12 months Debt Index Fund - Regular Growth	49,99,750	5.34	49,99,750	5.02

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	As at March 31, 2026		As at March 31, 2025	
	Units	Amount ₹ in Crores	Units	Amount ₹ in Crores
Aditya Birla Sun Life Money Manager Fund - Growth- Direct Plan	85,899	3.82	1,37,469	5.05
Axis Money Market Fund - Regular Growth		-	35,978	5.05
Axis Money Market Fund - Direct Growth		-	35,642	5.05
Tata Money Market Fund Regular Plan-Growth		-	10,908	5.05
Nippon India CRISIL IBX AAA Financial Services Jan 2028 Index Fund - Growth Plan	49,99,750	5.54	49,99,750	5.17
Nippon India CRISIL IBX AAA Financial Services Jan 2028 Index Fund - Direct Growth Plan	49,99,750	5.54	49,99,750	5.18
Nippon India Money Market Fund - Direct Growth Plan Growth Option		-	10,238	4.22
UTI Money Market Fund - Direct Growth		-	17,079	5.23
Kotak Money Market Fund Direct Plan - Growth		-	11,368	5.05
ICICI Pru Liquid Fund - Reg - Growth	87,603	3.53		-
ICICI Prudential CRISIL IBX Financial Services 3-6 Months Debt Index Fund - Growth	12,44,008	1.33	50,57,817	5.08
HDFC Corporate Bond Fund Regular Growth	16,23,496	5.41	16,23,496	5.17
Kotak CRISIL IBX AAA Financial Services Index - Sep 2027 Fund Regular Plan - Growth	99,99,500	11.19	99,99,500	10.47
Kotak Corporate Bond Fund Direct Growth	13,467	5.50	13,467	5.18
Kotak Income Plus Arbitrage FOF Regular Plan	40,98,525	5.24		-
Axis Overnight Fund - Direct Growth	45,684	6.51		-
Edelweiss Liquid Fund - Reg - Growth	7,179	2.50		-
HDFC Flexi Cap Fund - Direct Plan - Growth	10,383	2.07		-
ICICI Prudential Equity & Debt - Direct Plan - Growth	35,618	1.49		-
UTI NIFTY 200 Momentum 30 Index Fund -DIR-GRW	9,29,943	1.74		-
Nippon India Index Fund-Nifty 50 Plan- Dir Grow Plan Option	2,09,563	0.86		-
Nippon India Index Fund - Nifty 50 Plan - Growth Plan	11,768	0.04		-
UTI Nifty 50 Index Fund - Direct Growth	63,650	0.99		-
Nippon India Index Fund - Nifty 50 Plan - Growth Plan - Growth Option	2,32,159	0.88		-
SBI Nifty Index Fund - Regular Plan - Growth	46,823	0.92		-
Nippon India Large Cap Fund - Direct Growth Plan	2,02,915	1.86		-
Canara Robeco Large Cap Fund - Direct - Growth	1,42,391	0.92		-
ICICI Prudential Multi-Asset Fund - Direct - Growth	26,980	2.26		-
Total		**89.73**		**96.45**

(All amounts are in ₹ Crores unless otherwise stated)

(ii) Investment in Corporate Bonds - as on March 31, 2026

Particulars	No. of Bonds	Current Investments (₹ In Crores)	Non-Current Investments (₹ In Crores)	TOTAL
State Bank of India	2	-	2.00	2.00
Total		**-**	**2.00**	**2.00**

(ii) Investment in Corporate Bonds - as on March 31, 2025

Particulars	No. of Bonds	Current Investments (₹ In Crores)	Non-Current Investments (₹ In Crores)	TOTAL
State Bank of India	2	-	2.00	2.00
Total		**-**	**2.00**	**2.00**

(iii) Investment in Debentures - as on March 31, 2026

Particulars	No. of Debentures	Current Investments (₹ In Crores)	Non-Current Investments (₹ In Crores)	TOTAL
Cholamandalam Investment and Finance Company Limited	50,000	5.00	-	5.00
HDB Financial Services Limited	2,750	-	50.16	50.16
Shriram Finance Limited	4,170	24.99	32.31	57.30
Tata Motors Finance Limited	321	39.35	-	39.35
Mahindra & Mahindra Financial services Limited	20	-	2.01	2.01
Piramal Finance Limited	4,841	10.00	38.45	48.45
Sundaram Finance Limited	300	-	38.15	38.15
L&T Finance Limited	1,000	-	10.02	10.02
Hinduja Leyland Finance Limited	2,000	-	20.14	20.14
GIC Housing Finance Limited	5,000	10.01	40.03	50.04
Godrej Industries Limited	2,500	-	25.21	25.21
Godrej Housing Finance Limited	1,500	-	15.23	15.23
Godrej Finance Limited	2,000	-	19.98	19.98
Godrej Properties Limited	2,000	20.00	-	20.00
Andhra Pradesh Mineral Development Corporation Limited	1,000	-	10.10	10.10
Aditya Birla Finance Limited	4,150	15.10	40.27	55.37
Axis Finance Limited	50	5.02	-	5.02
360 One Prime	3,500	-	35.04	35.04
TVS Credit Services Limited	280	20.05	81.34	101.39
Tata Capital Limited	400	4.00	-	4.00
Total		**153.52**	**458.44**	**611.96**

(All amounts are in ₹ Crores unless otherwise stated)

(iii) Investment in Debentures - as on March 31, 2025

Particulars	No. of Debentures	Current Investments (₹ In Crores)	Non-Current Investments (₹ In Crores)	TOTAL
Cholamandalam Investment & Finance Co. Limited	1,50,150	10.00	5.00	15.00
HDB Financial Services Limited	450	48.91	-	48.91
Shriram Finance Limited	4,500	20.04	24.92	44.96
Tata Motors Finance Limited	321	-	39.35	39.35
Mahindra & Mahindra Financial services Limited	120	8.27	2.01	10.28
Mahindra Rural Housing Finance Limited	40	4.21	-	4.21
TVS Credit Services Limited	430	19.98	50.45	70.43
L&T Finance Limited	250	25.87	-	25.87
HDFC Bank	100	9.99	-	9.99
Kotak Mahindra Investment Limited	1,130	21.36	-	21.36
Tata Cleantech Capital Limited	100	10.56	-	10.56
Hinduja Leyland Finance Limited	1,000	-	10.12	10.12
GIC Housing Finance Limited	1,000	-	10.02	10.02
Godrej Industries Limited	1,000	-	10.06	10.06
Godrej Properties Limited	2,000	-	19.99	19.99
Axis Finance Limited	50	-	5.08	5.08
Tata Capital Limited	712	20.69	3.99	24.68
Total		**199.88**	**180.99**	**380.87**

(iv) Investment in Commercial Paper - as on March 31, 2026

Particulars	No. of Bonds	Current Investments (₹ In Crores)	Non-Current Investments (₹ In Crores)	TOTAL
360 One Alternates Asset Management Limited	100	9.26	-	9.26

Particulars	Non-Current		Current	
	As at March 31, 2026	As at March 31, 2025	As at March 31, 2026	As at March 31, 2025
Aggregate amount of quoted investments - At Cost	0.33	0.33	85.93	94.38
Aggregate amount of quoted investments - At Market Value	1.04	0.92	89.73	96.45
Aggregate amount of unquoted investments	703.69	490.19	252.78	214.88
Aggregate amount of impairment in value of investments	-	-	-	-

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 9: TRADE RECEIVABLES

Particulars	As at March 31, 2026	As at March 31, 2025
(Carried at amortised cost unless otherwise stated)		
Trade Receivables - unsecured considered good	228.00	115.57
Receivables from related parties	37.96	59.76
Trade receivables which have significant increase in credit risk	-	-
Trade receivables - Credit impaired	-	-
Less: Provision for expected credit loss	-	-
Total	**265.96**	**175.33**

(i) The Company's trade receivables do not carry a significant financial element.

(ii) No trade or other receivables are due from directors or other officers of the Company either severally or jointly with any other person. There are no trade or other receivables which are due from firms or private companies respectively in which any director is a partner, a director or a member.

Trade Receivables ageing schedule

As on March 31, 2026:

Particulars	Outstanding for following periods from due date of payment						
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good	162.99	64.35	38.62	-	-	-	265.96
(ii) Undisputed Trade receivables – which have a significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed Trade receivables – Credit Impaired	-	-	-	-	-	-	-
(iv) Disputed Trade receivables – considered good	-	-	-	-	-	-	-
(v) Disputed Trade receivables –which have significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed Trade receivables – Credit Impaired	-	-	-	-	-	-	-

As on March 31, 2025:

Particulars	Outstanding for following periods from due date of payment						
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good	78.90	76.53	19.90	-	-	-	175.33
(ii) Undisputed Trade receivables – which have significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed Trade receivables – Credit Impaired	-	-	-	-	-	-	-
(iv) Disputed Trade receivables – considered good	-	-	-	-	-	-	-
(v) Disputed Trade receivables –Considered doubtful	-	-	-	-	-	-	-
(vi) Disputed Trade receivables – Credit Impaired	-	-	-	-	-	-	-

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 10: CASH AND CASH EQUIVALENTS

Particulars	As at March 31, 2026	As at March 31, 2025
Cash on Hand	0.05	0.09
Balance with Banks		
- Current accounts	37.04	48.84
- Earmarked balances for CSR*	7.00	5.71
In Bank Deposit Accounts		
- Bank Deposit accounts less than 3 months maturity	-	45.00
Total	**44.09**	**99.64**

* Unspent CSR amount had been deposited in a separate bank account before the due date.

NOTE 11: OTHER BANK BALANCES

Particulars	As at March 31, 2026	As at March 31, 2025
Unclaimed dividend accounts	2.75	2.50
In Bank Deposit Accounts		
- Bank Deposit accounts maturity more than 3 months but less than 12 months [Refer Note 37]	154.54	112.57
- Earmarked balances for CSR	4.70	-
Total	**161.99**	**115.07**

NOTE 12: OTHER FINANCIAL ASSETS

Particulars	As at March 31, 2026	As at March 31, 2025
Unsecured, Considered Good		
Loan to subsidiary*	0.30	-
Interest accrued on investments	39.12	25.92
Total	**39.42**	**25.92**

* The unsecured loan ₹ 0.30 Crores has been granted during the financial year to Argus Salud Pharma LLP at an interest rate of 11% p.a.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 13: OTHER CURRENT ASSETS

Particulars	As at March 31, 2026	As at March 31, 2025
Advances recoverable in cash or kind for the value to be received	2.50	1.48
Prepaid Expenses	1.31	1.14
Export Incentives Receivable	5.54	3.57
Balances with Statutory Authorities	26.90	25.88
Balances with Employee Benefits Fund (Net)	-	0.07
Total	**36.25**	**32.14**

NOTE 14: SHARE CAPITAL

Particulars	As at March 31, 2026	As at March 31, 2025
AUTHORISED		
8,50,00,000 (31st March, 2025: 8,50,00,000) equity shares of ₹ 2/- each	17.00	17.00
ISSUED, SUBSCRIBED AND PAID UP		
7,60,11,696 (31st March, 2025: 7,60,11,696) equity shares of ₹ 2/- each fully paid up	15.20	15.20
Total	**15.20**	**15.20**

a) Reconciliation of equity shares outstanding at the beginning and at the end of the Year

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of Equity Shares of ₹ 2/- each	Amount	No. of Equity Shares of ₹ 2/- each	Amount
Equity shares outstanding at the beginning of the year	7,60,11,696	15.20	7,59,41,746	15.19
Add: Equity shares allotted pursuant to employee stock option plan*	-	-	69,950	0.01
Less: Equity shares bought back during the year	-	-	-	-
Equity shares outstanding at the end of the year	**7,60,11,696**	**15.20**	**7,60,11,696**	**15.20**

*During the financial year, Nil (PY : 69,950) equity shares under ESOP scheme vested were exercised.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

b) Rights, preference & restrictions attached to shares

Equity Shares

The Company has only one class of equity shares having a par value of ₹ 2/- per share. Each holder of equity share is entitled to one vote per share.

The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting except in case of interim dividend.

In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

c) Shareholding of Promoter

The details of shares held by promoters are as follows:

Promoter Name	As at March 31, 2026		
	No. of shares	% of total shares	% change during the year
C.C. Paarthipan	1,41,67,192	18.64%	0.00%
Promoter Group			
P. Vijayalakshmi	1,87,78,790	24.71%	0.00%
Ashok Partheeban	90,50,000	11.91%	0.00%
Vivek Partheeban	90,09,371	11.85%	0.10%
May India Property Private Limited	21,17,000	2.79%	0.00%
First Dimension Holdings Private Limited	3,70,000	0.49%	0.00%
Kiraviz Properties And Consultancy LLP	1,50,000	0.20%	0.00%

Promoter Name	As at March 31, 2025		
	No. of shares	% of total shares	% change during the year
C.C. Paarthipan	1,41,67,192	18.64%	0.00%
Promoter Group			
P. Vijayalakshmi	1,87,78,790	24.71%	0.00%
Ashok Partheeban	90,50,000	11.91%	0.00%
Vivek Partheeban	90,00,000	11.84%	0.00%
May India Property Private Limited	21,17,000	2.79%	0.00%
First Dimension Holdings Private Limited	3,70,000	0.49%	0.00%
Kiraviz Properties And Consultancy LLP	1,50,000	0.20%	0.00%

(All amounts are in ₹ Crores unless otherwise stated)

d) Details of shares in the company held by each shareholder holding more than 5% shares:

Name of Shareholder	As at March 31, 2026 (of ₹ 2/- each)		As at March 31, 2025 (of ₹ 2/- each)	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
P. Vijayalakshmi	1,87,78,790	24.71%	1,87,78,790	24.71%
C.C. Paarthipan	1,41,67,192	18.64%	1,41,67,192	18.64%
Ashok Partheeban	90,50,000	11.91%	90,50,000	11.91%
Vivek Partheeban	90,09,371	11.85%	90,00,000	11.84%

e) Shares reserved for issuance under Employee Stock Option Plans of the Company

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of Shares of ₹ 2/- each	Amount (₹ in Crores)	No. of Shares of ₹ 2/- each	Amount (₹ in Crores)
Caplin Point Employee Stock Option Plan 2015*	24,000	0.00	30,500	0.01
Caplin Point Employee Stock Option Plan 2017	1,08,319	0.02	1,72,486	0.03
Caplin Point Employee Stock Option Plan 2021	94,650	0.02	1,46,900	0.03

*Value of the shares reserved for issuance under Caplin Point Employee Stock Option Plan 2015 is ₹ 48,000.

f) Aggregate number of shares issued pursuant to Stock Option Plans of the Company

Particulars	Aggregate No. of Shares
Issued in FY 2016-17	26,750
Issued in FY 2017-18	26,750
Issued in FY 2018-19	26,750
Issued in FY 2019-20	12,500
Issued in FY 2021-22	1,46,126
Issued in FY 2022-23	1,13,870
Issued in FY 2023-24	39,000
Issued in FY 2024-25	69,950
Issued in FY 2025-26	-
Total	**4,61,696**

g) No shares have been allotted without payment being received in cash or by way of bonus shares during the period of five years immediately preceding the balance sheet date.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 15: OTHER EQUITY

Particulars	As at March 31, 2026	As at March 31, 2025
OTHER EQUITY		
a) Capital Reserve		
Balance as at the beginning of the year	0.41	0.41
Add: Additions during the year	-	-
Balance as at the Year end	**0.41**	**0.41**
b) Securities Premium		
Balance as at the beginning of the year	19.36	15.41
Add: Additions during the year	-	3.95
Balance as at the Year end	**19.36**	**19.36**
c) General Reserve		
Balance as at the beginning of the year	11.29	11.29
Add: Additions during the year	-	-
Balance as at the Year end	**11.29**	**11.29**
d) Employee Stock Options Outstanding		
- Employee Stock options outstanding		
Balance as at the beginning of the year	35.23	25.58
Add: Options granted during the year (net)	(14.14)	13.60
Less: Exercised during the year	-	(3.95)
Balance as at the Year end (A)	**21.09**	**35.23**
- Deferred Employees Stock Options Cost		
Balance as at the beginning of the year	15.59	11.36
Add: Options granted during the year (net)	(14.14)	13.60
Less: Amortised during the year in statement of P&L	1.38	(6.46)
Less: Amortised during the year in Cost of investment in subsidiary	(0.05)	(2.91)
Balance as at the Year end (B)	**2.78**	**15.59**
Balance (A-B)	**18.31**	**19.64**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	As at March 31, 2026	As at March 31, 2025
e) Surplus in the Statement of Profit & Loss		
Balance as at the beginning of the Year	1,634.99	1,333.49
Add: Profit during the Period	396.58	339.49
Final Dividend paid for FY 24-25 / FY 23-24	(22.80)	(19.00)
Interim Dividend Paid for FY 24-25 / FY 23-24	(22.81)	(18.99)
Balance as at the Year end	**1,985.96**	**1,634.99**
f) Other Comprehensive Income		
Actuarial Gain/(Loss) on employee benefit obligation		
Balance as at the beginning of the year	0.04	0.14
Add/(Less): Additions during the year	(0.07)	(0.10)
Balance as at the Year end	**(0.03)**	**0.04**
Total	**2,035.30**	**1,685.73**

Nature of Reserve

a) Capital Reserve

The Capital Reserve has been created on restructuring of the capital of the Company under a scheme of amalgamation.

b) Securities Premium

Securities premium account has been created on issue of shares under employee stock option scheme.

c) General Reserve

The General Reserve is created by time to time transfer of profits from retained earnings for appropriation purposes. As the General Reserve is created by transfer from one component of equity to another and is not an item of other comprehensive income, items included in the General Reserve will not be reclassified subsequently to the statement of profit and loss.

NOTE 16: LEASE LIABILITIES (NON CURRENT LIABILITIES)

Particulars	As at March 31, 2026	As at March 31, 2025
Lease Liabilities	1.34	1.13
Total	**1.34**	**1.13**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 17: DEFERRED TAX LIABILITIES (NET)

Particulars	As at March 31, 2026	As at March 31, 2025
Deferred Tax Liabilities on account of temporary differences	10.67	9.25
Total	**10.67**	**9.25**

Deferred Tax Liabilities on Account of	As at March 31, 2026	As at March 31, 2025
- Property, Plant & Equipment	10.20	9.25
- Unrealised Gain on revaluation of investments	0.47	-
Total	**10.67**	**9.25**

NOTE 18: OTHER NON CURRENT LIABILITIES

Particulars	As at March 31, 2026	As at March 31, 2025
Government grant - refer note (i) below	2.85	2.47
Total	**2.85**	**2.47**

(i) Systematic recognition of Government grant, in the nature of waiver of duty on depreciable tangible assets, over the useful life of the such assets. Refer Note 2A

NOTE 19: PROVISIONS

Particulars	As at March 31, 2026	As at March 31, 2025
Provision for employee benefits - gratuity (net)	1.61	0.85
Provision for employee benefits - leave encashment (net)	0.60	-
Total	**2.21**	**0.85**

NOTE 20: TRADE PAYABLES

Particulars	As at March 31, 2026	As at March 31, 2025
Total outstanding dues of micro enterprises and small enterprises - (refer note "i" below)	4.46	1.78
Total outstanding dues of creditors other than micro enterprises and small enterprises	88.56	59.18
Total	**93.02**	**60.96**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

(i) Disclosure under the Micro, Small And Medium Enterprises Development Act, 2006 are provided as under for the year 2025-26, to the extent the Company has received Intimation from the "Suppliers" regarding their status under the Act.

Particulars	As at March 31, 2026	As at March 31, 2025
(i) Principal amount and the interest due thereon remaining unpaid to each supplier at the end of each accounting year		
Principal amount due to micro and small enterprise	4.46	1.78
Interest due on above	-	-
(ii) Interest paid by the Company in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along-with the amount of the payment made to the supplier beyond the appointed day during the period	-	-
(iii) Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the period) but without adding interest specified under the Micro, Small and Medium Enterprises Act, 2006	-	-
(iv) The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
(v) Interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises	-	-

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management. This has been relied upon by the auditors.

Trade Payables Ageing As at March 31, 2026

Particulars	Outstanding for following periods from due date of payment					Total
	Not Due	< 1 year	1 - 2 years	2 - 3 years	> 3 years	
(i) MSME	4.46	-	-	-	-	**4.46**
(ii) Others	50.78	37.75	0.01	0.02	-	**88.56**
(iii) Disputed dues-MSME	-	-	-	-	-	-
(iv) Disputed dues-Others	-	-	-	-	-	-

Trade Payables Ageing As at March 31, 2025

Particulars	Outstanding for following periods from due date of payment					Total
	Not Due	< 1 year	1 - 2 years	2 - 3 years	> 3 years	
(i) MSME	1.78	-	-	-	-	**1.78**
(ii) Others	33.27	25.79	0.12	-	-	**59.18**
(iii) Disputed dues-MSME	-	-	-	-	-	-
(iv) Disputed dues-Others	-	-	-	-	-	-

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 21: LEASE LIABILITIES (CURRENT LIABILITIES)

Particulars	As at March 31, 2026	As at March 31, 2025
Lease Liabilities	0.85	0.53
Total	**0.85**	**0.53**

NOTE 22: OTHER FINANCIAL LIABILITIES

Particulars	As at March 31, 2026	As at March 31, 2025
Creditors for Capital Goods	3.89	6.92
Unclaimed Dividend	2.75	2.50
Salary and bonus payable	1.41	1.62
Provision for CSR Expenses	11.67	5.45
Rental Deposit received	0.05	0.01
Total	**19.77**	**16.50**

NOTE 23: PROVISIONS

Particulars	As at March 31, 2026	As at March 31, 2025
Provision for employee benefits - gratuity (net)	0.40	0.14
Provision for employee benefits - leave encashment (net)	0.23	-
Provision for expenses	8.47	10.54
Total	**9.10**	**10.68**

NOTE 24: OTHER CURRENT LIABILITIES

Particulars	As at March 31, 2026	As at March 31, 2025
Statutory Dues payable	1.10	1.13
Advance received from Customers	20.33	10.05
Total	**21.43**	**11.18**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 25: REVENUE FROM OPERATIONS

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Revenue From Operations	**726.21**	**739.32**
Sale of products	725.89	736.36
Service income	0.32	2.96
Other operating revenues		
Export Incentives	12.12	13.09
Total	**738.33**	**752.41**

Contract balances	As at March 31, 2026	As at March 31, 2025
Trade receivables	265.96	175.33
Contract assets (unbilled revenue) (refer note (i) below)	-	-
Contract liabilities (advance received from customers) (refer note (i) below)	20.33	10.05

(i) Contract assets are initially recognised for revenue from sale of goods or services. Contract liabilities are on account of the upfront revenue received from customer for which performance obligation has not yet been completed.

NOTE 26: OTHER INCOME

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Interest income	49.36	49.22
Interest income from subsidiary	28.15	26.22
Dividend on non-current investment from subsidiary company (a)	62.30	35.53
Share of profit/(loss) from subsidiary LLP (b)	1.22	0.83
Realised gain on sale of financial instruments	15.05	3.48
Fair value gain/(loss) on financial instruments through profit or loss	1.85	1.11
Gain on foreign exchange (net)	34.21	16.35
Government grant (c)	0.64	0.71
Miscellaneous income	2.59	1.14
Total	**195.37**	**134.59**

(a) Dividend received from Caplin Point Far East Limited, Hong Kong, a Wholly owned subsidiary, on equity shares held by the Company.

(b) Share of profit/(loss) of the Company with respect to 99.90% share in Argus Salud Pharma LLP.

(c) Systematic recognition of Government grant, in the nature of waiver of duty on depreciable tangible assets, over the useful life of the such assets.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 27: COST OF MATERIALS CONSUMED

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Opening Stock	25.76	21.39
Add: Purchases (Net)	165.85	141.01
Less: Closing Stock	32.79	25.76
Total	**158.82**	**136.64**

NOTE 28: CHANGES IN INVENTORIES OF FINISHED GOODS INCLUDING STOCK -IN-TRADE AND WORK-IN-PROGRESS

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Inventories at the end of the year		
Work in Progress	6.61	4.23
Finished Goods	35.75	26.93
Stock-in-Trade	10.51	9.34
(A)	**52.87**	**40.50**
Inventories at the beginning of the year		
Work in Progress	4.23	3.20
Finished Goods	26.93	47.80
Stock-in-Trade	9.34	13.86
(B)	**40.50**	**64.86**
Net (Increase)/Decrease in Inventories (B - A)	**(12.37)**	**24.36**

NOTE 29: EMPLOYEE BENEFITS EXPENSE

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Salaries,wages, bonus and allowances	41.84	39.60
Contribution to provident and other funds	1.86	1.83
Gratuity expense (Refer Note 38)	1.74	0.83
Employee share based expense	(1.38)	6.46
Staff welfare expenses	3.66	3.41
Total	**47.72**	**52.13**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 30: FINANCE COSTS

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Interest Expense on Lease	0.20	0.12
Total	**0.20**	**0.12**

NOTE 31: DEPRECIATION AND AMORTISATION

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Depreciation on property, plant and equipment (Refer note: 2A)	23.66	22.76
Amortisation of intangible assets (Refer note: 2C)	0.90	1.08
Depreciation on right-of-use asset (Refer note: 2D)	0.87	0.93
Total	**25.43**	**24.77**

NOTE 32: RESEARCH AND DEVELOPMENT EXPENSES

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
R & D Expenses - (Refer note (i) & (ii) below)	37.74	39.82
Total	**37.74**	**39.82**

(i) Details on R&D- Expenditure

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Capital expenditure included in fixed assets	18.37	11.56
Revenue expenditure incurred during the financial year - refer note (ii) below.	37.74	39.82
Total	**56.11**	**51.38**

(ii) Revenue Expenditure includes:

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Cost of consumables	9.13	12.05
Employee benefits expense	20.85	21.28
- Includes contribution to provident and other funds for the year ended March 31, 2026 ₹ 0.81 Crores (March 31, 2025: ₹ 0.87 Crores)		

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
- Includes gratuity expenses for the year ended March 31, 2026 ₹ 0.49 Crores (March 31, 2025: ₹ 0.53 Crores)		
Other expenses	7.76	6.49
Total	**37.74**	**39.82**

NOTE 33: OTHER EXPENSES

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Loss on sale of asset	4.14	3.91
Power and fuel	13.64	14.11
Contract labour charges	7.25	5.41
Other manufacturing expenses	2.19	2.30
Communication expenses	0.63	0.64
Donations	0.19	0.08
Corporate social responsibility expenses (refer note 47)	7.65	6.24
Professional and consultancy charges	2.35	2.57
Rates and taxes	1.31	2.71
Product registration, filing & regulatory charges	4.42	3.45
Travelling expenses	3.29	3.14
Auditors' remuneration (Refer Note 33 (i) below)	0.27	0.30
Insurance	1.54	1.05
Repairs and maintenance		
a) Plant and Machinery	6.42	4.86
b) Building	9.33	9.67
c) Others	1.86	1.76
Rent and amenities	1.84	1.75
Freight outwards	12.42	20.07
Sundry expenses	5.39	6.30
Total	**86.13**	**90.32**

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 33 (i): AUDITORS' REMUNERATION

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
For statutory audit	0.18	0.18
For tax audit*	0.05	0.05
Other services	0.03	0.06
For reimbursement of expenses	0.01	0.01
Total	**0.27**	**0.30**

*Tax audit fee of ₹ 4,50,000 (PY ₹ 4,50,000)

NOTE 34: EARNINGS PER SHARE IS CALCULATED AS UNDER

Basic

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Net Profit attributable to equity shareholders (₹ in Crores)	396.58	339.49
Weighted average number of equity shares of ₹ 2/- each outstanding during the year (in Nos.)	7,60,11,696	7,59,96,261
Earnings per share (in ₹)	52.17	44.67

Diluted

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Net Profit attributable to equity shareholders (₹ in Crores)	396.58	339.49
Weighted average number of equity shares of ₹2/- each outstanding during the year (in Nos.)	7,62,38,665	7,63,46,147
Earnings per share (in ₹)	52.02	44.47

NOTE 35: COMMITMENT (TO THE EXTENT NOT PROVIDED FOR)

Particulars	As at March 31, 2026	As at March 31, 2025
Estimated amount of contracts remaining to be executed on capital account	13.89	32.30
Other commitments (Raw material, Packing Material, Finished Goods, Other services)	54.00	31.85
Interim dividend of ₹ 4.00 (200%) per equity share of ₹ 2 each for the financial year 2025-26 payable after 30th May' 2026, not recognized as a liability in the financial statements for the year ended 31st March' 2026 (Interim dividend of ₹ 3.00 (150%) per equity share of ₹ 2 each for the financial year 2024-25 payable after 30th May' 2025, not recognized as a liability in the financial statements for the year ended 31st March' 2025)	30.40	22.80

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 36: CONTINGENT LIABILITIES (TO THE EXTENT NOT PROVIDED FOR)

a) Disputed statutory dues: **(in ₹ Crores)**

Name of the statute	Nature of dues	As at March 31, 2026	As at March 31, 2025	Forum where dispute is pending
Income Tax Act, 1961	Income tax - AY 2018-19	0.64	0.64	CIT (Appeals)

b) Others

Particulars	As at March 31, 2026	As at March 31, 2025
Bank guarantees	3.77	-

NOTE 37: BALANCES WITH SCHEDULED BANKS IN DEPOSIT ACCOUNTS INCLUDES:

Bank deposit accounts under Note no: 11 for the current year include ₹ 0.37 Crores (as at 31.03.2025 ₹ 0.24 Crores) earmarked as lien towards margin for letter of credit and bank guarantee.

NOTE 38: EMPLOYEE BENEFITS

(i) Defined Contribution Plan:

Contributions to defined contribution scheme as employees' state insurance, labour welfare fund, etc are charged as expense based on the amount of contribution required to be made as and when services are rendered by the employees. Company's provident fund contributions is made to a government administered fund and charged as expense to the statement of profit and loss. The contributions payable to these plans are at the rates specified in the rules of the schemes.

The company recognized ₹ 2.49 crores (previous year ₹ 2.51 crores) towards provident and pension fund contributions, ₹ 0.17 crores (previous year ₹ 0.20 Crores) towards ESI in the statement of profit and loss. [refer Note-29 & 32 (i)]

(ii) Defined Benefit Plan:

a. Gratuity

The company has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The plan provides a lump sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount equivalent to 15 days salary payable for each completed year of service. Vesting occurs upon completion of five years of service. The company makes contributions to Life Insurance Corporation of India (LIC). The company accounts for the liability for gratuity benefits payable in the future based on actuarial valuation.

b. Compensated Absences

The expected cost of accumulating compensated absences is determined by actuarial valuation performed by an independent actuary at each Balance Sheet date using projected unit credit method on the additional amount expected to be paid/availed as a result of the unused entitlement that has accumulated at the balance sheet date.

(All amounts are in ₹ Crores unless otherwise stated)

The Company is exposed to various risks in providing the above gratuity benefit which are as follows:

Interest Rate risk: The plan exposes the Company to the risk of fall in interest rates. A fall in interest rates will result in an increase in the ultimate cost of providing the above benefit and will thus result in an increase in the value of the liability (as shown in financial statements).

Investment Risk: The probability or likelihood of occurrence of losses relative to the expected return on any particular investment.

Salary Escalation Risk: The present value of the defined benefit plan is calculated with the assumption of salary increase rate of plan participants in future. Deviation in the rate of increase of salary in future for plan participants from the rate of increase in salary used to determine the present value of obligation will have a bearing on the plan's liability.

Demographic Risk: The Company has used certain mortality and attrition assumptions in valuation of the liability. The Company is exposed to the risk of actual experience turning out to be worse compared to the assumption.

Longevity risk: The present value of the defined benefit obligation is calculated by reference to the best estimate of the mortality of plan participants during their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.

Particulars	Gratuity		Compensated Absences	
	As at March 31, 2026	As at March 31, 2025	As at March 31, 2026	As at March 31, 2025
a. Change in Defined Benefit Obligation during the period				
Present Value of Obligation at the beginning of the year	**8.00**	**6.21**	**2.50**	**2.08**
Current service cost	1.55	1.31	0.18	0.16
Interest cost	0.55	0.46	0.16	0.14
Past service cost	0.60	-	0.24	-
Remeasurement gains/(losses):				
- Due to finance assumption	0.17	0.24	-	-
- Due to experience assumption	(0.18)	(0.02)	-	-
- Due to demographic assumption	0.14	-	-	-
Actuarial gains/(losses)	-	-	0.92	1.04
Liabilities (transferred)/assumed*	(0.02)	0.58	(0.00)	0.28
Benefits paid	(1.33)	(0.78)	(1.40)	(1.21)
Present Value of Obligation at the end of the year	**9.48**	**8.00**	**2.60**	**2.50**
b. Change in Fair Value of Plan Assets				
Fair Value of Plan Assets at the beginning of the year	**7.01**	**5.71**	**2.57**	**2.37**
Actuarial gains/(losses)	0.04	0.09	(0.00)	0.03
Interest income	0.47	0.41	0.17	0.17
Contribution by the employer	1.30	1.00	0.10	0.40
Plan assets (transferred)/assumed*	(0.02)	0.58	(0.28)	0.28
Benefits paid	(1.33)	(0.78)	(0.79)	(0.68)
Fair Value of the plan assets at the end of the year	**7.47**	**7.01**	**1.77**	**2.57**

* Liabilities (transferred)/assumed and plan assets (transferred)/assumed represents transfer of liabilities/plan assets on account of transfer for employees between the company and its subsidiaries.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Gratuity		Compensated Absences	
	As at March 31, 2026	As at March 31, 2025	As at March 31, 2026	As at March 31, 2025
a. Amount recognised in Balance Sheet				
Projected benefit obligation at the end of the year	(9.48)	(8.00)	(2.60)	(2.50)
Fair value of plan assets at end of the year	7.47	7.01	1.77	2.57
Funded status of the plans – Liability recognised in the balance sheet	**(2.01)**	**(0.99)**	**(0.83)**	**0.07**
b. Components of defined benefit cost recognised in Statement of Profit and Loss				
Current service cost	1.55	1.31	0.18	0.16
Past service cost	0.60	-	0.24	-
Net interest expense	0.08	0.05	(0.01)	(0.03)
Remeasurements	-	-	0.92	1.01
Total Defined Benefit Cost recognised in statement of profit and loss	**2.23**	**1.36**	**1.33**	**1.14**
c. Components of defined benefit cost recognised in other comprehensive income				
Remeasurement due to;				
- Change in finance assumption	0.17	0.24	-	-
- Change in experience adjustment	(0.18)	(0.02)	-	-
- Change in demographic assumption	0.14	-	-	-
- Return on Plan Assets	(0.04)	(0.09)	-	-
Total defined benefit cost recognised in other comprehensive income	**0.09**	**0.13**	**-**	**-**

Actuarial Assumptions used for Valuation of Gratuity and Compensated Absences

Assumptions	As at March 31, 2026	As at March 31, 2025
Economic Assumptions		
Discount Rate	6.97%	6.70%
Salary Escalation Rate	For First Two years : 10% Thereafter : 7%	7.00%
Expected Rate of Return on Assets	6.97%	6.70%

(All amounts are in ₹ Crores unless otherwise stated)

Assumptions	As at March 31, 2026	As at March 31, 2025
Demographic Assumptions		
Mortality	IALM (2012-14) Ultimate	IALM (2012-14) Ultimate
Employee Turnover/Withdrawal Rate	For age upto 30 years : 20% For age above 30 years : 15%	7.00%
Leave Availment Ratio	1.00%	1.00%
Retirement Age	58 Years	58 Years

Sensitivity Analysis	As at March 31, 2026	As at March 31, 2025
Discount Rate		
- 1% increase (+100 Basis Points)	(0.43)	(0.59)
- 1% decrease (-100 Basis Points)	0.47	0.68
Salary Escalation Rate		
- 1% increase (+100 Basis Points)	0.39	0.48
- 1% decrease (-100 Basis Points)	(0.38)	(0.49)
Withdrawal Rate		
- 1% increase (+100 Basis Points)	0.00	0.03
- 1% decrease (-100 Basis Points)	0.01	0.04

Sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

There was no change in the methods of assumptions used in preparing the sensitivity analysis from prior years.

(All amounts are in ₹ Crores unless otherwise stated)

Expected Cashflows for the Next Ten years	As at March 31, 2026	As at March 31, 2025
Year-1	1.97	1.16
Year-2	1.27	0.51
Year-3	1.17	0.63
Year-4	1.12	0.56
Year-5	1.02	0.75
Beyond 5 years	3.88	3.10

(iii) Employee Stock Option Scheme

Valuation of Stock Options

The fair value of services received in return for stock options granted to employees is measured by reference to the fair value of stock options granted. The fair value of stock options granted under the Caplin Point Employee Stock Option Plan 2015, 2017 & 2021 has been measured using the Black–Scholes-Merton model at the date of the grant.

The Black-Scholes-Merton model includes assumptions regarding expected volatility, expected terms and risk free interest rates. In respect of par value options granted, the expected term of an option (or "option life") is estimated based on the vesting term and contractual term, as well as the expected exercise behavior of the employees receiving the option.

In respect of fair market value options granted, the option life is estimated based on the simplified method. Expected volatility of the option is based on historical volatility, during a period equivalent to the option life, of the observed market prices of the Company's publicly traded equity shares. Risk-free interest rates are based on the government securities yield in effect at the time of the grant. These assumptions reflect management's best estimates, but these assumptions involve inherent market uncertainties based on market conditions generally outside of the Company's control.

As a result, if other assumptions had been used in the current period, stock-based compensation expense could have been materially impacted. Further, if management uses different assumptions in future periods, stock based compensation expense could be materially impacted in future years. The estimated fair value of stock options is recognized in the standalone income statement on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in substance, multiple awards.

No Grant of Options have been made during the year ended 31st March 2026.

The Fair Value of Options granted during the year ended 31st March, 2025 and the Significant Assumptions used to arrive at those Fair values are as follows:

Grant Date	May 16, 2024	June 19, 2024	July 16, 2024	November 7, 2024
Market Stock Price at the time of Option Grant	₹ 1,363.80	₹ 1,401.80	₹ 1,533.90	₹ 2,121.70
Expected Life	3	3	3	3
Risk Free Interest Rate	6.00%	6.00%	6.00%	6.00%
Expected Volatility	36.35%	37.88%	38.11%	42.79%

Refer Note 42(c) towards value of stock options allotted to the Key Managerial Personnel

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 39: INCOME TAXES:

a. Tax expenses recognised in profit and loss:

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Current Tax Expense for the year	109.49	102.90
Deferred income tax liability/(asset), net	1.43	(0.75)
Tax expense for the year	**110.92**	**102.15**

b. Reconciliation of effective tax rate:

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Profit before Tax	507.52	441.67
Tax using the Company's domestic tax rate @ 25.168%	127.73	111.16
Tax effect of :		
Tax impact on Donation & CSR expenses disallowance	1.97	1.59
Tax on Foreign dividend income received by the company is exempt on redistribution of the same as dividend by the company	(15.68)	(8.94)
Tax incentive on additional employment	(0.37)	(0.37)
Tax impact on fair value of Mutual fund & shares	0.28	(0.28)
Tax impact - Timing difference on R&D capital asset, book and tax depreciation and others	(3.01)	(1.01)
Current and Deferred Tax expenses as per note (a) above	**110.92**	**102.15**

NOTE 40: REMUNERATION TO MANAGING DIRECTOR

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Salaries	0.53	0.53
Contribution to provident and other funds	0.04	0.04
Total*	**0.57**	**0.57**

* Refer Note 42(c)

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 41: AMOUNT DUE TO INVESTOR EDUCATION AND PROTECTION FUND

The due amount of ₹ 0.36 Crores (PY : ₹ 0.45 Crores) were transferred to investor education and protection fund and there is no outstanding due amount to be transferred to investor education and protection fund.

NOTE 42: RELATED PARTY DISCLOSURES, AS REQUIRED BY INDIAN ACCOUNTING STANDARD 24 (IND AS 24) ARE GIVEN BELOW.

(a) Related parties and Nature of relationship

Name of the Related parties	Nature of Relationship	Percentage of Shares held by Caplin Point Laboratories Limited / its Subsidiaries as at March 31, 2026	Percentage of Shares held by Caplin Point Laboratories Limited / its Subsidiaries as at March 31, 2025
Caplin Point Meenakshi CSR Trust	Trust in which Promoter/Promoter Group are Board of Trustees.	NA^	NA^
Ashok Partheeban	Vice Chairman	NA	NA
Vivek Partheeban	Vice Chairman	NA	NA
Caplin Point Far East Limited, (Hong Kong)	Wholly owned Subsidiary Company	100.00%	100.00%
Caplin Point (S) PTE Ltd (Singapore)	Wholly owned Subsidiary Company	100.00%	100.00%
Caplin One Labs Limited	Wholly owned Subsidiary Company	100.00%	100.00%
Caplin Steriles Limited, (India)	Subsidiary Company	99.999%	99.999%
Caplin Steriles USA Inc.	Step down subsidiary Company	100.00%	100.00%
Argus Salud Pharma LLP, (India)	Subsidiary LLP	99.90%	99.90%
Caplin Point Laboratories Colombia SAS, (Colombia)	Step down subsidiary Company	100.00%	100.00%
Caplin Point El Salvador, S.A. DE C.V.,(El Salvador)	Step down subsidiary Company	100.00%	100.00%
Nuevos Eticos Neo Ethicals S.A (Guatemala)	Step down subsidiary Company	69.00%	69.00%
Neoethicals CIA.LTDA (Ecuador)	Step down subsidiary Company	100.00%	100.00%
Drogueria Saimed de Honduras S.A. (Honduras)	Step down subsidiary Company	100.00%	100.00%
Neo Ethicals S.A (Nicaragua)	Step down subsidiary Company	100.00%	100.00%
Neo Ethicals Chile SPA Ltda (Chile)	Step down subsidiary Company	100.00%	NA
Triwin Pharma S.A de C.V (Mexico)	Step down subsidiary Company	100.00%	NA
Ashvich Infotek Private Limited	Directors & Director's relatives are interested	NA	NA
Sunsole Solar Private Limited	Associate of Caplin Steriles Limited	28.01%	28.01%
May India Property Private Limited	Directors & Director's relatives are interested	NA	NA
Kiraviz Properties and Consultancy LLP	Director's relatives are interested	NA	NA
First Dimension Holdings Private Limited	Director & Director’s relatives are interested	NA	NA
Ashvich Properties Private Limited	Directors & Director's relatives are interested	NA	NA

^Trust formed by the company for undertaking its CSR Activities

(All amounts are in ₹ Crores unless otherwise stated)

(b) Key Managerial Personnel

Dr. Sridhar Ganesan – Managing Director
Mr. D Muralidharan – Chief Financial Officer
Mr. G Venkatram – Company Secretary

(c) Details of Transactions that have taken place during the Financial Year with Key Management Personnel/Related Party:

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Remuneration*		
Mr. Vivek Partheeban-Chief Operating officer (till 05.11.2025) (Related Party)	0.12	0.19
Dr. Sridhar Ganesan	0.57	0.57
Mr. D Muralidharan	0.60	0.54
Mr. G Venkatram**	0.51	0.54

* Remuneration includes basic salary, house rent allowance, special allowance, leave travel assistance, medical reimbursement, contribution to provident fund and such other perquisites, payable to Key Management Personnel, as per company policy except provision for contribution to gratuity fund, leave encashment on retirement and other defined benefits which are made based on Actuarial valuation on an overall Company basis.

** Remuneration to Mr. G Venkatram includes perquisites value of stock option amounting to Nil (PY: ₹ 0.13 Cr) pertaining to allotment of Nil (PY: 1,000) equity shares under ESOP scheme during the year.

(d) Details of Transactions that have taken place during the Financial Year with Subsidiary Companies/LLP:

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Revenue from Sale of Goods or Services to Subsidiaries including Step down subsidiaries		
Nuevos Eticos Neo Ethicals, S A - Guatemala	219.06	207.78
Neo Ethicals S.A - Nicaragua	33.23	126.96
Drogueria Saimed de Honduras S.A	11.56	34.06
Neo Ethicals CIA.LTDA - Ecuador	23.42	17.35
Caplin Point Laboratories Colombia SAS	3.96	-
Caplin Point El Salvador, S.A. De.C.V.	0.75	-
Neo Ethicals Chile SPA Ltda	21.83	-
Argus Salud Pharma LLP	4.96	7.51
Caplin Steriles Limited	0.02	-
Caplin One Labs Limited	0.12	0.07

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Lease Rentals received from Subsidiaries		
Rent received from Caplin One Labs Limited	0.67	0.63
Rent received from Caplin Steriles Limited	0.05	0.05
Share of profit (Loss) in LLP		
Argus Salud Pharma LLP	1.22	0.83
Dividend Income from Subsidiaries		
Dividend income received from Caplin Point Far East Limited	62.30	35.53
Reimbursement of expenses from subsidiaries including Step down Subsidiaries		
Recovery of Corporate Office common expenses from Caplin Steriles Limited	0.37	0.54
Recovery of Software and system related expenses from Caplin Steriles Limited	0.92	0.94
SAP License charges recovered from Caplin One Labs Limited	0.12	-
Services from related party		
Rent & Consultancy charges paid to Ashvich Infotek Private Limited	2.06	1.62
Rent paid to Ashvich Properties Private Limited	0.35	0.35
Purchase/Sale of Assets from/to subsidiaries including step down subsidiaries		
Sale of MEIS Licence/RODTEP Scrip to Caplin Steriles Limited	0.66	1.11
Sale of Assets to Caplin Steriles Limited	0.21	0.04
Purchase of Assets and Materials from Caplin Steriles Limited	2.22	0.80
Sale of Assets to Caplin One Labs Limited	0.16	-
Purchase of Assets and Materials from Caplin One Labs Limited	0.73	-
Equity Investment made in Subsidiaries		
Caplin One Labs Limited	16.00	4.00
Loans given to subsidiaries		
Capex Loan -Caplin Steriles Limited	21.74	18.80

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Working Capital Loan - Caplin One Labs Limited	-	0.10
Working Capital Loan - Argus Salud Pharma LLP	0.30	-
Loans repaid by subsidiaries		
Capex Loan -Caplin Steriles Limited	-	35.00
Working Capital Loan - Caplin One Labs Limited	-	0.70
Interest Income on Loans given		
Interest Income on Capex Loan to Caplin Steriles Limited	28.15	26.22
Interest Income on working capital loan to Caplin One Labs Limited (i)	-	0.00
Interest Income on Working Capital Loan to Argus Salud Pharma LLP (ii)	0.00	-
Contribution to Trust for CSR Activities		
Amount contributed to Caplin Point Meenakshi CSR Trust	1.00	12.23

(i) Interest on working capital loan from Caplin One Labs Limited ₹ Nil/-(PY. ₹ 33,589/-)

(ii) Interest on working capital loan from Argus Salud Pharma LLP ₹ 18,082/-(PY. ₹ Nil)

(e) Sitting Fee paid to Non-Executive Directors

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Mr. C C Paarthipan	-	-
Mr. Ashok Partheeban (Vice Chairman w.e.f 05.11.2025)	-	-
Mr. Vivek Partheeban (Vice Chairman w.e.f 05.11.2025)	-	-
Mr. D Sathyanarayanan (Director till 08.11.2024)	-	0.03
Mr. Ranganathan Vijayaraghavan (Director w.e.f 30.09.2024)	0.04	0.02
Dr. C K Gariyali (Director till 03.03.2026)	0.03	0.03
Mr. S Deenadayalan	0.07	0.06
Dr. R Nagendran	0.04	0.02
Dr. K C John (Director w.e.f 05.11.2025)	0.02	-
Mrs. Susan Mathew (Director w.e.f 31.01.2026)	0.01	-

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

(f) Outstanding Balances

Particulars	As at March 31, 2026	As at March 31, 2025
Amount receivable/(Payable) from Argus Salud Pharma LLP	5.33	9.22
Amount receivable/(Payable) from Nuevos Eticos Neo Ethicals S.A - Guatemala	3.29	3.18
Amount receivable/(Payable) from Drogueria Saimed de Honduras S.A	5.16	(2.51)
Amount receivable/(Payable) from Neo Ethicals S.A Nicaragua	2.64	42.50
Amount receivable/(Payable) from Neo Ethicals CIA.LTDA-Ecuador	1.36	1.81
Amount receivable/(Payable) from Caplin Point Laboratories Colombia SAS	3.83	-
Amount receivable/(Payable) from Neo Ethicals Chile SPA Ltda - Chile	15.54	-
Amount receivable/(Payable) from Caplin Point El Salvador, S.A. DE.C.V.	0.81	-
Amount receivable/(Payable) from Caplin Steriles Limited	0.28	-
Balance outstanding w.r.t Project Loan given to Caplin Steriles Limited	267.54	245.80
Balance outstanding w.r.t Loan given to Argus Salud Pharma LLP	0.30	-
Amount receivable/(Payable) to Ashvich Infotek Private Limited	(0.12)	(0.12)
Amount receivable/(Payable) to Ashvich Properties Private Limited	(0.02)	(0.02)

NOTE 43: FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS - FAIR VALUE AND RISK MANAGEMENT

A. Accounting classification and fair values:

Carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy, are presented below. It does not include the fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

Fair value hierarchy

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Category	As at March 31, 2026		As at March 31, 2025	
		Total Carrying Amount	Total Fair Value/ Amortised Cost	Total Carrying Amount	Total Fair Value/ Amortised Cost
Financial Assets					
Non - Current Investments -Equity	FVTPL	1.04	1.04	0.92	0.92
Non - Current Investments -Subsidiaries	Cost	233.25	233.25	217.20	217.20
Investment in Corporate Bonds,Debentures, Commercial Paper and Inter Corporate Deposits	Amortised Cost	470.44	470.44	272.99	272.99
Non - Current Loans					
-Loan to Subsidiary	Amortised Cost	267.54	267.54	245.80	245.80
Other Non Current Financial Assets	Amortised Cost	18.04	18.04	18.81	18.81
Other Current Financial Assets	Amortised Cost	39.42	39.42	25.92	25.92
Current Investments- Mutual Funds	FVTPL	89.73	89.73	96.45	96.45
Current Investments- Others	Amortised Cost	252.78	252.78	214.88	214.88
Trade Receivables	Amortised Cost	265.96	265.96	175.33	175.33
Cash and Cash Equivalents	Amortised Cost	44.09	44.09	99.64	99.64
Other Bank Balances other than Cash and Cash Equivalents	Amortised Cost	161.99	161.99	115.07	115.07
Total		**1,844.28**	**1,844.28**	**1,483.01**	**1,483.01**
Financial Liabilities					
Non - Current Borrowings	Amortised Cost	-	-	-	-
Non - Current Lease Liabilities	Amortised Cost	1.34	1.34	1.13	1.13
Trade Payables	Amortised Cost	93.02	93.02	60.96	60.96
Current -Lease Liabilities	Amortised Cost	0.85	0.85	0.53	0.53
Current Borrowings	Amortised Cost	-	-	-	-
Other Current financial Liabilities	Amortised Cost	19.77	19.77	16.50	16.50
Total		**114.98**	**114.98**	**79.12**	**79.12**

(i) The Company estimates that the fair value of these investments are not materially different as compared to its cost

B. Measurement of fair values:

Valuation techniques and significant unobservable inputs:

The following tables show the valuation techniques used in measuring Level 2 and Level 3 fair values, for financial instruments measured at fair value in the statement of financial position, as well as the significant unobservable inputs used:

(All amounts are in ₹ Crores unless otherwise stated)

Type	Valuation Technique	Significant unobservable input	Inter-relationship between significant unobservable inputs and fair value measurement
Non - Current Financial Assets (other than investments in mutual fund) and Liability measured at amortised cost	Discounted cash flows: The valuation model considers the present value of expected receipt/payment discounted using appropriate discounting rate	Not applicable	Not applicable

C. Financial risk management:

The Company has exposure to the following risks arising from financial instruments:

- Credit risk;

- Liquidity risk; and

- Market risk

The Company's board of directors have overall responsibility for the establishment and oversight of the Company's risk management framework. The board of directors have established the risk management framework. The Company's risk management policies are established to set appropriate risk limits and to monitor risks and adherence to limits. Risk management policies and systems are reviewed periodically to reflect changes in market condition and the Company's activities. The Company through its training, standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The audit committee oversees how management monitors compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and adhoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

i. Credit Risk:

Credit Risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investment securities. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of the customers to which the Company grants credit terms in the normal course of business.

Trade Receivables

Summary of the Company's exposure to credit	As at March 31, 2026	As at March 31, 2025
Neither past due nor impaired	265.96	175.33
Total	**265.96**	**175.33**

Expected credit loss assessment

The Company allocates each exposure to a credit risk grade based on a variety of data that is determined to be predictive of the risk of loss (e.g timeliness of payments, available information, etc) and applying experienced credit judgement.

Exposures to the customers outstanding at the end of each reporting period are reviewed by the Company to determine incurred and expected credit losses, if any. Historical trends of impairment of trade receivables reflects no credit losses. Given that the macroeconomic indicators affecting customers of the Company have not undergone any substantial change, the Company expects the historical trend of “no credit loss” to continue.

No allowance for impairment in respect of trade and other receivables was provided during the year and immediate preceding year.

Cash and cash equivalents

As at the year end, the Company held cash and cash equivalents of ₹ 44.09 Crores (31.03.2025 ₹ 99.64 Crores). The cash and cash equivalents are held with banks with good credit rating.

Other Bank balances

As at the year end, the Company held other Bank balance of ₹ 161.99 Crores (31.03.2025 ₹ 115.07 Crores). The balances are held with banks with good credit rating.

Investment in mutual funds, Corporate Bond, Debentures, Commercial Paper and Term Deposits (Intercorporate & Banks).

As at the year end, the Company held Investment in Mutual Fund ₹ 89.73 Crores (31.03.2025 ₹96.45 Crores), Corporate Bonds of ₹ 2.00 Crores (31.03.2025 ₹ 2.00 Crores) and Debentures ₹ 611.96 crores (31.03.2025 ₹ 380.87 Crores). The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non - performance by these counter-parties.

As at the year end, the Company held Inter Corporate Deposits/Bank Deposits of ₹ 100 Crores (31.03.2025 ₹ 105 Crores) under Investments.

ii. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations with its financial liabilities that are settled by delivering cash or another financial asset. The Company’s approach to managing liquidity is to ensure that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company’s reputation.

The company was sanctioned working capital limits to the extent of ₹ 52.10 crores by various Banks. The Company invests its surplus funds in bank fixed deposit and liquid and liquid plus schemes of mutual funds which carry no/low mark to market risks. The Company monitors funding options available in the debt and capital markets with a view to maintain financial flexibility.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Exposure to liquidity risk

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted.₹ in Crores

As at March 31, 2026	Carrying amount	Contractual cash flow					
		Total	0-12 months	1-2 years	2-3 Years	3-5 Years	More than 5 Years
Non - derivative financial liabilities							
Borrowing	-	**-**	-	-	-	-	-
Interest Payable on non-current borrowing	-	**-**	-	-	-	-	-
Lease Liabilities	2.19	**2.19**	0.85	0.87	0.47	-	-
Trade payables	93.02	**93.02**	93.02	-	-	-	-
Other current Financial Liabilities	19.77	**19.77**	19.77	-	-	-	-
Total	**114.98**	**114.98**	**113.64**	**0.87**	**0.47**	**-**	**-**

As at March 31, 2025	Carrying amount	Contractual cash flow					
		Total	0-12 months	1-2 years	2-3 Years	3-5 Years	More than 5 Years
Non - derivative financial liabilities							
Borrowing	-	-	-	-	-	-	-
Interest Payable on non-current borrowing	-	-	-	-	-	-	-
Lease Liabilities	1.66	**1.66**	0.53	0.43	0.37	0.33	-
Trade payables	60.96	**60.96**	60.96	-	-	-	-
Other current Financial Liabilities	16.50	**16.50**	16.50	-	-	-	-
Total	**79.12**	**79.12**	**77.99**	**0.43**	**0.37**	**0.33**	**-**

iii. Market Risk

Market risk is the risk that changes in market prices - such as foreign exchange rates, interest rates and equity prices - will affect the Company's income or the value of its holdings of financial instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivable and payable. We are exposed to market risk primarily related to foreign exchange rate risk as the Company's product is exported to various countries and a certain portion of its export is sourced through import. Thus our exposure to market risk is a function of revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs. The Company does not use any derivative to manage market risk since certain degree of a natural hedge available in the form of foreign currency realised from exports are paid against imports.

Currency risk

The Company is exposed to currency risk on account of its export and import of pharmaceuticals and import of raw material, capital goods,etc . The functional currency of the Company is Indian Rupee, where as majority of its export and imports are settled through USD($).

Exposure to Currency risk

Following is the currency profile of non-derivative financial assets and financial liabilities

Particulars	Currency	As at March 31, 2026		As at March 31, 2025	
		USD in Crores	₹ in Crores	USD in Crores	₹ in Crores
Export Debtors	USD	2.69	254.93	1.89	162.06
Cash and cash equivalents	USD	0.20	18.96	0.22	18.97
Total			**273.89**		**181.03**
Creditors (including Capex creditors)	USD	0.05	4.48	0.03	2.42
	EURO*	-	-	0.00	0.27
Total			**4.48**		**2.69**
Net statement of financial position exposure			**269.41**		**178.34**

*As at March 31, 2025 - 29,806 Euros.

Sensitivity analysis

A reasonable strengthening (weakening) of the Indian Rupee against US dollars as at March 31 would have affected the measurement of financial instruments denominated in US dollars and affected equity and profit or loss by the amount shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

1% appreciation/depreciation of the respective foreign currencies with respect to functional currency of the Company would result in increase/ decrease in the profit before taxes by approximately ₹ 2.69 Crores for the year ended March 31, 2026 (₹ 1.78 Crores for the year ended March 31, 2025)

Interest rate risk

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest rate risk is the risk of changes in fair values of fixed interest bearing financial assets or borrowings because of fluctuations in the interest rates, if such assets/borrowings are measured at fair value through profit or loss. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing borrowings will fluctuate because of fluctuations in the interest rates.

Exposure to interest rate risk

As on 31 March 2026 and 31 March 2025, the Company has not availed any long term borrowings. Further, the Company has not availed any fund based working capital lines.

Fair value sensitivity analysis for fixed rate instruments

The Company does not account for any fixed-rate borrowings at fair value through profit or loss. Therefore, change in interest rates at the reporting date would not affect profit or loss.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Commodity rate risk

The Company's operating activity involve purchase of Active Pharmaceutical Ingredients (API) and other direct materials, whose prices are exposed to the risk of fluctuation over short period of time. The commodity price risk exposure is evaluated and managed through procurement and other related operating policies. As on March 31, 2026 and March 31, 2025, the Company had not entered into any material derivative contracts to hedge exposure to fluctuations in commodity prices.

NOTE 44: THE RATIOS FOR THE YEARS ENDED MARCH 31, 2026 AND MARCH 31, 2025 ARE AS FOLLOWS :

Ratio	Definition of ratios	Numerator	Denominator	As at March 31, 2026	As at March 31, 2025	% Variance	Reason (If variation is more than 25%)
Current Ratio (Number of times)	Ratio that indicates company's capacity to repay short-term loans or those due within one year	Current Assets	Current Liabilities	6.77	8.27	-18.15%	
Debt - Equity Ratio	Debt Equity ratio is a measure of the degree to which a company is financing its operations through debt versus wholly owned funds.	Total Debt	Shareholder's Equity	NA	NA		
Debt Service Coverage Ratio	This ratio is used to analyse the firm's ability to pay-off current interest and instalments	Earnings available for debt service	Debt Service	NA	NA		
Return on Equity Ratio	Ratio that measures company'proficiency to generate profits from its shareholders investment.	Net Profits after taxes	Average Shareholder's Equity	21.14%	21.97%	(3.76%)	
Inventory Turnover ratio (Number of times)	Inventory Turnover measures the efficiency with which a company utilises or manages its inventory. It establishes the relationship between Cost of Goods Sold and average inventory held during the period	Cost of goods sold	Average Inventory	3.01	3.12	(3.39%)	
Trade receivables turnover ratio (Number of times)	Ratio that measures how efficiently a firm manages its receivables.	Net Sales	Avg. Accounts Receivable	3.35	4.95	(32.40%)	Primarily attributable to increased sales during the latter part of the year, coupled with the normal credit period available to customers.
Trade Payables turnover ratio (Number of times)	Ratio that depicts the efficiency with which the business makes payment to the creditors.	Net Purchases	Average Trade Payables	3.23	3.13	3.06%	
Net Capital turnover ratio	Ratio that indicates a company's effectiveness in using its working capital	Net Sales	Working Capital	0.95	1.15	(17.56%)	
Net Profit ratio	The Net Profit Margin is equal to how much net profit is generated as a percentage of revenue	Net Profit	Total Income	42.47%	38.27%	10.99%	
Return on Capital employed	Return on Capital Employed indicates the ability of a company's management to generate returns for both the debt holders and the equity holders.	Earning before interest and taxes	Capital Employed	26.95%	28.46%	(5.31%)	

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Ratio	Definition of ratios	Numerator	Denominator	As at March 31, 2026	As at March 31, 2025	% Variance	Reason (If variation is more than 25%)
Return on Investment	Return on investment (ROI) is a performance measure used to evaluate the efficiency or profitability of an investment or compare the efficiency of a number of different investments	Income during the year	Time weighted average of investment				
(a)	Return on Mutual Funds			5.09%	8.20%	(37.96%)	Primarily attributable to lower market yields and reduced returns generated by debt and liquid mutual fund investments during the year.
(b)	Return on Fixed Deposit			8.20%	8.08%	1.45%	
(c)	Return on Bonds/Debentures/Commercial Paper			8.19%	8.47%	(3.27%)	

NOTE 45: CAPITAL MANAGEMENT

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on the capital as well as the level of dividends to ordinary shareholders.

As on date the Company has no borrowings.

NOTE 46: SEGMENT REPORTING

The company is engaged in manufacture of pharmaceuticals formulations which is the only business segment determined in accordance with the IndAS 108, "Operating segment". Hence there are no reportable business segments to be disclosed as required by the said standard.

NOTE 47: CSR:

Particulars	For the year Ending March 31, 2026	For the year Ending March 31, 2025
(i) Amount required to be spent by the company during the year,	7.65	6.24
(ii) Amount required to be set off for the financial year, if any	-	-
(iii) Amount of expenditure incurred,	0.43	0.53
(iv) Shortfall at the end of the year,	7.22	5.71
(v) Total of previous years shortfall, *	5.64	3.98
(vi) Reason for shortfall*,	The company has identified some long term projects where the CSR funds shall be utilised during next few years.	The company has identified some long term projects where the CSR funds shall be utilised during next few years.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	For the year Ending March 31, 2026	For the year Ending March 31, 2025
(vii) Nature of CSR activities,	Sanitation,Healthcare facilities,Educational Infrastructure,setting up care homes for orphans and women	Sanitation,Healthcare facilities,Educational Infrastructure,setting up care homes for orphans and women
(viii) Details of related party transactions, e.g., contribution to a trust controlled by the company in relation to CSR expenditure as per relevant Accounting Standard,	1.00**	12.23**
(ix) Where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year shall be shown separately.	NA	NA

*Unspent balance lying in Caplin point Meenakshi CSR Trust bank account is included in the above balance.

**During the year Company has transferred ₹ 1.00 Cr (FY'25 ₹ 12.23 Cr) to Caplin Point Meenakshi CSR Trust and out of which, the Trust has spent ₹ 4.16 Cr (FY'25 ₹ 7.96 Cr) during the year.

NOTE 48: DISCLOSURE OF ASSETS TAKEN ON LEASE

Maturity Analysis for the year ended 31st March 2026

Particulars	Less than 1 year	Between 1 to 5 Years	Over 5 Years	Total
Lease Liabilities	0.85	1.34	-	**2.19**

Maturity Analysis for the year ended 31st March 2025

Particulars	Less than 1 year	Between 1 to 5 Years	Over 5 Years	Total
Lease Liabilities	0.53	1.13	-	**1.66**

Movement In Lease Liabilities

Summary of the Company's exposure to credit	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Lease Liabilities at the beginning of the year	1.66	0.93
New leases during the year	1.30	1.66
Lease payments during the year	0.77	0.93
Lease Liabilities at the close of the year	2.19	1.66

Expenses relating to short-term leases and low-value assets for year ended March 31, 2026 is ₹ 1.84 Crores (March 31, 2025: ₹ 1.75 Crores).

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 49: ADDITIONAL REGULATORY INFORMATION REQUIRED BY SCHEDULE III TO THE COMPANIES ACT, 2013

(i) The Company did not have any transactions with companies struck off under Section 248 of the Companies Act, 2013 during the financial year.

(ii) The Company does not have any benami property held in its name. No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

(iii) The Company does not have any borrowings from banks or financial institutions against security of its current assets.

(iv) The Company has not been declared wilful defaulter by any bank or financial institution or other lender or government or any government authority.

(v) The Company has complied with the requirement with respect to number of layers as prescribed under section 2(87) of the Companies Act, 2013 read with the Companies (Restriction on number of layers) Rules, 2017.

(vi) No Scheme of Arrangements has been approved by the competent Authority in terms of sections 230 to 237 of the Companies Act 2013,during the year.

(vii) Utilisation of borrowed funds and share premium

I The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or

(b) Provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

II The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

(viii) The Company does not have any undisclosed income which is not recorded in the books of account that has been surrendered or disclosed as income during the year (previous year) in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.

(ix) The Company has not traded or invested in crypto currency or virtual currency during the year.

(x) The Company does not have any charges or satisfaction of charges which is yet to be registered with Registrar of Companies beyond the statutory period.

NOTE 50: DISCLOSURE AS PER REGULATION 34(3) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

The Company has given Project Loan to Caplin Steriles Ltd (Subsidiary Company) amounting to ₹ 267.54 Crs as at 31st March 2026 (₹ 245.80 Crs as at 31st March 2025) (The maximum amount of loan outstanding during the year is ₹ 267.54 Crs) for its Capex purposes. The terms of such transaction have been recorded in writing.

NOTES TO THE STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 51: NOTE ON NEW LABOUR CODES

Pursuant to the Notification of the New Labour Codes effective 21st November, 2025 by the Government of India whereby multiple existing labour legislations have been consolidated into a unified framework, the Company has assessed the implications of the revised definition of 'wages' for employees. The assessment has resulted in an increase of employee benefit obligations relating to gratuity and compensated absences aggregating to ₹ 0.84 Crores. The impact has been recognised in the financial statements. The company continues to monitor developments pertaining to the New Labour Codes, and the impact thereof, if any, will be accounted for in accordance with the applicable accounting standards.

NOTE 52: Previous year's figures have been regrouped/reclassified wherever necessary to correspond with the current year's classification/disclosure.

The accompanying notes are an integral part of the standalone financial statements.

As per our report of even date attached

For **Brahmayya & Co**
Chartered Accountants
Firm Registration No : 000511S

N. Sri Krishna
Partner
ICAI Membership No. 026575

Place : Chennai
Date : May 14, 2026

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Venkatram G
General Counsel & Company Secretary
M. No. A23989

Place : Chennai
Date : May 14, 2026

CAPLIN POINT®
Laboratories

CONSOLIDATED FINANCIAL STATEMENTS

INDEPENDENT AUDITOR'S REPORT

To
The Members of
Caplin Point Laboratories Limited,

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying Consolidated Financial Statements of Caplin Point Laboratories Limited (hereinafter referred to as "the Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate , which comprise the Consolidated Balance Sheet as at March 31, 2026, the Consolidated Statement of Profit and Loss (including other comprehensive income), the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows for the year then ended, and Notes to the Consolidated Financial Statements, including a Summary of the material Accounting Policies and Other Explanatory Information (hereinafter referred to as "the Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, based on the consideration of reports of other auditors on separate financial statements and on the other financial information of the subsidiaries and associate, the aforesaid Consolidated Financial Statements give the information required by the Companies Act, 2013, as amended, ("the Act") in the manner so required and give a true and fair view in conformity with accounting principles generally accepted in India including the Indian Accounting Standards prescribed under section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), of the consolidated state of affairs of the Group and its associate as at March 31, 2026, of its consolidated profit (including other comprehensive income), of its consolidated changes in equity and of its consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Consolidated Financial Statements in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group and its associate in accordance with the Code of Ethics issued by Institute of Chartered Accountants of India ("ICAI"), together with the ethical requirements that are relevant to our audit of the Consolidated Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Consolidated Financial Statements.

Key Audit Matters

Key Audit Matters are those matters that, in our professional judgement, were of the most significance in our audit of the Consolidated Financial Statements of the financial year ended March 31, 2026. These matters were addressed in the context of our audit of the Consolidated Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

We have determined following matters as Key Audit Matters to be communicated in our report:

Key Audit Matter	Auditor's Response
As per the principles of Revenue recognition set out in the Accounting standards involves certain key judgments relating to the identification of distinct performance obligations, determination of transaction price of the identified performance obligations, the appropriateness of the basis used to measure revenue recognised over a period. Additionally, the revenue accounting standard contains disclosures that involve collation of information in respect of disaggregated revenue and periods over which the remaining performance obligations will be satisfied subsequent to the balance sheet date. (Refer Note No. 1(q), 26 to the Consolidated Financial Statements)	Our audit approach includes: • Testing the design and operating effectiveness of the internal controls associated with contracts with customers. • Analysing contracts with customers from selected samples. • Analysing invoices with customers from selected samples. • Testing of the approval mechanism, access and change controls associated with the price. • Reviewing the report of Internal Auditors. • Performance of analytical procedures for reasonableness of the estimates.

Other Information

The Holding Company's Board of Directors are responsible for the preparation of the other information. The other information comprises the information included in the Holding Company's Annual Report, but does not include the Consolidated Financial Statements, Standalone Financial Statements and our auditors' report thereon.

Our opinion on the Consolidated Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Consolidated Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Consolidated Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's Responsibilities for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Consolidated Financial Statements that give a true and fair view of the consolidated financial position, consolidated financial performance, consolidated total comprehensive income, consolidated changes in equity and consolidated cash flows of the Group and its associate in accordance with the accounting principles generally accepted in India including Ind AS specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group and of its associate are responsible for maintenance of adequate accounting records in accordance with provisions of the Act for safeguarding of the assets of the Group and its associate and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Statements give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated Ind AS financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Statements, the respective Management and Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate are also responsible for overseeing the financial reporting process of the Group and of its associate.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

(a) Identify and assess the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

(b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Group and its associate has adequate internal financial controls system in place and the operating effectiveness of such controls.

(c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

(d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.

(e) Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

(f) Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group and its associate to express an opinion on the Consolidated Financial Statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of Holding Company of which we are the independent auditors. For the other entities included in the Consolidated Financial Statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatement in the Consolidated Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of the work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Statements.

We communicate with those charged with governance of the Holding Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Consolidated Financial Statements of the financial year ended March 31, 2026 and are therefore Key Audit Matters. We describe these matters in our auditor's reports unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

1. We did not audit the financial statements of five subsidiaries and eight step down subsidiaries included in the Consolidated Financial Statements, whose Financial Statements reflect assets of Rs. 3463.44 Crores as at March 31, 2026, revenues of Rs. 2038.02 Crores and net profit after tax of Rs. 302.97 Crores, and total other comprehensive income of Rs. 446.79 Crores and total net cash inflows of Rs. 44.75 Crores for the year ended on that date and one associate, whose financial statement reflect Group's share of total other comprehensive income of Rs. 0.04 Crores for the year ended on that date, as considered in the Consolidated Financial Statements. These Financial Statements have been audited by other auditors whose reports have been furnished to us by the Management and

our opinion on the Consolidated Financial Statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.

2. We did not audit the financial statements of one step down subsidiary, included in Consolidated Financial Statements, whose financial statements reflect assets of Rs. 28.33 Crores as at March 31, 2026, revenue of Rs. 0.05 Crores, net loss after tax of Rs. 3.33 Crores and total other comprehensive income of Rs. 3.33 Crores for the year ended on that date, as considered in the Consolidated Financial Statements. These Financial Statements are unaudited and have been furnished to us by the Management and our opinion on the Consolidated Financial Statements, in so far as it relates to the amounts and disclosures included in respect of these step down subsidiary, and our report in terms of sub sections (3) and (11) of section 143 of the Act in so far as it relates to the aforesaid subsidiaries and step down subsidiaries, is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Management, these financial statements are not material to the Group.

Our opinion on the Consolidated Financial Statements is not modified in respect of the above matters with respect to our reliance on the work done and the reports of other auditors and the financial statements certified by the Management.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020, ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, based on our audit and on the consideration of report of the other auditors on separate financial statements and the other financial information of the subsidiaries and associate incorporated in India, as noted in the Other Matter paragraph, we give in the "Annexure A" a statement on the matters specified in paragraph 3(xxi) and 4 of the Order, to the extent applicable.

2. As required by Section 143(3) of the Act, we report to the extent applicable that:

   (a) We / the other auditors whose report we have relied upon have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Consolidated Financial Statements.

   (b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid Consolidated Financial Statements have been kept so far as it appears from our examination of those books and the reports of the other auditors except for the matters stated in the paragraph 3(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.

   (c) the Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss (including other comprehensive income), the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the Consolidated Financial Statements.

   (d) In our opinion, the aforesaid Consolidated Financial Statements comply with the Ind AS specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended.

   (e) On the basis of the written representations received from the directors of the Holding Company as on March 31, 2026, taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiaries and associate incorporated in India, none of the Directors of the Group and its associate incorporated in India are disqualified as on March 31, 2026 from being appointed as a Director in terms of Section 164(2) of the Act.

   (f) The modifications relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 2(b) above on reporting under section 143(3)(b) of the Act and paragraph 3(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014, as amended.

   (g) With respect to the adequacy of the internal financial controls with reference to the Consolidated Financial Statements of the Group and its associate and the operating effectiveness of such controls, refer to our separate Report in "Annexure B" to this report.

(h) In our opinion and based on the consideration of reports of other statutory auditors of the subsidiaries incorporated in India, the managerial remuneration for the year ended March 31, 2026 has been paid / provided by the Holding Company, its subsidiaries incorporated in India to their directors in accordance with the provisions of section 197 read with Schedule V to the Act;

3. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the report of other statutory auditors on separate financial statements as also the other financial information of the subsidiaries and associate, as noted in the "Other matter" paragraph:

(a) The Holding Company has disclosed the impact of pending litigations on the consolidated financial position of the Group and its associate – Refer Note No. 37 to the Consolidated Financial Statements;

(b) The Group and its associate did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

(c) There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Holding Company.

(d) i) The respective managements of the Holding Company, its subsidiaries and its associate which are companies incorporated in India whose financial statements have been audited under the Act have represented to us and the other auditors of such subsidiaries and associate respectively that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company ,its subsidiaries, and its associate to or in any other person or entity, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company, its subsidiaries and its associate ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(ii) The respective managements of the Holding Company, its subsidiaries and its associate which are companies incorporated in India whose financial statements have been audited under the Act have represented to us and the other auditors of such subsidiaries and associate respectively that, to the best of its knowledge and belief, no funds have been received by the Holding Company and its subsidiaries, and its associate from any person or entity, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Holding Company, its subsidiaries and its associate shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us and that performed by the auditors of the subsidiaries, associate which are companies incorporated in India whose financial statements have been audited under the Act, nothing has come to our or other auditor's notice that has caused us or the other auditors to believe that the representations under sub-clause (i) and (ii) contain any material misstatement;

(e) The final dividend paid by the Holding Company during the year in respect of the same declared for the previous year is in accordance with section 123 of the Act to the extent it applies to payment of dividend.

The interim dividend declared and paid by Holding Company, during the year and until the date of this audit report is in accordance with section 123 of the Act.

(f) Based on our examination which included test checks performed by us on the Holding Company and as communicated by the respective auditor of two subsidiaries incorporated in India whose financial statements have been audited under the Act, except for the instances mentioned below, the Holding Company and its subsidiaries have used accounting softwares for maintaining its books of account, which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the respective softwares:

In case of the Holding Company, its two subsidiaries incorporated in India (listed in Annexure C), the feature of recording audit trail (edit log) facility was not enabled at the database level to log any direct data changes for the accounting softwares used for maintaining the books of account relating to payroll and the accounting software used for maintaining ledgers.

Further, the audit trail (edit log) facility was enabled and operated throughout the year for the respective accounting softwares and we did not come across any instance of the audit trail feature being tampered with.

In respect of subsidiaries incorporated outside India, whose management certified financial statements are included in these Consolidated Financial Statements, no comments have been included for the purpose of reporting under Rule 11(g) for such companies.

The audit trail has been preserved by the Holding company and its Subsidiary companies incorporated in India as per the statutory requirements for record retention.

For **Brahmayya & Co.**
Chartered Accountants
Firm Registration No: 000511S

N. Sri Krishna
Partner
Membership No: 026575
UDIN: 26026575PBJJZB2960

Place: Chennai
Date: May 14, 2026

Annexure A to the Independent Auditor's Report

The "**Annexure A**" referred to in Clause 1 of "**Report on Other Legal and Regulatory Requirements**" Paragraph of the Independent Auditor's Report of even date to the members of **Caplin Point Laboratories Limited** on the Consolidated Financial Statements as on and for the year ended March 31, 2026.

(xxi) In terms of the information and explanations sought by us and given by the Group and its associate and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that there are no qualifications or adverse remarks by the respective auditors in the CARO Reports of the said companies (listed in Annexure C).

For **Brahmayya & Co.**
Chartered Accountants
Firm Registration No: 000511S

N. Sri Krishna
Partner
Membership No: 026575
UDIN: 26026575PBJJZB2960

Place: Chennai
Date: May 14, 2026

Annexure B to the Independent Auditor's Report

The Annexure B, referred to in the Clause 2(g) of "**Report on other Legal and Regulatory Requirements"** Paragraph of the Independent Auditor's Report of even date to the members of **Caplin Point Laboratories Limited** on the Consolidated Financial Statements as of and the year ended March 31, 2026.

Report on the Internal Financial Controls with reference to the Consolidated Financial Statements under Clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the Consolidated Financial Statements of Caplin Point Laboratories Limited as of and for the year ended March 31, 2026, we have audited the internal financial controls with reference to the Consolidated Financial Statements of Caplin Point Laboratories Limited ("the Holding Company"), its subsidiaries (the holding company and its subsidiaries together referred as "the Group"), which are incorporated in India, as on that date (together referred to as the "Covered Entities" in this report). Refer Annexure C for the list of Covered Entities.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding Company and its subsidiaries which are incorporated in India are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the respective Companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting ("the Guidance Note") issued by the Institute of Chartered Accountants of India ("ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility for Internal Financial Controls

Our responsibility is to express an opinion on the internal financial controls with reference to the Consolidated Financial Statements of the Holding Company and its subsidiaries, incorporated in India, based on our audit. We conducted our audit in accordance with the Guidance Note issued by the ICAI and the SAs, issued by the ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both applicable to an audit of the Internal Financial Controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to the Consolidated Financial Statements and their operating effectiveness. Our audit of internal financial controls with reference to the Consolidated Financial Statements included obtaining an understanding of internal financial controls with reference to the Consolidated Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial control with reference to the Consolidated Financial Statements of the Holding Company and its subsidiaries incorporated in India.

Meaning of Internal Financial Controls with reference to the Consolidated Financial Statements

A company's internal financial control with reference to the Consolidated Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to the Consolidated Financial Statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to the Consolidated Financial Statements

Because of the inherent limitations of internal financial controls with reference to the Consolidated Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control with reference to the Consolidated Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion and to the best of our information and according to the explanation given to us, the Holding Company and its subsidiaries which are incorporated in India, have, in all material respects, an adequate internal financial controls system with reference to the Consolidated Financial Statements and such internal financial controls with reference to the Consolidated Financial Statements were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

Other Matter

Our report under Section 143 (3) (i) of the Act on the adequacy and operating effectiveness of the internal financial controls with reference to the Consolidated Financial Statements in so far as it relates to the covered entities as listed in Annexure C is based on the corresponding reports of the auditors of such companies.

For **Brahmayya & Co.**
Chartered Accountants
Firm Registration No: 000511S

N. Sri Krishna
Partner
Membership No: 026575
UDIN: 26026575PBJJZB2960

Place: Chennai
Date: May 14, 2026

Annexure C – Covered Entities

Sl. No.	Name of the Company	Relationship
1	Caplin Steriles Limited	Subsidiary
2	Caplin One Labs Limited	Subsidiary
3	Sunsole Solar Private Limited	Associate

CONSOLIDATED BALANCE SHEET

AS AT March 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Notes	As at March 31, 2026	As at March 31, 2025
ASSETS			
(1) Non-Current Assets			
(a) Property, Plant and Equipment	2A	547.49	530.32
(b) Capital work-in-progress	2B	208.62	139.22
(c) Intangible assets	2C	28.87	11.27
(d) Right of Use Assets	2D	3.65	4.19
(e) Intangible Assets under development	2E	24.96	4.28
(f) Financial Assets			
(i) Investments	3	473.31	279.13
(ii) Other Financial Assets	4	28.40	22.20
(g) Income tax assets (Net)		11.30	13.09
(h) Deferred Tax Assets (Net)	5	7.97	5.24
(i) Other Non-Current assets	6	125.25	67.97
Total-Non current assets		**1,459.82**	**1,076.91**
(2) Current Assets			
(a) Inventories	7	428.86	336.10
(b) Financial Assets			
(i) Investments	8	385.71	311.33
(ii) Trade Receivables	9	825.81	632.49
(iii) Cash and Cash equivalents	10	94.18	199.45
(iv) Bank balances other than (iii) above	11	526.86	391.96
(v) Other Financial Assets	12	74.17	57.37
(c) Other Current Assets	13	250.07	205.25
Total-Current assets		**2,585.66**	**2,133.95**
Total		**4,045.48**	**3,210.86**
EQUITY AND LIABILITIES			
(1) Equity			
Equity Share capital	14	15.20	15.20
Instruments entirely equity in nature	15	74.58	74.58
Other Equity	16	3,496.64	2,760.71
Equity attributable to shareholders of the company		**3,586.42**	**2,850.49**
Non controlling interest		44.38	35.90
Total-Equity		**3,630.80**	**2,886.39**
(2) Liabilities			
(A) Non-Current Liabilities			
(a) Financial Liabilities			
(i) Lease Liabilities	17	2.06	2.91
(b) Deferred tax liabilities	5	12.60	3.01
(c) Provisions	18	1.00	1.74
(d) Other non current liabilities	19	13.06	10.82
Total-Non current liabilities		**28.72**	**18.48**
(B) Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	20	0.57	0.55
(ii) Trade Payables			
(a) total outstanding dues of micro and small enterprises	21	9.26	2.28
(b) total outstanding dues other than (ii) (a) above	21	286.77	215.30
(iii) Lease Liabilities	22	1.98	1.56
(iv) Other financial Liabilities	23	50.76	45.26
(b) Provisions	24	20.02	23.58
(c) Other Current Liabilities	25	16.60	17.46
Total-Current liabilities		**385.96**	**305.99**
Total		**4,045.48**	**3,210.86**

The accompanying notes are an integral part of these consolidated financial statements.

As per our report of even date attached

For **Brahmayya & Co**
Chartered Accountants
Firm Registration No : 000511S

N. Sri Krishna
Partner
ICAI Membership No. 026575

Place : Chennai
Date : May 14, 2026

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Venkatram G
General Counsel & Company Secretary
M. No. A23989

Place : Chennai
Date : May 14, 2026

CONSOLIDATED STATEMENT OF PROFIT AND LOSS

FOR THE YEAR ENDED March 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Notes	For the year ended March 31, 2026	For the year ended March 31, 2025
I. INCOME			
(a) Revenue from Operations	26	2,187.19	1,937.47
(b) Other income	27	115.54	96.43
Total Income		**2,302.73**	**2,033.90**
II. EXPENSES			
(a) Cost of Materials Consumed	28	357.20	297.32
(b) Purchase of Stock-in-Trade		572.20	434.96
(c) Changes in inventories of Finished Goods,Work-in-progress and Stock-in-Trade	29	(63.72)	38.56
(d) Employee benefits expense	30	199.15	184.63
(e) Finance costs	31	0.87	0.61
(f) Depreciation and Amortisation Expenses	32	72.77	65.96
(g) Research and Development Expenses	33	79.89	76.68
(h) Other expenses	34	281.62	258.39
Total Expenses		**1,499.98**	**1,357.11**
III. Profit before share of profit in Associate, Exceptional Items and tax (I-II)		802.75	676.79
IV. Share of Profit in Associate		0.04	(0.01)
V. Exceptional Items		-	-
VI. Profit Before Tax (III+IV+V)		**802.79**	**676.78**
VII. Tax Expense (Net)			
- Current Tax		146.29	125.33
- Deferred tax (Benefits)/Charge		6.77	10.36
Total tax expense		**153.06**	**135.69**
VIII. Profit for the Year (VI-VII)		**649.73**	**541.09**
IX. Other Comprehensive Income			
Items that will not be reclassified to profit or loss:			
(i) Remeasurement of Defined Benefit Plans		0.29	0.14
(ii) Income tax relating to these items		(0.07)	(0.04)
		0.22	**0.10**
Items that will be reclassified to Profit or Loss			
(i) Exchange difference in translating the financial statements of foreign operations		141.42	26.97
		141.42	**26.97**
Other Comprehensive Income/(loss),net of tax		**141.64**	**27.07**
X. Total Comprehensive Income for the Year (VIII+IX)		**791.37**	**568.16**
XI. Profit attributable to:			
Owners of the Company		641.24	536.31
Non - Controlling Interests		8.49	4.78
		649.73	**541.09**
XII. Total Comprehensive Income for the Period attributable to:			
Owners of the Company		782.88	563.38
Non - Controlling Interests		8.49	4.78
		791.37	**568.16**
Earnings Per Equity Share (Nominal value per share ₹ 2/-)	35		
Basic EPS		**84.36**	**70.57**
Diluted EPS		**84.11**	**70.25**

The accompanying notes are an integral part of the consolidated financial statements.

As per our report of even date attached

For **Brahmayya & Co**
Chartered Accountants
Firm Registration No : 000511S

N. Sri Krishna
Partner
ICAI Membership No. 026575

Place : Chennai
Date : May 14, 2026

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Venkatram G
General Counsel & Company Secretary
M. No. A23989

Place : Chennai
Date : May 14, 2026

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED March 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars		For the Year ended March 31, 2026	For the Year ended March 31, 2025
A.	**Cash Flow from Operating Activities**		
	Profit before tax	**802.79**	**676.78**
	Adjustments for:		
	Depreciation and amortisation expense	72.77	65.96
	Finance costs	0.87	0.61
	Government grant	(2.38)	(2.10)
	(Profit)/Loss on sale/disposal of property, plant and equipment	4.18	3.76
	Employee stock option scheme expense	(1.34)	9.38
	Net unrealised foreign exchange fluctuation loss (gain)	(14.85)	(3.46)
	Fair value (gain)/loss on financial instruments through profit or loss	(2.14)	(1.11)
	Realised gain on financial assets	(16.81)	(3.90)
	Share of (profit)/loss in associate	(0.04)	0.01
	Interest income	(66.34)	(63.64)
	Operating Profit before Working Capital changes	**776.71**	**682.29**
	Adjustments for :		
	(Increase) / decrease in inventories	(92.76)	26.94
	(Increase) / decrease in trade receivables	(178.71)	(87.75)
	(Increase) / decrease in other financial assets	(3.43)	(2.34)
	(Increase) / decrease in other assets	(44.52)	(54.33)
	Increase / (decrease) in trade payables, other liabilities & provisions	69.03	(31.77)
	Impact of foreign currency translation	141.42	26.97
	CASH GENERATED FROM OPERATIONS	**667.74**	**560.01**
	Income tax paid (net)	(144.50)	(127.64)
	Net cash inflow / (outflow) from operating activities (A)	**523.24**	**432.37**
B.	**Cash Flow from Investing Activities**		
	Payment for acquisition of subsidiaries (net)	(0.05)	-
	Sale / (purchase) of investments	(266.38)	(213.76)
	Investment / (redemption) in bank deposits & debentures	(1.85)	(7.15)
	(Increase) / decrease in other bank balances	(134.90)	22.08
	Sale / (purchase) of property, plant and equipment (including CWIP)	(248.13)	(191.52)
	Interest received	51.10	51.72
	Realised gain on financial assets	16.81	3.90
	Increase / (decrease) in other financial assets	1.10	-
	Net cash inflow / (outflow) from investing activities (B)	**(582.30)**	**(334.73)**
C.	**Cash Flow from Financing Activities**		
	Proceeds from exercise of employee stock options*	-	0.01
	Increase / (decrease) in long and short term borrowings	0.02	0.27
	Interest paid (including interest on lease Liabilities)	(0.87)	(0.61)
	Dividend paid	(45.61)	(37.99)
	Net Cash inflow / (outflow) from financing activities (C)	**(46.46)**	**(38.32)**
	Net increase / (decrease) in cash and cash equivalents during the period (D=A+B+C)	**(105.52)**	**59.32**

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Cash and cash equivalents as at the beginning of the period (E)	**199.45**	**138.70**
Effect of exchange rate changes on cash and cash equivalents (F)	0.25	1.43
Cash and cash equivalents as at the end of the period (G=D+E+F)	**94.18**	**199.45**
Less: Bank balance Earmarked CSR account (H)	7.54	5.71
Net cash and cash equivalents as at the end of the period (I=G-H)	**86.64**	**193.74**

Notes:

* Proceeds from exercise of employee stock options amounting to Nil (PY: ₹ 1,39,900) for Nil (PY: 69,950) equity shares exercised during the year ended 31st March 2026 and 31st March 2025 respectively.

The above consolidated statement of cash flows has been prepared under the "Indirect method" as set out in Ind AS 7, 'Statement of Cash Flows'.

a) Reconciliation of cash and cash equivalents

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Cash and cash equivalents as per balance sheet	94.18	199.45
Total cash and cash equivalents as per balance sheet	**94.18**	**199.45**
Less: Bank balance Earmarked CSR account	7.54	5.71
Total cash and cash equivalents as per the statement of cash flows	**86.64**	**193.74**

b) Cash and Cash Equivalents do not include following:

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	For the Year ended March 31, 2026	For the Year ended March 31, 2025
Investment in mutual funds	132.93	96.45
Investment in corporate bonds & debentures - non current investments	460.44	187.83
Bank deposits with more than 1 year maturity (other financial assets - non-current)	9.01	7.16
Investment in corporate bonds, debentures & commercial papers - current investments	162.78	199.88
Inter corporate deposits- other financial assets (current & non current investments)	100.00	105.00
Bank deposits with maturity more than 3 months but less than 1 year	519.41	389.46
Total	**1,384.57**	**985.78**

The accompanying notes are an integral part of these consolidated financial statements.

As per our report of even date attached

For **Brahmayya & Co**
Chartered Accountants
Firm Registration No : 000511S

N. Sri Krishna
Partner
ICAI Membership No. 026575

Place : Chennai
Date : May 14, 2026

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Venkatram G
General Counsel & Company Secretary
M. No. A23989

Place : Chennai
Date : May 14, 2026

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED MARCH 31, 2026

A. EQUITY SHARE CAPITAL (Refer Note 14)

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of Equity Shares of ₹ 2/- each	AMOUNT	No. of Equity Shares of ₹ 2/- each	AMOUNT
Balance at the beginning of the reporting period	7,60,11,696	15.20	7,59,41,746	15.19
Changes in equity share capital due to prior period errors	-	-	-	-
Issue of equity shares during the year	-	-	69,950	0.01
Balance at the end of the reporting period	**7,60,11,696**	**15.20**	**7,60,11,696**	**15.20**

B. INSTRUMENTS ENTIRELY EQUITY IN NATURE (Refer Note 15)

Compulsorily Convertible Preference Shares (CCPS)

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	As at March 31, 2026		As at March 31, 2025	
	No of CCPS	Amount	No of CCPS	Amount
Balance as at the beginning of the year	7,45,82,875	74.58	7,45,82,875	74.58
Changes during the year	-	-	-	-
Balance as at the end of the year	**7,45,82,875**	**74.58**	**7,45,82,875**	**74.58**

C. OTHER EQUITY & NON CONTROLLING INTEREST (REFER NOTE 16)

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Reserves and Surplus									Non-controlling interest
	Capital Reserve	Securities Premium on equity shares	Securities Premium on Preference shares	General Reserve	Employee Stock Option Outstanding (Net)	Foreign Exchange Translation Reserve	Other Comprehensive Income	Retained Earnings	Total Other Equity	
Balance as at 31 March 2024	**3.21**	**15.41**	**141.99**	**11.29**	**14.22**	**77.03**	**0.08**	**1,962.71**	**2,225.94**	**31.12**
Changes due to prior period errors	-	-	-	-	-	-	-	-	-	-
Total Comprehensive Income for the year	-	-	-	-	-	26.97	0.10	541.09	568.16	4.78
Additions/ (deductions) during the year :										
Final Dividend on equity shares for FY 23-24	-	-	-	-	-	-	-	(19.00)	(19.00)	-
Interim Dividend on equity shares for FY 23-24	-	-	-	-	-	-	-	(18.99)	(18.99)	-
Issue of Bonus shares by a subsidiary	92.07	-	-	-	-	-	-	(92.07)	-	-

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Reserves and Surplus									Non-controlling interest
	Capital Reserve	Securities Premium on equity shares	Securities Premium on Preference shares	General Reserve	Employee Stock Option Outstanding (Net)	Foreign Exchange Translation Reserve	Other Comprehensive Income	Retained Earnings	Total Other Equity	
Exercise of Employee stock option	-	3.95	-	-	(3.95)	-	-	-	-	-
Share- based payment expenses (Net)	-	-	-	-	9.38	-	-	-	9.38	-
Add/ (Transfer) to non-controlling interest	-	-	-	-	-	-	-	(4.78)	(4.78)	-
Balance as at 31 March 2025	**95.28**	**19.36**	**141.99**	**11.29**	**19.65**	**104.00**	**0.18**	**2,368.96**	**2,760.71**	**35.90**
Changes due to prior period errors	-	-	-	-	-	-	-	-	-	
Total Comprehensive Income for the year	-	-	-	-	-	141.42	0.22	649.73	791.37	8.49
Additions/ (deductions) during the year :										
Final Dividend on equity shares for FY 24-25	-	-	-	-	-	-	-	(22.80)	(22.80)	-
Interim Dividend on equity shares for FY 24-25	-	-	-	-	-	-	-	(22.81)	(22.81)	-
Exercise of Employee stock option	-	-	-	-	-	-	-	-	-	-
Share- based payment expenses (Net)	-	-	-	-	(1.35)	-	-	-	(1.35)	-
Add/ (Transfer) to non-controlling interest	-	-	-	-	-	-	-	(8.49)	(8.49)	-
Balance as at 31 March 2026	**95.28**	**19.36**	**141.99**	**11.29**	**18.30**	**245.42**	**0.40**	**2,964.59**	**3,496.64**	**44.38**

As per our report of even date attached

For **Brahmayya & Co**
Chartered Accountants
Firm Registration No : 000511S

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

N. Sri Krishna
Partner
ICAI Membership No. 026575

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

Muralidharan D
Chief Financial Officer

Venkatram G
General Counsel & Company Secretary
M. No. A23989

Place : Chennai
Date : May 14, 2026

Place : Chennai
Date : May 14, 2026

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 1. MATERIAL ACCOUNTING POLICIES AND KEY ACCOUNTING ESTIMATES AND JUDGEMENTS

a) Basis of accounting and preparation of Consolidated Financial Statements:

i) Statement of Compliance

These Financial Statements are the Consolidated Financial Statements of the Group prepared in accordance with Indian Accounting Standards ('Ind AS') notified under section 133 of the Companies Act 2013, read together with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).

These Consolidated Financial Statements have been prepared and presented under the historical cost convention, on the accrual basis of accounting except for certain financial assets and financial liabilities that are measured at fair values at the end of each reporting period, as stated in the accounting policies set out below. The accounting policies have been applied consistently over all the periods presented in these Consolidated Financial Statements.

ii) Basis of Preparation

The consolidated financial statements have been prepared on accrual and going concern basis. Accounting Policies have been consistently applied except where a newly issued Accounting Standard is initially adopted or a revision to an existing Accounting Standard requires a change in the accounting policy hitherto in use.

All assets and liabilities have been classified as current or non-current as per Group's normal operating cycle as per paragraph 66 and 69 of Ind AS 1 and other criteria as set out in the Division II of Schedule III to the Companies Act, 2013.

Based on the nature of products and the time between acquisition of assets for processing and their realization in cash and cash equivalents the Group has ascertained its normal operating cycle as twelve months for the purpose of current/non-current classification of assets and liabilities.

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a noncash nature, any deferrals or accruals of past or future operating cash receipts or payments and items of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Group are segregated. Cash and cash equivalents for the purpose of the statement of cash flows comprise cash and cash deposits with banks and financial institutions. The Group considers all highly liquid investments with a remaining maturity at the date of purchase of three months or less and that are readily convertible to known amounts of cash to be cash equivalent.

These financial statements are prepared under the historical cost convention except in case of certain class of financial assets/liabilities, share based payments and net liability for defined benefit plan that are measured at fair value.

The Group has decided to round off the figures to the nearest Crores.

These financial statements were authorized for issue by the Company's Board of Directors on May 14, 2026.

iii) Functional and Presentation Currency

These financial statements are presented in Indian rupees, which is the functional currency of the Group. All financial information presented in Indian rupees (₹) has been rounded off to the nearest crores, except otherwise indicated.

iv) Use of Estimates and Judgements

The preparation of the Consolidated Financial Statements in conformity with Ind AS requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the Financial Statements are prudent and reasonable.

Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known/ materialize. Estimates and underlying assumptions are reviewed on an ongoing basis.

Information about critical judgments in applying accounting policies, as well as estimates and assumptions that have the most significant effect to the carrying amounts of assets and liabilities within the next financial year, are included in the accounting policies, given as under:

- Measurement of defined benefit obligations
- Measurement and likelihood of occurrence of provisions and contingencies
- Recognition of deferred tax assets
- Useful lives of property, plant, equipment and Intangibles
- Impairment of Assets
- Impairment of financial assets

b) Principles of Consolidation:

Subsidiaries

Subsidiaries are all entities that are controlled by the Company. Control exists when the Company is exposed to, or has rights, to variable returns from its involvement with the entity, and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases. The financial statements of the Company and its subsidiaries and its jointly controlled entity have been consolidated using uniform accounting policies for like transactions and other events in similar circumstances as mentioned in those policies.

Upon loss of control, the Group derecognizes the assets and liabilities of the subsidiary, any non-controlling interests and the other components of equity related to the subsidiary.

Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in full while preparing these consolidated financial statements. Unrealized gains or losses arising from transactions with equity accounted investees are eliminated against the investment to the extent of the Company's interest in the investee.

Non-controlling interests ("NCI")

NCI are measured at their proportionate share of the acquiree's net identifiable assets at the date of acquisition. Changes in the Group's equity interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

c) Business Combinations:

Business combinations are accounted for using the acquisition method. At the acquisition date, identifiable assets acquired and liabilities assumed are measured at fair value. For this purpose, the liabilities assumed include contingent liabilities representing present obligation and they are measured at their acquisition date fair values irrespective of the fact that outflow of resources embodying economic benefits is not probable. The consideration transferred is measured at fair value at acquisition date and includes the fair value of any contingent consideration. However, deferred tax asset or liability and any liability or asset relating to employee benefit arrangements arising from a business combination are measured and recognized in accordance with the requirements of Ind AS 12, Income Taxes and Ind AS 19, Employee Benefits, respectively.

Where the consideration transferred exceeds the fair value of the net identifiable assets acquired and liabilities assumed, the excess is recorded as goodwill. Alternatively, in case of a bargain purchase wherein the consideration transferred is lower than the fair value of the net identifiable assets acquired and liabilities assumed, the difference is recorded as a gain in other comprehensive income and accumulated in equity as capital reserve. The costs of acquisition excluding those relating to issue of equity or debt securities are charged to the Statement of Profit and Loss in the period in which they are incurred.

d) Goodwill:

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is initially measured at cost, being the excess of the consideration transferred over the net identifiable assets acquired and liabilities assumed, measured in accordance with Ind AS 103, Business Combinations. Goodwill is considered to have an indefinite useful life and hence is not subject to amortization but tested for impairment at least annually. After initial recognition, goodwill is measured at cost less any accumulated impairment losses.

e) Property, Plant and Equipment:

i) Recognition and Measurement

Property, plant and equipment are stated at their cost of acquisition / installation / construction net of accumulated depreciation, and impairment losses, if any, except freehold land which is carried at cost less impairment losses. Subsequent expenditure are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. When significant parts of property, plant and equipment are required to be replaced at intervals, the Group depreciates them separately based on their specific useful lives. Likewise, when a major improvement is performed, its cost is recognized in the carrying amount of the property, plant and equipment as a replacement if the recognition criteria are satisfied. All other repairs and maintenance are charged to the statement of profit and loss during the reporting period in which they are incurred. The present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset, if the recognition criteria for provisions are met.

Spares which meet the definition of property, plant and equipment are capitalized as on the date of acquisition. The corresponding old spares are decapitalized on such date with consequent impact in the statement of profit and loss.

Property, plant and equipment not ready for their intended use as on the balance sheet date are disclosed as "Capital work-in-progress". Such items are classified to the appropriate category of property, plant and equipment when completed and ready for their intended use. Advances given towards acquisition / construction of property, plant and equipment outstanding at each balance sheet date are disclosed as Capital Advances under "Other non-current assets".

An item of property, plant and equipment and any significant part thereof is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss in "other income / (expenses)" when the asset is derecognized.

ii) Depreciation

Depreciation is provided as per the useful life of assets which are determined based on technical parameters / assessment. Depreciation on tangible assets is provided on a straight line method over the estimated useful lives of the assets.

Estimated useful lives of the assets, are as follows:

Asset Category	Estimated useful life (Years)
Factory Building	30
Building other than factory building	20-60
Plant & Machinery	5-15
Furniture & Fixtures	5-10
Office Equipment	5
Computers	2-6
Electrical Fittings and installation	10
Motor Vehicles	5-10

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed during each financial year and adjusted prospectively, if appropriate.

Depreciation on additions is provided on a pro-rata basis for the number of days they are available for use. Depreciation on sale / disposal of assets is provided pro-rata basis up to the date of sale / disposal.

An asset purchased where the actual cost individually does not exceed ₹ 10,000 is depreciated at the rate of 100%.

f) Intangible Assets:

i) Recognition and Measurement

Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any. Expenditure on research and development eligible for capitalization are carried as Intangible assets under development where such assets are not yet ready for their intended use.

An intangible asset is derecognized on disposal, or when no future economic benefits are expected from its use or disposal. Gains or losses arising from derecognition of an intangible asset, if any, are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

ii) Subsequent Expenditure

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Group.

iii) Amortization

Intangible assets are amortized over their estimated useful life on Straight Line Method as follows:

Asset Category	Estimated useful life
Computer Software & licenses	6 Years or useful life whichever is lower

The estimated useful lives of intangible assets and the amortization period are reviewed at the end of each financial year and the amortization method is revised to reflect the changed pattern, if any.

g) Leases

The Group assesses whether a contract is or contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

i) Group as Lessee

At the date of commencement of the lease, the Group recognizes a right-of-use asset and a corresponding lease liability for all lease arrangements in which it is a lessee, except for short-term leases and leases of low-value assets.

The right-of-use assets are initially recognized at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses, if any. Right-of-use assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset. The Right-of-use assets is also subject to impairment. Right-of-use assets are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable.

The lease liability is initially measured at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates. The Group uses the incremental borrowing rate as the discount rate.

The Group applies the short-term lease recognition exemption to its short-term leases (i.e., those leases that have a lease term of 12 months or less from the commencement date). It also applies the lease of low value assets recognition exemption to leases that are considered of low value (range different for different class of assets). Lease payments on short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term.

ii) Group as Lessor

Leases for which the Group is a lessor are classified as either finance or operating leases. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the Lease is classified as a finance lease. All other leases are classified as operating leases.

In respect of assets provided on finance leases, amounts due from lessees are recorded as receivables at the amount of the Group's net investment in the leases. Finance lease income is allocated to accounting periods to reflect a constant periodic rate of return on the Group's net investment outstanding in respect of the leases. In respect of assets given on operating lease, lease rentals are accounted in the Statement of Profit and Loss, on accrual basis in accordance with the respective lease agreements.

h) Impairment of Assets:

Intangible assets and property, plant and equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the Cash Generating unit (CGU) to which the asset belongs.

If such assets are considered to be impaired, the impairment to be recognized in the Statement of Profit and Loss is measured by the amount by which the carrying value of the assets exceeds the estimated recoverable amount of the asset. An impairment loss is reversed in the Statement of Profit and Loss if there has been a change in the estimates used to determine the recoverable amount. The carrying amount of the asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

i) Research and Development:

Revenue expenditure pertaining to research is charged to the Statement of Profit and Loss. Development costs of products are also charged to the Statement of Profit and Loss in the year in the year in which they are incurred. Fixed assets utilized for research and development are capitalized and depreciated in accordance with the policies stated for Tangible Fixed Assets and Intangible Assets.

Expenditure on in-licensed development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalized, if the cost can be reliably measured, the product or process is technically and commercially feasible and the Group has sufficient resources to complete the development and to use and sell the asset.

j) Inventories

Inventories are valued at lower of cost or net realizable value. Cost is determined as follows:

i) Raw materials, Stores and Spares and Packing materials

Cost includes purchase price, other costs incurred in bringing the inventories to their present location and condition, and taxes for which credit is not available. Cost is determined on Weighted Average basis.

ii) Work-in-progress and Finished goods

Cost includes direct materials and labour and a proportion of manufacturing overheads based on normal operating capacity, but excluding borrowing costs.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

k) Government Grants and Assistance

Grants from the Government are recognized when the Group will comply with all the conditions attached to them and there is a reasonable assurance that the grant will be received and all attaching conditions will be complied with.

Government grants relating to an asset are initially recognized as deferred income and subsequently recognized in the Statement of Profit and Loss as other income on a systematic basis over the useful life of the asset.

l) Borrowing Costs

Borrowing cost directly attributable to acquisition and construction of assets that necessarily take substantial period of time to get ready for their intended use or sale are capitalized as part of the cost of such assets up to the date when such assets are ready for intended use or sale. All other borrowing costs are expensed in the period in which they occur. Borrowing cost consists of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

m) Fair Value Measurement

The Group measures some of its financial instruments at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

i. Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities.

ii. Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.

iii. Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

n) Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets and financial liabilities are initially measured at fair value.

Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through the statement of profit and loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition.

Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through the statement of profit and loss are recognized immediately in the statement of profit and loss.

I. Financial Assets

The Group's Financial Assets mainly comprise of;

Current financial assets- mainly consisting of trade receivables, investments in liquid mutual funds, cash and bank balances, fixed deposits with banks and financial institutions and other current receivables.

Non-current financial assets mainly consist of financial investments in equity, fixed deposits and non-current deposits.

Initial Recognition and measurement of Financial Assets

The Group recognizes a financial asset when it becomes party to the contractual provisions of the instrument. All financial assets are recognized initially at fair value, plus in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. However, trade receivables that do not contain a significant financing component are measured at transaction price. All regular purchases or sales of financial assets are recognized and derecognized on a trade date basis, i.e. the date on which Group commits to purchase or sell the asset.

Subsequent Measurement of Financial Assets

For purposes of subsequent measurement, financial assets are classified in the following categories:

i) Financial Assets at Amortized Cost;

A Financial asset is measured at the amortised cost if both the following conditions are met:

The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and

Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

Financial assets at amortized cost category is the most relevant to the Group. It comprises of current financial assets such as trade receivables, cash and bank balances, fixed deposits with bank and financial institutions, other current receivables and non-current financial assets such as non-current receivables and deposits.

After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate (EIR) method. The EIR amortization is included in other income in the statement of profit and loss. The losses arising from impairment, if any are recognized in the statement of profit and loss.

ii) Financial Assets at Fair Value through Profit and Loss

All equity investments in scope of Ind AS 109 “Financial Instruments” are measured at FVTPL with all changes in fair value recognized in the statement of profit and loss. The Group has designated its investments in equity instruments as FVTPL category.

iii) Financial Assets at Fair Value through Other Comprehensive Income

The Group may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Group has not designated investments in any equity instruments as FVTOCI.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a Group of similar financial assets) is primarily derecognized (i.e. removed from the Group’s balance sheet) when:

i) The rights to receive cash flows from the asset have expired, or

ii) The Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a ‘pass-through’ arrangement; and either:

the Group has transferred substantially all the risks and rewards of the asset, or

the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

Impairment of financial assets

In accordance with Ind AS 109, the Group applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss on the following financial assets:

i) Trade Receivables

ii) Other financial assets that are measured at amortized cost.

In case of trade receivables, the Group follows a simplified approach wherein an amount equal to lifetime ECL is measured and recognized as a loss allowance.

In case of other assets (as listed in ii above), the Group determines if there has been a significant increase in credit risk of the financial asset since initial recognition. If the credit risk of such assets has not increased significantly, an amount equal to 12-month ECL is measured and recognized as loss allowance. However, if credit risk has increased significantly, an amount equal to lifetime ECL is measured and recognized as a loss allowance

II. Financial Liabilities and Equity Instruments

i) Financial Liabilities

The Group's Financial Liabilities mainly comprise of;

Current financial liabilities- mainly consisting of trade payables and liability for capital expenditure.

Non-current financial liabilities mainly consist of Borrowings.

Initial Recognition and measurement of Financial Liabilities

The Group recognizes a financial liability in its balance sheet when it becomes party to the contractual provisions of the instrument. All financial liabilities are initially recognized at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

Financial liabilities are initially recognized and measured at amortized cost

Subsequent Measurement of Financial Liabilities at Amortized Cost

The carrying amounts of financial liabilities that are subsequently measured at amortized cost are determined using the effective interest rate method. Interest expense that is not capitalized as part of cost of an asset is included in the 'Finance costs' line item. The effective interest rate method is a method of calculating the amortized cost of a financial liability and to allocate interest expense over the relevant period.

Derecognition of Financial Liability

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of profit and loss.

ii) Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all its liabilities. Equity instruments issued by the Group are recognised at the proceeds received, net of direct issue costs.

Debt and equity instruments issued by the Group are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

III. Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously.

o) Foreign Currency Transactions

Transactions in foreign currencies are translated into the functional currency of the Group at the exchange rates at the dates of the transactions or an average rate if the average rate approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined.

Non-monetary assets and liabilities that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Exchange differences are recognized in the statement of profit and loss.

p) Provisions, Contingent Liabilities and Contingent Assets

A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows (representing the best estimate of the expenditure required to settle the present obligation at the balance sheet date) at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as finance cost. Expected future operating losses are not provided for.

A contract is considered onerous when the expected economic benefits to be derived by the Group from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Group recognizes any impairment loss on the assets associated with that contract.

Contingent liabilities and contingent assets are not recognized in the financial statements. Contingent liabilities are disclosed in the financial statements unless the possibility of any outflow in settlement is remote. Contingent assets are disclosed in the financial statements where an inflow of economic benefits is probable.

q) Revenue Recognition

Revenue from contracts with customers is recognized when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services. Revenue is only recognized to the extent that it is highly probable a significant reversal will not occur.

i) Sale of Goods

Revenue from the sale of goods is recognized when delivery has taken place , control of the goods has been transferred to the customer, and there are no longer any unfulfilled obligations. The customer obtains control of the goods when the significant risks and reward of products sold are transferred according to the specific delivery term that have been agreed upon with the customer.

Revenue towards satisfaction of a performance obligation is measured at the transaction price (net of variable consideration) allocated to that performance obligation, received or receivable, after deduction of any discounts, price concessions, volume rebates and any taxes or duties collected on behalf of the government such as goods and services tax, Value added tax etc., Accumulated experience is used to estimate the provision for such discounts, price concessions and rebates.

In determining the transaction price, the Group considers the effects of variable consideration, the existence of significant financing components, noncash consideration, and consideration payable to the customer (if any). The Group estimates variable consideration at contract inception until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

ii) Profit Sharing Revenues

The company has entered into arrangements with its business partners for sale of products in certain markets whereby the company is eligible for a share of profit over and above the base selling price. The share of profits is dependent on the ultimate sales made by the business partner and subject to any reductions or adjustments required by the terms of the arrangement. Such arrangements typically require the business partner to provide confirmation of units sold and net sales or net profit computations for the products covered under the arrangement. The profit share component is recognized as revenue only to the extent that it is highly probable that a significant reversal will not occur.

iii) Service Income

Revenue from services rendered is recognized in the profit or loss as the underlying services are performed. Upfront payments received under these arrangements are recognized as revenue upon satisfaction of performance obligations.

iv) Interest and Dividend Income

Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Dividend income is recognized when right to receive is established (provided that it is probable that the economic benefits will flow to the Parent company and the amount of income can be measured reliably).

r) Export Incentive

Export incentives comprise of Duty draw back and RODTEP (Remission of Duties or Taxes on Export Products) Scheme scrips.

Duty drawback and RODTEP is recognized as income when the right to receive credit as per the terms of the scheme is established in respect of the exports entitled for this benefit made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds. RODTEP scrips are freely transferable and can be utilised for the payment of customs duty.

s) Employee Benefits

i) Short term employee benefits

Short term employee benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized as an expense at the undiscounted amount in the statement of profit and loss of the year in which the related service is rendered.

Accumulated compensated absences, which are expected to be availed or encashed within 12 months from the end of the year are treated as short-term employee benefits. The obligation towards the same is measured at the expected cost of accumulating compensated absences as the additional amount expected to be paid is as a result of the unused entitlement as at the year end.

ii) Post-Employment Benefits:

Defined contribution plans

Employee benefits in the form of contribution to Provident Fund managed by Government Authorities, Employees State Insurance Corporation and Labor Welfare Fund are considered as defined contribution plans and the same are charged to the statement of profit and loss for the year in which the employee renders the related service.

Defined benefit plans

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan.

Gratuity

The Group's gratuity benefit scheme for its parent and its Indian subsidiaries is a defined benefit plan for which the net obligation is calculated by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. Obligation under the gratuity scheme is covered under a Scheme of Life Insurance Corporation of India (LIC) and contributions in respect of such scheme are recognized in the statement of profit or loss. The calculation of defined benefit obligation is performed annually by a qualified actuary using the projected unit credit method.

Remeasurement of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized in OCI. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognized immediately in Statement of Profit and Loss. The Group recognizes gains and losses on the settlement of a defined benefit plan when the settlement occurs.

For the Company's Non –Indian subsidiaries, the respective entities comply with their social security obligations in line with their local regulations.

Compensated absences:

For the Group's parent entity and its Indian subsidiaries, the accumulated compensated absences, which are expected to be availed or en-cashed beyond 12 months from the end of the year end are treated as other long term employee benefits. The Group's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. Actuarial losses/gains are recognized in the statement of profit and loss in the year in which they arise.

For the Company's Non –Indian subsidiaries, the respective entities comply with their social security obligations in line with their local regulations.

t) Share based Payments

The Company operates Employee Stock Option Plans (ESOP's) for its employees and for the employees of its Subsidiaries.

ESOP's for Parent Company Employees: The grant date fair value of options using Black Scholes model granted to employees is recognized as an employee expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the options. The expense is recorded for each separately vesting portion of the award as if the award was, in substance, multiple awards. The increase in equity recognized in connection with share based payment transaction is presented as a separate component in equity under "Employee Stock Options Outstanding Reserve". The amount recognized as an expense is adjusted to reflect the actual number of stock options that vest.

"ESOPs" for Subsidiary Company Employees : The cost of equity settled transactions is recognized in the Statement of Profit and Loss of the Subsidiary Company, together with a corresponding increase in equity, representing contribution received from the parent company, over the period in which the performance and/ or service conditions are fulfilled. The same is recognized under "Investment in Subsidiary" for the value of shares of Grant after reducing Exercise price, in the Standalone financials of the Parent (which is subject to appropriate consolidation adjustments in the presentation of the Consolidated financials of the Group) .

The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and Company's best estimate of the number of equity instruments that will ultimately vest. In case of forfeiture/lapse of stock option, which is not vested/not exercised, the amortized portion is reversed by credit to employee compensation expense

u) Taxation

Tax expense comprises current income tax and deferred income tax and includes any adjustments related to past periods in current and / or deferred tax adjustments that may become necessary due to certain developments or reviews during the relevant period.

i) Current Tax

Current income tax is measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognized amounts and there is an intention to settle the asset and the liability on a net basis.

ii) Deferred Tax

Deferred income tax is recognized using the balance sheet approach. Deferred income tax assets and liabilities are recognized for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount.

Deferred income tax liabilities are recognized for all taxable temporary differences. Deferred income tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be released simultaneously.

v) Earnings Per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

Diluted earnings per share are computed by dividing the profit after tax as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on conversion of all dilutive potential equity shares.

w) Operating Segments

Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM) of the Parent Company. The CODM is responsible for allocating resources and assessing performance of the operating segments of the Group.

The Group has identified two geographical segments as its reportable segments in accordance with Ind AS 108 - Operating Segments. Segment 1 : Rest of the World and Segment 2 : United States of America (USA).

x) Dividends to Shareholders

The Company recognises Final dividend to the shareholders as a liability in the period in which the dividends are approved by the shareholders. Any Interim Dividend paid is recognised based on the approval by the Board of Directors.

y) Recent Accounting Pronouncements

Ministry of Corporate Affairs (“MCA”) notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time.

Ind AS 21 - The Effects of Changes in Foreign Exchange Rates:

In May 2025, MCA notified amendments to Ind AS 21 - The Effects of Changes in Foreign Exchange Rates, applicable w.e.f. April 1, 2025. The amendment specifies the exchange rate to use in reporting foreign currency transactions when exchangeability between two currencies is temporarily lacking. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

In August 2025, MCA notified the following amendments to:

1) **Ind AS 1, Presentation of Financial Statements, applicable w.e.f. April 1, 2025 –** The amendment relates to classification of liabilities as current or non-current and non-current liabilities with covenants. In the context of classifying a liability as current, it removes the requirement of existence of a right to defer settlement for at least 12 months after the reporting date and instead requires that the said right should exist on the reporting date and have substance.

   The amendment also introduces guidance on classification of liabilities with covenants. The Company has no impact of these amendments in its classification criteria of current and noncurrent liabilities.

2) **Ind AS 7, Statement of Cash Flows and Ind AS 107, Financial Instruments:** Disclosures, applicable w.e.f. April 1, 2025 – The amendment in Ind AS 7 requires to inform users of financial statements of the existence of supplier finance arrangements and explain the nature of the arrangements, the carrying amount of liabilities and the range of payment due dates. Ind AS 107 has been amended to add supplier finance arrangements as a factor that may cause concentration of liquidity risk. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

3) **Ind AS 12, International Tax Reform - Piller Two Model Rules**

   The amendments provide a temporary mandatory relief from deferred tax accounting for top-up tax and disclose that they have applied the relief. This relief is immediate and applies retrospectively. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact in its financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE: 2A PROPERTY, PLANT AND EQUIPMENT

Particulars	Gross block					Accumulated Depreciation					Net Block	
	As at 01-04-2025	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2026	As at 01-04-2025	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2026	As at 31-03-2026	As at 31-03-2025
Tangible assets												
Land (i)	43.24	0.11	22.00	0.02	65.33	-	-	-	-	-	65.33	43.24
Leasehold land (ii)	14.04	-	-	-	14.04	0.68	-	0.15	-	0.83	13.21	13.36
Factory buildings (i)	145.20	-	5.78	0.02	150.96	25.71	-	4.97	-	30.68	120.28	119.49
Buildings - others	18.99	1.02	1.68	0.44	21.25	2.10	0.01	0.64	0.20	2.55	18.70	16.89
Plant & machinery (iii)	359.04	0.47	24.90	5.66	378.75	131.38	1.15	36.96	0.69	168.80	209.95	227.66
Air conditioner	15.34	-	1.17	-	16.51	3.36	-	1.25	-	4.61	11.90	11.98
Furniture & fixtures	37.36	-	1.93	0.06	39.23	18.77	-	3.21	-	21.98	17.25	18.59
Office equipment	17.62	-	2.50	0.30	19.82	10.53	-	2.09	0.19	12.43	7.39	7.09
Computers	16.27	0.29	2.49	0.04	19.01	11.86	0.55	2.28	0.03	14.66	4.35	4.41
Electrical fittings	31.31	-	0.67	0.05	31.93	14.36	-	2.74	0.01	17.09	14.84	16.95
Motor vehicles	17.79	0.57	3.59	0.69	21.26	9.46	0.43	1.92	0.62	11.19	10.07	8.33
Tools & spares	0.49	-	-	-	0.49	0.49	-	-	-	0.49	-	-
Lab equipment (iii)	111.83	-	23.97	0.97	134.83	69.50	-	11.60	0.49	80.61	54.22	42.33
Total Tangible Assets	**828.52**	**2.46**	**90.68**	**8.25**	**913.41**	**298.20**	**2.14**	**67.81**	**2.23**	**365.92**	**547.49**	**530.32**

(i) The title deeds of immovable properties included in Property, Plant & Equipment are held in the name of the Company, except for one property (land and factory building) for ₹ 17.38 Crores purchased by the Company during the financial year 2020-21 through e-auction from Punjab National Bank under the SARFAESI Act, 2002 and rules thereof, for which the transfer of title is in progress.

(ii) In respect of immovable properties taken on lease and disclosed as property, plant and equipment in the financial statements, the lease agreements are in the name of the Company.

(iii) Gross Block for 31st March 2026 includes ₹ 24.82 Crs (PY: ₹ 20.19 Crs) of government grant in the nature of waiver of duty on purchase of plant and machinery & lab equipments. Accumulated Depreciation for Plant & Machinery as at 31st March 2026 includes ₹ 11.76 Crs (PY: ₹ 9.37 Crs) on such government grant.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Gross block					Accumulated Depreciation					Net Block	
	As at 01-04-2024	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2025	As at 01-04-2024	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2025	As at 31-03-2025	As at 31-03-2024
Tangible assets												
Land (i)	23.81	0.06	20.19	0.82	43.24	-	-	-	-	-	43.24	23.81
Leasehold land (ii)	14.04	-	-	-	14.04	0.54	-	0.14	-	0.68	13.36	13.50
Factory buildings (i)	134.14	-	11.50	0.44	145.20	21.34	-	4.39	0.02	25.71	119.49	112.80
Buildings - others	11.06	0.14	8.66	0.87	18.99	2.70	(0.05)	(0.52)	0.03	2.10	16.89	8.36
Plant & machinery (iii)	276.18	-	90.10	7.24	359.04	96.46	-	35.47	0.55	131.38	227.66	179.72
Air conditioner	12.03	-	3.31	-	15.34	2.45	-	0.91	-	3.36	11.98	9.58
Furniture & fixtures	35.91	(0.03)	1.48	-	37.36	16.25	0.08	2.45	0.01	18.77	18.59	19.66
Office equipment	16.05	0.08	1.90	0.41	17.62	9.14	0.05	1.40	0.06	10.53	7.09	6.91
Computers	12.88	0.05	3.34	-	16.27	10.01	0.06	1.80	0.01	11.86	4.41	2.87
Electrical fittings	29.65	-	1.66	-	31.31	11.78	-	2.58	-	14.36	16.95	17.87
Motor vehicles	14.95	0.02	3.68	0.86	17.79	7.95	0.02	2.32	0.83	9.46	8.33	7.00
Tools & spares	0.49	-	-	-	0.49	0.49	-	-	-	0.49	-	-
Lab equipment (iii)	95.49	-	16.62	0.28	111.83	58.95	-	10.70	0.15	69.50	42.33	36.54
Total Tangible Assets	**676.68**	**0.32**	**162.44**	**10.92**	**828.52**	**238.06**	**0.16**	**61.64**	**1.66**	**298.20**	**530.32**	**438.63**

(i) The title deeds of immovable properties included in Property, Plant & Equipment are held in the name of the Company, except for one property (land and factory building) for ₹ 17.38 Crores purchased by the Company during the financial year 2020-21 through e-auction from Punjab National Bank under the SARFAESI Act, 2002 and rules thereof, for which the transfer of title is in progress .

(ii) In respect of immovable properties taken on lease and disclosed as property, plant and equipment in the financial statements, the lease agreements are in the name of the Company.

(iii) Gross Block for 31st March 2025 includes ₹ 20.19 Crs (PY: ₹ 14.87 Crs) of government grant in the nature of waiver of duty on purchase of plant and machinery & lab equipments. Accumulated Depreciation for Plant & Machinery as at 31st March 2025 includes ₹ 9.37 Crs (PY: ₹ 7.26 Crs) on such government grant.

NOTE : 2B - CAPITAL WORK IN PROGRESS

Ageing for capital work-in-progress as at March 31, 2026

Particulars	Amount in Capital Work-in-Progress for a period of				Total
	< 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in progress	114.22	91.25	3.15	-	208.62

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Ageing for capital work-in-progress as at March 31, 2025

Particulars	Amount in Capital Work-in-Progress for a period of				Total
	< 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in progress	112.26	26.96	-	-	139.22

NOTE : 2C INTANGIBLE ASSETS

Particulars	Gross block					Accumulated Depreciation					Net Block	
	As at 01-04-2025	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2026	As at 01-04-2025	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2026	As at 31-03-2026	As at 31-03-2025
Computer software	21.51	-	1.37	-	22.88	13.01	-	2.81	-	15.82	7.06	8.50
Goodwill (acquisition)	2.77	-	18.14	-	20.91	-	-	-	-	-	20.91	2.77
Other intangibles	-	-	1.00	-	1.00	-	-	0.10	-	0.10	0.90	-
Total intangible assets	**24.28**	**-**	**20.51**	**-**	**44.79**	**13.01**	**-**	**2.91**	**-**	**15.92**	**28.87**	**11.27**

Particulars	Gross block					Accumulated Depreciation					Net Block	
	As at 01-04-2024	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2025	As at 01-04-2024	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2025	As at 31-03-2025	As at 31-03-2024
Computer software	19.83	0.12	1.56	-	21.51	10.08	0.01	2.92	-	13.01	8.50	9.75
Goodwill (acquisition)	2.77	-	-	-	2.77	-	-	-	-	-	2.77	2.77
Total intangible assets	**22.60**	**0.12**	**1.56**	**-**	**24.28**	**10.08**	**0.01**	**2.92**	**-**	**13.01**	**11.27**	**12.52**

NOTE : 2D RIGHT OF USE (ROU) ASSETS

Particulars	Gross block					Accumulated Depreciation					Net Block	
	As at 01-04-2025	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2026	As at 01-04-2025	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2026	As at 31-03-2026	As at 31-03-2025
ROU Assets	6.27	0.34	1.29	1.42	6.48	2.08	0.13	2.04	1.42	2.83	3.65	4.19
Total ROU Assets	**6.27**	**0.34**	**1.29**	**1.42**	**6.48**	**2.08**	**0.13**	**2.04**	**1.42**	**2.83**	**3.65**	**4.19**

Note: In respect of immovable properties taken on lease and disclosed as property, ROU Assets in the financial statements, the lease agreements are in the name of the Company.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Gross block					Accumulated Depreciation					Net Block	
	As at 01-04-2024	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2025	As at 01-04-2024	Translation Difference	Additions during the year	Deletions during the year	As at 31-03-2025	As at 31-03-2025	As at 31-03-2024
ROU Assets	3.03	0.01	4.06	0.83	6.27	1.51	-	1.40	0.83	2.08	4.19	1.52
Total ROU Assets	**3.03**	**0.01**	**4.06**	**0.83**	**6.27**	**1.51**	**-**	**1.40**	**0.83**	**2.08**	**4.19**	**1.52**

NOTE : 2E INTANGIBLE ASSETS UNDER DEVELOPMENT

Ageing for Intangible Assets under Development as at March 31, 2026

Particulars	Amount in Intangibles under Development for a period of				Total
	< 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in Progress	20.68	4.28	-	-	24.96

Ageing for Intangible Assets under Development as at March 31, 2025

Particulars	Amount in Intangibles under Development for a period of				Total
	< 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in Progress	4.28	-	-	-	4.28

NOTE 3 FINANCIAL ASSETS - NON-CURRENT INVESTMENTS

Particulars	As at March 31, 2026	As at March 31, 2025
A. Fully paid Ordinary Equity shares (unquoted)		
(i) Investment in associate (carrying amount determined using equity method of accounting) - carried at amortised Cost		
1,75,000 (1,75,000) equity shares of ₹ 10/- each at a premium of ₹ 70/- each in Sunsole Solar Private Ltd (Note-1)	1.77	1.73
(ii) Investment in Others - carried at amortised Cost		
56,700 (56,700) shares of Thangamman Renewable Energy Private Limited of ₹ 10/- each fully paid up	0.06	0.06

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	As at March 31, 2026	As at March 31, 2025
B. Fully paid ordinary / equity shares (quoted) - Carried at fair valued through Profit & Loss		
26,800 (26,800) shares of CSB Bank Limited of ₹ 10/- each fully paid up	0.91	0.81
4,400 (4,400) shares of Karnataka Bank Limited of ₹ 10/- each fully paid up	0.10	0.08
4,800 (4,800) shares of Indian Overseas Bank of ₹ 10/- each fully paid up	0.02	0.02
700 (700) shares of Bank of India of ₹ 10/- each fully paid up	0.01	0.01
C. Investments in security bonds - carried at amortised cost		
Investment in corporate bonds - refer note 8(ii)	2.00	2.00
Investment in debentures- refer note 8(iii)	458.44	184.42
D. Investment in corporate deposits - carried at amortised cost	10.00	90.00
Total (A+B+C+D)	**473.31**	**279.13**

Note-1: Share of Profit/(Loss) from the Associate for FY'26 Profit of ₹ 0.04 Crs (FY'25 Loss of ₹ 0.01 Crs) has been included in the above.

NOTE 4 OTHER FINANCIAL ASSETS

Particulars	As at March 31, 2026	As at March 31, 2025
Electricity deposit - unsecured & considered good	4.16	3.87
Security deposit - unsecured & considered good	10.40	3.68
Bank deposits with more than 12 months maturity	9.01	7.16
Interest accrued on Investments	4.83	7.49
Total	**28.40**	**22.20**

NOTE 5 DEFERRED TAX ASSETS / (LIABILITIES)

Particulars	As at March 31, 2026	As at March 31, 2025
Deferred tax liabilities on account of temporary differences	(12.60)	(3.01)
Deferred tax assets on account of temporary differences	7.97	5.24

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 6 OTHER NON CURRENT ASSETS

Particulars	As at March 31, 2026	As at March 31, 2025
Capital Advances (unsecured & considered good)	125.25	67.97
Total	**125.25**	**67.97**

NOTE 7 INVENTORIES

Particulars	As at March 31, 2026	As at March 31, 2025
Raw materials	59.46	48.15
Packing materials	46.17	31.71
Work-in-progress	10.49	6.44
Stock-in-trade	225.20	165.99
Finished goods	72.41	71.95
Stores and spares	15.13	11.86
Total	**428.86**	**336.10**

NOTE 8 CURRENT INVESTMENTS

Particulars	As at March 31, 2026	As at March 31, 2025
Investment in mutual fund - fair value through profit or loss (i)	132.93	96.45
Investment in debentures - carried at amortised cost (iii)	153.52	199.88
Investment in commercial paper - carried at amortised cost (iv)	9.26	-
Investment in corporate deposits - carried at amortised cost	90.00	15.00
Total	**385.71**	**311.33**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

(i) Investment in mutual fund at fair value through profit or loss

Particulars	As at March 31, 2026		As at March 31, 2025	
	Units	Amount ₹ in Crs	Units	Amount ₹ in Crs
Aditya Birla Sun Life CRISIL IBX Financial Services 3 to 6 months Debt Index Fund - Direct Growth	99,77,102	10.90	99,77,102	10.21
Aditya Birla Sun Life CRISIL IBX Financial Services 3 to 6 months Debt Index Fund - Regular Growth	30,69,968	3.35	1,00,44,052	10.27
Aditya Birla Sun Life CRISIL IBX Financial Services 9 to 12 months Debt Index Fund - Regular Growth	49,99,750	5.34	49,99,750	5.02
Aditya Birla Sun Life Money Manager Fund - Growth- Direct Plan	85,899	3.82	1,37,469	5.05
Axis Money Market Fund - Regular Growth	-	-	35,978	5.05
Axis Money Market Fund - Direct Growth	-	-	35,642	5.05
Tata Money Market Fund Regular Plan-Growth	-	-	10,908	5.05
Nippon India CRISIL IBX AAA Financial Services Jan 2028 Index Fund - Growth Plan	49,99,750	5.54	49,99,750	5.17
Nippon India CRISIL IBX AAA Financial Services Jan 2028 Index Fund - Direct Growth Plan	49,99,750	5.54	49,99,750	5.18
Nippon India Money Market Fund - Direct Growth Plan Growth Option	-	-	10,238	4.22
UTI Money Market Fund - Direct Growth	-	-	17,079	5.23
Kotak Money Market Fund Direct Plan - Growth	-	-	11,368	5.05
ICICI Pru Liquid Fund - Reg - Growth	87,603	3.53	-	-
ICICI Prudential CRISIL IBX Financial Services 3-6 Months Debt Index Fund - Growth	12,44,008	1.33	50,57,817	5.08
HDFC Corporate Bond Fund Regular Growth	16,23,496	5.41	16,23,496	5.17
Kotak CRISIL IBX AAA Financial Services Index - Sep 2027 Fund Regular Plan - Growth	99,99,500	11.19	99,99,500	10.47
Kotak Corporate Bond Fund Direct Growth	13,467	5.50	13,467	5.18
Kotak Income Plus Arbitrage FOF Regular Plan	40,98,525	5.24	-	-
Axis Overnight Fund - Direct Growth	45,684	6.51	-	-
Edelweiss Liquid Fund - Reg - Growth	7,179	2.50	-	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	As at March 31, 2026		As at March 31, 2025	
	Units	Amount ₹ in Crs	Units	Amount ₹ in Crs
HDFC Flexi Cap Fund - Direct Plan - Growth	10,383	2.07	-	-
ICICI Prudential Equity & Debt - Direct Plan - Growth	35,618	1.49	-	-
UTI NIFTY 200 Momentum 30 Index Fund -DIR-GRW	9,29,943	1.74	-	-
Nippon India Index Fund-Nifty 50 Plan- Dir Grow Plan Option	2,09,563	0.86	-	-
Nippon India Index Fund - Nifty 50 Plan - Growth Plan	11,768	0.04	-	-
UTI Nifty 50 Index Fund - Direct Growth	63,650	0.99	-	-
Nippon India Index Fund - Nifty 50 Plan - Growth Plan - Growth Option	2,32,159	0.88	-	-
SBI Nifty Index Fund - Regular Plan - Growth	46,823	0.92	-	-
Nippon India Large Cap Fund - Direct Growth Plan	2,02,915	1.86	-	-
Canara Robeco Large Cap Fund - Direct - Growth	1,42,391	0.92	-	-
ICICI Prudential Multi-Asset Fund - Direct - Growth	26,980	2.26	-	-
Aditya Birla Sun Life Liquid Fund Reg - Growth	50,112	2.20	-	-
ABSL Money Manager Fund - Reg - Growth	36,352	1.41	-	-
ABSL Money Manager Fund-Growth-Direct Plan	60,644	2.38	-	-
ICICI Prudential Overnight Fund - Growth	6,941	1.00	-	-
ICICI Prudential Money Market Fund - Reg - Growth	1,45,450	5.77	-	-
ABSL Money Manager Fund - Reg - Growth	1,09,588	4.24	-	-
ABSL Money Manager Fund-Growth-Direct	91,411	3.58	-	-
Nippon India Money Market Fund Growth Option	5,961	2.59	-	-
Nippon India CRISIL- 9-12 Months Debt Index Fund -Direct Plan - Growth	99,87,116	10.02	-	-
Nippon India CRISIL- 9-12 Months Debt Index Fund - Regular Plan - Growth	34,95,595	3.51	-	-
Axis Overnight Fund - Regular Plan - Growth	3,528	0.50	-	-
Aditya Birla Sun Life Overnight Fund-Direct Plan-Growth	41,202	6.00	-	-
Total		**132.93**		**96.45**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

(ii) Investment in Corporate Bonds - as on March 31, 2026

Particulars	No. of Bonds	Current Investments (₹ in Crores)	Non-Current Investments (₹ in Crores)	TOTAL
State Bank of India	2	-	2.00	2.00
Total		**-**	**2.00**	**2.00**

(ii) Investment in Corporate Bonds - as on March 31, 2025

Particulars	No. of Bonds	Current Investments (₹ in Crores)	Non-Current Investments (₹ in Crores)	TOTAL
State Bank of India	2	-	2.00	2.00
Total		**-**	**2.00**	**2.00**

(iii) Investment in Debentures - as on March 31, 2026

Particulars	No. of Debentures	Current Investments (₹ in Crores)	Non-Current Investments (₹ in Crores)	TOTAL
Cholamandalam Investment and Finance Company Limited	50,000	5.00	-	5.00
HDB Financial Services Limited	2,750	-	50.16	50.16
Shriram Finance Limited	4,170	24.99	32.31	57.30
Tata Motors Finance Limited	321	39.35	-	39.35
Mahindra & Mahindra Financial services Limited	20	-	2.01	2.01
Piramal Finance Limited	4,841	10.00	38.45	48.45
Sundaram Finance Limited	300	-	38.15	38.15
L&T Finance Limited	1,000	-	10.02	10.02
Hinduja Leyland Finance Limited	2,000	-	20.14	20.14
GIC Housing Finance Limited	5,000	10.01	40.03	50.04
Godrej Industries Limited	2,500	-	25.21	25.21
Godrej Housing Finance Limited	1,500	-	15.23	15.23
Godrej Finance Limited	2,000	-	19.98	19.98
Godrej Properties Limited	2,000	20.00	-	20.00
Andhra Pradesh Mineral Development Corporation Limited	1,000	-	10.10	10.10
Aditya Birla Finance Limited	4,150	15.10	40.27	55.37
Axis Finance Limited	50	5.02	-	5.02
360 One Prime	3,500	-	35.04	35.04
TVS Credit Services Limited	280	20.05	81.34	101.39
Tata Capital Limited	400	4.00	-	4.00
Total		**153.52**	**458.44**	**611.96**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

(iii) Investment in Debentures - as on March 31, 2025

Particulars	No. of Debentures	Current Investments (₹ in Crores)	Non-Current Investments (₹ in Crores)	TOTAL
Cholamandalam Investment and Finance Company Limited	1,50,150	10.00	5.00	15.00
HDB Financial Services Limited	450	48.91	-	48.91
Shriram Finance Limited	4,500	20.04	24.92	44.96
Tata Motors Finance Limited	321	-	39.35	39.35
Mahindra & Mahindra Financial Services Limited	120	8.27	2.01	10.28
Mahindra Rural Housing Finance Limited	40	4.21	-	4.21
TVS Credit Services Limited	430	19.98	50.45	70.43
L&T Finance Limited	250	25.87	-	25.87
HDFC Bank	100	9.99	-	9.99
Kotak Mahindra Investment Limited	1,130	21.36	-	21.36
Tata Cleantech Capital Limited	100	10.56	-	10.56
Hinduja Leyland Finance Limited	1,000	-	10.12	10.12
GIC Housing Finance Limited	1,000	-	10.02	10.02
Godrej Industries Limited	1,000	-	10.06	10.06
Godrej Properties Limited	2,000	-	19.99	19.99
Axis Finance Limited	50	-	5.08	5.08
Tata Capital Limited	712	20.69	3.99	24.68
TML Holdings PTE Limited	100	-	3.43	3.43
Total		**199.88**	**184.42**	**384.30**

(iv) Investment in Commercial Paper - as on March 31, 2026

Particulars	No. of units	Current Investments (₹ in Crores)	Non-Current Investments (₹ in Crores)	TOTAL
360 One Alternates Asset Management Limited	100	9.26	-	9.26

Particulars	Non-Current		Current	
	As at March 31, 2026	As at March 31, 2025	As at March 31, 2026	As at March 31, 2025
Aggregate book value of quoted investments	0.33	0.33	128.84	94.38
Aggregate market value of quoted investments	1.04	0.92	132.93	96.45
Aggregate value of unquoted investments	472.27	278.21	252.78	214.88
Aggregate amount of impairment in value of investments	-	-	-	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 9 TRADE RECEIVABLES

Particulars	As at March 31, 2026	As at March 31, 2025
(Carried at amortised cost unless otherwise stated)		
Trade Receivables - Unsecured considered good	848.78	632.49
Receivables from related parties	-	-
Trade receivables which have significant increase in credit risk	-	-
Trade receivables - Credit impaired	-	-
Less: Provision for expected credit loss	(22.97)	-
Total	**825.81**	**632.49**

(i) The Company's trade receivables do not carry a significant financial element.

(ii) In accordance with Ind AS 109, the Company uses the expected credit loss ("ECL") model for measurement and recognition of impairment loss on its trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of Ind AS 115.

(iii) No trade or other receivables are due from directors or other officers of the Company either severally or jointly with any other person. There are no trade or other receivables which are due from firms or private companies respectively in which any director is a partner, a director or a member.

As on March 31, 2026:

Particulars	Outstanding for following periods from due date of payment						
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Others:							
(i) Undisputed trade receivables – considered good	563.06	223.67	38.97	23.08	-	-	848.78
(ii) Undisputed trade receivables – which have a significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed trade receivables – Credit Impaired	-	-	-	-	-	-	-
(iv) Disputed trade receivables – considered good	-	-	-	-	-	-	-
(v) Disputed trade receivables –which have significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed trade receivables – credit impaired	-	-	-	-	-	-	-
Less: Provision for expected credit loss							(22.97)
Total							**825.81**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

As on March 31, 2025:

Particulars	Outstanding for following periods from due date of payment						
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Others:							
(i) Undisputed trade receivables – considered good	315.13	168.25	149.11	-	-	-	632.49
(ii) Undisputed trade receivables – which have a significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed trade receivables – Credit Impaired	-	-	-	-	-	-	-
(iv) Disputed trade receivables – considered good	-	-	-	-	-	-	-
(v) Disputed trade receivables –which have significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed trade receivables – credit impaired	-	-	-	-	-	-	-

NOTE 10 CASH AND CASH EQUIVALENTS

Particulars	As at March 31, 2026	As at March 31, 2025
Cash on Hand	0.22	0.22
Balance with Banks		
- Current accounts	86.42	134.52
- Earmarked balances for CSR*	7.54	5.71
In Bank Deposit Accounts		
- Bank Deposit accounts less than 3 months maturity	-	59.00
Total	**94.18**	**199.45**

* Unspent CSR amount had been deposited in a separate bank account before the due date.

NOTE 11 OTHER BANK BALANCES

Particulars	As at March 31, 2026	As at March 31, 2025
Unpaid Dividend account	2.75	2.50
In Bank Deposit Accounts		
- Bank deposit accounts maturity (more than 3 months but less than 12 months)	519.41	389.46
- Earmarked balances for CSR	4.70	-
Total	**526.86**	**391.96**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 12 OTHER FINANCIAL ASSETS - CURRENT

Particulars	As at March 31, 2026	As at March 31, 2025
Interest accrued on investments (unsecured & considered good)	46.80	28.90
Insurance receivable	27.37	28.47
Total	**74.17**	**57.37**

The insurance claim receivable as on 31st March'2026 has been reduced to Rs 27.37 Crores from 28.47 Crores as on 31st March 2025 due to sale of loss assets as per the process monitored by "The Hon'ble High Court of Madras" and the proceeds of the same has been adjusted against insurance claim receivable.

The Company is of the firm view that the outcome of the litigation would be favourable, based on strong and positive legal opinion and hence the above insurance claim which has been earlier recognised in the books of accounts is considered good and recoverable.

NOTE 13 OTHER CURRENT ASSETS

Particulars	As at March 31, 2026	As at March 31, 2025
Advances recoverable in cash or kind for the value to be received	89.81	66.93
Prepaid expenses	15.80	13.60
Export incentives receivable	7.95	5.53
Balance with statutory authorities	126.33	110.65
Provision for compensated absences	-	0.61
Unbilled revenue	10.18	7.93
Total	**250.07**	**205.25**

NOTE 14 EQUITY SHARE CAPITAL

Particulars	As at March 31, 2026	As at March 31, 2025
AUTHORISED		
8,50,00,000 (31st March, 2025: 8,50,00,000) equity shares of ₹ 2/- each	17.00	17.00
ISSUED, SUBSCRIBED AND PAID UP		
7,60,11,696 (31st March, 2025: 7,60,11,696) equity shares of ₹ 2/- each fully paid up	15.20	15.20
Total	**15.20**	**15.20**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

a) Reconciliation of equity shares outstanding at the beginning and at the end of the Year

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of Equity Shares of ₹ 2/- each	Amount	No. of Equity Shares of ₹ 2/- each	Amount
Equity shares outstanding at the beginning of the Year	7,60,11,696	15.20	7,59,41,746	15.19
Add: Equity shares allotted pursuant to employee stock option plan*	-	-	69,950	0.01
Equity shares outstanding at the end of the Year	**7,60,11,696**	**15.20**	**7,60,11,696**	**15.20**

*During the financial year, Nil (PY : 69,950) equity shares under ESOP scheme vested were exercised.

b) Rights, preference & restrictions attached to shares

The company has only one class of equity shares having a par value of ₹ 2/- per share. Each holder of equity share is entitled to one Vote per Share.

The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting except in case of interim dividend.

In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

c) Shareholding of promoter & promoter group

The details of shares held by promoters are as follows:

Promoter Name	As at March 31, 2026		
	No. of shares	% of total shares	% change during the year
C.C. Paarthipan	1,41,67,192	18.64%	0.00%
Promoter group			
P. Vijayalakshmi	1,87,78,790	24.71%	0.00%
Ashok Partheeban	90,50,000	11.91%	0.00%
Vivek Partheeban	90,09,371	11.85%	0.10%
May India Property Private Limited	21,17,000	2.79%	0.00%
First Dimension Holdings Private Limited	3,70,000	0.49%	0.00%
Kiraviz Properties And Consultancy LLP	1,50,000	0.20%	0.00%

Promoter Name	As at March 31, 2025		
	No. of shares	% of total shares	% change during the year
C.C. Paarthipan	1,41,67,192	18.64%	0.00%
Promoter group			
P. Vijayalakshmi	1,87,78,790	24.71%	0.00%
Ashok Partheeban	90,50,000	11.91%	0.00%
Vivek Partheeban	90,00,000	11.84%	0.00%
May India Property Private Limited	21,17,000	2.79%	0.00%
First Dimension Holdings Private Limited	3,70,000	0.49%	0.00%
Kiraviz Properties And Consultancy LLP	1,50,000	0.20%	0.00%

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

d) Details of shares in the company held by each shareholder holding more than 5% shares:

Name of Shareholder	As at March 31, 2026 (of ₹ 2/- each)		As at March 31, 2025 (of ₹ 2/- each)	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
P. Vijayalakshmi	1,87,78,790	24.71%	1,87,78,790	24.71%
C.C. Paarthipan	1,41,67,192	18.64%	1,41,67,192	18.64%
Ashok Partheeban	90,50,000	11.91%	90,50,000	11.91%
Vivek Partheeban	90,09,371	11.85%	90,00,000	11.84%

e) Shares reserved for issuance under Employee Stock Option Plans of the Company

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of Shares of ₹ 2/- each	Amount	No. of Shares of ₹ 2/- each	Amount
Caplin Point Employee Stock Option Plan 2015*	24,000	0.00	30,500	0.01
Caplin Point Employee Stock Option Plan 2017	1,08,319	0.02	1,72,486	0.03
Caplin Point Employee Stock Option Plan 2021	94,650	0.02	1,46,900	0.03

*Value of the shares reserved for issuance under Caplin Point Employee Stock Option Plan 2015 is ₹ 48,000.

f) Aggregate number of shares issued pursuant to Stock Option Plans of the Company

Particulars	Aggregate No. of Shares
Issued in FY 2016-17	26,750
Issued in FY 2017-18	26,750
Issued in FY 2018-19	26,750
Issued in FY 2019-20	12,500
Issued in FY 2021-22	1,46,126
Issued in FY 2022-23	1,13,870
Issued in FY 2023-24	39,000
Issued in FY 2024-25	69,950
Issued in FY 2025-26	-
Total	**4,61,696**

g) No shares have been allotted without payment being received in cash or by way of bonus shares during the period of five years immediately preceding the balance sheet date by the parent company.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 15 INVESTMENTS ENTIRELY EQUITY IN NATURE

Particulars	As at March 31, 2026	As at March 31, 2025
Instruments entirely equity in nature		
Series A Compulsorily Convertible Preference Shares of ₹ 10/- each fully paid up (Issued by subsidiary Caplin Steriles Limited)	74.58	74.58
Total	**74.58**	**74.58**

Details of shares in the company held by each shareholder holding more than 5% shares:

Name of Shareholder	As at March 31, 2026 (of ₹ 10/- each)		As at March 31, 2025 (of ₹ 10/- each)	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
Eight Road Ventures India LLP	5,22,08,013	70.00%	5,22,08,013	70.00%
F- Prime Capital Partners Life Sciences Fund VI LLP	2,23,74,862	30.00%	2,23,74,862	30.00%

NOTE 16 OTHER EQUITY

Particulars	As at March 31, 2026	As at March 31, 2025
a) Capital reserve		
Balance as at the beginning of the year	95.28	3.21
Add: Additions during the year	-	92.07
Balance as at the year end	**95.28**	**95.28**
b) Securities premium reserve		
Balance as at the beginning of the year	19.36	15.41
Add: Additions during the year	-	3.95
Balance as at the year end	**19.36**	**19.36**
c) General reserve		
Balance as at the beginning of the year	11.29	11.29
Add: Additions during the year	-	-
Balance as at the year end	**11.29**	**11.29**
d) Employee stock options outstanding		
- Employee stock options outstanding		
Balance as at the beginning of the year	35.23	25.58
Add: Options granted during the year	(14.14)	13.60

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars		As at March 31, 2026	As at March 31, 2025
	Less: Exercised during the year	-	(3.95)
	Less: Lapsed during the year	-	-
	Balance as at the year end (A)	**21.09**	**35.23**
	- Deferred employees stock options cost		
	Balance as at the beginning of the year	15.58	11.36
	Add: Options granted during the year	(14.14)	13.60
	Less: Amortised during the year	1.35	(9.38)
	Balance as at the year end (B)	**2.79**	**15.58**
	(A-B)	**18.30**	**19.65**
e)	**Retained earnings / surplus in the statement of profit & loss**		
	Balance as at the beginning of the year	2,368.96	1,962.71
	Add : Profit during the year	641.24	536.31
	Final dividend paid for FY 24-25 / FY 23-24	(22.80)	(19.00)
	Interim dividend paid for FY 24-25 / FY 23-24	(22.81)	(18.99)
	Issue of bonus shares by a subsidiary	-	(92.07)
	Balance as at the year end	**2,964.59**	**2,368.96**
f)	**Other comprehensive income**		
	i) Foreign currency translation reserve		
	Balance as at the beginning of the year	104.00	77.03
	Add/(Less): Profit/ (Loss) on foreign currency translation	141.42	26.97
	Balance as at the year end	**245.42**	**104.00**
	ii) Actuarial Gain/ (Loss) on employee benefit obligation		
	Balance as at the beginning of the year	0.18	0.08
	Add/(Less): Additions during the year	0.22	0.10
	Balance as at the year end	**0.40**	**0.18**
g)	**Securities premium - preference shares**	**141.99**	**141.99**
	Total	**3,496.64**	**2,760.71**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 17 LEASE LIABILITIES (NON CURRENT)

Particulars	As at March 31, 2026	As at March 31, 2025
Lease Liabilities	2.06	2.91
Total	**2.06**	**2.91**

NOTE 18 PROVISIONS (NON CURRENT)

Particulars	As at March 31, 2026	As at March 31, 2025
Provision for social security	1.00	0.89
Provision for employees benefits- gratuity (net)	-	0.85
Total	**1.00**	**1.74**

NOTE 19 OTHER NON CURRENT LIABILITIES

Particulars	As at March 31, 2026	As at March 31, 2025
Government grant - refer note (i) below	13.06	10.82
Total	**13.06**	**10.82**

(i) Systematic recognition of Government grant, in the nature of waiver of duty on depreciable tangible assets, over the useful life of the such assets. Refer note 2A

NOTE 20 CURRENT BORROWINGS

Particulars	As at March 31, 2026	As at March 31, 2025
Borrowings refer note (i) below	0.57	0.55
Total	**0.57**	**0.55**

(i) Borrowings are towards Vehicle loans from Banks and other financial institutions which are repayable in equal monthly instalments.

NOTE 21 TRADE PAYABLES

Particulars	As at March 31, 2026	As at March 31, 2025
Total outstanding dues of micro enterprises and small enterprises (refer note below)	9.26	2.28
Total outstanding dues of creditors other than micro enterprises and small enterprises	286.77	215.30
Total	**296.03**	**217.58**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Trade Payables Ageing As at March 31, 2026

Particulars	Outstanding for following periods from the due date of payment					Total
	Not Due	< 1 year	1 - 2 years	2 - 3 years	> 3 years	
(i) MSME	9.26	-	-	-	-	**9.26**
(ii) Others	84.25	202.08	0.31	0.13	-	**286.77**
(iii) Disputed dues-MSME	-	-	-	-	-	-
(iv) Disputed dues-Others	-	-	-	-	-	-
Total	**93.51**	**202.08**	**0.31**	**0.13**	**-**	**296.03**

Trade Payables Ageing As at March 31, 2025

Particulars	Outstanding for following periods from the due date of payment					Total
	Not Due	< 1 year	1 - 2 years	2 - 3 years	> 3 years	
(i) MSME	2.28	-	-	-	-	**2.28**
(ii) Others	60.68	154.29	0.29	0.02	0.02	**215.30**
(iii) Disputed dues-MSME	-	-	-	-	-	-
(iv) Disputed dues-Others	-	-	-	-	-	-
Total	**62.96**	**154.29**	**0.29**	**0.02**	**0.02**	**217.58**

Dues to Micro, Small and Medium Enterprises

Disclosure under the Micro, Small And Medium Enterprises Development Act, 2006 are provided as under for the year 2025-26, to the extent the Company has received Intimation from the "Suppliers" regarding their status under the Act.

Particulars	As at March 31, 2026	As at March 31, 2025
(i) Principal amount and the interest due thereon remaining unpaid to each supplier at the end of each accounting year		
(a) Principal amount due to micro and small enterprise	9.26	2.28
(b) Interest due on above	-	-
(ii) Interest paid by the Company in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along-with the amount of the payment made to the supplier beyond the appointed day during the period	-	-
(iii) Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the period) but without adding interest specified under the Micro, Small and Medium Enterprises Act, 2006	-	-
(iv) The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
(v) Interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises	-	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 22 LEASE LIABILITIES (CURRENT)

Particulars	As at March 31, 2026	As at March 31, 2025
Lease Liabilities	1.98	1.56
Total	**1.98**	**1.56**

NOTE 23 OTHER FINANCIAL LIABILITIES

Particulars	As at March 31, 2026	As at March 31, 2025
Payable for purchase of property, plant & equipment	19.33	26.33
Unclaimed dividend (refer note 42)	2.75	2.50
Salary and bonus payable	16.42	10.97
Provision for CSR	12.21	5.45
Rental deposit received	0.05	0.01
Total	**50.76**	**45.26**

NOTE 24 PROVISIONS-CURRENT

Particulars	As at March 31, 2026	As at March 31, 2025
Provision for gratuity (net)	2.74	0.44
Provision for compensated absences	0.71	-
Provision for expenses	16.57	23.14
Total	**20.02**	**23.58**

NOTE 25 OTHER CURRENT LIABILITIES

Particulars	As at March 31, 2026	As at March 31, 2025
Statutory dues payable	5.77	5.60
Advance received from customers	10.83	11.86
Total	**16.60**	**17.46**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 26 REVENUE FROM OPERATIONS

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Revenue from operations	**2,171.38**	**1,921.23**
Sale of products	2,083.90	1,823.98
Service income	87.48	97.25
Other operating revenues		
Export incentives	15.81	16.24
Total	**2,187.19**	**1,937.47**

Disaggregation of Revenue	For the year ended March 31, 2026	For the year ended March 31, 2025
USA	453.40	354.51
Rest of the World	1,733.79	1,582.96
Total	**2,187.19**	**1,937.47**

Contract balances	As at March 31, 2026	As at March 31, 2025
Trade receivables	825.81	632.49
Contract assets (unbilled revenue) (refer note (i) below)	10.18	7.93
Contract liabilities (advance received from customers)(refer note (i) below)	10.83	11.86

(i) Contract assets are initially recognised for revenue from sale of goods or services. Contract liabilities are on account of the upfront revenue received from customer for which performance obligation has not yet been completed.

NOTE 27 OTHER INCOME

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Interest income	66.34	63.64
Dividend income*	0.00	0.00
Realised gain on sale of financial instruments	16.81	3.90
Fair value gain on financial instruments through profit or loss	2.14	1.11
Gain on foreign exchange, net	18.62	20.78

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Government grant	2.38	2.10
Profit on sale of assets	-	0.19
Miscellaneous income	9.25	4.71
Total	**115.54**	**96.43**

*Dividend income amounts to ₹ 24,835 in FY26 (FY25: ₹ 24,200)

NOTE 28 COST OF MATERIALS CONSUMED

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Opening stock	91.72	80.10
Add : Purchases (Net)	386.25	308.94
Less: Closing Stock	120.77	91.72
Total	**357.20**	**297.32**

NOTE 29 CHANGES IN INVENTORIES OF FINISHED GOODS INCLUDING STOCK -IN-TRADE AND WORK-IN-PROGRESS

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Inventories at the end of the year		
Work-in-progress	10.49	6.44
Finished goods	72.41	71.95
Stock-in-trade	225.20	165.99
(A)	**308.10**	**244.38**
Inventories at the beginning of the year		
Work-in-progress	6.44	6.81
Finished goods	71.95	77.56
Stock-in-trade	165.99	198.57
(B)	**244.38**	**282.94**
(Increase) / Decrease in inventories (B – A)	**(63.72)**	**38.56**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 30 EMPLOYEE BENEFITS EXPENSE

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Salaries, wages, bonus and allowances	169.22	148.88
Contribution to provident and other funds	12.46	11.25
Gratuity expense (Refer note - 39)	4.46	1.98
Employee share based expense	(1.35)	9.38
Staff welfare expenses	14.36	13.14
Total	**199.15**	**184.63**

NOTE 31: FINANCE COSTS

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Interest expense on borrowings	0.54	0.37
Interest expense on lease	0.33	0.24
Total	**0.87**	**0.61**

NOTE 32: DEPRECIATION AND AMORTISATION

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Depreciation on property, plant and equipment (Refer note - 2A)	67.82	61.64
Amortisation of intangible assets (Refer note - 2C)	2.91	2.92
Depreciation on right-of-use assets (Refer note - 2D)	2.04	1.40
Total	**72.77**	**65.96**

NOTE 33: RESEARCH AND DEVELOPMENT EXPENSES

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
R & D expenses (refer note 33 (i) below)	79.89	76.68
Total	**79.89**	**76.68**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 33 (i)

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Capital expenditure included in fixed assets	20.81	12.19
Revenue expenditures incurred during the financial year - refer below.	79.89	76.68
Total	**100.70**	**88.87**

Revenue expenditure includes

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Cost of consumables	30.00	32.22
Employee benefit expenses	31.39	30.50
- Includes contribution to provident and other funds for the year ended March 31, 2026 ₹ 1.14 Crores (March 31, 2025 : ₹ 1.19 Crores)		
- Includes gratuity expenses for the year ended March 31, 2026 ₹ 0.69 Crores (March 31, 2025 : ₹ 0.74 Crores)		
Other expenses	18.50	13.96
Total	**79.89**	**76.68**

NOTE 34: OTHER EXPENSES

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Power and fuel	37.38	37.83
Contract labour charges	7.58	5.50
Other manufacturing expenses	8.90	7.13
Communication expenses	2.65	2.43
Donations	0.20	0.10
Corporate social responsibility expenses	8.30	6.24
Professional and consultancy charges	10.46	8.84

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Rates and taxes	9.28	10.99
Product registration, filing and regulatory charges	38.46	31.89
Travelling expenses	8.58	6.85
Auditors' remuneration (refer note (i) below)	1.06	1.00
Insurance	5.79	4.00
Repairs and maintenance		
a) Plant and machinery	20.04	15.94
b) Building	10.97	11.01
c) Others	4.68	3.87
Rent and amenities	13.14	10.73
Freight outwards	29.60	40.61
Other selling expenses	23.75	14.73
Software maintenance charges	7.03	6.28
Loss on sale of assets	4.18	3.95
Sundry expenses	29.59	28.47
Total	**281.62**	**258.39**

(i) Auditors' remuneration

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
For statutory audit	0.75	0.63
For tax audit	0.26	0.25
For other services	0.04	0.10
For reimbursement of expenses	0.01	0.02
Total	**1.06**	**1.00**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 35: EARNINGS PER SHARE IS CALCULATED AS UNDER

Basic

Particulars	As at March 31, 2026	As at March 31, 2025
Net profit after minority interest attributable to equity shareholders (₹ in Crores)	641.24	536.31
Weighted average number of equity shares of ₹ 2 each outstanding during the year (in Nos.)	7,60,11,696	7,59,96,261
Earnings per share (in ₹)	84.36	70.57

Diluted

Particulars	As at March 31, 2026	As at March 31, 2025
Net Profit after minority interest attributable to equity shareholders (₹ in Crores)	641.24	536.31
Weighted average number of equity shares of ₹ 2/- each outstanding during the year (in Nos.)	7,62,38,665	7,63,46,147
Earnings per share (in ₹)	84.11	70.25

NOTE 36: COMMITMENT (TO THE EXTENT NOT PROVIDED FOR)

Particulars	As at March 31, 2026	As at March 31, 2025
Estimated amount of contracts remaining to be executed on capital account	118.88	148.77
Other Commitments (Raw material, Packing Material, Finished Goods, Other services)	130.25	69.43
Interim dividend of ₹ 4.00 (200%) per equity share of ₹ 2 each for the Financial Year 2025-26 payable after 30th May' 2026, not recognized as a liability in the financial statements for the year ended 31st March' 2026 (Interim dividend of ₹ 3.00 (150%) per equity share of ₹ 2 each for the Financial Year 2024-25 payable after 30th May' 2025, not recognized as a liability in the financial statements for the year ended 31st March' 2025)	30.40	22.81

NOTE 37: CONTINGENT LIABILITIES (TO THE EXTENT NOT PROVIDED FOR)

a) Disputed statutory dues:

Name of the statute	Nature of dues	As at March 31, 2026	As at March 31, 2025	Forum where dispute is pending
Income Tax Act, 1961	Income tax	0.64	0.64	DCIT,Chennai

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

b) Others

Particulars	As at March 31, 2026	As at March 31, 2025
Letter of credit issued	10.24	-
Bank guarantees	6.65	-

NOTE 38: BALANCES WITH SCHEDULED BANKS IN DEPOSIT ACCOUNTS INCLUDES:

Bank deposit accounts under Note no: 11 for the current year include ₹ 3.25 Crores (as at 31.03.2025 ₹ 4.11 Crores) earmarked as lien towards Margin for Letters of Credit and Bank Guarantees.

NOTE 39: EMPLOYEE BENEFITS

(i) Defined Contribution Plan:

Contributions to defined contributions schemes such as employees state insurance, labour welfare fund, etc are charged as expense based on the amount of contribution required to be made as and when services are rendered by the employees. Company's provident fund contributions is made to a Government administered fund and charged as expense to the Statement of Profit and Loss. The contributions payable to these plans are at the rates specified in the rules of the schemes.

The company recognized ₹ 5.06 Crores (previous year ₹4.90 Crores) towards provident fund, ₹ 0.58 Crores (previous year ₹ 0.53 Crores) towards Employee State Insurance (ESI) and ₹ 7.96 Crores (previous year ₹ 7.03 Crores) towards other social security obligations in the Statement of Profit and Loss. (Refer Note- 30 & 33)

(ii) Defined Benefit Plan:

a. Gratuity

The parent company, its Indian subsidiaries and some of its foreign subsidiaries have obligation towards gratuity, a defined benefit retirement plan covering eligible employees. The contribution of the parent company and its Indian Subsidiaries are paid to Life Insurance Corporation of India towards meeting the gratuity obligations.

For the company's Non–Indian subsidiaries, the respective entities comply with their social security obligations in line with their local regulations.

The Group is exposed to various risks in providing the above gratuity benefit which are as follows.

Interest Rate risk: The plan exposes the company to the risk of fall in interest rates. A fall in interest rates will result in an increase in the ultimate cost of providing the above benefit and will thus result in an increase in the value of the liability (as shown in financial statements).

Investment Risk: The probability or likelihood of occurrence of losses relative to the expected return on any particular investment.

Salary Escalation Risk: The present value of the defined benefit plan is calculated with the assumption of salary increase rate of plan participants in future. Deviation in the rate of increase of salary in future for plan participants from the rate of increase in salary used to determine the present value of obligation will have a bearing on the plan's liability.

(All amounts are in ₹ Crores unless otherwise stated)

Demographic Risk: The company has used certain mortality and attrition assumptions for valuation of the liability. The company is exposed to the risk of actual experience turning out to be worse compared to the assumption.

Longevity risk: The present value of the defined benefit obligation is calculated by reference to the best estimate of the mortality of plan participants during their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.

b. Compensated Absences

For the Group's parent entity and its Indian subsidiaries, the accumulated compensated absences, which are expected to be availed or en-cashed beyond 12 months from the end of the year end are treated as other long term employee benefits. The group's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. Actuarial losses/gains are recognized in the statement of profit and loss in the year in which they arise.

For the Company's Non –Indian subsidiaries, the respective entities comply with their social security obligations in line with their local regulations.

Particulars		Gratuity		Compensated Absences	
		As at March 31, 2026	As at March 31, 2025	As at March 31, 2026	As at March 31, 2025
a.	**Change in Defined Benefit Obligation during the period**				
	Present Value of Obligation at the beginning of the year	**13.06**	**11.27**	**4.43**	**4.27**
	Current service cost	2.91	2.67	0.37	0.34
	Interest cost	0.93	0.84	0.29	0.29
	Past service cost	0.96		0.43	
	Remeasurement gains/(losses):				
	-Due to finance assumption	0.35	0.33	-	-
	-Due to experience assumption	(0.66)	(0.38)	-	-
	-Due to Demographic assumption	0.11	-	-	-
	Actuarial gains/(losses)	-	-	1.88	1.34
	Benefits paid	(1.76)	(1.68)	(2.37)	(1.81)
	Present Value of Obligation at the end of the year	**15.90**	**13.06**	**5.03**	**4.43**
b.	**Change in Fair Value of Plan Assets**				
	Fair Value of Plan Assets at the beginning of the year	**11.76**	**10.54**	**5.03**	**4.82**
	Actuarial gains/(losses)	0.09	0.09	0.04	0.08
	Interest income	0.79	0.75	0.35	0.34
	Contribution by the employer	2.27	2.06	0.23	0.84
	Benefits paid	(1.75)	(1.68)	(1.33)	(1.05)
	Fair Value of the plan assets at the end of the year	**13.16**	**11.76**	**4.32**	**5.03**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Gratuity		Compensated Absences	
	As at March 31, 2026	As at March 31, 2025	As at March 31, 2026	As at March 31, 2025
a. Amount recognised in Balance Sheet				
Projected benefit obligation at the end of the year	(15.90)	(13.06)	(5.03)	(4.43)
Fair value of plan assets at the end of the year	13.16	11.76	4.32	5.03
Funded status of the plans – Liability recognised in the balance sheet	**(2.74)**	**(1.30)**	**(0.71)**	**0.60**
b. Components of defined benefit cost recognised in Statement of Profit and Loss				
Current service cost	2.91	2.67	0.37	0.26
Past service cost	0.96	-	0.43	-
Net interest expense	0.14	0.09	(0.06)	(0.02)
Remeasurements	-	-	1.84	1.68
Total Defined Benefit Cost recognised in Statement of Profit and Loss	**4.01**	**2.76**	**2.58**	**1.92**
c. Components of defined benefit cost recognised in Other Comprehensive Income				
Remeasurement due to;				
- Change in finance assumption	0.35	0.33	-	-
- Change in experience adjustment	(0.66)	(0.38)	-	-
- Change in demographic assumption	0.11	-	-	-
Return of plan assets	(0.09)	(0.09)	-	-
Total Defined Benefit Cost recognised in Other Comprehensive Income	**(0.29)**	**(0.14)**	**-**	**-**

Actuarial Assumptions used for Valuation of Gratuity and Compensated Absences

Assumptions	As at March 31, 2026	As at March 31, 2025
Economic Assumptions		
Discount rate	6.97%	6.70%
Salary escalation rate	For First Two years : 10% Thereafter : 7%	7.00%
Expected rate of return on assets	6.97%	6.70%

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Assumptions	As at March 31, 2026	As at March 31, 2025
Demographic Assumptions		
Mortality	IALM (2012-14) Ultimate	IALM (2012-14) Ultimate
Employee turnover/withdrawal rate	For age upto 30 years : 20% For age above 30 years : 15%	7.00%
Leave availment ratio	1.00%	1.00%
Retirement age	58 Years	58 Years

Sensitivity Analysis	As at March 31, 2026	As at March 31, 2025
Discount rate		
- 1% increase (+100 basis points)	(0.75)	(1.01)
- 1% decrease (-100 basis points)	0.82	1.17
Salary Escalation Rate		
- 1% increase (+100 basis points)	0.68	0.83
- 1% decrease (-100 basis points)	(0.65)	(0.83)
Withdrawal Rate		
- 1% increase (+100 basis points)	(0.00)	0.03
- 1% decrease (-100 basis points)	0.01	(0.05)

Sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

There was no change in the methods of assumptions used in preparing the sensitivity analysis from prior years.

Expected Cashflows for the next ten years	As at March 31, 2026	As at March 31, 2025
Year - 1	2.92	1.57
Year - 2	2.10	0.83
Year - 3	2.09	0.96

(All amounts are in ₹ Crores unless otherwise stated)

Expected Cashflows for the next ten years	As at March 31, 2026	As at March 31, 2025
Year - 4	1.93	1.08
Year - 5	1.77	1.22
Year -6 to 10	6.65	5.07

(iii) Employee Stock Option Scheme

Valuation of Stock Options

The fair value of services received in return for stock options granted to employees is measured by reference to the fair value of stock options granted. The fair value of stock options granted under the Caplin Point Employee Stock Option Plan 2015, 2017 & 2021 has been measured using the Black–Scholes-Merton model at the date of the grant.

The Black-Scholes-Merton model includes assumptions regarding expected volatility, expected terms and risk free interest rates. In respect of par value options granted, the expected term of an option (or “option life”) is estimated based on the vesting term and contractual term, as well as the expected exercise behavior of the employees receiving the option.

In respect of fair market value options granted, the option life is estimated based on the simplified method. Expected volatility of the option is based on historical volatility, during a period equivalent to the option life, of the observed market prices of the Company’s publicly traded equity shares. Risk-free interest rates are based on the government securities yield in effect at the time of the grant. These assumptions reflect management’s best estimates, but these assumptions involve inherent market uncertainties based on market conditions generally outside of the Company’s control.

As a result, if other assumptions had been used in the current period, stock-based compensation expense could have been materially impacted. Further, if management uses different assumptions in future periods, stock based compensation expense could be materially impacted in future years. The estimated fair value of stock options is recognized in the standalone income statement on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in substance, multiple awards.

No Grant of Options have been made during the year ended March 31, 2026.

The fair value of options granted during the year ended March 31, 2025 and the Significant Assumptions used to arrive at those fair values are as follows :

Grant Date	May 16 2024	June 19 2024	July 16 2024	November 7 2024
Market stock price at the time of option grant	₹ 1,363.80	₹ 1,401.80	₹ 1,533.90	₹ 2,121.70
Expected life	3	3	3	3
Risk free interest rate	6.00%	6.00%	6.00%	6.00%
Expected volatility	36.35%	37.88%	38.11%	42.79%

Refer Note 43(c) towards value of stock options allotted to the key managerial personnel

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 40: INCOME TAXES:

a. Tax expenses recognised in profit and loss:

Particulars	As at March 31, 2026	As at March 31, 2025
Current tax expense for the year	146.29	125.33
Deferred income tax charge/(benefits), net	6.84	10.40
Tax expense for the year	**153.13**	**135.73**

b. Reconciliation of effective tax rate:

Particulars	As at March 31, 2026	As at March 31, 2025
Profit before Tax	802.75	676.79
Tax using the Company's domestic tax rate @ 25.168%	202.04	170.33
Tax effect of :		
Tax impact on Donation & CSR expenses disallowance	2.14	1.59
Differences in tax rates of subsidiary companies	(51.25)	(35.90)
Tax incentive on additional employment	(0.59)	(0.37)
Tax impact on fair value of mutual fund & shares (disallowance)	0.28	(0.28)
Tax impact - timing difference on R&D capital asset, book and tax depreciation and others	0.51	0.36
Current and deferred tax expenses as per note (a) above	**153.13**	**135.73**

NOTE 41: REMUNERATION TO MANAGING DIRECTOR/WHOLE-TIME DIRECTORS OF THE PARENT COMPANY

Particulars	As at March 31, 2026	As at March 31, 2025
Salaries	0.53	0.53
Contribution to provident and other funds	0.04	0.04
Total *	**0.57**	**0.57**

* Refer note 43 (c)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 42: AMOUNT DUE TO INVESTOR EDUCATION AND PROTECTION FUND

The due amount of ₹ 0.36 Crores (PY : ₹ 0.45 Crores) were transferred to investor education and protection fund and there is no outstanding due amount to be transferred to investor education and protection fund.

NOTE 43: RELATED PARTY DISCLOSURES, AS REQUIRED BY INDIAN ACCOUNTING STANDARD 24 (IND AS 24) ARE GIVEN BELOW.

(a) Related parties and nature of relationship

Name of the Related parties	Nature of Relationship	Percentage of Shares held by Caplin Point Laboratories Limited / its Subsidiaries as at March 31, 2026	Percentage of Shares held by Caplin Point Laboratories Limited / its Subsidiaries as at March 31, 2025
Caplin Point Meenakshi CSR Trust	Trust in which Promoter / Promoter Group are Board of Trustees.	NA^	NA^
Ashok Partheeban	Vice Chairman	NA	NA
Vivek Partheeban	Vice Chairman	NA	NA
Caplin Point Far East Limited, (Hong Kong)	Wholly owned subsidiary company	100.00%	100.00%
Caplin Point (S) PTE Ltd (Singapore)	Wholly owned subsidiary company	100.00%	100.00%
Caplin One Labs Limited	Wholly owned subsidiary company	100.00%	100.00%
Caplin Steriles Limited, (India)	Subsidiary company	99.999%	99.999%
Caplin Steriles USA Inc.	Step down subsidiary company	100.00%	100.00%
Argus Salud Pharma LLP, (India)	Subsidiary LLP	99.90%	99.90%
Caplin Point Laboratories Colombia SAS, (Colombia)	Step down subsidiary company	100.00%	100.00%
Caplin Point El Salvador, S.A. DE C.V.,(El Salvador)	Step down subsidiary company	100.00%	100.00%
Nuevos Eticos Neo Ethicals S.A - Guatemala	Step down subsidiary company	69.00%	69.00%
Neoethicals CIA.Ltda - Ecuador	Step down subsidiary company	100.00%	100.00%
Drogueria Saimed de Honduras S.A.	Step down subsidiary company	100.00%	100.00%
Neo Ethicals S.A - Nicaragua	Step down subsidiary company	100.00%	100.00%
Neo ethicals Chile SPA Ltda - Chile	Step down subsidiary company	100.00%	NA
Triwin Pharma S.A de C.V - Mexico	Step down subsidiary company	100.00%	NA
Ashvich Infotek Private Limited	Directors & Director's relatives are interested	NA	NA
Sunsole Solar Private Limited	Associate of Caplin Steriles Limited	28.01%	28.01%
May India Property Private Limited	Directors & Director's relatives are interested	NA	NA
Kiraviz Properties and Consultancy LLP	Director's relatives are interested	NA	NA
First Dimension Holdings Private Limited	Directors & Director’s relatives are interested	NA	NA
Ashvich Properties Private Limited	Directors & Director's relatives are interested	NA	NA

^Trust formed by the company for undertaking its CSR Activities.

(All amounts are in ₹ Crores unless otherwise stated)

(b) Key Managerial Personnel

Dr. Sridhar Ganesan – Managing Director

Mr. D Muralidharan – Chief Financial Officer

Mr. G Venkatram – Company Secretary

(c) Details of Transactions that have taken place during the Financial Year with Key Management Personnel / Related party:

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Remuneration*		
Mr. Ashok Partheeban (Related Party)	2.65	2.54
Mr. Vivek Partheeban-Chief Operating officer (till 05.11.2025) (Related Party)	0.12	0.19
Dr. Sridhar Ganesan	0.57	0.57
Mr. D Muralidharan	0.60	0.54
Mr. G Venkatram**	0.51	0.54

* Remuneration includes basic salary, house rent allowance, special allowance, leave travel assistance, medical reimbursement, contribution to provident fund and such other perquisites, payable to Key Management Personnel, as per company policy except provision for contribution to gratuity fund, leave encashment on retirement and other defined benefits which are made based on actuarial valuation on an overall Company basis.

** Remuneration to Mr. G Venkatram includes perquisites value of stock option amounting to Nil (PY: ₹ 0.13 Cr) pertaining to allotment of Nil (PY: 1,000) equity shares under ESOP scheme during the year.

(d) Details of related party transactions during the year ended 31st March, 2026 (after consolidation adjustments):

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
Rent paid to Ashvich Infotek Private Limited by Caplin Steriles Limited	1.32	1.30
Rent & Consultancy charges paid to Ashvich Infotek Private Limited by Caplin Point Laboratories Limited	2.06	1.62
Rent paid to Ashvich Infotek Private Limited by Caplin One Labs Limited	0.01	0.01
Rent paid to Ashvich Infotek Private Limited by Argus Salud Pharma LLP*	0.01	0.00
Amount contributed to Caplin Point Meenakshi CSR Trust	1.00	12.23
Rent paid to Ashvich Properties Private Limited by Caplin Point Laboratories Limited	0.35	0.35
Purchase of Solar power from Sunsole Solar Private Limited by Caplin Steriles Limited	2.16	2.22

Note: Transactions & Balances with companies own subsidiaries are eliminated on consolidation.

* Rent paid to Ashvich Infotek Private Limited by Argus Salud Pharma LLP is ₹ 70,188 (Previous year ₹ 40,950/-)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

(e) Sitting Fee paid to Non Executive Directors

Particulars	For the Year Ended Mar 31,2026	For the Year Ended Mar 31,2025
Mr. C C Paarthipan	-	-
Mr. Ashok Partheeban (Vice Chairman w.e.f 05.11.2025)	-	-
Mr. Vivek Partheeban (Vice Chairman w.e.f 05.11.2025)	-	-
Mr. D Sathyanarayanan (Director till 08.11.2024)	-	0.03
Mr. Ranganathan Vijayaraghavan (Director w.e.f from 30.09.2024)	0.04	0.02
Dr. C K Gariyali (Director till 03.03.2026)	0.07	0.03
Mr. S Deenadayalan	0.07	0.06
Dr. R Nagendran	0.04	0.02
Dr. K C John (Director w.e.f 05.11.2025)	0.06	-
Mrs. Susan Mathew (Director w.e.f 31.01.2026)	0.01	-

Note: Includes Sitting Fees paid to Directors from Subsidiaries also.

(f) Outstanding Balances

Particulars	As at March 31, 2026	As at March 31, 2025
Amount receivable/(Payable) to Ashvich Infotek Private Ltd by Caplin Steriles Limited	(0.12)	(0.36)
Amount receivable/(Payable) to Ashvich Infotek Private Ltd by Caplin Point Laboratories Limited	(0.12)	(0.12)
Amount receivable/(Payable) to Ashvich Properties Private Ltd by Caplin Point Laboratories Limited	(0.02)	(0.02)
Share of Profit from Argus Salud Pharma LLP to May India Property Private Limited#	0.00	0.00

#Share of Profit from Argus Salud Pharma LLP to May India Property Private Limited ₹ 12,249 (FY25 : ₹ 8,272).

NOTE 44: FINANCIAL INSTRUMENTS

Financial Instruments - fair value and risk management

A. Accounting classification and fair values:

Carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy, are presented below. It does not include the fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

(All amounts are in ₹ Crores unless otherwise stated)

Fair value hierarchy

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

Particulars	Category	As at March 31, 2026		As at March 31, 2025	
		Total Carrying Amount	Total Fair Value/ Amortised Cost	Total Carrying Amount	Total Fair Value/ Amortised Cost
Financial Assets					
Non - current investments - equity	FVTPL	1.04	1.04	0.92	0.92
Non - current investments - subsidiaries	Cost	1.83	1.83	1.79	1.79
Investment in corporate bonds, debentures, commercial paper and inter corporate deposits	Amortised cost	470.44	470.44	276.42	276.42
Other non current financial assets	Amortised cost	28.40	28.40	22.20	22.20
Other current financial assets	Amortised cost	74.17	74.17	57.37	57.37
Current investments- mutual funds	FVTPL	132.93	132.93	96.45	96.45
Current investments- others	Amortised cost	252.78	252.78	214.88	214.88
Trade receivables	Amortised cost	825.81	825.81	632.49	632.49
Cash and cash equivalents	Amortised cost	94.18	94.18	199.45	199.45
Other bank balances other than cash and cash equivalents	Amortised cost	526.86	526.86	391.96	391.96
Total		**2,408.44**	**2,408.44**	**1,893.93**	**1,893.93**
Financial Liabilities					
Lease liabilities (non current)	Amortised cost	2.06	2.06	2.91	2.91
Trade payables	Amortised cost	296.03	296.03	217.58	217.58
Lease liabilities (current)	Amortised cost	1.98	1.98	1.56	1.56
Current borrowings	Amortised cost	0.57	0.57	0.55	0.55
Other current financial liabilities	Amortised cost	50.76	50.76	45.26	45.26
Total		**351.40**	**351.40**	**267.86**	**267.86**

(i) The Company estimates that the fair value of these investments are not materially different as compared to its cost.

B. Measurement of fair values:

Valuation techniques and significant unobservable inputs:

The following tables show the valuation techniques used in measuring Level 2 and Level 3 fair values, for financial instruments measured at fair value in the statement of financial position, as well as the significant unobservable inputs used:

Type	Valuation Technique	Significant unobservable input	Inter-relationship between significant unobservable inputs and fair value measurement
Non - current financial assets and Liability measured at amortised cost	Discounted cash flows: The valuation model considers the present value of expected receipt / payment discounted using appropriate discounting rate	Not applicable	Not applicable

C. Financial risk management:

The Company has exposure to the following risks arising from financial instruments:

- Credit risk;
- Liquidity risk; and
- Market risk

The company's board of directors have overall responsibility for the establishment and oversight of the Company's risk management framework. The board of directors has established the risk management framework. The company's risk management policies are established to set appropriate risk limits and to monitor risks and adherence to limits. Risk management policies and systems are reviewed periodically to reflect changes in market condition and the Company's activities. The Company through its training, standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The audit committee oversees how management monitors compliance with the company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the company. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and adhoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

i. Credit Risk:

Credit Risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investment securities. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of the customers to which the Company grants credit terms in the normal course of business.

Trade Receivables

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of customers to which the Company grants the credit terms in the normal course of business.

Refer note: 9 for the aging analysis of the Trade Receivables (gross of provision).

Expected credit loss assessment

In accordance with Ind AS 109 - Financial Instruments, the Group uses the expected credit loss (“ECL”) model for measurement and recognition of impairment loss on its trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of ‘Ind AS 115 - Revenue from Contracts with Customers’.

The Group applies the simplified approach prescribed under Ind AS 109 and recognises lifetime expected credit losses for trade receivables. The ECL is estimated using a provision matrix that incorporates historical credit loss experience, ageing of receivables, customer-specific factors, current creditworthiness, and forward-looking information, including relevant macroeconomic indicators where applicable. Receivables are assessed by grouping customers with similar credit risk characteristics, and management applies judgement in evaluating the probability of default and expected loss.

Historically, the Group has experienced no credit losses, reflecting the strong credit quality of its customer base and effective collection practices. While there have been no significant adverse changes in macroeconomic conditions or customer credit profiles that would indicate a material increase in credit risk, the Group has recognised a provision for expected credit losses in accordance with the requirements of Ind AS 109 as a matter of prudence. Based on historical experience, current conditions and forward-looking information, management expects credit losses to remain insignificant.

Cash and cash equivalents

As at the year end, the Company held cash and cash equivalents of ₹94.18 Crores (31.03.2025 ₹ 199.45 Crores). The cash and cash equivalents are held with banks with good credit rating.

Other Bank balances

As at the year end, the Company held other Bank balance of ₹ 526.86 Crores (31.03.2025 ₹ 391.96 Crores). The balances are held with banks with good credit rating.

Investment in mutual funds, Corporate Bond, Debentures, Commercial Paper and Term Deposits (Intercorporate & Banks).

As at the year end, the Company held Investment in Mutual Fund of ₹ 132.93 Crores (31.03.2025 ₹ 96.45 Crores),Corporate Bonds ₹ 2 Crores (31.03.2025 ₹ 2 Crores) ,Debentures ₹ 611.96 Crores (31.03.2025 ₹ 384.30 Crores), Commercial Paper ₹ 9.26 Crores (31.03.2025 : Nil). The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non - performance by these counter-parties.

Other financial assets

As at the year end, the Company held Inter Corporate Deposits/Bank Deposits of ₹ 100 Crores (31.03.2025 ₹ 105 Crores) under Investments.

ii. Liquidity risk

Liquidity risk is the risk that the company will encounter difficulty in meeting the obligations with its financial liabilities that are settled by delivering cash or another financial asset. The Company’s approach to managing liquidity is to ensure that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company’s reputation.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

The parent company and its Indian subsidiaries was sanctioned working capital limits to the extent of ₹ 61.04 crores on the basis of security of Current Assets by various Banks. The group invests its surplus funds in bank fixed deposit and liquid and liquid plus schemes of mutual funds which carry no/low mark to market risks. The group monitors funding options available in the debt and capital markets with a view to maintain financial flexibility.

Exposure to liquidity risk

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted.

As at March 31, 2026	Carrying amount	Contractual cash flow					
		Total	0-12 months	1-2 years	2-3 Years	3-5 Years	More than 5 Years
Non - Derivative Financial Liabilities							
Borrowing	0.57	**0.57**	0.57	-	-	-	-
Lease Liabilities	4.04	**4.04**	1.98	1.59	0.47	-	-
Trade payables	296.03	**296.03**	296.03	-	-	-	-
Other financial Liabilities	50.76	**50.76**	50.76	-	-	-	-
Total	**351.40**	**351.40**	**349.34**	**1.59**	**0.47**	**-**	**-**

As at March 31, 2025	Carrying amount	Contractual cash flow					
		Total	0-12 months	1-2 years	2-3 Years	3-5 Years	More than 5 Years
Non - Derivative Financial Liabilities							
Borrowing	0.55	**0.55**	0.55	-	-	-	-
Lease Liabilities	4.47	**4.47**	1.56	2.21	0.37	0.33	-
Trade payables	217.58	**217.58**	217.58	-	-	-	-
Other financial Liabilities	45.26	**45.26**	45.26	-	-	-	-
Total	**267.86**	**267.86**	**264.95**	**2.21**	**0.37**	**0.33**	**-**

iii) Market Risk

Market risk is the risk that changes in market prices - such as foreign exchange rates, interest rates and equity prices - will affect the Company's income or the value of its holdings of financial instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivable and payable. We are exposed to market risk primarily related to foreign exchange rate risk as the Company's product is exported to various countries and a certain portion of its export is sourced through import. Thus our exposure to market risk is a function of revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs. The Company does not use any derivative to manage market risk since certain degree of a natural hedge available in the form of foreign currency realised from exports are paid against imports.

Currency risk

The Company is exposed to currency risk on account of its export and import of pharmaceuticals and import of raw material, capital goods,etc. The functional currency of the Company is Indian Rupee, where as majority of its export and imports are settled through USD($).

Exposure to Currency risk

Following is the currency profile of non-derivative financial assets and financial liabilities

Particulars	Currency	As at March 31, 2026		As at March 31, 2025	
		USD in Crores	₹ in Crores	USD in Crores	₹ in Crores
Export Debtors	USD	8.60	813.92	7.11	608.26
Cash and Bank Balances	USD	3.87	366.19	3.05	260.78
Total			**1,180.11**		**869.04**
Creditors Payable in Foreign Currency	USD	1.72	162.97	1.27	109.03
	Euro*	-	-	0.00	0.28
Total			**162.97**		**109.31**
Net statement of financial position exposure			**1,017.14**		**759.73**

*As at March 31, 2025, 29,806 Euros

Sensitivity analysis

A reasonable strengthening (weakening) of the Indian Rupee against US dollars as at March 31 would have affected the measurement of financial instruments denominated in US dollars and affected equity and profit or loss by the amount shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

1% appreciation / depreciation of the respective foreign currencies with respect to functional currency of the Company would result in decrease / increase in the profit before taxes by approximately ₹ 10.17 Crores for the year ended March 31, 2026 (₹ 7.59 Crores for the year ended March 31, 2025).

Interest rate risk

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest rate risk is the risk of changes in fair values of fixed interest bearing financial assets or borrowings because of fluctuations in the interest rates, if such assets/ borrowings are measured at fair value through profit or loss. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing borrowings will fluctuate because of fluctuations in the interest rates.

Exposure to interest rate risk

As on 31 March 2026 and 31 March 2025, the Company has not availed any long term borrowings except for loans on vehicles on fixed rate basis. Further, the Company has not availed any fund based working capital limits.

(All amounts are in ₹ Crores unless otherwise stated)

Fair value sensitivity analysis for fixed rate instruments

The Company does not account for any fixed-rate instruments at fair value through profit or loss. Therefore, change in interest rates at the reporting date would not affect profit or loss.

Commodity rate risk

The Company's operating activity involve purchase of Active Pharmaceutical Ingredients (API) and other direct materials, whose prices are exposed to the risk of fluctuation over short period of time. The commodity price risk exposure is evaluated and managed through procurement and other related operating policies. As on 31 March 2026 and 31 March 2025, the Company had not entered into any material derivative contracts to hedge exposure to fluctuations in commodity prices.

NOTE 45: CAPITAL MANAGEMENT

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on the capital as well as the level of dividends to ordinary shareholders.

As on date the group has certain cash credit facilities with banks and vehicle loans.

NOTE 46: CSR

Particulars	For the year Ended March 31, 2026	For the year Ended March 31, 2025
(i) Amount required to be spent by the company during the year,	8.30	6.24
(ii) Amount required to be set off for the financial year ,if any	-	-
(iii) Amount of expenditure incurred,	0.55	0.53
(iv) Shortfall at the end of the year,	7.75	5.71
(v) Total of previous years shortfall,*	5.64	3.98
(vi) Reason for shortfall,	The company has identified some long term projects where the CSR funds shall be utilised during next few years.	The company has identified some long term projects where the CSR funds shall be utilised during next few years.
(vii) Nature of CSR activities,	Sanitation,Healthcare facilities, Educational Infrastructure,setting up care homes for orphans and women	Sanitation,Healthcare facilities, Educational Infrastructure,setting up care homes for orphans and women
(viii) Details of related party transactions, e.g., contribution to a trust controlled by the company in relation to CSR expenditure as per relevant Accounting Standard,	1.00**	12.23**
(ix) Where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year shall be shown separately.	NA	NA

*Unspent balance lying in Caplin Point Meenakshi CSR Trust bank account is included in the above balance.

**During the year Company has transferred ₹ 1.00 Cr (FY'25 ₹ 12.23 Cr) to Caplin Point Meenakshi CSR Trust and out of which, the Trust has spent ₹ 4.16 Cr (FY'25 ₹ 7.96 Cr) during the year.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

NOTE 47: ADDITIONAL INFORMATION AS REQUIRED BY PARAGRAPH 2 OF THE GENERAL INSTRUCTIONS FOR THE PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS TO SCHEDULE III TO THE COMPANIES ACT, 2013

Name of the Entity	Net Assets, i.e., total assets minus total liabilities				Share in Profit / (Loss)			
	As % of consolidated net assets		₹ in Crores		As % of consolidated profit/ Loss		₹ in Crores	
	2025-26	2024-25	2025-26	2024-25	2025-26	2024-25	2025-26	2024-25
Parent								
Caplin Point Laboratories Limited	56.48	58.93	2,050.50	1,700.93	61.04	62.74	396.58	339.49
Subsidiaries								
Indian								
1. Argus Salud Pharma LLP	0.06	0.06	2.21	1.82	0.19	0.15	1.23	0.83
2. Caplin Steriles Limited **(Refer Note 1)**	10.73	11.42	389.59	329.49	8.47	9.04	54.97	48.92
3. Caplin One Labs Limited	2.07	2.58	75.14	74.60	(2.50)	0.86	(16.19)	4.68
Foreign subsidiaries								
1. Caplin Point Far East Limited **(Refer Note 2)**	38.88	37.48	1,411.59	1,081.92	37.91	39.17	246.29	211.93
2. Caplin Point (S) PTE. LTD	0.01	0.01	0.24	0.26	-	-	-	-
Indian Associate								
1. Sunsole Solar Private Limited	0.05	0.06	1.77	1.73	0.01	(0.00)	0.04	(0.01)
Minority interest in subsidiary	1.22	1.24	44.38	35.90	1.31	0.88	8.49	4.78
Total Eliminations / Consolidation Adjustments	(9.50)	(11.78)	(344.62)	(340.26)	(6.43)	(12.84)	(41.68)	(69.53)
	100.00	**100.00**	**3,630.80**	**2,886.39**	**100.00**	**100.00**	**649.73**	**541.09**

Note 1: Represents details as per Consolidated financial statements of Caplin Steriles Limited which includes the financial statements of its subsidiary Caplin Steriles USA Inc.

Note 2: Represents details as per consolidated financial statements of Caplin Point Far East Limited which includes the financial statements of its subsidiaries Caplin Point El Salvador, S.A. De C.V., Drogueria Saimed de Honduras S.A , Neoethicals CIA.Ltda - Ecuador, Neo Ethicals S.A - Nicaragua and Nuevos Eticos Neo Ethicals S.A - Guatemala ,Caplin Point Laboratories Colombia, SAS., Triwin Pharma S.A. de C.V. Mexico, Neo Ethicals Chile SPA Ltda

NOTE 48: SEGMENT REPORTING

The group has identified two geographical segments as its reportable segments in accordance with Ind AS 108 - Operating Segments. Segment 1 : Rest of the World. Segment 2 - United States of America (USA). Accordingly, segment reporting has been presented along with the results on the above basis.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

Particulars		For the year ended March 31, 2026	For the year ended March 31, 2025
1)	Segment revenue (Total Revenue)		
	Rest of the World	1,733.79	1,582.96
	USA	453.40	354.51
	Unallocated	115.54	96.43
	Total	**2,302.73**	**2,033.90**
2)	Segment Results (Profit Before Tax)		
	Rest of the World	631.20	540.34
	USA	56.05	40.01
	Unallocated	115.54	96.43
	Total	**802.79**	**676.78**
3)	Segment Assets		
	Rest of the World	1,918.28	1,451.26
	USA	656.00	580.09
	Unallocated	1,471.20	1,179.51
	Total	**4,045.48**	**3,210.86**
4)	Segment Liabilities		
	Rest of the World	332.52	271.19
	USA	82.16	53.28
	Unallocated	-	-
	Total	**414.68**	**324.47**

NOTE 49: DISCLOSURE OF ASSETS TAKEN ON LEASE

Maturity Analysis for the year ended 31st March 2026

Particulars	Less than 1 year	Between 1 to 5 year	Over 5 years	Total
Lease Liabilities	1.98	2.06	-	4.04

Maturity Analysis for the year ended 31st March 2025

Particulars	Less than 1 year	Between 1 to 5 year	Over 5 years	Total
Lease Liabilities	1.56	2.91	-	4.47

Movement in Lease Liabilities

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Lease liability at the beginning of the year	4.47	1.69
New leases during the year	1.29	4.06
Lease payments during the year	1.72	1.28
Lease Liability at the close of the year	4.04	4.47

Expenses relating to short-term leases and low-value assets for the year ended March 31, 2026 is ₹ 13.14 Crores (March 31, 2025 ₹ 10.73 Crores).

NOTE 50: REGISTRATION OF CHARGES OR SATISFACTION WITH REGISTRAR OF COMPANIES

The Group does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

NOTE 51: DISCLOSURE OF TRANSACTION WITH STRUCK OFF COMPANIES

The Group did not have any material transactions with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the financial year.

NOTE 52: ADDITIONAL REGULATORY INFORMATION REQUIRED BY SCHEDULE III TO THE COMPANIES ACT, 2013

(i) The Parent and Indian subsidiaries do not have any benami property held in its name. No proceedings have been initiated on or are pending against the Parent and Indian subsidiaries for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

(ii) The Parent and Indian subsidiaries have not been declared wilful defaulter by any bank or financial institution or other lender or government or any government authority.

(iii) The Parent and Indian subsidiaries have complied with the requirement with respect to number of layers as prescribed under section 2(87) of the Companies Act, 2013 read with the Companies (Restriction on number of layers) Rules, 2017.

(iv) Utilisation of borrowed funds and share premium;

I The Parent and Indian subsidiaries have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or

(b) Provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts are in ₹ Crores unless otherwise stated)

II The Parent and Indian subsidiaries have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

(v) The Parent and Indian subsidiaries does not have any undisclosed income which is not recorded in the books of account that has been surrendered or disclosed as income during the year (previous year) in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.

(vi) The Group has not traded or invested in crypto currency or virtual currency during the year.

(vii) The Parent and Indian subsidiaries do not have any charges or satisfaction of charges which is yet to be registered with Registrar of Companies beyond the statutory period.

NOTE 53: NOTE ON NEW LABOUR CODES

Pursuant to the Notification of the New Labour Codes effective 21st November, 2025 by the Government of India whereby multiple existing labour legislations have been consolidated into a unified framework, the Company has assessed the implications of the revised definition of ‘wages’ for employees. The assessment has resulted in an increase of employee benefit obligations relating to gratuity and compensated absences aggregating to ₹ 1.39 Crores. The impact has been recognised in the financial statements. The company continues to monitor developments pertaining to the New Labour Codes, and the impact thereof, if any, will be accounted for in accordance with the applicable accounting standards.

NOTE 54: Previous year’s figures have been regrouped / reclassified wherever necessary to correspond with the current year’s classification / disclosure.

The accompanying notes are an integral part of the consolidated financial statements.

As per our report of even date attached

For **Brahmayya & Co**
Chartered Accountants
Firm Registration No : 000511S

N. Sri Krishna
Partner
ICAI Membership No. 026575

Place : Chennai
Date : May 14, 2026

For and on behalf of the Board of Directors of Caplin Point Laboratories Limited;
CIN: L24231TN1990PLC019053

C.C. Paarthipan
Chairman
DIN:01218784

Dr.Sridhar Ganesan
Managing Director
DIN:06819026

D Muralidharan
Chief Financial Officer

Venkatram G
General Counsel & Company Secretary

Place : Chennai
Date : May 14, 2026

AGM
NOTICE

NOTICE

NOTICE is hereby given that the 35th Annual General Meeting ("AGM") of the members of Caplin Point Laboratories Limited ("The Company") will be held on **Friday, September 25, 2026** at **10.00 A.M** through Video Conferencing ("VC") or other Audio Visual Means ("OAVM") to transact the following businesses:

ORDINARY BUSINESS:

1. Adoption of Financial Statements

To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the Financial year ended March 31, 2026, along with the Reports of the Board of Directors and the Auditors thereon.

2. Declaration of Final Dividend and ratification of Interim Dividend

To declare a final dividend of ₹ 4/- (200%) per equity share of ₹ 2/- as recommended by the Board of Directors of the Company and to ratify the Interim Dividend of ₹4/- (200%) per equity share of ₹ 2/-, aggregating to ₹ 8/- (400%) for the year ended March 31, 2026.

3. Retirement by rotation of Dr. Sridhar Ganesan (DIN: 06819026) and consideration of his re-appointment

To appoint a Director in place of Dr. Sridhar Ganesan (DIN: 06819026) who retires by rotation, and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS

4. Re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director of the Company

To consider and, if thought fit, to pass the following Resolution as a **Special Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Sections 196, 197, 198, 203 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act"), Schedule V thereto and the Rules made thereunder including any amendment(s), statutory modification(s) or re-enactment(s) thereof for the time being in force, Regulation 17 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and based on the recommendation of the Nomination and Remuneration Committee and approval of Board of Directors, Articles of Association of the company, consent of the Members be and is hereby accorded for re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director of the Company, who has attained the age of 71 years, for a period of 2 years with effect from August 25, 2026 to August 24, 2028, at a remuneration recommended by the Nomination & Remuneration Committee as set out below.

1. Salary: ₹ 55,20,000 per annum
2. Allowances and Perquisites: As may be determined by the Nomination and Remuneration Committee including employee stock options.
3. Retirement benefits: Contribution to Provident fund, superannuation benefits and gratuity as per the rules of the fund/ scheme in force from time to time.
4. General:
   i. Perquisites shall be calculated in terms of Income Tax Act, 2025 and Rules notified thereunder;
   ii. The following shall not be considered as part of perquisites:
      a. Contribution to provident funds, superannuation benefits or annuity funds to the extent that is singly or put together are not taxable under the Income Tax Act, 2025;
      b. Gratuity payable at a rate not exceeding half a month's salary for each completed year of service; and
      c. Encashment of leave at the end of the tenure.
   iii. The Board/ Nomination and Remuneration Committee shall have the power to vary the aggregate remuneration (including salary, allowances, perquisites, incentive and retirement

benefits) for any Financial Year which shall be subject to an overall ceiling of 5% of the net profit of the Financial Year computed in the manner prescribed under the Act;

iv. Dr. Sridhar Ganesan will not be entitled to any sitting fees for attending meetings of the Board and the committees thereof;

v. Dr. Sridhar Ganesan will be subject to all other service conditions as applicable to any other employees of the Company;

vi. Dr. Sridhar Ganesan will be liable to retire by rotation, in terms of relevant provisions of Section 152 of the Companies Act,2013;

RESOLVED FURTHER THAT the Board of Directors of the Company (which term shall include the Nomination and Remuneration Committee of the Board) or the Company Secretary of the Company, be and are hereby authorized, to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution."

5. **Continuation of Mr. C. C. Paarthipan (DIN: 01218784) as the Chairman and Non-Executive, Non-Independent Director of the Company.**

To consider and, if thought fit, to pass the following Resolution as a **Special Resolution**.

"RESOLVED THAT pursuant to the provisions of Regulation 17(1A) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the Articles of Association of the Company, and based on the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, consent of the Members, be and is hereby accorded for the continuation of Mr. C. C. Paarthipan (DIN: 01218784) as the Chairman and Non-Executive, Non-Independent Director of the Company, notwithstanding the fact that he will attain the age of 75 (seventy five) years during his tenure.

RESOLVED FURTHER THAT the Board of Directors of the Company (which term shall include the Nomination and Remuneration Committee of the Board) or the Company Secretary of the Company, be and are hereby authorized, to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution."

6. **Appointment of Mr. D Muralidharan (DIN: 08301904) as a Whole Time Director of the Company.**

To consider and, if thought fit, to pass the following Resolution as a **Special Resolution**

"RESOLVED THAT pursuant to the provisions of Sections 152, 160, 161, 196, 197, 198, and 203 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, and Regulation 17 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Articles of Association of the Company, and based on the recommendation of the Nomination and Remuneration Committee and the Board of Directors, Mr. D Muralidharan (DIN: 08301904), who was appointed as an Additional Director, be and is hereby appointed as a Whole Time Director of the Company, for a term of two (2) consecutive years ("Term") with effect from August 12, 2026 to August 11, 2028.

RESOLVED FURTHER THAT taking into account the recommendation of the Nomination and Remuneration Committee and the Board of Directors, approval of members be and is hereby accorded to the appointment of Mr. D Muralidharan (DIN: 08301904) for the term, notwithstanding the fact that he has attained the age of 70 years, on the following terms and conditions:

1. Salary: ₹ 62,37,600 per annum
2. Allowances and Perquisites: As may be determined by the Nomination and Remuneration Committee including employee stock options.
3. Retirement benefits: Contribution to Provident fund, superannuation benefits and gratuity as per the rules of the fund/ scheme in force from time to time.

4. General:

   i. Perquisites shall be calculated in terms of Income Tax Act, 2025 and Rules notified thereunder;

   ii. The following shall not be considered as part of perquisites:

      a. Contribution to provident funds, superannuation benefits or annuity funds to the extent that is singly or put together are not taxable under the Income Tax Act, 2025;

      b. Gratuity payable at a rate not exceeding half a month's salary for each completed year of service; and

      c. Encashment of leave at the end of the tenure.

   iii. The Board/ Nomination and Remuneration Committee shall have the power to vary the aggregate remuneration (including salary, allowances, perquisites, incentive and retirement benefits) for any Financial Year which shall be subject to an overall ceiling of 5% of the net profit of the Financial Year computed in the manner prescribed under the Act

   iv. Mr. D Muralidharan will not be entitled to any sitting fees for attending meetings of the Board and the committees thereof;

   v. Mr. D Muralidharan will be subject to all other service conditions as applicable to any other employees of the Company;

   vi. Mr. D Muralidharan will be liable to retire by rotation, in terms of relevant provisions of Section 152 of the Companies Act, 2013;

   vii. Mr. D. Muralidharan (DIN: 08301904) shall continue to hold the designation and discharge the functions of Chief Financial Officer (CFO) of the Company alongside his appointment as Whole-Time Director, without any additional monetary compensation.

RESOLVED FURTHER THAT the Board of Directors of the Company (which term shall include the Nomination and Remuneration Committee of the Board) or the Company Secretary of the Company, be and are hereby authorized, to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution."

By Order of the Board of Directors

For Caplin Point Laboratories Limited
Venkatram G
(General Counsel & Company Secretary)
Membership No A23989

PLACE: Chennai
DATE: August 12, 2026

NOTES:

1. The Statement pursuant to Section 102(1) of the Companies Act, 2013 ("Act") and Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") setting out the material facts regarding the special business items specified above is annexed hereto.

2. The Ministry of Corporate Affairs ("MCA") has vide its Circular No 03/2025 dated September 22, 2025 with various other circulars issued from time to time (collectively referred to as "MCA Circulars") and the Securities and Exchange Board of India vide its circulars SEBI/ HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020, SEBI/HO/CFD/ CMD2/CIR/P/2021/11 dated January 15, 2021 and various other circulars issued from time to time (collectively referred to as "SEBI Circulars") permitted the conduct of the Annual General Meeting ("AGM") through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM"), without the physical presence of the Members at a common venue. The registered office of the Company shall be deemed to be the venue for the AGM.

3. Since this AGM will be held through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'), (a) Members will not be able to appoint proxies for the meeting, and (b) Attendance Slip & Route Map are not annexed to this Notice. However, Body Corporates / Institutional shareholders (i.e. Other than Individuals, HUF, NRI etc.) are entitled to appoint authorised representatives for the purpose of voting through remote e-voting and participation in the AGM through VC/OAVM and cast their votes through e-voting during the AGM. Corporate members intending to authorize their representatives to participate and vote at the meeting are requested to send a certified copy of the Board resolution / authorization letter to the Scrutinizer by email to alagar@alagarassociates.com with a copy marked to evoting@nsdl.com. In the case of joint holders, the vote of the first holder who tenders a vote shall be accepted to the exclusion of the votes of the other joint holders.

4. The attendance of members attending the AGM through VC/ OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Act, 2013.

5. Members may note that the Board has recommended a Final Dividend of ₹4/- per equity share.

6. The final dividend as recommended by the Board of Directors, if approved at the AGM, will be paid as per the Statutory timelines to those members, whose names appear in the Register of Members on September 18, 2026, and in respect of shares held in dematerialized form, dividend will be paid to members whose names are furnished by National Securities Depository Limited and Central Depository Services (India) Limited as beneficial owners as on that date.

7. Members holding shares in physical forms are requested to notify any change in their address to the Company / Share Transfer Agents quoting Registered Folio number. Members holding shares in electronic form are requested to intimate any change in their address or bank mandates to their respective Depository Participants. Members are encouraged to utilize the Electronic Clearing System (ECS) for receiving dividend. For members who have not updated their bank account details, dividend warrants / demand drafts / cheques will be sent to their registered addresses in the mode permitted for the purpose.

8. As per the Income Tax Act, 2025 ("the IT Act"), dividends paid or distributed by the Company is taxable in the hands of the shareholders. Accordingly, companies are required to deduct tax at source from dividends paid to shareholders. To enable us to determine the appropriate TDS rate as applicable, members are requested to submit relevant documents and/or update their Residential Status, PAN, Category as per the IT Act with their Depository Participants or in case shares are held in physical form, with the Share Transfer Agents by sending email to einward@integratedindia.in.

   However, no tax shall be deducted on the dividend payable to resident individual shareholders if the total dividend to be received by them during Financial Year 2025-26 does not exceed ₹ 10,000, and also in cases where members provide valid Form 121 [earlier Form 15G / 15H] as per Income Tax Rules, 2026 (for individuals, with no tax liability on total income and income not exceeding the maximum amount which is not chargeable to tax or individuals above the age of 60 years with no tax liability on the total income). Resident shareholders may also submit any other document as prescribed under the IT Act to claim a lower / nil withholding of tax. PAN is mandatory for members providing Form 121 [earlier Form 15G / 15H] or any other document as mentioned above.

9. Members are requested to intimate changes, if any, pertaining to their name, postal address, email address, telephone/mobile numbers, Permanent Account Number (PAN), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc.

    a) For shares held in electronic form: to their Depository Participants ("DPs")

    b) For shares held in physical form: to the Company/RTA in prescribed Form ISR-1 and other forms pursuant to SEBI Master Circular No. SEBI/HO/MIRSD/SECFATF/P/ CIR/2023/169 dated October 12, 2023. To mitigate unintended challenges on account of freezing of folios, SEBI vide its Circular No. SEBI/HO/MIRSD/POD-1/P/ CIR/2023/181 dated November 17, 2023, has done away with the provision regarding freezing of folios not having PAN, KYC, and Nomination details.

    Members may please note that SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022 and through Regulation 40 of the Listing Regulations has mandated the Listed Companies to issue securities in dematerialized form only while processing service requests viz. Issue of duplicate securities certificate; claim from unclaimed suspense account; renewal/ exchange of securities certificate; endorsement; sub-division/splitting of securities certificate; consolidation of securities certificates/folios; transmission and transposition. In this regard, Members are requested to dematerialize / demat their shares or securities held in physical form. Members are requested to make the service requests by submitting a duly filled and signed Form ISR – 4, the format of which is available on the Company's website at https://www.caplinpoint.net/index.php/shareholder-information/ and on the website of the Company's Share Transfer Agents Integrated India at https://www.integratedindia.in/. It may be noted that any service request can be processed only after the folio is KYC Compliant.

10. Members who have not yet registered their e-mail addresses and mobile numbers are requested to update the said details in the records of the relevant depositories (National Securities Depository Limited / Central Depository Services (India) Limited) through their depository participants or may contact the Registrar and Share Transfer Agent, Integrated Registry Management Services Private Limited, Kences Towers, 2nd Floor, No 1, Ramakrishna Street, North Usman Road, T Nagar, Chennai – 600 017, Telephone: 91-44-28140801-803, E-mail: einward@integratedindia.in for receiving any documents / communication from the Company.

11. Members wishing to claim dividends, which remain unclaimed, are requested to correspond with Company Secretary at the Company's Registered Office or the RTA. Members are requested to note that dividends not encashed or claimed within seven years from the date of transfer to the Company's Unpaid Dividend Account, will, as per Section 124(5) of the Act, 2013 be transferred to the Investor Education and Protection Fund. The Members, whose unclaimed dividends/shares have been transferred to IEPF, may claim the same by making an application to the IEPF Authority, in Form No. IEPF-5 available on www.iepf.gov.in. The Members/ claimants can file only one consolidated claim in a financial year as per the IEPF Rules.

12. In compliance with the provisions of Section 108 of the Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended from time to time and pursuant to Regulation 44 of the SEBI Listing Regulations and in terms of SEBI circular the Company is pleased to offer e-voting facility to its Members to exercise their right to vote at the 35th AGM by electronic means in respect of the businesses to be transacted at the AGM through the remote e-Voting platform provided by National Securities Depository Limited (NSDL).

13. The Board has appointed M/s. Alagar & Associates LLP, (FCS 7488; CoP 8196) Practicing Company Secretaries as the scrutinizers for conducting the e-voting in a fair and transparent manner. The scrutinizers will submit the report to the Chairman of the Company or to any person authorized by the Chairman after completing the scrutiny of the e-voting (votes cast during the AGM and votes cast through remote e-voting), within two working days from

the conclusion of the AGM. The results declared along with the Scrutinizer's report shall be communicated to the Stock Exchanges, Depositories and RTA and also be displayed on the Company's website www.caplinpoint.net.

14. In compliance with the MCA and SEBI Circulars the Annual Report for Financial Year 2025-26 along with the Notice of the 35th AGM is being sent to the members through e-mail. A letter containing a weblink for accessing the Notice and Annual Report for the financial year 2025-26 will be sent to those shareholders who have not registered their email address with the Company/ Depositories/ RTA.

15. Members holding shares in demat form are requested to update their email address with their Depository Participants. In line with the MCA Circulars, the notice calling the AGM has been uploaded on the website of the Company at https://www.caplinpoint.net/index.php/annual- report/. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.

16. SEBI vide Circular Nos. SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/131 dated July 31, 2023, and SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/135 dated August 4, 2023, read with Master Circular No. SEBI/HO/ OIAE/OIAE_IAD-1/P/CIR/2023/145 dated July 31, 2023 (updated as on August 11, 2023), has established a common Online Dispute Resolution Portal ("ODR Portal") for resolution of disputes arising in the Indian Securities Market.

    Pursuant to above-mentioned circulars, post exhausting the option to resolve their grievances with the RTA/Company directly and through existing SCORES platform, the investors can initiate dispute resolution through the ODR Portal (smartodr.in/login).

17. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors who are allowed to attend the AGM without restriction on account of first come first served basis.

18. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under Section 170 of the Act and the Register of Contracts or Arrangements in which the Directors are interested, maintained under Section 189 of the Act, will be available electronically for inspection by the members during the AGM.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:-

The remote e-voting period begins on Tuesday, September 22, 2026 at 9.00 A.M. and ends on Thursday, September 24, 2026 at 5.00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the cut-off date i.e. Friday, September 18, 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut- off date, being Friday, September 18, 2026.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility. Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual shareholders holding securities in demat mode with NSDL	1. For OTP-based login, click on the NSDL e-Voting login link. You will need to enter your 8-digit DP ID, 8-digit Client ID, PAN, and Verification Code, then generate an OTP. Enter the OTP received on your registered email ID/mobile number and click Login. After successful authentication, you will be redirected to the NSDL Depository site where you can see the e-Voting page. Click on the company name or e-Voting service provider (NSDL) to be redirected to the NSDL e-Voting website for casting your vote during the remote e-Voting period or for joining the virtual meeting and voting during the meeting. 2. Existing IDeAS users can visit the e-Services website of NSDL, either on a personal computer or mobile. On the e-Services home page, click the “Beneficial Owner” icon under “Login” available under the ‘IDeAS’ section; this will prompt you to enter your existing User ID and Password. After successful authentication, you will see e-Voting services under Value Added Services. Click “Access to e-Voting” under e-Voting services to see the e-Voting page, then click on the company name or e-Voting service provider (NSDL) to be redirected accordingly. 3. If you are not registered for IDeAS e-Services, the option to register is available on the NSDL e-Services website by selecting “Register Online for IDeAS Portal.” 4. Visit the e-Voting website of NSDL. Once the home page of the e-Voting system is launched, click the “Login” icon available under the ‘Shareholder/Member’ section. Enter your User ID (your sixteen-digit demat account number held with NSDL), Password/OTP, and the Verification Code shown on screen. After successful authentication, you will be redirected to the NSDL Depository site to access the e-Voting page. 5. Shareholders/members can also download the NSDL Mobile App “NSDL Speede” by scanning the QR code provided, for a seamless voting experience.
Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for the CDSL Easi/Easiest facility can log in using their existing user ID and password to reach the e-Voting page without further authentication. Users should visit the CDSL website and click the login icon and the New System Myeasi tab, then use their existing Easi username and password. 2. After successful login, the Easi/Easiest user will see the e-Voting option for eligible companies where e-voting is in progress. Clicking the e-voting option opens the e-Voting page of the relevant service provider for casting votes during the remote e-Voting period or during the meeting. Links are also provided to access all e-Voting service providers directly. 3. If not registered for Easi/Easiest, registration is available on the CDSL website under the login and New System Myeasi tab. 4. Alternatively, users can directly access the e-Voting page by providing their Demat Account Number and PAN from the e-Voting link on the CDSL website home page. The system authenticates the user via OTP sent to the registered mobile number and email as recorded in the demat account.
Individual shareholders (holding securities in demat mode) logging in through their Depository Participant	You can also log in using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for the e-Voting facility. After logging in, you will see the e-Voting option. Click on it to be redirected to the NSDL/CDSL Depository site after successful authentication, where you can access the e-Voting feature. Click on the company name or e-Voting service provider (NSDL) to be redirected to the NSDL e-Voting website for casting your vote.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below:

Password details for shareholders other than Individual shareholders are given below:

5. a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.

   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.

   c) How to retrieve your 'initial password'?

      (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.

      (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.

6. If you hold shares in Physical mode or are unable to retrieve or have not received the "Initial Password" or have forgotten your password:

   a) Click on "Forgot User Details/Password?" (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.

   b) "Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.

   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.

d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.

8. Now, you will have to click on "Login" button.

9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.

2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".

3. Now you are ready for e-Voting as the Voting page opens.

4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

5. Upon confirmation, the message "Vote cast successfully" will be displayed.

6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.

7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to alagar@alagarassociates.com with a copy marked to evoting@ nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting. nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request to Ms. Pallavi Mhatre, Senior Manager, at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to compliance. officer@caplinpoint.net.

2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to compliance.officer@caplinpoint.net. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.

3. Alternatively shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.

4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.

2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.

3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.

4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the EGM/AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for Access to NSDL e-Voting system. After successful login, you can see link of "VC/OAVM" placed under "Join meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at compliance.officer@caplinpoint.net from September 21, 2026 to September 23, 2026. The same will be replied by the company suitably. They may also register themselves as speakers.

6. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013 AND ADDITIONAL INFORMATION AS REQUIRED UNDER SEBI LISTING REGULATIONS AND CIRCULARS ISSUED THERE UNDER.

ITEM NO. 4: Re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director of the Company

Dr. Sridhar Ganesan (DIN: 06819026) was re-appointed as the Managing Director of the Company for a period of two (2) years with effect from August 25, 2024, and his present term of office expires on August 24, 2026.

Profile Summary & Core Skills:

Dr. Sridhar Ganesan has over four decades of distinguished global leadership experience in the pharmaceutical industry. His expertise spans Profit Centre Management, Global Marketing, Middle East and African business operations, international collaborations and strategic partnerships, pharmaceutical project planning and implementation, manufacturing, new product development, Quality Assurance and Factory Management. Under his guidance, the Company has continued to strengthen its business operations, enhance operational efficiencies, achieve sustained growth and create long-term value for its stakeholders.

His deep understanding of the pharmaceutical business, regulatory environment and global markets continues to provide valuable guidance in driving the Company's long-term objectives.

Justification for Re-appointment:

Dr. Sridhar Ganesan has attained the age of 71 years. In terms of Section 196(3)(a) of the Companies Act, 2013 read with Schedule V thereto, his continuation in office as Managing Director, having attained the age of 70 years, requires the approval of the Members by way of Special Resolution. Dr. Sridhar Ganesan plays a pivotal role in overseeing the ongoing product/ project expansion of the Company and the Group. Further, he has extensive industry experience, distinguished leadership, comprehensive knowledge of the Company's business. His valuable contribution to the sustained growth and success of the Company, in the opinion of the Board, is in the best interests of the Company. Hence, the Nomination and Remuneration Committee and Board recommends the Special Resolution for approval by the Members.

Dr. Sridhar Ganesan fulfil all the conditions given under Section 196 and Schedule V of the Companies Act, 2013 ("the Act") to be eligible for his re-appointment and has confirmed that he is not disqualified from being re-appointed as Director in terms of Section 164 of the Act and has given his consent to act as Managing Director in terms of Section 152 of the Act, subject to approval by the Members.

Based on the above, the Nomination and Remuneration Committee, recommended his re-appointment as the Managing Director and the Board of Directors, at its meeting held on August 12, 2026, approved the re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director of the Company for a further period of two (2) years commencing from August 25, 2026, to August 24, 2028, on the terms and conditions, including remuneration, as set out in the Resolution. The disclosures required under the Companies Act, 2013, Schedule V thereto, the Secretarial Standard on General Meetings (SS-2) and Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in the Annexure forming part of this Notice.

Memorandum of Interest

Except Dr. Sridhar Ganesan, none of the Directors, Key Managerial Personnel of the Company and their relatives, is in any way concerned or interested in the aforesaid resolution proposed to be passed as a Special resolution.

The Board recommends the resolution set forth in the Notice for the approval of the members.

ITEM NO. 5: Continuation of Mr. C. C. Paarthipan (DIN: 01218784) as the Chairman and Non-Executive, Non-Independent Director of the Company

Mr. C. C. Paarthipan (DIN: 01218784) is a first-generation entrepreneur with nearly four decades of rich and diverse experience in the pharmaceutical industry. Beginning his career in the 1980s as a Medical Representative, he established the Company with a vision to make quality pharmaceutical products affordable and accessible across emerging markets.

Under his visionary leadership, the Company has established a strong global presence across Latin America and other international geographies while maintaining its commitment to delivering high quality and affordable healthcare solutions. He continues to lead the Company's strategic growth initiatives, fostering innovation, expanding global operations and creating sustainable long-term value for stakeholders. His leadership has also played a significant role in strengthening the Company's governance framework and strategic direction.

Profile Summary & Core Skills

As the Founder of the Company, Mr. C. C. Paarthipan has been instrumental in transforming the organisation into a globally recognised pharmaceutical enterprise with a strong presence across emerging markets. His entrepreneurial mindset, strategic foresight and deep understanding of international pharmaceutical markets have enabled the Company to build a sustainable business model focused on underserved markets. His expertise in business strategy, international expansion, corporate governance, leadership development and stakeholder management continues to provide invaluable guidance to the Board and the management in shaping the long-term strategic direction of the Company. Guided by his philosophy of exploring untapped opportunities, he has successfully taken the Company's products to diverse global markets, predominantly serving the bottom of the pyramid through high-quality, affordable pharmaceutical solutions.

Justification for the proposed approval sought

Mr. C. C. Paarthipan will attain the age of 75 years on August 2, 2027. Pursuant to Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the continuation of a Non-Executive Director who has attained the age of seventy-five years requires the approval of the Members by way of a Special Resolution, prior to attaining 75 years. Based on the above, the Board at its meeting held on August 12, 2026, approved the continuation of Mr. C. C. Paarthipan (DIN: 01218784) as the Chairman and Non-Executive, Non-Independent Director of the Company. Being a Non-executive Director, he will not be entitled to any remuneration from the Company, and he shall continue to be liable to retire by rotation in accordance with the provisions of the Companies Act, 2013 and the Articles of Association of the Company.

The disclosures required under the Companies Act, 2013, the Secretarial Standard on General Meetings (SS-2) and Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in the Annexure forming part of this Notice.

Mr. C. C. Paarthipan has confirmed that he is not disqualified from continuing as Director in terms of Section 164 of the Companies Act, 2013 ("the Act") and has given his consent to act as Chairman and Non-executive Director in terms of Section 152 of the Act, subject to approval by the Members.

The Board is of the opinion that Mr. C C Paarthipan possesses the identified core skills, expertise and competencies fundamental for effective functioning in his role as a Chairman and Non-executive Director.

Memorandum of Interest

Except Mr. C. C. Paarthipan, and his relatives Mr. Ashok Partheeban and Mr. Vivek Partheeban (who are also Directors and Vice Chairmen of the Company), none of the Directors or Key Managerial Personnel of the Company or their relatives are concerned or interested, financially or otherwise in the aforesaid resolution proposed to be passed as a Special resolution.

The Board recommends the resolution set forth in the Notice for the approval of the members.

ITEM NO. 6: Appointment of Mr. D. Muralidharan (DIN: 08301904) as the Whole Time Director of the Company

Profile Summary & Core Skills:

Mr. D. Muralidharan (DIN: 08301904) has been serving as the Chief Financial Officer (CFO) of the Company since February 19, 2016. He is a seasoned finance professional holding a bachelor's degree in commerce (B. Com), Associate Membership of the Institute of Company Secretaries of India (ACS), and Cost & Management Accountant (CMA) qualification from ICMAI. He is also a member of the Risk Management Committee of the Company. Mr. Muralidharan's profile reflects the following skill set and experience.

S. NO	SKILL AREA	RELEVANT EXPERIENCE
1	Finance	Over Four decades of experience as a Finance professional.
2	Law	Knowledge of corporate and financial regulatory framework
3	Management	Core member of senior leadership managing finance and operations
4	Administration	Administrative oversight as part of senior management responsibilities
5	Corporate Governance	Rich experience in Board processes and member of the Risk Management Committee of the Company in his executive capacity.

Justification for appointment:

In recognition of his exceptional skill set, proven leadership, and extensive contributions as Chief Financial Officer, and with a view to further strengthening corporate governance, the Nomination and Remuneration Committee recommended the appointment of Mr. D. Muralidharan as Additional Director designated as Whole-Time Director of the Company for a term of two (2) years commencing from August 12, 2026 to August 11, 2028, subject to the approval of the Members. The Committee firmly believes that his elevation to the Board will enrich its diversity of thought and enhance decision-making by bringing his deep expertise in financial strategy and corporate governance.

Mr. D. Muralidharan has attained the age of 70 years. In terms of Section 196(3)(a) of the Companies Act, 2013, read with Schedule V thereto, his appointment as Whole Time Director, having attained the age of 70 years, requires the approval of the Members by way of a Special Resolution.

Mr. D. Muralidharan fulfils all the conditions prescribed under Section 196 and Schedule V of the Companies Act, 2013 (“the Act”) to be eligible for appointment, and has confirmed that he is not disqualified from being appointed as a Director in terms of Section 164 of the Act. He has also given his consent to act as Whole Time Director in terms of Section 152 of the Act, subject to approval by the Members.

Based on the recommendation of Nomination & Remuneration Committee, the Board of Directors, at its meeting held on August 12, 2026, approved the appointment Mr. D. Muralidharan (DIN: 08301904) as a Whole Time Director of the Company for a period of two (2) years commencing from August 12, 2026, to August 11, 2028, on the terms and conditions, including remuneration, as set out in the Resolution. The disclosures required under the Companies Act, 2013, Schedule V thereto, the Secretarial Standard on General Meetings (SS-2) and Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in the Annexure forming part of this Notice.

Memorandum of Interest

Except Mr. D Muralidharan, none of the Directors, Key Managerial Personnel of the Company and their relatives, is in any way concerned or interested in the aforesaid resolution proposed to be passed as a Special resolution.

The Board recommends the resolution set forth in the Notice for the approval of the members.

ANNEXURE TO NOTICE

ADDITIONAL INFORMATION ON DIRECTORS AS REQUIRED UNDER REGULATION 36 OF THE SEBI LISTING REGULATIONS AND APPLICABLE SECRETARIAL STANDARDS ISSUED BY THE INSTITUTE OF COMPANY SECRETARIES OF INDIA

Name of the director	Dr. Sridhar Ganesan (DIN: 06819026)	Mr. C. C. Paarthipan (DIN: 01218784)	Mr. D Muralidharan (DIN: 08301904)
Age and Date of Birth	71 years (23-03-1955)	74 years (02-08-1952)	70 years (25-08-1955)
Designation	Managing Director	Chairman and Non-Executive, Non-Independent Director	Whole Time Director
Qualifications	MS in Pharmaceuticals and Doctorate in Homeopathic Medicines	B. A.	B.Com, CMA and CS
Experience (Including a brief resume and expertise in specific functional areas)	Dr Sridhar Ganesan has more than 42 years of experience in the Pharma industry. He had provided effective leadership for setting higher goals and objectives for the Company and driving the team to achieve those goals and objectives.	• Mr. C C Paarthipan is the Chairman of Caplin Point Laboratories Limited and has been in the Board since 1993. • He has more than four decades of rich experience in the Pharmaceutical Industry. • Possesses extensive expertise in business strategy, international market expansion, corporate governance, leadership development and stakeholder management. • He has been the guiding force of the Company in achieving business targets/ goals. • Continues to provide strategic leadership and guidance to the Board and management in shaping the Company's long-term vision and business strategy.	Mr. D. Muralidharan has been serving as the Chief Financial Officer (CFO) of the Company since February 19, 2016. He has more than four decades experience as a Finance professional.
Terms and conditions of appointment/ re-appointment	As provided in the Explanatory Statement to the Notice under Item No. 4	As provided in the Explanatory Statement to the Notice under Item No. 5	As provided in the Explanatory Statement to the Notice under Item No. 6
Remuneration last drawn	Salary – ₹ 55,20,000 per annum and other perquisites subject to Schedule V limits	Nil	Salary - ₹ 62,37,600 per annum as the Chief Financial Officer of the Company along with other perquisites.
Remuneration sought to be paid	Salary – ₹ 55,20,000 per annum, along with other perquisites, with power to the Board/Nomination and Remuneration Committee to vary the remuneration,subject to overall ceiling of 5% of the net profit.	Nil	Salary - ₹ 62,37,600 per annum, along with other perquisites, with power to the Board/Nomination and Remuneration Committee to vary the remuneration,subject to overall ceiling of 5% of the net profit

Name of the director	Dr. Sridhar Ganesan (DIN: 06819026)	Mr. C. C. Paarthipan (DIN: 01218784)	Mr. D Muralidharan (DIN: 08301904)
Date of first appointment on the board	February 12, 2014	October 01, 1993	August 12, 2026
Shareholding (Including beneficial ownership), if any, in the company	Holds 98,750 equity shares in the Company	Holds 1,41,67,192 equity shares in the Company	Holds 20,000 equity shares in the Company.
Relationship with other directors/ Key Managerial Person	NIL	Father of Mr. Ashok Partheeban and Mr. Vivek Partheeban, Directors and Vice-Chairmen.	NIL
Number of meetings of the Board attended during the year	Five (5) meetings during the Financial Year 2025-26	Five (5) meetings during the Financial Year 2025-26	NIL
Listed entities in which the person holds the directorship	1 (Including Caplin Point Laboratories Limited)	1 (Including Caplin Point Laboratories Limited)	1 (Including Caplin Point Laboratories Limited)
Memberships/ Chairmanship in committees of the board (Audit & Stakeholders Relationship Committee) *	NIL	NIL	NIL
Listed entities from which the director has resigned in the past three years	NIL	NIL	NIL

** Companies other than Caplin Point Laboratories Limited.*

By Order of the Board of Directors

For Caplin Point Laboratories Limited
Venkatram G
(General Counsel & Company Secretary)
Membership No A23989

PLACE: Chennai
DATE: August 12, 2026

REGISTERED OFFICE:
Caplin Point Laboratories Limited
CIN: L24231TN1990PLC019053
Ashvich Towers, 3rd Floor,
No.3, Developed Plots, Industrial Estates,
Perungudi, Chennai – 600096
Website: https://www.caplinpoint.net/
E-mail: compliance.officer@caplinpoint.net

INFORMATION AT A GLANCE

Particulars	Details
Day, Date and time of AGM	September 25, 2026, Friday and 10:00 A.M
Mode	Video Conferencing / Other Audio Visual Means
E-voting website of NSDL	https://www.evoting.nsdl.com/
Record Date for dividend	September 18, 2026
Dividend payment date	On or before October 24, 2026
Cut-off date for e-voting	September 18, 2026
E-voting start date and time	September 22, 2026; 9.00 A.M.
E-voting end date and time	September 24, 2026; 5:00 P.M.
Start date for speaker registration and sending questions	September 21, 2026
End date for speaker registration and sending questions	September 23, 2026
Date of declaration of voting results	On or before September 29, 2026
Name and contact details of e-voting service provider	Ms. Pallavi Mhatre Sr. Manager-NSDL Email address: evoting@nsdl.com Contact Number: 022 - 4886 7000 and 022 - 2499 7000
Name, address, and contact details of Registrar and Share Transfer Agent	Integrated Registry Management Services Private Limited Kences Towers, 2nd Floor, No 1, Ramakrishna Street, North Usman Road, T Nagar, Chennai – 600 017, Telephone: 91-44-28140801-803, E-mail: einward@integratedindia.in

NOTE

NOTE

Mr. C.C. Paarthipan, Chairman handing over Rs. 1 crore cheque to Hon'ble Chief Minister of Tamil Nadu towards TN Nalam Fund.

CAPLIN POINT®
Laboratories

Pitchcraft communications
info@pitchcraft.in